{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "executionInfo": {
     "elapsed": 18956,
     "status": "ok",
     "timestamp": 1610616869075,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "au5Z9XQAC7C-"
   },
   "outputs": [],
   "source": [
    "magma_dir = '/home/marco/epfl/magma/'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "S0FByNNOIRvG"
   },
   "source": [
    "### **Config**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "executionInfo": {
     "elapsed": 45120,
     "status": "ok",
     "timestamp": 1610616895249,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "3BHImWfNKpDN"
   },
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "\n",
    "sys.path.insert(0, magma_dir)\n",
    "import config\n",
    "\n",
    "from torch import cuda\n",
    "device = 'cuda' if cuda.is_available() else 'cpu'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "executionInfo": {
     "elapsed": 45119,
     "status": "ok",
     "timestamp": 1610616895251,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "82WSp6khIcua"
   },
   "outputs": [],
   "source": [
    "MODEL = 'led'\n",
    "MODELS = {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "executionInfo": {
     "elapsed": 45117,
     "status": "ok",
     "timestamp": 1610616895252,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "5ti6XKYnFzSr"
   },
   "outputs": [],
   "source": [
    "# Dataset path\n",
    "data_dir = magma_dir + 'datasets/karger_books_base/'\n",
    "\n",
    "# Output path\n",
    "OUTPUT_PATH = magma_dir+'summarization/karger_books_base/'+MODEL+'/'\n",
    "if not os.path.exists(OUTPUT_PATH):\n",
    "    os.makedirs(OUTPUT_PATH)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "JFd0ppeJyX1o"
   },
   "source": [
    "### **Init**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "executionInfo": {
     "elapsed": 45115,
     "status": "ok",
     "timestamp": 1610616895253,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "yCzod0OizR5U"
   },
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "import torch\n",
    "import re\n",
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "from textwrap import fill\n",
    "tqdm.pandas()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "dllOnKR9Os5i"
   },
   "source": [
    "### **Function Definition**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "U2mpXoSaQiQE"
   },
   "source": [
    "##### Import Model and Tok"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "executionInfo": {
     "elapsed": 45113,
     "status": "ok",
     "timestamp": 1610616895255,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "XhBGMJVFOs5l"
   },
   "outputs": [],
   "source": [
    "def import_model_tok(model_name_or_path, verbose=False):\n",
    "    global MODELS\n",
    "\n",
    "    if model_name_or_path in MODELS.keys():\n",
    "        if verbose : print('[+] model already present in cache\\n')\n",
    "        return MODELS[model_name_or_path]\n",
    "    if verbose : print('[*] importing the model\\n')\n",
    "        \n",
    "    from transformers import AutoModelForSeq2SeqLM, AutoTokenizer\n",
    "\n",
    "    model = AutoModelForSeq2SeqLM.from_pretrained(model_name_or_path)\n",
    "    tokenizer = AutoTokenizer.from_pretrained(model_name_or_path)\n",
    "\n",
    "    if verbose : print(model.config)\n",
    "    MODELS[model_name_or_path] = model, tokenizer\n",
    "    if verbose : print('[+] the model is now present in cache\\n')\n",
    "    return MODELS[model_name_or_path]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "JiYIkI5xN2VA"
   },
   "source": [
    "##### Print Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "executionInfo": {
     "elapsed": 45112,
     "status": "ok",
     "timestamp": 1610616895257,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "dxsXYs1kN5HX"
   },
   "outputs": [],
   "source": [
    "def print_examples(model_name_list, df, n_examples=10):\n",
    "    \n",
    "    df_examples = df.sample(n_examples, axis='index', random_state=config.SEED)\n",
    "    \n",
    "    for idx, row in df_examples.iterrows():\n",
    "        print(idx)\n",
    "        print(fill(row.text, 100))\n",
    "        print()\n",
    "        for model_name in model_name_list:\n",
    "            model, tokenizer = import_model_tok(model_name)\n",
    "            model = model.to(device)\n",
    "            \n",
    "            summ_enc = model.generate(\n",
    "                tokenizer.encode(row.text, return_tensors='pt').to(device),\n",
    "                min_length = config.ONE_BULLET_MIN_LEN,\n",
    "                max_length = config.ONE_BULLET_MAX_LEN,\n",
    "                length_penalty = config.LENGTH_PENALTY,\n",
    "                num_beams = config.NUM_BEAMS,\n",
    "                no_repeat_ngram_size = config.NO_REPEAT_NGRAM_SIZE,\n",
    "                early_stopping = True)[0]\n",
    "            summ_num_tok = len(summ_enc)\n",
    "            summ = tokenizer.decode(summ_enc, skip_special_tokens=True)\n",
    "\n",
    "            print('Prediction\\n%s (%d tok):\\n'%(model_name, summ_num_tok))\n",
    "            print(fill(summ, 100))\n",
    "            print()\n",
    "            \n",
    "        print('Reference:')\n",
    "        print(fill(row.bullets, 100))\n",
    "        print()\n",
    "        print(''.join(['#']*100))\n",
    "        print()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "KV669nVZQnzT"
   },
   "source": [
    "##### Plot Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "executionInfo": {
     "elapsed": 45379,
     "status": "ok",
     "timestamp": 1610616895526,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "PrKd0tI7PBi5"
   },
   "outputs": [],
   "source": [
    "def plot_evaluation(model_name_or_path):\n",
    "    df = pd.read_csv(OUTPUT_PATH+model_name_or_path.replace('/', '?')+'.csv').set_index(['book', 'chapter'])\n",
    "\n",
    "    prf = ['precision', 'recall', 'fmeasure']\n",
    "    num_rouge = len(config.ROUGE_TYPES)\n",
    "\n",
    "    from matplotlib.cm import get_cmap\n",
    "    color = get_cmap('tab10')(range(num_rouge))\n",
    "    def set_box_color(b, c):\n",
    "        for k in b.keys():\n",
    "            plt.setp(b[k], color=c)\n",
    "    \n",
    "    xticks = 2*np.array(np.arange(1, num_rouge+1))\n",
    "    \n",
    "    box_plt_list = []\n",
    "\n",
    "    fig, ax = plt.subplots(figsize=(10, 6))\n",
    "    for r, var in zip(prf, np.linspace(-0.15*num_rouge, 0.15*num_rouge, num_rouge)):\n",
    "    \n",
    "        box_plt_list.append(\n",
    "            plt.boxplot(\n",
    "            [df[rouge+'_'+r+'_'+model_name_or_path].tolist() for rouge in config.ROUGE_TYPES],\n",
    "            positions= xticks+var,\n",
    "            sym='+',\n",
    "            widths=0.4,\n",
    "            patch_artist=False,\n",
    "            meanline=True,\n",
    "            showmeans=True))\n",
    "\n",
    "    for i, bp in enumerate(box_plt_list):\n",
    "        set_box_color(bp, color[i])\n",
    "        plt.plot([], c=color[i], label=prf[i])\n",
    "    plt.legend()\n",
    "\n",
    "    ax.grid(True, axis='y', alpha=0.7, linestyle='--')\n",
    "    ax.set_title('Evaluation Results', fontsize='xx-large')\n",
    "    ax.set_ylabel('Rouge', fontsize='x-large')\n",
    "    plt.xticks(xticks, config.ROUGE_TYPES, fontsize='x-large')\n",
    "    plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "vb_MdivVauzb"
   },
   "source": [
    "## **LED on Karger Books**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "executionInfo": {
     "elapsed": 18765,
     "status": "ok",
     "timestamp": 1610616898502,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "K98cwOLys0XX"
   },
   "outputs": [],
   "source": [
    "df_train = pd.read_csv(data_dir+'train.csv').set_index(['book', 'chapter'])\n",
    "df_val = pd.read_csv(data_dir+'val.csv').set_index(['book', 'chapter'])\n",
    "df_test = pd.read_csv(data_dir+'test.csv').set_index(['book', 'chapter'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "dpNmnjXn3u2U"
   },
   "source": [
    "### **Print and Summarization**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "WIiEnpvbMkJa"
   },
   "source": [
    "##### Print Train Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000,
     "referenced_widgets": [
      "addb9bfe4b084b61a77f19962f2919d1",
      "01e3a51fe914437187fb471f042cbc4e",
      "8ef14e9327d84807a95686427993ebcd",
      "0795dec75e4f4a9cad293877eddef047",
      "37bb8348b38e45b981c8e2c580de608b"
     ]
    },
    "executionInfo": {
     "elapsed": 78849,
     "status": "ok",
     "timestamp": 1610617032580,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "wgZKNh2f3u2l",
    "outputId": "fabe9770-ee41-42bc-9726-a13e121e11ab",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(9781910797150, 'ch04')\n",
      "Prevention and management of acute and delayed CINV It is essential that oncologists and oncology\n",
      "practitioners take significant time and effort to prepare patients adequately for their first course\n",
      "of chemotherapy. Clinicians have a wide variety of antiemetics to choose from for the prevention of\n",
      "chemotherapy-induced nausea and vomiting (CINV), and patients should receive the most effective\n",
      "antiemetic agents available Outcomes are improved by following the recommendations of national or\n",
      "international guidelines for CINV. Both the Multinational Association for Supportive Care in\n",
      "Cancer/European Society for Medical Oncology (MASCC/ESMO) and American Society of Clinical Oncology\n",
      "(ASCO) guidelines concur that the primary goal of CINV therapy is not to manage nausea and vomiting\n",
      "but to prevent these symptoms from happening in the first place. - All of the guidance for managing\n",
      "CINV in this book adheres to these international guidelines If antiemetic therapy is used correctly,\n",
      "CINV can be prevented in up to 70-75% of patients receiving highly emetogenic chemotherapy (HEC) and\n",
      "up to 80% receiving moderately emetogenic chemotherapy (MEC) Management principles Patients should\n",
      "be individually evaluated for their specific risk factors (see Table 2.2, page 18), as well as the\n",
      "level of anxiety present before the first course of treatment (see page 72). If the patient has a\n",
      "high level of anxiety before the first course of chemotherapy, serious consideration should be given\n",
      "to adding an antianxiety agent to the antiemetic regimen. To select the optimal antiemetic regimen,\n",
      "the emetogenic potential of the individual chemotherapy agents (Table 4.1) and overall emetogenicity\n",
      "of the chemotherapy regimen (Table 4.2) must be taken into consideration, according to the well-\n",
      "established antiemetic guidelines described above Antiemetic therapy should be started before\n",
      "chemotherapy is administered on day 1 and continued through the acute and delayed phase for as long\n",
      "as the chemotherapy is emetic (usually 2-3 days). The route of delivery will depend on what the\n",
      "patient is best able to tolerate. In general, antiemetics given either orally or intravenously in\n",
      "appropriate doses have equivalent efficacy. If CINV can be prevented after the first course of\n",
      "chemotherapy, it is likely that subsequent courses of chemotherapy will be well tolerated and\n",
      "breakthrough, refractory and anticipatory CINV will be minimized Highly emetogenic chemotherapy\n",
      "Prophylactic control of acute and delayed CINV that occurs as a result of cisplatin- or\n",
      "anthracycline and cyclophosphamide (AC)-based chemotherapy or other highly emetogenic chemotherapy\n",
      "(HEC) requires an initial three-drug regimen, administered before chemotherapy starts on day 1 of\n",
      "treatment (Figures 4.1 and 4.2). This should include a 5-HT receptor antagonist (RA) (granisetron,\n",
      "ondansetron, tropisetron, dolasetron or palonosetron; see pages 25-34), dexamethasone (see page 43)\n",
      "and a neurokinin (NK)-1 RA (aprepitant, fosaprepitant, rolapitant or netupitant/NEPA; see pages\n",
      "34-43). The recommended doses for these agents are shown in Table 4.3 Women with breast cancer\n",
      "receiving AC chemotherapy have a particularly high risk of CINV and are included in these\n",
      "recommendations Choice of antiemetic agent. Many clinical institutions have pharmacy committees that\n",
      "provide recommendations or formularies for specific antiemetic regimens. These recommendations\n",
      "should be based on cost, efficacy and toxicity Choice of 5-HT RA. There are no differences in\n",
      "efficacy between the first-generation 5-HT RAs (dolasetron, granisetron, ondansetron and\n",
      "tropisetron), and all of the agents in this class have similar or minimal toxicity Two studies have\n",
      "compared the second-generation 5-HT RA palonosetron with ondansetron and granisetron in the\n",
      "prevention of cisplatin-induced nausea and vomiting., In the first trial, intravenous palonosetron,\n",
      "0.25 mg and 0.75 mg, was compared with intravenous ondansetron, 32 mg. In the second trial,\n",
      "palonosetron, 0.75 mg, was compared with granisetron, 40 μg/kg. The two studies demonstrated that\n",
      "palonosetron induced better protection against delayed emesis, but did not discuss whether\n",
      "palonosetron was superior to other 5-HT RAs when an NK-1 RA is used, as endorsed by current\n",
      "guidelines In addition, a meta-analysis of 16 randomized clinical trials compared palonosetron to\n",
      "the first-generation 5-HT RAs. When administered without an NK-1 RA, palonosetron was statistically\n",
      "superior to the other 5-HT RAs in its control of CINV in patients receiving both MEC and HEC. As\n",
      "discussed on page 34, this meta-analysis revealed that palonosetron is statistically superior in the\n",
      "acute, delayed and overall phases Ondansetron, granisetron and (oral) dolasetron are available as\n",
      "generics; palonosetron is not available as a generic and has a higher acquisition cost. Tropisetron\n",
      "is distributed in various countries worldwide, but is not available in the USA International\n",
      "guidelines recommend the use of palonosetron as the preferred agent because of its higher efficacy\n",
      "compared with ondansetron or granisetron (see above). If the use of palonosetron results in better\n",
      "control of CINV with fewer visits to the clinic or the emergency department after chemotherapy and\n",
      "fewer admissions to the hospital for control of CINV, then its use may be cost-effective despite its\n",
      "initial higher acquisition cost Choice of NK-1 RA. Aprepitant, fosaprepitant, netupitant and\n",
      "rolapitant have all been shown to be safe and effective in phase III clinical trials, with few\n",
      "adverse events (see Chapter 3). Aprepitant, fosaprepitant and netupitant are metabolized by the\n",
      "liver enzyme CYP3A4 and are moderate inhibitors of CYP3A4, potentially resulting in drug\n",
      "interactions, although few, if any, clinical adverse events attributable to CYP3A interactions have\n",
      "been reported. Rolapitant does not induce CYP3A4 To date, no definitive clinical trials have\n",
      "directly compared the efficacy and safety of the various NK-1 RAs. One of the netupitant-\n",
      "palonosetron (NEPA) clinical trials involving patients receiving HEC included a comparative arm of\n",
      "oral aprepitant plus intravenous ondansetron. All patients in both arms received standard doses of\n",
      "dexamethasone. There appeared to be no significant differences in adverse events or in the\n",
      "prevention of CINV between NEPA and the aprepitant-ondansetron combination. A formal statistical\n",
      "comparison of the NEPA and aprepitant/ondansetron arms was not reported. For the present, the choice\n",
      "among these agents may be based on cost and the availability of oral or intravenous forms Moderately\n",
      "emetogenic chemotherapy Standard prophylactic control of acute and delayed CINV that may occur as a\n",
      "result of a non-AC MEC requires a combination of a 5-HT RA (palonosetron is preferred) and\n",
      "dexamethasone administered before chemotherapy on day 1, followed by dexamethasone treatment on days\n",
      "2-3 for the prevention of delayed nausea and vomiting (Figure 4.3) Prophylactic control of\n",
      "carboplatin-based CINV requires a triple-drug combination of a NK-1 RA, a 5-HT RA and dexamethasone\n",
      "before chemotherapy is administered on day 1. If aprepitant, 125 mg, is used on day 1, aprepitant,\n",
      "80 mg, is recommended on days 2-3 for the prevention of delayed CINV. If another NK-1 RA is used on\n",
      "day 1, no additional NK-1 prophylaxis for delayed CINV prevention is recommended (Figure 4.4). At\n",
      "present there is no consensus as to whether to administer dexamethasone on days 2-3 Prophylactic\n",
      "control of CINV induced by a multiple-day cisplatin regimen comprises a 5-HT RA, dexamethasone and\n",
      "an NK-1 RA (aprepitant or fosaprepitant) for acute nausea and vomiting, and dexamethasone and an\n",
      "NK-1 RA (aprepitant or fosaprepitant) for delayed nausea and vomiting (Figure 4.5). However, it\n",
      "should be noted that there are only limited data on the use of aprepitant in this setting and, given\n",
      "the few studies to date in this patient population, the optimal doses of aprepitant and\n",
      "fosaprepitant still need to be determined. Some clinicians add 2 days of aprepitant to the regimen\n",
      "after completion of multiple-day chemotherapy to control the delayed nausea and vomiting that may\n",
      "occur after the final day of chemotherapy. There are no data for rolapitant or netupitant in\n",
      "patients receiving multiple-day cisplatin treatment, and the optimal doses of 5-HT RA and\n",
      "dexamethasone have yet to be determined Furthermore, the 20-mg dose of dexamethasone that is often\n",
      "used on each day of chemotherapy has only been studied in patients receiving single-day higher doses\n",
      "of cisplatin-based chemotherapy (>= 50 mg/m). It is not known whether a lower dexamethasone dose\n",
      "administered on days 1-5 would be equivalent to a 20-mg dose Low or minimally emetogenic\n",
      "chemotherapy Limited evidence from clinical studies support the choice of antiemetic therapy or of\n",
      "any treatment at all for patients receiving low or minimally emetogenic chemotherapy. Of the\n",
      "patients who receive low or minimally emetogenic chemotherapy, it is hard to categorize those at\n",
      "risk of developing nausea and vomiting Patients with no previous history of nausea and vomiting who\n",
      "undergo chemotherapy of low emetic potential as an intermittent schedule could be managed with a\n",
      "single antiemetic agent such as dexamethasone, a 5-HT RA or a dopamine RA (Figure 4.6) High-dose\n",
      "chemotherapy Although the natural history of CINV in patients treated with high-dose chemotherapy\n",
      "and stem cell transplantation is, for the most part, unknown, most of these patients have\n",
      "experienced emesis with previous chemotherapy or irradiation The cause of CINV in this setting is\n",
      "multifactorial. Contributing causes include the use of prophylactic antibiotics, narcotic analgesics\n",
      "administered for the management of mucositis and total-body irradiation. Until recently, only phase\n",
      "II studies of antiemetic treatment with a 5-HT RA alone or combined with dexamethasone had been\n",
      "carried out in these patients. A cross comparison of these trials was challenging given the various\n",
      "chemotherapy regimens employed, the duration of high-dose chemotherapy, and the different patient\n",
      "populations and tumor types involved. Furthermore, most of these trials were underpowered, included\n",
      "only a small number of patients, and had different clinical endpoints to those used in standard\n",
      "phase III antiemetic trials, making interpretation particularly challenging In recent years, phase\n",
      "III studies have been published that investigated the use of modern triple-antiemetic therapy\n",
      "consisting of a 5-HT RA, dexamethasone and aprepitant. In a phase III study, 179 patients were\n",
      "randomized to receive ondansetron and dexamethasone with or without aprepitant on each day of the\n",
      "high-dose preparative regimen. A complete response (significant reduction in emesis without\n",
      "increasing toxicity or use of rescue medication) was demonstrated in 82% of those receiving\n",
      "aprepitant compared with 66% in those who did not The efficacy of aprepitant has also been evaluated\n",
      "in a phase III study in patients with multiple myeloma undergoing a high-dose chemotherapy regimen\n",
      "of intravenous melphalan, 100 mg/m, on days 1-2, with autologous stem cell transplantation on day 4.\n",
      "The patients were randomized to receive either oral aprepitant, 125 mg, on day 1 followed by 80 mg\n",
      "on days 2-4, or oral granisetron, 2 mg, on days 1-4 with oral dexamethasone, 4 mg, on day 1 and 2 mg\n",
      "on days 2-3, or matching placebo with oral dexamethasone, 8 mg, on day 1 and 4 mg on days 2-3. A\n",
      "total of 362 patients were available for the efficacy analysis, with 181 in each treatment arm. The\n",
      "complete response rate was significantly greater in the aprepitant group than the control group (58%\n",
      "vs 41%) CINV in children The incidence and severity of CINV in the pediatric age group is similar to\n",
      "that in adults The use of antiemetics should follow the same principles as those used to treat\n",
      "adults. The literature on the use of specific agents for particular chemotherapy regimens in\n",
      "children is not as well developed as that in adults, mainly because the phase III clinical trials\n",
      "performed for the approval of 5-HT and NK-1 RAs were performed in adults only The main antiemetics\n",
      "administered to children have been the 5-HT RAs (ondansetron, granisetron, palonosetron) with or\n",
      "without the use of corticosteroids. The use of corticosteroids has depended on the risk:benefit\n",
      "ratio in specific age groups and the particular chemotherapy regimen being used Recently, aprepitant\n",
      "has been recommended for use in various age groups and various clinical applications., To date,\n",
      "there have been no studies in children with netupitant or rolapitant\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Prevention and management of acute and delayed CINV in patients receiving high-dose chemotherapy and\n",
      "stem cell transplantation.It is essential that oncologists and oncology practitioners take\n",
      "significant time and effort to prepare patients adequately for their first course of chemotherapy.\n",
      "Clinicians have a wide variety of antiemetics to choose from for the prevention of chemotherapy-\n",
      "induced nausea and vomiting (CINV), and patients should receive the most effective antiemetic agents\n",
      "available to them.The use of antiemetic agents in the treatment of CINV is limited to patients\n",
      "receiving high doses of high-dose chemotherapy or stem cell transplantation (Figure 4.6).Outcomes\n",
      "are improved by following the recommendations of national or international guidelines for CIN\n",
      "\n",
      "Reference:\n",
      "The primary goal of CINV therapy is the prevention of nausea and vomiting. Patients should be\n",
      "individually evaluated for their specific risk factors as well as the level of anxiety present\n",
      "before the first course of treatment. Outcomes are improved by following international guidelines\n",
      "when selecting the antiemetic regimen to use in relation to emetogenicity of the type of\n",
      "chemotherapy involved. The triple-drug regimen of a NK-1 receptor antagonist (RA), 5-HT RA and\n",
      "dexamethasone is recommended for patients receiving highly emetogenic chemotherapy. The two-drug\n",
      "combination of palonosetron and dexamethasone is recommended for patients receiving moderately\n",
      "emetogenic chemotherapy. A single 8-mg dose of dexamethasone before chemotherapy is recommended for\n",
      "patients receiving low emetogenic chemotherapy; no antiemetic should be administered routinely for\n",
      "patients receiving minimally emetogenic chemotherapy. The final choice of antiemetic agent will\n",
      "depend on efficacy, toxicity and cost. To determine overall cost-effectiveness of any given regimen,\n",
      "the acquisition cost of the antiemetic agent should be weighed against the probability and cost of\n",
      "post-chemotherapy visits to the clinic or emergency department and/or admissions to hospital. The\n",
      "incidence and severity of CINV in children is similar ito that in adults. The use of antiemetics in\n",
      "children should follow the same principles as those used to treat adults.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541703, 'ch_5')\n",
      "Symptoms of breast cancer Although a lump in the breast is the most common presenting symptom of\n",
      "breast cancer, a variety of other symptoms may be present (Table 4.1) Lumps resulting from breast\n",
      "cancer are generally single, hard and painless, and may be irregular in shape. Fibroadenomas,\n",
      "however, may also appear as single hard lumps. Typically, breast cancers are about 2 cm in diameter\n",
      "by the time they become large enough to palpate. Approximately 60% arise in the upper outer quadrant\n",
      "of the breast, but any area of the breast can be affected Pain in the breast is seldom due to\n",
      "cancer. The most common cause is the normal periodic pain during the menstrual cycle (cyclic\n",
      "mastalgia). In many cases it is due to costochondritis (Tietze's syndrome) and it is possible that\n",
      "referred pain from this may explain many cases of non-cyclic mastalgia; the pathophysiology of\n",
      "Tietze's syndrome is poorly understood. However, pain does not exclude a cancer Bleeding from the\n",
      "nipple is a rare symptom of breast cancer; fewer than 3% of women report bleeding as a first\n",
      "symptom. The likelihood of cancer is increased if a lump is found on examination. In the absence of\n",
      "a lump, the most common cause of bleeding or bloodstained discharge is benign duct papilloma. In\n",
      "postmenopausal women, discharges from the nipple that are not bloodstained are usually due to duct\n",
      "ectasia. Discharges may also occur during early pregnancy, after breastfeeding and during treatment\n",
      "with certain drugs, such as oral contraceptives, some antihypertensive agents and some\n",
      "antidepressants. Persistent discharge from a single duct in the nipple needs to be investigated,\n",
      "especially if a dipstick is positive for blood. The usual method is microdochectomy (removal of a\n",
      "single duct), or in older women, total duct excision; the value of ductoscopy is being investigated,\n",
      "and some advocate using MRI to identify any pathology far from the usual limits of duct excision\n",
      "Changes in size or shape of the breasts may also indicate breast cancer. The affected breast may\n",
      "increase in size or become pendulous; conversely, in advanced breast cancer the breast may shrink\n",
      "owing to loss of normal breast tissue and retraction because of cicatrization. The skin may dimple\n",
      "or pucker because of edema and infiltration of Cooper's ligaments, and the nipple may become\n",
      "inverted. The veins in the breast may become more prominent as the tumor enlarges Skin involvement.\n",
      "In advanced cases, the tumor may involve the skin, leading to ulceration (Figure 4.1). Blockage of\n",
      "the lymphatic circulation can cause lymphedema, resulting in swelling of the arm. Accumulation of\n",
      "fluid in the dermis, which maintains its thickness at the sites of sweat glands and hair follicles,\n",
      "causes the typical 'peau d'orange' (orange skin) appearance. This is a late sign of cancer (stage\n",
      "T4) Lymph nodes. Occasionally, it is not possible to identify the primary tumor, and the only\n",
      "evidence of breast cancer is enlarged lymph nodes. A few women find the axillary lump first and can\n",
      "feel the breast lump only after the doctor shows it to them Metastatic breast cancer can cause a\n",
      "variety of symptoms, including bone pain, breathlessness, nausea and jaundice. It is, however, rare\n",
      "for a woman to present with metastatic disease When to refer? Breast symptoms that require referral\n",
      "to a specialist physician/surgeon or clinic are summarized in Table 4.2. The following patient\n",
      "groups can be managed, at least initially, by the primary care physician young women with tender\n",
      "lumpy breasts and older women with symmetric nodularity provided there is no localized abnormality\n",
      "or family history (Figure 4.2) women with minor or moderate breast pain that is not localized to one\n",
      "place and who do not have a palpable lesion women of any age who have nipple discharge that is from\n",
      "one or more ducts or is intermittent and not spontaneous, bloodstained or troublesome There is no\n",
      "single test or group of tests that provides perfect accuracy in the diagnosis of breast cancer. An\n",
      "'index of suspicion' remains the paramount principle. A suspicious mass with negative mammographic\n",
      "findings warrants biopsy. Negative biopsy findings in such a patient should be reviewed for anatomic\n",
      "and histopathological accuracy Triple assessment Algorithms used for general screening or for\n",
      "incidental findings may not apply to patients who present with a well-defined abnormality. A much\n",
      "higher level of accuracy is required for patients with symptomatic lumps: the risk of a false\n",
      "negative is too high (1-10%) with two assessments only (exempli gratia physical examination and\n",
      "imaging), so a tissue sample (preferable to cytology) should be taken in any patient with a\n",
      "clinically or radiologically identifiable lesion. Triple assessment, comprising clinical\n",
      "examination, imaging and pathological evaluation (preferably a core biopsy) will provide a confident\n",
      "diagnosis in 95% of patients with suspected breast cancer, and should be carried out before the\n",
      "patient is discharged History. The importance of a thorough history cannot be overemphasized; for\n",
      "example, a history of regular ibuprofen use in a young girl would suggest a diagnosis of\n",
      "fibromatosis for a lump that otherwise may mimic breast cancer A standard 'breast history' includes\n",
      "a history of the presenting complaint, such as duration, associated pain (a cyst is often painful\n",
      "and tender at the outset), discharge, change in size a menstrual, obstetric and gynecologic history\n",
      "the family history of breast and ovarian cancer a drug history, including use of oral contraceptives\n",
      "and hormone replacement therapy previous and concurrent diseases and surgery A social history and an\n",
      "understanding of the family and occupational circumstances are also important, because the treatment\n",
      "of breast cancer can span several months and psychological support needs to be individualized\n",
      "Clinical examination is an essential first step in the diagnosis of breast cancer. A gentle\n",
      "examination is the key to success, with maintenance of the patient's dignity always paramount The\n",
      "patient must be initially examined while sitting upright and in several positions: with arms on her\n",
      "side, above her head, on her hips - with pectoralis muscle contracted - and bent forwards. These\n",
      "positions put the Cooper's ligaments under tension and enhance any subtle dimpling of skin caused by\n",
      "their contracture - an early sign of cancer. One of the authors has serendipitously spotted this\n",
      "sign when a patient lifted herself off the couch with her arms while adjusting her position. The\n",
      "patient should then be asked to lie in a semi-recumbent position and the breasts examined quadrant\n",
      "by quadrant with the flat (not palm, but fingers) of a (warm) hand; lubricating the skin often makes\n",
      "this examination more sensitive. This procedure can distinguish between a distinct lump and coarse\n",
      "nodular tissue, which is a common feature of benign dysplasia. The axillary nodes and supra- and\n",
      "infraclavicular nodes should then be examined by palpation under the arms, above and below the\n",
      "collar bone, and from the front and the back of the patient The color and site of discharge should\n",
      "be noted and tested for the presence of blood. Discharge from a single duct is usually due to a duct\n",
      "papilloma. The likelihood of finding carcinoma is about 1%. The patient should also be asked to\n",
      "check if a retracted nipple can be completely everted - as that would remove any suspicion of cancer\n",
      "Imaging. Both mammography and ultrasonography have important roles in the diagnosis of breast\n",
      "cancer. MRI is also useful, particularly when the breasts are dense Mammography has a diagnostic\n",
      "accuracy of over 95% for clinically detectable tumors, and approximately 50% for subclinical\n",
      "cancers; this falls to about 35% if cancers found only on whole-organ analysis of mastectomy\n",
      "specimens are included. The technique can provide single oblique views of each breast, or both\n",
      "lateral and craniocaudal views. However, because it involves compressing the breast between two\n",
      "plates, the procedure can be uncomfortable Although mammography contributes little to the management\n",
      "of a patient with a discrete palpable lump, in whom the diagnosis should be based on cytology and\n",
      "histology if appropriate, it does have an important role in specific situations to increase the\n",
      "likelihood of detecting a relatively small cancer in patients whose breasts have a coarse nodular\n",
      "texture to locate a non-palpable cancer accurately for excision biopsy (Figure 4.3) to reveal, in\n",
      "women with a palpable lump, a non-palpable lump in the same or opposite breast; it should therefore\n",
      "be a prerequisite before conservative breast surgery for regular monitoring of women who have\n",
      "undergone mastectomy for breast cancer because of increased risk of developing cancer in the\n",
      "remaining breast Mammography is also the most common method for localizing impalpable tumors before\n",
      "surgery, although ultrasound is being used increasingly It should be remembered that mammography is\n",
      "particularly insensitive when the breasts are radiographically dense Ultrasonography has now become\n",
      "part of the standard evaluation of clinical abnormalities in the breast. It has a specificity of\n",
      "over 95% in distinguishing a solid mass from a cystic mass (Figure 4.4); the diagnosis can then be\n",
      "confirmed and treated (in the case of a simple cyst) by needle aspiration. Improvements in\n",
      "technology and easy assessment of vascularity have also increased both the sensitivity and\n",
      "specificity of ultrasound in the diagnosis of solid breast lumps. Benign lumps are well\n",
      "circumscribed with no acoustic shadow or isodense echoes, whereas malignant lumps have irregular\n",
      "outlines, are poorly defined and are variable in density or have echoes suggestive of\n",
      "microcalcifications Distinguishing discrete lumps from areas of nodularity in a relatively young\n",
      "woman can be difficult. Ultrasound can provide reassurance if it fails to detect any localized\n",
      "abnormality. Ultrasound is also used routinely to guide a needle for core biopsy or fine needle\n",
      "aspiration cytology and to localize subclinical lesions with needles prior to excision biopsy The\n",
      "use of ultrasound with enhanced color Doppler assessment of blood flow is now the primary tool for\n",
      "assessment of axillary metastases. In addition to detecting masses, it can detect increased\n",
      "vascularity, which can indicate lymph-node involvement. Assessment of the axilla is now part of the\n",
      "standard procedure that includes either guided cytology or core biopsy of a suspicious lymph node;\n",
      "if malignancy is found, sentinel node biopsy is unnecessary and axillary clearance can be performed\n",
      "at the time of the first operation (Z-11 trial). In addition, enhanced color Doppler ultrasound\n",
      "scanning of the breast postoperatively is likely to improve the early diagnosis of local recurrence,\n",
      "which is otherwise difficult to achieve because of surgical scarring and the effects of radiotherapy\n",
      "Magnetic resonance imaging. After the initial explosion of interest in MRI of the breast, concerns\n",
      "about its overuse are now being raised: MRI will detect more disease than the observed rate of local\n",
      "recurrence and increases mastectomy rates by up to six times. Most importantly, randomized trials\n",
      "have found that MRI does not reduce the necessity for reoperation, the likelihood of recurrence or\n",
      "contralateral breast cancer (incidence is 6% with or without preoperative MRI at 8-year follow-up),\n",
      "and does not improve surgical accuracy. It does, however, delay surgery (in one trial, 108 versus 38\n",
      "days) and detect additional lesions that can prompt more extensive surgery, which has been shown to\n",
      "be of no benefit. The expense is now less of an issue, as the cost of the additional MRI breast coil\n",
      "is a fraction of the total cost of an MRI machine MRI, which is based on the nuclear spin of\n",
      "molecules within a powerful magnetic field, is free of the hazards of conventional X-ray imaging. It\n",
      "produces remarkable digitized images that allow three-dimensional reconstruction of the breast\n",
      "(Figure 4.5). Furthermore, injection of a contrast agent enables the vascularity of the lesion to be\n",
      "visualized either as a dynamic function of uptake or as a static image (Figure 4.5b). However, an\n",
      "experienced radiological and surgical team is needed to interpret the images appropriately MRI may\n",
      "aid the diagnosis and management of breast cancer in certain clinical situations (Table 4.3).\n",
      "However, in the authors' opinion, caution should be exercised to avoid ascribing undue importance to\n",
      "'latent' lesions at a distance from the dominant primary, which persuades many surgeons to recommend\n",
      "a mastectomy. This clearly ignores evidence from the clinical trials of the past, which point to the\n",
      "safety of breast-conserving techniques. Large series have found that patients who underwent breast-\n",
      "conserving surgery after a preoperative MRI (therefore excluding those in whom additional lesions\n",
      "were found) have the same outcome as those who did not have a preoperative MRI evaluation,\n",
      "suggesting that the lesions found on MRI may never have progressed to a clinical tumor. The\n",
      "Comparative Effectiveness of MRI in Breast Cancer (COMICE) trial that randomized women to either\n",
      "receive or not receive a preoperative MRI, found that MRI does not reduce reoperation rates (even\n",
      "with lobular cancers), but increases the mastectomy rates (7% vs 1%). No difference in local\n",
      "recurrence was found, although we need to await longer-term results before we dispense with the use\n",
      "of preoperative MRI A high-impact study found that additional cancers found on MRI in the\n",
      "contralateral breast may have prompted an increase in contralateral mastectomy rates, especially in\n",
      "the USA. After MRI and magnetic-resonance-guided biopsy of the contralateral breast, some women are\n",
      "increasingly opting for a contralateral prophylactic mastectomy, even if the biopsy is benign. This\n",
      "appears to be more likely if the woman is having a reconstruction. There is no evidence that such a\n",
      "drastic measure saves lives, and the availability of a good reconstruction service should not be an\n",
      "excuse for mastectomy of either the breast with the primary tumor or the contralateral side, even if\n",
      "lobular carcinoma is present Pathology. If a discrete lump is present, and clinical examination and\n",
      "ultrasound suggests that it is a cyst, it can be aspirated with a 10/20-mL syringe and venipuncture\n",
      "(blue hub) needle. Aspiration of non-bloody fluid confirms the diagnosis of a benign cyst and the\n",
      "fluid need not be sent for further examination. Such aspiration will provide immediate relief and\n",
      "reassurance. Biochemical examination of the fluid, albeit interesting, has no clinical relevance;\n",
      "and cytological examination can yield non-specific changes that can sometimes lead to unnecessary\n",
      "anxiety A blood-stained aspirate may indicate the presence of an intracystic cancer requiring open\n",
      "biopsy (see Open biopsy). If the lump is solid, fine-needle aspiration can be used to obtain cells\n",
      "for cytological examination, which in some centers can be completed within 30 minutes Fine-needle\n",
      "aspiration cytology (FNAC) was popularized in Sweden decades ago and has been widely adopted in the\n",
      "rest of Europe, though it is less commonly used in the USA. The technique is simple, and a skilled\n",
      "operator can usually produce an adequate sample from very small tumors by inserting the needle\n",
      "either into a clinically palpable lump or stereotactically under radiological or ultrasound control.\n",
      "The aspirate is immediately smeared on a series of slides and stained for conventional microscopic\n",
      "examination (Figure 4.6) Experienced cytopathologists can diagnose breast cancer with almost 100%\n",
      "specificity. The sensitivity (id est false-negative rate) depends to a large extent on the operating\n",
      "skills of the clinician taking the sample and the experience of the cytologist. In many centers\n",
      "around the world where cytopathology results have been audited, surgeons are happy to carry out\n",
      "definitive cancer surgery on this result alone. However, the trend is changing worldwide, perhaps\n",
      "prompted by the few false-negative results that may have delayed a cancer diagnosis Biopsy. If\n",
      "cytological examination of cells obtained by FNAC is equivocal or not concordant with clinical or\n",
      "radiological features, especially in women over 35 years old, a core biopsy should be obtained under\n",
      "local anesthesia using an automatic core biopsy needle (widely available and, in many cases,\n",
      "disposable). Histological examination of the sample can then be used to confirm the cancer diagnosis\n",
      "An image-guided core biopsy with examination of at least four core specimens is recommended before a\n",
      "lump is confirmed as benign. The clinical and imaging findings should also be concordant. Modern\n",
      "core-cut biopsy techniques are considered the 'standard of care', particularly for lesions detected\n",
      "on screening Mammotome. This device can sample a large amount of tissue using a specialized needle\n",
      "apparatus that uses a vacuum to suck breast tissue towards the needle receptacle. As there is less\n",
      "sampling error, the false-negative rate is reduced to a very low level. It is increasingly being\n",
      "used, especially for lesions detected by screening. If the lesion is particularly small, it is\n",
      "prudent for the radiologist to insert a tiny radio-opaque clip at the site of the lesion, as it may\n",
      "be difficult to localize later if cancer is diagnosed Open biopsy involves the removal of the entire\n",
      "lump under general anesthesia. This procedure is associated with significant morbidity;\n",
      "approximately 20% of patients develop a further lump under the scar, or experience pain at the\n",
      "biopsy site. Thus, it should only be performed in patients who have been fully investigated by FNAC,\n",
      "mammography and core biopsy, and in whom the diagnosis still remains equivocal Metastatic spread If\n",
      "the tumor is large and there is extensive lymph-node involvement, preoperative staging is required.\n",
      "This typically involves chest and abdominal CT, and a bone scan, though a chest radiograph and\n",
      "ultrasound of the abdomen are also considered adequate. MRI and positron emission tomography (PET)\n",
      "are sometimes used for staging indeterminate lesions It should be emphasized that routine staging\n",
      "for metastatic spread in early breast cancer, especially when detected by screening or when a node-\n",
      "negative T1 tumor is present, is not advisable as the yield is less than 4%. The investigations can\n",
      "result in equivocal results that are clinically irrelevant, but can delay the definitive treatment\n",
      "and provoke considerable anxiety The aim of screening is to reduce mortality by detecting tumors\n",
      "before they have spread beyond the breast. Since over 90% of breast cancers are first detected by\n",
      "the woman herself, the rationale for regular self-examination is to increase the likelihood of\n",
      "detecting a tumor as early as possible Screening by regular mammography can reduce the risk of\n",
      "mortality from breast cancer by 20-30% in certain groups. Significant benefits are, however, seen\n",
      "only in women over the age of 50 years. In trials in Sweden, for example, mortality during 12 years\n",
      "of follow-up was reduced by 29% in women over 50 years of age, but by only 13% in younger women.\n",
      "Furthermore, the reduction in younger women was not statistically significant, and was delayed by at\n",
      "least 8 years. There is, therefore, no evidence to support regular screening in women under 50 years\n",
      "of age. This is an ongoing controversy. The current medical consensus suggests that the relative\n",
      "risk reduction achieved by regular screening with mammography in the 50-65-year-old age group is\n",
      "about 18%. The absolute risk reduction is much smaller, because the background risk of dying from\n",
      "breast cancer is about 3% in the general population It is worth noting that consumer advocacy groups\n",
      "also hold this viewpoint. The National Breast Cancer Coalition (NBCC) in the USA states: 'Women\n",
      "deserve to know the truth - and the truth is that there is no evidence of a mortality reduction in\n",
      "women under the age of 50 and the evidence for women over the age of 50 is currently unclear. Broad\n",
      "public health recommendations should only be made when it is clear that the potential benefits of\n",
      "the recommended intervention will outweigh the potential harms. NBCC believes that women are capable\n",
      "of educating themselves so that they can make their own individual decisions about screening.'\n",
      "Screening programs for breast cancer are associated with a number of problems Only about 70-80% of\n",
      "women accept mammography. It is much lower in some areas Of all the cancers diagnosed, over 50% are\n",
      "diagnosed between screening mammograms It is possible that a woman who is reassured by a negative\n",
      "result might ignore changes in her breasts between mammograms. Since 20-30% of breast cancers are\n",
      "not detected by mammography, some tumors could, therefore, be missed False-positive results are\n",
      "obtained in about 1% of mammograms. Such results could generate unnecessary anxiety, particularly if\n",
      "further investigations are undertaken For every breast cancer detected, a substantial number of\n",
      "women will undergo biopsies or surgery for benign breast disease, with attendant morbidity Although\n",
      "the total dose of radiation received during mammography is low (< 1.5 mGy), it has been suggested\n",
      "that repeated exposure could increase the risk of breast cancer. This risk is, however, low. It has\n",
      "been estimated that screening 2 million women over 50 years of age by a single mammogram would\n",
      "result in one extra case of breast cancer each year after 10 years; by contrast, the normal\n",
      "incidence of breast cancer in women over 60 years of age is approximately 2000 cases/million Small\n",
      "breast cancers detected by mammography may be biologically different from those detected clinically.\n",
      "Approximately 20% of cancers detected by mammography are carcinomas in situ, of which some would\n",
      "never progress to invasive disease if left undetected, and the optimal treatment for such tumors is\n",
      "unknown. If these cancers are treated in the same way as invasive cancers, some women may undergo\n",
      "unnecessarily extensive surgery. Conversely, in other women, delaying treatment of asymptomatic\n",
      "disease may ultimately compromise the chance of cure. Furthermore, there is good evidence that\n",
      "screening leads to overdiagnosis. Many invasive cancers detected by screening would never have\n",
      "progressed to clinical disease For every 2000 women screened for 10 years, 43 (vs 33 if not\n",
      "screened) cancers would be diagnosed. This means that 10 additional cancers will be diagnosed,\n",
      "resulting in about 3 fewer deaths (10 deaths instead of 13) from breast cancer. Even though some\n",
      "calculations suggest that this number could be 1 rather than 3, many women may choose to take this\n",
      "risk of overdiagnosis for the benefit of reduction in mortality, particularly if the treatments are\n",
      "made less intrusive. For example, the UK Marmot committee has recommended a single dose of targeted\n",
      "intraoperative radiotherapy (TARGIT) concurrent with lumpectomy, which has been found to be as\n",
      "effective for cancer control as several weeks of whole breast radiotherapy, while reducing deaths\n",
      "from other causes such as cardiovascular and other cancers The optimum interval between mammograms\n",
      "has not been determined. The UK screening program currently recommends a 3-yearly interval, but this\n",
      "is judged to be too long by some advocates of screening. However, a shorter interval would have\n",
      "major cost implications The issue of risk and its importance when discussing screening with women is\n",
      "discussed in Chapter 2. One of the most important benefits of a screening program is that it can\n",
      "raise the quality of investigation and complete multidisciplinary management of breast diseases to\n",
      "the highest level. It brings with it the infrastructure and quality assurance mechanisms that\n",
      "improve the treatment of all breast cancers and therefore benefits all women - those with\n",
      "symptomatic and screen-detected cancers. This substantial effect should not be underestimated Breast\n",
      "self-examination. In the latter part of the 20th century, several large-scale programs were\n",
      "established to teach self-examination techniques and encourage women to examine their breasts each\n",
      "month. Although this approach does appear to lead to the detection of smaller tumors, there is no\n",
      "evidence that it improves long-term survival. Indeed, two large-scale randomized controlled trials\n",
      "performed in St Petersburg and China found no difference in breast cancer mortality rates between\n",
      "women trained in breast self-examination and a control group. In these trials, compliance with the\n",
      "instructions was very high and could not be the reason for the absence of benefit. An adverse effect\n",
      "of self-examination training was the disproportionate number of women presenting with lumpy breasts\n",
      "who were then subjected to futile biopsies. The self-examination approach also has a potential\n",
      "problem in that random biopsies among premenopausal women may disclose ductal carcinoma in situ or\n",
      "lobular carcinoma in situ, the natural history of which is unknown. Such findings may result in\n",
      "inappropriate radical surgery or, at the very least, a lifetime of uncertainty and anxiety for the\n",
      "patient In 2001, the Canadian Medical Association went one step further when it published new\n",
      "guidelines following a systematic review of the literature. As a public health measure, self-\n",
      "examination was relegated from category C (of no proven value) to category D (of proven harm)! This\n",
      "report, as expected, provoked storms of protest on both sides of the Atlantic. The controversy has\n",
      "deep roots. Part of the difficulty lies in the intuitive notion that detecting a tumor 'earlier' (id\n",
      "est when it is smaller) is necessarily better, but it is becoming apparent that not all breast\n",
      "cancers are the same, even if they appear so morphologically. Thus, the disappointing results with\n",
      "early diagnostic attempts, including both imaging and self-examination, probably reflect our\n",
      "incomplete understanding of breast cancer as a process In the UK, emphasis was cleverly switched to\n",
      "'breast awareness' rather than regular self-examination. Women are encouraged to become familiar\n",
      "with their breasts and to distinguish between normal cyclic fluctuations and abnormal changes for\n",
      "which medical advice should be sought (Table 4.4). This can be done by feeling the breasts with a\n",
      "soapy hand while washing. The breast awareness approach should allow prompt reassurance to be given\n",
      "in most cases, and increase the likelihood that conservative surgery would be possible if breast\n",
      "cancer were detected. However, it should be remembered that breast awareness has no proven value\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "clinical lesions with needles prior to excision biopsy (Figure 4.1)The use of ultrasound with\n",
      "enhanced color Doppler assessment of blood flow is now the primary tool for assessment of axillary\n",
      "metastases. In addition to detecting masses, it can detect increased vascularity, which can indicate\n",
      "lymph-node involvement. Assessment of the axilla is now part of the standard procedure that includes\n",
      "either guided cytology or core biopsy of a suspicious lymph node; if malignancy is found, sentinel\n",
      "node biopsy is unnecessary and axillary clearance can be performed at the time of the first\n",
      "operation (Z-11 trial). In addition, enhanced color doppler ultrasound scanning of the breast\n",
      "postoperatively is likely to improve the early\n",
      "\n",
      "Reference:\n",
      "A logical process for assessing breast pain or masses will greatly enhance diagnostic accuracy.\n",
      "Triple assessment - clinical examination plus imaging plus cytological or histopathological\n",
      "examination - represents the diagnostic gold standard. All suspicious findings on MRI require\n",
      "pathological confirmation. No test is pathognomonic. Clinical judgment has high value. Breast\n",
      "screening programs have modest utility. Their greatest value may be in increasing patient self-\n",
      "awareness and in the improved organization of clinical services. Breast self-examination can no\n",
      "longer be recommended, though women should be aware of normal physiological changes and thus be\n",
      "alerted to the first chance observation of a pathological change.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541406, 'ch_3')\n",
      "Normal hemostasis In health, hemostasis ensures that blood remains fluid and contained within the\n",
      "vasculature. If a vessel wall is damaged, a number of mechanisms are promptly activated to limit\n",
      "bleeding by a complex series of interrelated reactions involving endothelial cells, plasma\n",
      "coagulation factors, platelets and fibrinolytic proteins. The activities of these components are\n",
      "finely balanced between keeping the blood fluid and preventing excessive activation of the\n",
      "procoagulants, which would lead to intravascular thrombosis It is helpful to consider the hemostatic\n",
      "process as three distinct phases Primary hemostasis occurs after damage to the vessel wall, and\n",
      "involves vasoconstriction and adhesion of platelets in a monolayer on exposed subendothelial\n",
      "fibrils. Subsequently, further platelets aggregate to form a platelet plug, which stems the flow of\n",
      "blood Secondary hemostasis involves activation of the coagulation system, leading to the generation\n",
      "of fibrin strands, which are laid down between platelets and reinforce the platelet plug\n",
      "Fibrinolysis entails activation of fibrin-bound plasminogen, resulting in clot lysis. Lysis is\n",
      "modulated by inhibitors of fibrinolysis, which are activated by thrombin or released by platelets In\n",
      "reality, these processes tend to merge, with the activated platelet and endothelial cell membranes\n",
      "providing the foundation on which the clotting factors can become activated, and fibrin formed and\n",
      "lysed Endothelial cells Blood vessels are lined with endothelial cells, which promote hemostasis and\n",
      "keep the blood fluid by preventing excessive deposition of fibrin through the synthesis and\n",
      "secretion of various antithrombotic agents. Proteins that directly promote hemostasis - von\n",
      "Willebrand factor (VWF) and P-selectin - are stored in specialized organelles called Weibel-Palade\n",
      "bodies. Other endothelial constituents are plasminogen activator inhibitor-1 (PAI-1) and cell\n",
      "adhesion molecules (exempli gratia vascular cell adhesion molecule 1 [VCAM1]), which promote the\n",
      "accumulation of white cells. Antithrombotic agents secreted by endothelial cells include: heparan\n",
      "sulfate, which inhibits activated clotting factors; prostacyclin and nitric oxide, which inhibit\n",
      "platelet aggregation and induce vasodilatation; and tissue plasminogen activator (tPA), which\n",
      "promotes the dissolution of fibrin that is deposited within the vasculature. This prevents excessive\n",
      "fibrin deposition and thrombosis Each bone marrow megakaryocyte produces 1000-2000 platelets, which\n",
      "remain in the circulation for about 10 days. These highly specialized anucleate cells (Figure 1.1)\n",
      "take part in a series of complex reactions to prevent blood loss. Trauma induces neurally mediated\n",
      "vasoconstriction and increases the shear rate of the flowing blood. Platelets leave the axial column\n",
      "of blood and move to the periphery, where they are activated by P-selectin exposed on the injured\n",
      "endothelium. The platelet membrane glycoprotein 1b-IX-V becomes the receptor for high-molecular-\n",
      "weight strings of VWF, released from Weibel-Palade bodies in the endothelial cells (see above). The\n",
      "VWF tethers platelets to the endothelium, and glycoprotein VI binds platelets to subendothelial\n",
      "collagen Platelet activation exposes the fibrinogen receptor glycoprotein alphaIIbbeta3, and there\n",
      "are also receptors for thrombin and thromboxane. Binding of these ligands to their receptors induces\n",
      "platelet activation and aggregation. Hemostatic proteins, such as VWF and fibrinogen, are released\n",
      "from alpha-granules (one of two unique types of granule found in platelets) and promote cross-\n",
      "linking between platelets to help the development of a platelet plug to stem hemorrhage. In\n",
      "addition, adenosine diphosphate (ADP) is released from the second type of granule (called platelet\n",
      "dense granules because of their calcium content), and promotes further aggregation of platelets by\n",
      "binding to platelet P2Y1 and P2Y12 receptors. The platelet membrane also has receptors for plasma\n",
      "coagulation factors (exempli gratia prothrombin and factors V, X and XI). Thus, the activated\n",
      "platelet membrane provides a surface on which the components of coagulation can gather very rapidly,\n",
      "leading to the development of a 'fibrin-reinforced' stable platelet plug Inhibitors. The\n",
      "participation of platelets and endothelial cells in the formation of the platelet plug is mediated\n",
      "by inhibitors: ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif, 13)\n",
      "cleaves the high-molecular-weight strings of VWF, ADP is converted to adenosine monophosphate (AMP)\n",
      "by ADPase, and platelet aggregation is inhibited by nitric oxide and prostacyclin, which also are\n",
      "vasodilators Coagulation system The coagulation factors are a series of plasma proteins synthesized\n",
      "by the liver that, when activated, generate thrombin and convert fibrinogen to fibrin via a sequence\n",
      "of complex reactions. Although originally conceived as a simple cascade, it is now viewed as an\n",
      "interrelated network of reactions, consisting of three phases: initiation, propagation and\n",
      "termination Initiation phase. When the endothelium is damaged the subendothelial vessel wall\n",
      "components become exposed, and circulating VWF promotes adhesion of platelets to the exposed\n",
      "subendothelial connective tissue. P-selectin is exposed on activated endothelial cells and binds to\n",
      "P-selectin glycoprotein ligand on leukocytes and platelets, initiating the rolling of these cells on\n",
      "the endothelium toward the site of injury and the release of membrane microparticles (Figure 1.2).\n",
      "Tissue factor (TF), a transmembrane glycolipoprotein, is expressed by injured endothelium,\n",
      "subendothelial connective tissue and microparticles. At the site of injury, TF forms a complex with\n",
      "factor (F)VII (TF-FVIIa) on the surface of activated platelets. The TF-FVIIa complex activates FIX\n",
      "and FX, and the activated FX cleaves prothrombin to form small amounts of thrombin. Thrombin is a\n",
      "potent activator of platelets, which provide an enhanced catalytic surface on which further\n",
      "coagulation is promoted. The activated platelets release hemostatic factors (exempli gratia\n",
      "fibrinogen and VWF) and polyphosphate, which accelerate the activation of FXI by thrombin.\n",
      "Polyphosphate is also capable of activating FV, further enhancing thrombin formation Propagation\n",
      "phase. The small amounts of thrombin that are formed during the initiation phase activate FV, FVIII\n",
      "and FXI, leading to the formation of sufficient thrombin to overcome inhibitors and generate fibrin\n",
      "from fibrinogen, as well as activate FXIII to cross-link the fibrin and form a stable clot (Figure\n",
      "1.3) Termination phase. This occurs when protein C is activated and, together with protein S,\n",
      "inhibits activated FV and FVIII, as described below Inhibitors of coagulation. The plasma contains a\n",
      "series of proteins that inhibit activated procoagulant enzymes and prevent excessive intravascular\n",
      "coagulation. Raised levels of these inhibitors are usually not associated with a bleeding state, but\n",
      "a reduced concentration may predispose to thrombosis Tissue factor pathway inhibitor binds FXa,\n",
      "forming a complex that rapidly inhibits the TF-FVIIa complex Antithrombin is a potent and clinically\n",
      "very important inhibitor of thrombin, FXa, FXIa and the TF-FVIIa complex. It limits the overall\n",
      "activation of the coagulation mechanism, preventing excessive fibrin deposition and thrombosis\n",
      "Protein C. The protein C pathway is a further mechanism by which intravascular coagulation is\n",
      "limited (Figure 1.4). This pathway is initiated by thrombin when it binds to thrombomodulin on the\n",
      "endothelial surface and activates protein C bound to its receptor on the cell membrane. Activated\n",
      "protein C - along with its cofactor, free protein S - inactivates the activated coagulation factors\n",
      "Va and VIIIa by proteolysis. Protein Z binds to the Z-protease inhibitor and the complex inactivates\n",
      "FXa Small amounts of fibrin are constantly being deposited within the vasculature and are removed by\n",
      "the fibrinolytic system (Figure 1.5). This pathway consists of an initiator, tPA, which is\n",
      "synthesized and released from endothelial cells. tPA converts its substrate plasminogen (bound\n",
      "within the clot to fibrin) to plasmin. In turn, plasmin lyses intravascular fibrin to soluble\n",
      "fibrin-degradation products. These consist of fragments of cross-linked fibrin known as D-dimers,\n",
      "levels of which can be measured in the laboratory and reflect the amount of fibrin degradation. The\n",
      "small amount of plasmin escaping from the clot is neutralized by circulating antiplasmin Inhibitors\n",
      "of fibrinolysis. Fibrinolysis is inhibited by the following factors Plasminogen activator\n",
      "inhibitor-1 and antiplasmin inhibit tPA and plasmin, respectively. Raised levels of PAI-1 are\n",
      "associated with atheroma, though it is unclear whether a high plasma level predisposes to, or is a\n",
      "consequence of, atherothrombosis. Raised antiplasmin levels do not appear to predispose to\n",
      "thrombosis, though low levels occasionally lead to a bleeding state because of the unopposed action\n",
      "of plasmin Plasminogen activator inhibitor-2 is synthesized by the placenta and is an important\n",
      "inhibitor of tPA, especially at the end of pregnancy Thrombin activatable fibrinolytic inhibitor is\n",
      "a carboxypeptidase that is activated by thrombin and cleaves lysine from fibrin, preventing\n",
      "plasminogen binding to fibrin. Defective thrombin generation, as in the various forms of hemophilia,\n",
      "impairs activation of this inhibitor, resulting in enhanced fibrinolysis and bleeding Regulation of\n",
      "hemostasis Sequential steps activate specific procoagulants (identified by Roman numerals;\n",
      "a=activated), eventually culminating in thrombin generation and fibrin formation. However, as\n",
      "previously described, each step is regulated by clotting inhibitors TF-FVIIa complex is inhibited by\n",
      "tissue factor pathway inhibitor FXIa is inactivated by the protease nexin 2 FIXa and FXa are\n",
      "inhibited by antithrombin FVa and FVIIIa are inhibited by activated protein C and protein S Thrombin\n",
      "is inhibited by thrombomodulin and antithrombin Bleeding occurs when the hemostatic balance between\n",
      "clotting factors and inhibitors is altered. For example, hemorrhages occur in hemophilia (deficiency\n",
      "of either FVIII or FIX) because tissue factor pathway inhibitor inhibits the alternative pathway for\n",
      "thrombin generation via the TF-FVIIa complex (see Chapter 6)\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      ", atherothrombosis. Raised antiplasmin levels do not appear to predispose to thrombosis, though low\n",
      "levels occasionally lead to a bleeding state because of the unopposed action of plasminogen\n",
      "activator inhibitor-2.Coagulation system is a complex of coagulation factors.The coagulation factors\n",
      "are a series of plasma proteins synthesized by the liver that, when activated, generate thrombin and\n",
      "convert fibrinogen to fibrin via a sequence of complex reactions. Although originally conceived as a\n",
      "simple cascade, it is now viewed as an interrelated network of reactions, consisting of three\n",
      "phases: initiation, propagation and termination.Initiation phase. When the endothel\n",
      "\n",
      "Reference:\n",
      "The immediate arrest of hemorrhage depends on vasoconstriction together with the adhesion and\n",
      "aggregation of platelets at the site of vessel injury. The coagulation system is activated by tissue\n",
      "factor expression. This binds and converts factor (F)VII to FVIIa, which initiates a catalytic\n",
      "series of reactions leading to the rapid generation of small amounts of thrombin. Trace\n",
      "concentrations of thrombin trigger the explosive generation of a much larger quantity of thrombin by\n",
      "activating FXI, FVIII and FV in a positive feedback loop. Thrombin further promotes the stability of\n",
      "the platelet-fibrin hemostatic plug by activating platelets, FXIII (cross-linking fibrin strands)\n",
      "and thrombin activatable fibrinolytic inhibitor.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797273, 'chp8')\n",
      "Lifestyle considerations and the multidisciplinary team Multiple sclerosis (MS) is a clinically\n",
      "heterogeneous condition, and the advice given must be tailored to the individual patient's disease\n",
      "phenotype, medical history and social circumstance. Counseling should not only involve what we know\n",
      "about the disease but also what effect MS will have on all aspects of life, including career,\n",
      "family, travel, insurance and the concerns raised by having a new diagnosis of MS. Patients are keen\n",
      "to know whether their life expectancy will be affected and whether the disease is transmissible to\n",
      "their children (Table 8.1). The diagnosis may affect their employment status, whether they decide to\n",
      "have children and where they decide to live. Patients often ask if they could have avoided the\n",
      "disease by changing their behavior in any way The multidisciplinary team Neurologist. The medical\n",
      "team is important in coordinating multidisciplinary patient care. It is the neurologist's role to\n",
      "make a firm diagnosis as early as possible in the course of the disease. Once the diagnosis has been\n",
      "established, the neurologist must ensure that the patient is fully informed of all approved\n",
      "treatment options and understands both their benefits and risks. Neurologists are also well-\n",
      "positioned to provide patients with the opportunity to participate in local clinical trials of\n",
      "emerging disease-modifying and symptomatic therapies. Neurologists strive to understand more about\n",
      "the pathophysiology and evolution of MS, and translate this information to the clinical care of\n",
      "their patients. Studies show that patients with MS do not always seek specialty care; this results\n",
      "in lower use of disease-modifying therapies (DMTs) and higher disability General practitioner/family\n",
      "doctor. The primary care provider will be able to coordinate all the threads of care for a patient\n",
      "with MS throughout their life. They will have access to allied healthcare professionals, and will be\n",
      "able to refer to specialists (neurologist, urologist, obstetrician, psychiatrist, rehabilitation\n",
      "therapist) for the wide range of symptoms and concerns that patients may have at different stages of\n",
      "the disease. As care providers over a lifetime, they have a unique insight into the needs of the\n",
      "individual. Good communication within the healthcare support team will ensure a well-integrated\n",
      "approach to the management of MS and its resulting morbidity. It is vital patients are provided with\n",
      "consistent messages, including guidance on preventative care, smoking cessation, stress management,\n",
      "regular exercise and healthy nutrition Advanced practice clinician. In large centers, the advanced\n",
      "practice clinician (APC), who could be a specialist nurse or physician's assistant, has become an\n",
      "integral and invaluable member of the multidisciplinary team. APCs are a reliable source of\n",
      "information about all aspects of MS, and can provide patients with practical advice on living with\n",
      "the condition. The APC can counsel people who have recently received a diagnosis of MS, and they are\n",
      "usually easy to contact when questions arise outside the consultation. After diagnosis, APCs are\n",
      "often the first port of call when a patient is concerned that they may be having a relapse. They can\n",
      "provide prompt clinical assessment and, where necessary, review The MS specialist APC is well placed\n",
      "to explain the practical aspects associated with all DMTs. Traditionally, training in the use of\n",
      "injectable therapies has been a principal role for the MS nurse. In the modern therapeutic era, the\n",
      "APC also supervises patients who receive infusions, and coordinates and runs first-dose clinics for\n",
      "fingolimod. They can be called upon if adverse effects occur, or if patients are having difficulty\n",
      "adhering to a particular therapy. Finally, the APC helps patients deal with the social impact of MS\n",
      "and can provide a link to other services such as social workers and clinical psychologists\n",
      "Physiotherapist. The physiotherapist is vital in helping patients remain mobile for as long as\n",
      "possible, and plays a crucial synergistic role in the management of spasticity. As well as providing\n",
      "the patient with specific exercises that help prevent the development of contractures and pressure\n",
      "sores, the physiotherapist can offer practical advice and training in fall prevention.\n",
      "Physiotherapists are a valuable source of encouragement, and help to optimize the functional\n",
      "abilities of patients with MS, maintaining a range of movement and limb strength for as long as\n",
      "possible Speech and language therapist. The 'SALT' team are highly skilled in the assessment of\n",
      "speech and swallowing. They can aid communication in patients who have severe dysarthria, and also\n",
      "delineate the nature of swallowing problems in MS. They can recommend dietary changes and actions to\n",
      "maximize swallowing and to minimize the risk of aspiration. They are able to identify when\n",
      "swallowing has deteriorated to high risk levels, and can recommend when institutional enteral\n",
      "feeding should be considered Occupational therapist. The occupational therapist works with the\n",
      "patient to allow them to remain independent for as long as possible. They will assess functional\n",
      "ability and evaluate how activities of daily living are carried out. They can then recommend\n",
      "training or equipment to make life easier, and potentially allow the person to return home or to the\n",
      "working environment Occupational therapists can install handrails in the home, and can plan\n",
      "conversion of bathrooms to 'wet' rooms to minimize the risk of falls. They will assess how safe it\n",
      "is for certain functions to be carried out (exempli gratia boiling a kettle) and either recommend\n",
      "equipment or behavioral changes (avoidance) to ensure the patient's safety Nutritionist. The\n",
      "nutritionist can help plan a diet that is high in fiber to improve bowel function in patients with\n",
      "constipation. Nutritionists also plan diets designed to maintain health, particularly in patients\n",
      "who require an exclusion diet for other reasons (exempli gratia gluten intolerance). In advanced MS,\n",
      "which is typically associated with weight loss and swallowing difficulties, they may design a diet\n",
      "that is tailored to the needs of the individual. The risk of osteoporosis may increase in patients\n",
      "with MS, for which the dietitian can recommend a diet rich in calcium or, when required, supplements\n",
      "such as vitamin D and calcium. Nutritionists also manage enteral feeding if a gastrostomy becomes\n",
      "necessary Social worker. It is important that people with MS receive help with housing,\n",
      "transportation, personal finance and insurance, along with other practical assistance as and when\n",
      "required. Patients may not always be aware of their entitlement, and for various reasons may\n",
      "struggle with completing forms. Social workers have an understanding of the social system of their\n",
      "country and are able to advise and assist people with MS, to ensure that they receive appropriate\n",
      "assistance from the government and relevant non-governmental organizations. Rehousing to incorporate\n",
      "the needs of the patient and their family requires vital input from social workers. They are also\n",
      "able to monitor for any signs of abuse in the vulnerable, and act to protect those in need of help\n",
      "Other valuable members of the team. Psychologists can assess and improve the patient's mood,\n",
      "cognition and coping skills, and assist with adjusting to the new diagnosis, dealing with chronic\n",
      "illness and its challenges, and providing healthy coping skills along with educational support.\n",
      "Continence nurses can assess bladder problems, assist with continence training, provide advice on\n",
      "pelvic floor exercises and urinary aids, and ensure appropriate maintenance of catheters to minimize\n",
      "infection Patient rights - education and employment MS affects people mainly between the ages of 20\n",
      "and 40 years, generally the most productive time of their lives, especially with regards to children\n",
      "and career. Some people are diagnosed early in their career, and it is important that they are not\n",
      "discriminated against on the basis of the diagnosis. In early stages of the disease, disability may\n",
      "not be visible but symptoms such as fatigue and cognitive dysfunction can be disabling. People with\n",
      "MS may encounter a lack of understanding about the severity of the disability, and they may face the\n",
      "dilemma of when to disclose the condition to their employers. Consequently, concerns regarding\n",
      "employment can become a great source of stress Maintaining a place in education and the workforce\n",
      "has numerous financial, physical and psychological benefits. It is therefore important that people\n",
      "with MS receive appropriate information and support to assist them to stay in education and\n",
      "employment for as long as possible. It is important to highlight to patients that they are not\n",
      "obliged to disclose their illness to everyone at work, according to local laws, but as MS can affect\n",
      "physical, cognitive and emotional functioning, they are likely to need support in the workplace as\n",
      "the disease progresses. The specific diagnosis does not need to be disclosed to employers at\n",
      "interview (although disability will usually need to be). In the UK, for example, employers must be\n",
      "informed of the diagnosis if employment is in the armed forces, on a plane or on a ship. Some\n",
      "employment contracts specifically request disclosure of diagnoses like MS, as most employers need to\n",
      "know about specific disabilities in order to adhere to the relevant laws in their country Employers\n",
      "have an obligation to aid employees as much as possible to remain in employment. Functional capacity\n",
      "evaluation and neuropsychological testing can help determine the patient's limitations and strengths\n",
      "in relation to their condition to help plan for periods of disability. Even if there is little\n",
      "disability at the time of employment, employers will need to allow time off to recover from relapses\n",
      "or to attend hospital appointments. If 'reasonable adjustments' can be made to the workplace setting\n",
      "to enable the employee to continue working, in many countries the employer is required by law to\n",
      "make these. The nature of these adjustments will depend on the individual circumstances and what is\n",
      "considered 'reasonable' by both the employee and the employer. Such adjustments could include\n",
      "allowing the employee to work from home providing longer break periods providing ramps and\n",
      "wheelchair access transferring the employee to a role with fewer physical demands The provision of\n",
      "legislation designed to protect people with MS from discrimination, based on their disability,\n",
      "varies from country to country (see Useful resources). The primary carers in some countries may also\n",
      "be covered If a job involves driving, employers must be informed of the MS diagnosis. In the UK,\n",
      "people with a driving licence who have been diagnosed with MS must tell the Driver and Vehicle\n",
      "Licensing Agency (DVLA). In Australia, the relevant authority in each state must be informed. The\n",
      "driving authority may then contact the patient's doctor, and will decide whether they are suitable\n",
      "to drive on a case-by-case basis. In the USA, people with MS may need to be assessed by a member of\n",
      "the Association for Driver Rehabilitation Specialists. They will recommend no driving, adaptations\n",
      "to the car to assist driving or unrestricted driving, depending on the results of a full assessment\n",
      "including input from the medical team\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (80 tok):\n",
      "\n",
      "'s doctor, and will decide whether they are suitable to drive on a case-by-case basis. In the USA,\n",
      "people with MS may need to be assessed by a member of the Association for Driver Rehabilitation\n",
      "Specialists. They will recommend no driving, adaptations to the car to assist driving or\n",
      "unrestricted driving, depending on the results of a full assessment including input from the medical\n",
      "team\n",
      "\n",
      "Reference:\n",
      "Counseling can be helpful for all people with multiple sclerosis (MS): it will involve explaining\n",
      "the nature of the disease, the risks and benefits of therapy and the effect MS will have on all\n",
      "aspects of life, including career, family, travel and insurance. Common concerns raised by patients\n",
      "include life expectancy, heritability of the disease, long-term planning and effect of pregnancy.\n",
      "Healthcare teams need to stress the importance of overall health and wellness in MS given the known\n",
      "consequences of comorbidities in patients. A multidisciplinary team is important for the\n",
      "coordination of patient care, and comprises neurologists, primary care providers, specialist nurses,\n",
      "physician assistants, physiotherapists, speech and language therapists, occupational therapists,\n",
      "dietitians, social workers, psychologists and continence nurses. Advanced practice clinicians (APCs)\n",
      "are a reliable source of information about all aspects of the condition. They have an important role\n",
      "in helping patients recognize the signs and symptoms of relapse, providing practical advice on\n",
      "living with MS and providing a link with other services. Concerns about employment can become a\n",
      "great source of stress. Employers have an obligation to aid people with MS as much as possible to\n",
      "remain in employment. Functional capacity evaluation and neuropsychological testing can help\n",
      "determine a person's employability.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781912776238, 'ch9')\n",
      "Formulary considerations: supportive care biosimilars Many of the currently approved biosimilars are\n",
      "of interest to hematologists, oncologists and pharmacists specializing in those disciplines and are\n",
      "likely to feature strongly in formulary committee discussions. This and the following chapter\n",
      "summarize the important special issues that arose in approving these biosimilars, as discussed in\n",
      "European Public Assessment Reports (EPARs) and the US Food and Drug Administration (FDA) Oncology\n",
      "Drug Advisory Committee (ODAC) briefings and discussions. Three are supportive care growth factors -\n",
      "epoetin alfa, filgrastim and pegfilgrastim - which are almost identical to natural products the body\n",
      "makes. They are often used as replacement therapy or to augment the body's own response and are\n",
      "characterized by simple modes of action through one receptor-mediated pathway The second group of\n",
      "three are direct anti-cancer therapies: rituximab, trastuzumab and bevacizumab. These are monoclonal\n",
      "antibodies that bind to soluble or cell-surface proteins and block pathways or cells, often with\n",
      "multiple modes of action and toxicity Epoetin alfa Epoetin alfa is a 165-amino acid erythropoiesis-\n",
      "stimulating glycoprotein produced in mammalian cell culture using recombinant DNA technology. It is\n",
      "used for the treatment of patients with anemia associated with various clinical conditions,\n",
      "including chronic renal failure, and cytotoxic chemotherapy (Table 9.1). For several years, epoetin\n",
      "alfa accounted for the single greatest drug expenditure paid by the US Medicare system; in 2016, the\n",
      "global erythropoietin (EPO) drugs market size was valued at US$7.4 billion. Epoetin alfa had also\n",
      "been the subject of follow-on originator competition, in the form of epoetin beta, and the long-\n",
      "acting versions of each, darbepoetin and methoxy polyethylene glycol-epoetin beta (Micera),\n",
      "collectively known as erythropoiesis-stimulating agents (ESAs) The need for epoetin biosimilars is\n",
      "underlined by forecasts suggesting that the increasing incidence of cancer, chronic kidney disease,\n",
      "and anemia associated with HIV will drive annual growth of 11.5%. Market research data show\n",
      "biosimilar competition in Europe was associated with real price reductions of 51%, 53% and 66% in\n",
      "Norway, Slovakia and Portugal, respectively Recombinant human red cell growth factors were first\n",
      "approved in Europe in 2007 and the USA in 2018. However, three issues combined to undermine\n",
      "confidence in the potential safety of biosimilar epoetin Formulation changes, medicines handling and\n",
      "differences in injection device were associated with serious drug safety events Outbreaks of\n",
      "epoetin-associated pure red cell aplasia (PRCA; Table 9.2) followed formulation changes to reference\n",
      "epoetin alfa in Europe (Eprex) PRCA at increased rates was associated with epoetin beta - but in a\n",
      "key presentation to the European Medicines Agency (EMA) it was shown that 13 of the 16 cases had\n",
      "followed a brand switch between epoetin alfa and epoetin beta Outbreaks of PRCA in Thailand were\n",
      "associated with the use of intended-copy epoetins and illegal cross-border smuggling of epoetins\n",
      "(breaking the critical cold-chain for supply) (see pages 62-3) TABLE 9.2 Diagnostic criteria for\n",
      "epoetin-antibody-mediated PRCA Unexplained loss of drug effect and Anemia (Hb decreases by about 0.1\n",
      "g/dL/day) Low reticulocyte count (< 10 000/μL) Platelets and white blood cells are normal Bone\n",
      "marrow (strongly recommended) shows Normal cellularity Erythroblasts very rare (< 5%) Positive\n",
      "epoetin-antibody test and evidence of their neutralizing capacity Hb, hemoglobin; PRCA, pure red\n",
      "cell aplasia From Casadevall et al. 2014 Two cases of PRCA occurred in a proposed biosimilar epoetin\n",
      "trial - associated with drug aggregation triggered by tungsten fragments from fixing the syringe\n",
      "needle to the single-use glass syringe Epoetin was suggested to promote cancer growth The US FDA\n",
      "issued a Public Health Advisory and a clinical alert over the use of epoetins in cancer patients\n",
      "following a higher proportion of deaths in the epoetin arms of trials looking to expand the label\n",
      "into prevention of anemia associated with chemotherapy (which differs from treatment of established\n",
      "anemia) and as a sensitizer for curative radiation therapy. As a result, the label for treating\n",
      "anemia associated with cancer chemotherapy was 'black boxed' in the USA, and the EMA issued a drug\n",
      "alert and mandated a Risk Evaluation and Mitigation Strategy (REMS). The REMS required that patients\n",
      "be counseled of a risk of shortened overall survival and/or increased risk of tumor progression with\n",
      "ESAs before prescribing. The question of a potential unknown 'off-target' effect of epoetins on\n",
      "cancer growth was raised. A potential unknown mechanism of toxicity creates difficulties for\n",
      "biosimilars as there is, by definition, no analytic test that can be used to demonstrate\n",
      "comparability other than large-scale clinical data Changes in the manufacturing process of a\n",
      "reference ESA were shown to cause differences that could not be resolved through analytics alone\n",
      "Process changes to darbepoetin (hyperglycosylated long-acting epoetin alfa) resulted in analytic\n",
      "differences between what the EMA called 'darbepoetin alfa RB' and 'darbepoetin alfa HT' that\n",
      "required Phase I pharmacokinetics, Phase III efficacy/safety and Phase IV clinical confirmatory\n",
      "studies for continuing European approval. ,10 The US ODAC briefings, discussions and slide decks\n",
      "from the FDA meeting of 25 May 2017 provide the most comprehensive update of how these outstanding\n",
      "issues were resolved - and all are in the public domain and free to access. ,12 Immunogenicity. The\n",
      "immunogenicity of biosimilar epoetin was assessed for comparability in analytics and clinical\n",
      "confirmatory studies. This was supported by four large postmarketing studies with more than 4700\n",
      "patients and pharmacovigilance with a total estimated population exposure (in the oncology and\n",
      "nephrology indication between 18 December 2007 and 30 November 2013) of 54 554 947 patient-days with\n",
      "over 35 000 000 patient-days' experience in the oncology indication. Furthermore, in over 10 years\n",
      "of European experience with biosimilars there has been no approval for which comparable\n",
      "immunogenicity in regulatory studies has not predicted real-world outcomes For cancer chemotherapy.\n",
      "An updated meta-analysis of more than 60 randomized trials assessed for the REMS program showed that\n",
      "the association of poorer outcomes with epoetin was confined to off-label trials looking to extend\n",
      "approved indications rather than the core indication of treatment of symptomatic chemotherapy-\n",
      "induced anemia and avoidance of transfusion. The existence of a different safety profile between\n",
      "reference and biosimilar ESAs further to a potential unknown mechanism of toxicity was excluded\n",
      "through a population-based cohort study of more than 13 000 patients (8161 with chronic kidney\n",
      "disease [CKD] and 5309 in oncology); no differences in risk estimates for all-cause mortality, blood\n",
      "transfusion, major cardiovascular events (MACE) or blood dyscrasia (including PRCA) were found\n",
      "between patients on biosimilars or all originator epoetins or ESAs (Figure 9.1) As a result,\n",
      "biosimilar epoetin alfa Retacrit was approved by 14 votes to 1 and the FDA closed the REMS program\n",
      "for treating patients with anemia related to associated myelosuppressive chemotherapy Filgrastim and\n",
      "pegfilgrastim Filgrastim is a non-glycosylated recombinant human (rh) granulocyte colony-stimulating\n",
      "factor (G-CSF) made in bacterial cell culture; its indications in hematology and oncology are\n",
      "summarized in Table 9.3. It has one known target, the G-CSF receptor. In bone marrow, precursor\n",
      "G-CSF promotes maturation into mature neutrophils and stimulates their release into the circulation.\n",
      "It also acts on mature neutrophils to increase their phagocytic activity against infections The\n",
      "first recombinant G-CSF filgrastim was approved in 1991, and its value has been evolving ever since.\n",
      "Initial health technology assessments suggested low value because of high drug costs and no evidence\n",
      "for significant gain in overall survival. However, more recent meta-analyses of placebo-controlled\n",
      "randomized trial data showed overall survival gains of 3.2% (95% confidence interval 2.1-4.2%) from\n",
      "filgrastim support of cytotoxic chemotherapy In Europe, the competition from biosimilars had\n",
      "significantly reduced prices and increased access, with recorded price discounts of 62%, 61% and 57%\n",
      "in Romania, Slovakia and Slovenia, respectively. This explains the inclusion of filgrastim in the\n",
      "WHO Essential Drug List for cancer In contrast to epoetin alfa, G-CSF was a much more\n",
      "straightforward biosimilar to assess. The increase in mature neutrophils in the blood of healthy\n",
      "human volunteers is a sensitive pharmacodynamic marker for efficacy and a predictor of its effect on\n",
      "neutropenia. The probability of discovering a clinically meaningful difference between reference and\n",
      "biosimilar brands is likely to be greater in volunteers with normal bone marrow function than in\n",
      "cancer patients treated with cytotoxic chemotherapy and radiotherapy - this was seriously proposed\n",
      "as the confirmatory clinical study for a pegfilgrastim biosimilar to the US regulator by one\n",
      "biosimilar maker Serious toxicity of filgrastim is related to its mode of action - stimulated white\n",
      "cells cause events such as splenic enlargement, bone pain from marrow expansion, lung reactions from\n",
      "lymphocytic pulmonary infiltrates, skin infiltration causing itching and generalized allergic\n",
      "reactions, potentially causing capillary leak syndrome No clinically relevant neutralizing anti-drug\n",
      "antibody problems had been reported with the reference drug, which was important as this medication\n",
      "could be given to healthy bone marrow or stem cell donors. The US National Marrow Donor Program had\n",
      "reported no difference in the incidence of autoimmune diseases in healthy donors of peripheral blood\n",
      "stem cells exposed (n = 6768) and not exposed (n = 2726) to G-CSF Finally, brand switching was\n",
      "unlikely to be a clinical issue, as typical chemotherapy treatment courses last only 3-4 months.\n",
      "This contrasts strongly with ESAs in renal disease or biological anti-inflammatory drugs in\n",
      "rheumatoid disease, where treatment duration is measured in years The US ODAC discussed the\n",
      "significant supporting data for EP2006 (Zarxio, Sandoz) (see Figure 9.2 for examples of data\n",
      "considered). A month prior to the meeting, Pioneer trial data released at the annual meeting of the\n",
      "American Society of Hematology (ASH) showed no loss of efficacy when six sequential brand switches\n",
      "were applied to G-CSF-Zarxio and reference Neupogen during docetaxel (Taxotere), adriamycin and\n",
      "cyclophosphamide (TAC) chemotherapy in 218 patients with breast cancer. There had also been five\n",
      "confirmatory post-approval studies, with 1302 participants, of the European-approved version of\n",
      "biosimilar G-CSF (Zarzio), coupled with successful pharmacovigilance of approximately 4.5 million\n",
      "patient-days to June 2013. Data presented at the ODAC meeting, held 1 month after the ASH\n",
      "conference, also confirmed successful use of the G-CSF biosimilar for donor stem cell\n",
      "transplantation (subsequently summarized in the endorsement of biosimilars by the Working Group\n",
      "Medical of the World Marrow Donor Association). The ODAC unanimously approved the filgrastim\n",
      "biosimilar, Zarxio The Phase III Pioneer trial (EP06-302 in the ODAC documents) had a novel four-arm\n",
      "design (Table 9.4). Patient selection was typical for filgrastim use, supporting optimal dose\n",
      "density of chemotherapy in women with histologically proven breast cancer who were eligible for\n",
      "neoadjuvant or adjuvant treatment and who were given six cycles of TAC chemotherapy (docetaxel\n",
      "[Taxotere] at 75 mg/m, adriamycin at 50 mg/m and cyclophosphamide at 500 mg/m, all intravenously on\n",
      "day 1 of each 21-day cycle). Unlike a typical two-arm confirmatory clinical study, patients were\n",
      "randomized into four arms. Blood counts and toxicity could be compared between 192 patients split\n",
      "evenly into two groups on cycle 1. The first cycle of chemotherapy is typically the most sensitive\n",
      "to neutropenic fever, so this represents the best pharmacodynamic endpoint for discovering any\n",
      "clinical difference between the two versions of filgrastim. Over the full six cycles of the trial,\n",
      "there is a second potential comparison of efficacy and toxicity for both brands. This increases the\n",
      "total events studied, giving additional efficacy and safety data. The third comparison is between\n",
      "the 96 patients in arms 1 and 4 who remain on the same brand of filgrastim through chemotherapy and\n",
      "the 96 patients in arms 2 and 3, who switch brands on each alternate chemotherapy cycle; this\n",
      "explores whether brand switching leads to loss of efficacy or increased toxicity (especially\n",
      "immunogenicity), and anticipated the US regulator's requirement for clinical data to support a\n",
      "further label as an 'interchangeable biosimilar' Pegfilgrastim is filgrastim modified with the\n",
      "addition of polyethylene glycol (PEG). The addition of PEG more than doubles the molecular weight of\n",
      "filgrastim, and the repeating carbohydrate structure of PEG, H舑(O舑CH 舑CH) n 舑OH, means that PEG is\n",
      "itself a potentially highly variable mixture of many different-sized carbohydrate molecules. The\n",
      "increase in size means that renal clearance does not occur, prolonging the duration of action such\n",
      "that one dose of pegfilgrastim replaces seven or more doses of short-acting filgrastim. The relevant\n",
      "indications for pegfilgrastim are summarized in Table 9.5 Before any pegfilgrastim biosimilars were\n",
      "approved, several applications from manufacturers such as Sandoz, Apotex-Intas, Coherus Biosciences\n",
      "and Gedeon Richter had been initially rejected by regulators in Europe and the USA. While the detail\n",
      "of dialog between drug developers and regulators is secret, sufficient public discussion was\n",
      "available to suggest that the problems in assessment lay in the analytics of PEG and the variability\n",
      "of pharmacokinetic studies. In April 2017, the US FDA raised questions about the PEG accumulation\n",
      "reported in animal models. This is important, as PEG is used extensively in skin creams, toothpastes\n",
      "and as an anti-foaming agent in food and drink, as well as an excipient in many pharmaceutical\n",
      "products. In its meeting addressing the concern, the FDA discussed the pegylated factor IX clotting\n",
      "factor concentrate Rebinyn, indicated for use in hemophilia: 'throughout that meeting, FDA officials\n",
      "repeatedly pushed back on efforts to assert any general safety of PEG based on experience with other\n",
      "products and formulations.' Some reasons for delays and difficulties can be discovered from the\n",
      "European Public Assessment report (EPAR) and the FDA review letters (Center for Drug Evaluation and\n",
      "Research), although the latter are often heavily redacted. It seemed the speculation over the\n",
      "pharmacokinetic variability of a long-acting drug with multiple mechanisms for clearance was\n",
      "correct, as participant numbers were significantly higher than most biosimilars have required to\n",
      "date: for example, Sandoz performed two pharmacokinetic studies with 463 healthy participants for\n",
      "pegfilgrastim Ziextenzo (compared with just 112 participants in four pharmacokinetic studies for\n",
      "filgrastim Zarxio); Mylan required two pharmacokinetic studies with 256 healthy participants for the\n",
      "pegfilgrastim biosimilar Fulphila. These manufacturers also performed confirmatory efficacy and\n",
      "safety studies; Sandoz with three studies involving 682 patients in breast cancer chemotherapy while\n",
      "Mylan performed one confirmatory efficacy and safety study in breast cancer with 194 patients. ,25\n",
      "Late 2018 finally saw the approval of five biosimilar brands of pegfilgrastim in Europe: Fulphila\n",
      "(pegfilgrastim-jmbd, Mylan); Pelgraz (Accord); Pelmeg (Cinfa Biotech/Mundipharma); Udenyca\n",
      "(pegfilgrastim-cbqv, Coherus BioSciences); and Ziextenzo (Sandoz). In the same period, the USA\n",
      "approved Fulphila and Udenyca\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Pegfilgrastim has been approved by the US FDA as a Risk Evaluation and Mitigation Strategy (REMS).\n",
      "The REMS required that patients be counseled of a risk of shortened overall survival and/or\n",
      "increased risk of tumor progression with ESAs before prescribing. The question of a potential\n",
      "unknown 'off-target' effect of epoetins on cancer growth was raised. A potential unknown mechanism\n",
      "of toxicity creates difficulties for biosimilars, as discussed in European Public Assessment Reports\n",
      "(EPARs) and the US Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC)\n",
      "briefings and discussions. Three are supportive care growth factors - epoetin alfa, filgrastim and\n",
      "peg\n",
      "\n",
      "Reference:\n",
      "No biosimilar has been approved for which comparable immunogenicity in regulatory studies has not\n",
      "predicted real-world outcomes in more than 10 years of European experience. For epoetin, comparable\n",
      "composite outcomes were found in more than 13 000 patients treated with reference or biosimilar\n",
      "epoetins and erythropoiesis-stimulating agents, which reassured the regulator about the safety of\n",
      "biosimilar epoetin for symptomatic chemotherapy-induced anemia. The design of the four-arm Pioneer\n",
      "study allowed data collection for participants who switched from originator to biosimilar filgrastim\n",
      "or vice versa on each round of chemotherapy, in anticipation of regulatory requirements to\n",
      "demonstrate interchangeability.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9783318067095, 'ch4')\n",
      "Ethical principles and our responsibilities As more digital tools are deployed in health research\n",
      "and care settings, new questions emerge about how to use them responsibly and ethically. Anyone\n",
      "developing and/or testing a digital tool for use in disease prevention and treatment within the USA\n",
      "should be aware of the regulatory requirement to obtain institutional review board (IRB) approval\n",
      "prospectively when involving people as research participants The development of the IRB peer review\n",
      "process stemmed from egregious acts whereby researchers disregarded the rights and welfare of\n",
      "research participants. One example, known as the 'Tuskegee Study of Untreated Syphilis in the Negro\n",
      "Male', was an observational study of the natural progression of syphilis initiated by the Public\n",
      "Health Services in 1932. ,2 At that time, there was no treatment for syphilis; however, after\n",
      "penicillin was developed, the study participants were not treated and the study continued for nearly\n",
      "40 years. The National Research Act was passed in 1974; it involved creating a National Commission\n",
      "for the Protection of Human Subjects of Biomedical and Behavioral Research with a goal of preventing\n",
      "future atrocities. It was this Commission that required the formation of IRBs and also wrote the\n",
      "Belmont Report. Published in 1979, the Belmont Report describes three guiding principles of ethical\n",
      "biomedical and behavioral research: respect for persons, beneficence and justice As cybersecurity\n",
      "concerns increased with research involving information and communication technologies (ICT), the\n",
      "Department of Homeland Security developed the Menlo Report. Published in 2012, this Report adapted\n",
      "the ethical principles of the Belmont Report to ICT research and added a fourth principle - that of\n",
      "respect for the law and public interest, which focuses on transparence of potential conflicting\n",
      "interests and accountability of stakeholders Informed by guiding ethical principles, a federal\n",
      "policy for the protection of human subjects was published in 1991 and adopted by 15 federal agencies\n",
      "and institutes. The regulations speak to basic protections for human research participants in\n",
      "subpart A, known as the Common Rule. Additional subparts speak to protections for vulnerable\n",
      "populations, including children and prisoners Core principles Here, we describe the ethical\n",
      "principles and how the regulations and Common Rule are implemented in practice. The three core\n",
      "principles of biomedical ethics described in the Belmont Report are at the core of research ethics\n",
      "and should be carefully considered during the study design phase and ethics review process Respect\n",
      "for persons is demonstrated through the informed consent process, which occurs when a person is\n",
      "given the information needed to make a sound decision about whether to volunteer to willingly\n",
      "participate. How this information is conveyed is important because volunteering to be a research\n",
      "participant is different from, say, accepting terms of service (ToS) to access an app, or signing a\n",
      "consent form to obtain medical care. In the latter, a person will not be able to access the app if\n",
      "they do not accept the ToS nor will they receive medical care if they do not sign the medical\n",
      "consent form. Consent to participate in research is a choice that an individual can only make if\n",
      "presented with information in a setting conducive to good decision-making. There can be no coercive\n",
      "actions (exempli gratia high incentive payments, free services) that may compromise an individual's\n",
      "ability to volunteer. The informed consent process involves more than signing a form to document\n",
      "voluntary participation - it is the first of what may be many interactions between a participant and\n",
      "the research team and is part of developing a trusted relationship Technological literacy is another\n",
      "important consideration. For informed consent to be meaningful, participants will need to be 'tech-\n",
      "literate' enough to understand the specifics of how their data will be obtained and used. Likewise,\n",
      "concerns about privacy are often raised when discussing the passive and ubiquitous nature of the\n",
      "tools used in digital medicine. Attitudes and preferences also vary across generations, with older\n",
      "adults preferring more privacy control compared with teens and young adults Education. All these\n",
      "concerns suggest a need to better educate prospective participants - and yet, integrating these\n",
      "concepts into the consent process is not easy. Moving forward, this charge will require a commitment\n",
      "from the medical community to provide accessible public-facing educational modules. For example, one\n",
      "way to improve tech literacy might be to include a brief animation describing the difference between\n",
      "de-identification and anonymity when describing data-sharing practices, or an illustration of what\n",
      "it means to store data in a cloud. A participant may also think that if the study team has access to\n",
      "their health data in real time, 24/7, then that means someone is paying attention to them (which may\n",
      "not be the case). Clarifying these concepts is important and how best to do this will require\n",
      "experts in instructional design who can deliver creative educational content. One organization\n",
      "working to advance meaningful informed consent in digital health research is Sage Bionetworks; it\n",
      "has published a toolkit to assist researchers Beneficence is where the probability and magnitude of\n",
      "potential harms are weighed against the possible benefits to a participant, the people they\n",
      "represent and society. Determining risk of harm is a somewhat subjective process, yet worth breaking\n",
      "down. We need to consider potential sources of harm and try to quantify the likelihood of something\n",
      "going wrong as well as the consequences. For instance, if a technology collects and then transmits a\n",
      "study participant's location data to a publicly accessible or non-secure website, the likelihood of\n",
      "a loss of privacy is 100% for all users - yet the consequences will vary. For most people, these\n",
      "will be negligible, but for a domestic abuse survivor or undocumented migrant, the consequences\n",
      "might be severe. Thus, the same potential harm presents a low risk for most, but a high risk for\n",
      "some important groups Safeguarding data and managing data-sharing protocols are important\n",
      "considerations when applying the principle of beneficence, and researchers, IRBs and research\n",
      "participants need to think about carefully these. When using third-party commercial apps or\n",
      "measurement tools, it is critical that ToS and end user license agreements (EULAs) be reviewed to\n",
      "ensure they do not introduce unnecessary risks to the end user, be it a research participant or\n",
      "patient Harm. Other factors specific to risk assessment include the type of potential harm (exempli\n",
      "gratia physical, psychological, economic, social) as well as the duration and severity of harm to\n",
      "research participants. Research is inherently risky because we are learning something that is not\n",
      "yet known. Research participants are often told about risks as an odds ratio. For example, in\n",
      "studies that include a test for maximum oxygen uptake, participants are required to exercise to\n",
      "exhaustion. There is a 1 in 12 000 chance that a healthy individual doing this study will have a\n",
      "cardiac event that may lead to death. Because of this particular risk of harm, the research team can\n",
      "mitigate risk by having access to personnel and equipment used to treat a cardiac event. Having this\n",
      "information, an individual can decide whether they want to take that chance or not Validity and\n",
      "reliability. Within the domain of beneficence is the need for the digital measurement tools to be\n",
      "valid and reliable (see chapter 9). There is no potential benefit of knowledge gain if the study is\n",
      "poorly designed and the tools are not trustworthy. The old adage 'garbage in, garbage out' is a\n",
      "serious concern and one that must be addressed by doing the appropriate studies early to ensure the\n",
      "products, regardless of whether there is a medical claim, are safe and produce useful data Justice.\n",
      "The principle of justice focuses on the fair distribution of the benefits and burdens of research\n",
      "and recruitment protocols that are inclusive of those most likely to benefit from knowledge gained.\n",
      "With digital tools, we have the opportunity to reach a more diverse audience, including those in\n",
      "communities where health disparities are most prevalent. To do that requires that we design\n",
      "technologies that are accessible and, in some cases, culturally tailored. With that in mind,\n",
      "including end users in the development process who represent a wide cross-section of our society is\n",
      "one way we can be responsive to the principle of justice For example, in a study designed to\n",
      "increase physical activity in refugee women, the researcher decided to use a wrist-worn\n",
      "accelerometer to assess daily movement. The participants were given the sensor and shown how to use\n",
      "it. One week later, the researcher returned to gather the measurement tools and found that no data\n",
      "had been collected. Turns out a wrist-worn mobile technology was culturally unacceptable and drew\n",
      "unwanted attention to the women, so they did not wear it. This story sheds light on the fact that\n",
      "while digital tools should improve access to health research and healthcare, they can also\n",
      "perpetuate disparities and prevent access if not well designed and deployed\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Ethical principles and our responsibilities to protect human subjects.As more digital tools are\n",
      "deployed in health research and care settings, new questions emerge about how to use them\n",
      "responsibly and ethically. Anyone developing and/or testing a digital tool for use in disease\n",
      "prevention and treatment within the USA should be aware of the regulatory requirement to obtain\n",
      "institutional review board (IRB) approval prospectively when involving people as research\n",
      "participants.The development of the IRB peer review process stemmed from egregious acts whereby\n",
      "researchers disregarded the rights and welfare of research participants. One example, known as the\n",
      "'Tuskegee Study of Untreated Syphilis in the Negro Male', was an observational study of the natural\n",
      "progression of syphilis initiated by the Public Health Services in 1932\n",
      "\n",
      "Reference:\n",
      "The principles that guide the ethical conduct of biomedical and behavioral research include: respect\n",
      "for persons, beneficence, justice (Belmont Report) and respect for law and public interest (Menlo\n",
      "Report). Knowing how to apply ethical principles is a responsibility of all stakeholders involved in\n",
      "digital health research, including technologists, researchers and ethics review boards.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541178, 'ch_5')\n",
      "It is relatively easy to think of radiological or laboratory tests that could be performed after an\n",
      "initial history and physical examination has been completed. However, it is important to decide\n",
      "which, if any, of these tests will increase understanding of the patient's problem or result in a\n",
      "specific modification of therapy. As the specific pain generator of many low back pain disorders\n",
      "cannot be precisely characterized, the diagnostic limitations of modern, expensive technology must\n",
      "be acknowledged. However, the realities of modern clinical practice puts the physician under\n",
      "pressure from the patient or family to perform 'all the necessary tests', or from a medical insurer\n",
      "not to perform them. The practitioner may also feel compelled to do 'marginal' tests under\n",
      "medicolegal pressure. All these factors need to be considered as you evaluate patients with low back\n",
      "pain, beyond the information gathered during the office examination The main options for further\n",
      "investigations include electrodiagnostic studies laboratory studies A significant proportion of\n",
      "individuals over 40 years of age show some disc space narrowing, osteophytic spurs or age-related\n",
      "spondylolisthesis on radiographs without corresponding clinical symptoms. Identifiable radiographic\n",
      "abnormalities are found in almost all individuals over 50 years old. In addition, disc bulges,\n",
      "protrusions or extrusions at one or more vertebral levels have been identified by magnetic resonance\n",
      "imaging (MRI) in over 50% of asymptomatic subjects. In geriatric patients, there are often many more\n",
      "abnormalities than necessary to explain the acute, subacute or chronic painful disorder. Further,\n",
      "when remission of symptoms occurs, in all likelihood the osseous abnormalities will remain\n",
      "unchanged, and even the soft-tissue disc-related lesions will still be present or little changed.\n",
      "This has been confirmed in several studies comparing a baseline MRI taken for a symptomatic disc\n",
      "derangement with a follow-up MRI These radiographic anatomic abnormalities are often perceived as\n",
      "the causal factor of low back pain in a wide range of individuals, but in view of these statistics -\n",
      "and as pain cannot be assessed from a radiological scan of any type - it is worthwhile considering\n",
      "when, and even if, the various radiological techniques are appropriate Radiography. In a young and\n",
      "otherwise healthy patient who develops acute low back pain after bending and lifting or during\n",
      "vigorous sport activities, radiography or other radiological assessment serves only to reassure the\n",
      "anxious patient or family, and possibly establish a baseline for future comparisons. A plain\n",
      "roentgenogram has little likelihood of discovering a significant abnormality. Guidelines based on an\n",
      "evidence-based review of the available literature advise a minimum deferment of 4-6 weeks before\n",
      "radiological testing to allow for the usual spontaneous improvement to occur In contrast,\n",
      "significant radiographic findings are highly likely in a patient with low back pain and/or sciatica\n",
      "and evidence of any 'red flags' (see Table 1.1), or in a patient who has suffered a severe trauma\n",
      "capable of causing a fracture. Osteoporotic fractures can potentially occur in any part of the\n",
      "spine, though they are typically found in the thoracic and upper lumbar spine. They are less common\n",
      "in the lower lumbar vertebrae and rare in the cervical spine. A concern for low back pain associated\n",
      "with osteoporotic-associated lower lumbar fracture (L3-L5) is a possible neoplasm, either benign or\n",
      "malignant. Tumors may occur anywhere in the spine. Benign growths tend to affect the posterior\n",
      "vertebral elements, while malignant tumors preferentially involve the vertebral bodies. Vertebral\n",
      "tumors can be confused with atraumatic or traumatic osteoporotic fractures (Figure 2.1), but are\n",
      "most likely in patients with night pain or in those whose pain is not relieved by rest. Bony lesions\n",
      "in these patients may be better characterized by a computed tomography (CT) scan If reactive\n",
      "arthritis or a related spondyloarthropathy is suspected, radiography of the pelvis will usually\n",
      "easily identify characteristic sacroiliitis and spinal longitudinal ligament ossifications (bamboo\n",
      "spine if severe). Tilting of the X-ray tube by about 30° (Ferguson view) can identify erosion and\n",
      "pseudo-widening of the sacroiliac joints that may be overlooked by plain anterioposterior views of\n",
      "the pelvis. These sacroiliac lesions may be identified earlier, however, and monitored more easily\n",
      "during observation by MRI evaluation Flexion and extension view radiographs can very occasionally\n",
      "assist in assessing abnormal intervertebral motion and instability in cases of spondylolisthesis or\n",
      "scoliosis (Figure 2.2) Magnetic resonance imaging. Soft tissue abnormalities, disc protrusions,\n",
      "infections, cysts, tumors and facet joint arthritis are characterized better by MRI than by plain\n",
      "radiography, though the findings may still be poorly correlated with clinical findings. MRI is more\n",
      "sensitive than either radiography or CT in identifying abnormalities in patients with low back pain,\n",
      "and does not carry the risk of X-ray exposure, but it is more expensive and more likely to provide\n",
      "worrisome detail rather than useful information In general, many MRI investigations requested are\n",
      "unnecessary. A simple rule for the physician is that an MRI should be carried out if malignancy is a\n",
      "major concern or if surgical intervention is likely to be required. Indeed, given that discogenic\n",
      "disease often settles spontaneously, it is sometimes useful to ask the patient whether their\n",
      "symptoms warrant an operation. If not, a decision regarding an MRI can be postponed Gadolinium-\n",
      "enhanced MRI utilizes a contrast material to detect spinal tissues with increased blood flow. For\n",
      "example, gadolinium-enhanced MRI can detect radiculitis (nerve root inflammation), where there is a\n",
      "high correlation between marked nerve root enhancement and clinically relevant radiculopathy in\n",
      "patients with or without disc protrusions. The technique can also detect tumors and infections, and\n",
      "evaluate postoperative complications. However, mass effects on the thecal sac indicative of epidural\n",
      "fibrosis have been observed in more than 50% of patients tested in the immediate postoperative\n",
      "period. The enhancement may persist for a year or more in successfully operated patients without any\n",
      "demonstrable, associated symptoms. With the possible exception of radiculopathy, these gadolinium-\n",
      "enhanced MRI scans reveal far more abnormalities than can be meaningfully interpreted Descriptions\n",
      "of disc abnormalities are very important in patients with low back pain, but the nomenclature used\n",
      "to describe disc modifications is not standardized. The absence of consistent definitions can lead\n",
      "to overinterpretation of the significance of the anatomic changes noted in the radiological reports.\n",
      "The descriptions given below represent a partial consensus of the terminology used in these reports\n",
      "Disc degeneration is associated with a reduction in disc height and blackening of the nucleus\n",
      "pulposus on T2-weighted images (Figure 2.3) Annular fissures are a possible marker of clinically\n",
      "significant disc pathology. They can be located concentrically, transversely or radially. Nuclear\n",
      "material displacing annular fibers and stimulating in-growth of blood vessels and sensory nerves in\n",
      "the annulus may be a possible mechanism for ongoing discogenic pain A generalized disc bulge is a\n",
      "small circumferential overlap of the annulus over the vertebral endplates, and may be associated\n",
      "with slight disc space narrowing. However, a finding of an abnormal disc bulge may be coincidental\n",
      "and is not indicative of pathology A disc protrusion is an asymmetrically located focal outpouching\n",
      "that extends into the spinal canal, but maintains intact some of the outer annular fibers A disc\n",
      "extrusion extends through the annulus and the posterior longitudinal ligament into the epidural\n",
      "space. It may remain partly attached to the outer annulus or be positioned fully in the epidural\n",
      "space, when it is termed a sequestration. Identification of a sequestration is important if surgery\n",
      "under microscopic visualization is undertaken Disc herniation is a non-specific term commonly used\n",
      "to describe protrusion or extrusion Not all disc protrusions or extrusions require surgical\n",
      "intervention for clinical improvement. Large protrusions and extrusions are often associated with\n",
      "hematoma formation and edema, and thereby have a favorable prognosis for spontaneous resolution\n",
      "Other radiological investigations. Less commonly used radiological procedures include CT scans, bone\n",
      "scans and myelography Computed tomography utilizes X-rays to create cross-sectional images of the\n",
      "bony structures of the spine. CT also can assess soft tissues including fat, nerve roots, ligaments\n",
      "and discs. CT is most appropriate for individuals who cannot undergo MRI evaluation because of\n",
      "pacemakers, metal vessel clips or claustrophobia. CT is particularly illuminating in spinal stenosis\n",
      "patients who require three-dimensional reformatting of their spines to help guide their spinal\n",
      "surgeon in planning the appropriate extent of spinal decompression Radiation exposure from CT scans\n",
      "is an increasing concern. An increased risk of developing cancer is related to the duration of\n",
      "ionizing radiation exposure as used in CT scans. Therefore, CT should be used only if it is the sole\n",
      "test that will provide the diagnosis Bone scans involve the injection of a small amount of\n",
      "radioactive material intravenously. The material travels to bony structures with increased blood\n",
      "flow throughout the skeleton. These areas with increased activity indicative of an inflammatory\n",
      "process look dark on the scan. The presence of these areas is not indicative of a specific\n",
      "diagnosis, but is very sensitive in identifying spinal fractures. Additional evaluation is required\n",
      "to identify the potential cause of the increased activity. Again, there is concern regarding the\n",
      "degree of radiation exposure from bone scans, as well as the financial cost Myelography utilizes a\n",
      "water-soluble contrast agent. It is used only occasionally to assess the extent and precise location\n",
      "of a multilevel spinal stenosis Interventional radiology represents a new frontier in radiology.\n",
      "Several procedures are now utilized with increasing frequency by orthopedists, neurosurgeons and\n",
      "specialized intervention radiologists. These include selective nerve blocks, facet injections,\n",
      "epidural injections and percutaneous lumbar discectomies Discography is the injection of a\n",
      "radiopaque substance under fluoroscopic guidance into the intradiscal space. Intradiscal contrast\n",
      "injections have been used as a diagnostic tool for disc-related pathologies for over 35 years, but\n",
      "the technique is associated with a high rate of both false-positive and false-negative findings. In\n",
      "a geriatric population and for patients with chronic pain, the specificity is only about 20%. The\n",
      "ability of patients to localize a specific disc derangement by pain-provoking stimulations during\n",
      "discography, and to relate the provoked pain to their symptoms, is also unreliable. The lack of\n",
      "correlation between this provocative test and clinical findings, and the potential for disc damage\n",
      "resulting in rapidly progressive disc degeneration, means that discography is rarely performed\n",
      "Electrodiagnostic studies When clinical testing for neurological defects is normal or equivocal, or\n",
      "when the radiological findings present too few or too many abnormalities to identify specifically\n",
      "the source of the neural abnormality, electrodiagnostic testing may add greater specificity. It can\n",
      "be particularly useful for distinguishing a unilateral distal peripheral neuropathy or entrapment\n",
      "from a disc-related nerve root impingement, or polyneuropathy from spinal stenosis. Although\n",
      "electrodiagnostic testing can confirm the presence of a nerve root lesion, it cannot indicate the\n",
      "precise level of the nerve root compression Electrodiagnostic testing consists of sensory nerve\n",
      "conduction studies - sensory evoked potentials (SEPs) and sensory F-wave latencies - and\n",
      "electromyography (EMG), which may be used singly or in combination Sensory evoked potentials measure\n",
      "sensory nerve conduction, which is most commonly affected by compression of nerve roots Sensory\n",
      "F-wave latency is mainly used to assess motor nerve functioning, but has slightly less sensitivity\n",
      "and no greater precision than EMG in determining nerve root compression levels. F-wave stimulation\n",
      "of the peroneal nerve is primarily conducted via the L5 and S1 nerve roots by the tibial nerve. The\n",
      "F-wave is generated by leg muscle stimulations transmitted via the nerve root to the anterior horn\n",
      "cells and then orthodromically to be recorded in the leg muscles Electromyography is the most\n",
      "sensitive electrodiagnostic method for detecting nerve root lesions, with precision reported as high\n",
      "as 78%. Nonetheless, the precision of EMG in one study of patients with clinical and radiographic\n",
      "(CT) findings of nerve root compression was as low as 20% when the EMG was correlated with surgical\n",
      "findings. It is also important to note that 'benign' fibrillations (the EMG marker for denervation)\n",
      "can be seen in normal subjects. Thus, the interpretation of EMG abnormality is examiner dependent,\n",
      "and the skill of the electrodiagnostician can be the crucial variable in interpretation of the test\n",
      "findings Indications for electrodiagnostic studies. Electrodiagnostic studies are not required for\n",
      "patients with low back pain of any severity if there is no subjective or objective evidence of nerve\n",
      "root impingement manifested by hypesthesia, asymmetric hypoactive reflexes, incontinence, sexual\n",
      "dysfunction or muscle weakness Assuming that access to a competent electrodiagnostic consultant is\n",
      "available, electrodiagnostic studies are needed when any of the above manifestations are present,\n",
      "but are not readily explained by the physical or radiological findings the patient cannot cooperate\n",
      "in the examination because of psychological or pharmacological (medication, sedation) problems there\n",
      "is more than one apparent cause of the neurological findings (diabetic neuropathy, prior sciatica,\n",
      "traumatic peripheral neuropathy, spinal cord injury or tumor, myopathy, dystrophy or multiple\n",
      "sclerosis, among others) It should be remembered, however, that for most low back pain syndromes, a\n",
      "careful history and examination and radiological studies will provide the necessary information for\n",
      "starting appropriate conservative therapies, or for considering surgical intervention, even without\n",
      "electrodiagnostic testing Laboratory testing For the most part, with the exception of patients with\n",
      "'red flags' (see Table 1.1), laboratory testing for patients with low back pain disorders is of\n",
      "little value. Laboratory tests are indicated when a malignancy or infection is suspected. Blood\n",
      "tests are also indicated to identify the potential causes of vertebral osteoporotic fractures.\n",
      "Additionally, an HLA-B27 test and determination of erythrocyte sedimentation rate (ESR) may help to\n",
      "confirm a suspected diagnosis of spondyloarthropathy. Laboratory tests are most useful if medical\n",
      "complications such as renal and hepatic diseases, diabetes or drug sensitivities are suspected or\n",
      "have previously been confirmed. The most common indication for blood and urine laboratory testing is\n",
      "to monitor tolerance of pharmacological therapies and their potential side effects\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "X-ray exposure, but it is more expensive and more likely to provide worrisome detail rather than\n",
      "useful information about the patient's condition.In general, many MRI investigations requested are\n",
      "unnecessary. A simple rule for the physician is that an MRI should be carried out if malignancy is a\n",
      "major concern or if surgical intervention is likely to be required. Indeed, given that discogenic\n",
      "disease often settles spontaneously, it is sometimes useful to ask the patient whether their\n",
      "symptoms warrant an operation. If not, a decision regarding an MRI can be postponed until the\n",
      "patient is able to make an informed decision about their condition.Gadolinium-enhanced MRI utilizes\n",
      "a contrast material to detect spinal tissues with increased blood flow. For example, gadolinium-\n",
      "\n",
      "Reference:\n",
      "Identifiable radiographic abnormalities such as disc degeneration, disc protrusions and osteophytes\n",
      "are common in individuals over 40 years of age and almost universal in those over 50, but without\n",
      "corresponding clinical findings. In geriatric patients, radiographic evidence of spinal degeneration\n",
      "is commonplace but may not be a source of back pain. In addition, geriatric radiographic\n",
      "abnormalities tend to persist after a patient goes into remission. In individuals over the age of\n",
      "50, radiographic evaluation has a greater likelihood of identifying a tumor, osteoporotic fracture,\n",
      "infection or severe spinal stenosis. MRI is the most sensitive radiographic technique to identify\n",
      "anatomic alterations of the spinal elements. Discography is a relatively unreliable method of\n",
      "determining the locus of disc symptomatology, with numerous false positives. When CT/MRI and the\n",
      "examination do not define the pathology, electromyography (EMG) may be helpful, but at best this has\n",
      "less than 80% accuracy in detecting a nerve root lesion. Laboratory tests usually are not needed for\n",
      "acute low back pain unless 'red flags' are present, or for patient monitoring to avoid potential\n",
      "hematologic, hepatic or renal drug-related complications.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797662, 'ch02')\n",
      "Pathology and biology The histological types of primary carcinoma that occur in the bladder are\n",
      "shown in Table 2.1 Urothelial cancer (UC; Figure 2.1) is derived from the transitional epithelium.\n",
      "It accounts for almost 90% of the bladder cancers that occur in industrialized countries such as the\n",
      "USA and the UK, and most discussion of bladder cancer relates to this type. Such tumors may be\n",
      "papillary (confined to the urothelium or lamina propria) (70-75%) or solid and invasive (20-25%)\n",
      "Carcinoma in situ (CIS) is an additional and important type seen in about 10% of cases (sometimes as\n",
      "secondary CIS associated with papillary UC). CIS is a flat, intraepithelial, high-grade carcinoma,\n",
      "often with increased numbers of mitotic structures. In approximately half of all cases, CIS occurs\n",
      "as one or more de novo lesions (primary CIS), while in the remainder it occurs in association with\n",
      "either papillary or solid tumors (secondary CIS). Coexistent CIS and papillary non-muscle-invasive\n",
      "bladder cancer confers a worse prognosis than papillary disease alone UC can coexist with elements\n",
      "of squamous and glandular differentiation. The classification of the tumor depends on the dominant\n",
      "histological type An important development has been the identification of a common stem cell of\n",
      "origin in xenograft and cell culture studies. This stem cell type has features of UC as well as\n",
      "showing squamous and glandular differentiation within individual tumor cells. This may explain why\n",
      "metastases with variant histology (exempli gratia as squamous cell carcinoma or adenocarcinoma) are\n",
      "seen in patients with pure UC primary tumors Squamous cell carcinoma has a nodular, infiltrative\n",
      "growth pattern and is usually invasive. It accounts for 5-10% of bladder cancers in the USA and UK.\n",
      "Historically, squamous cell carcinoma accounted for up to 70% of bladder cancers in areas where\n",
      "schistosomiasis is endemic, such as Egypt (see page 12), whereas contemporary data suggest that UC\n",
      "is now the predominant histology in Egypt as the prevalence of schistosomiasis has decreased.\n",
      "Squamous cell carcinoma is also associated with chronic infection or inflammation, such as that due\n",
      "to indwelling suprapubic catheters Adenocarcinoma is rare, accounting for about 2% of bladder\n",
      "cancers. Approximately 30-35% of adenocarcinomas are derived from the urachus and classically appear\n",
      "as a solid, invasive-appearing tumor in the dome of the bladder. (The urachus is the remnant of the\n",
      "embryonic cavity, the allantois; it usually forms a fibrous cord connecting the bladder to the\n",
      "umbilicus.) The remainder of adenocarcinomas are associated with bladder exstrophy or are non-\n",
      "urachal in origin Adenocarcinomas are usually solitary, high grade and ulcerative. They can be\n",
      "difficult to distinguish histologically from adenocarcinomas of the colon or rectum, and clinical\n",
      "determination of the source is often difficult. Any bladder adenocarcinoma may be mucin-producing.\n",
      "Many patients with adenocarcinoma have poor prognosis because the tumor is already at an advanced\n",
      "stage at diagnosis. Urachal adenocarcinomas present as invasive tumors often visible on the dome of\n",
      "the bladder and tend to be asymptomatic until late in the disease course, since they arise in a\n",
      "minimally functional part of the bladder. Surgical therapy is closed partial cystectomy\n",
      "Micropapillary cancer (Figure 2.2) is a particularly aggressive form of high-grade UC and is\n",
      "associated with a high risk of early muscle invasion and metastasis. Lymphovascular invasion is seen\n",
      "in more than 50% of cases. Amplification of human Her2 and/or increased HER2 protein expression has\n",
      "been reported with this variant and the proportion of the tumor that is micropapillary may correlate\n",
      "with outcome Small-cell neuroendocrine bladder cancer is similar to the more common small-cell\n",
      "cancer of the lung. This histological pattern is associated with rapid growth and early metastasis,\n",
      "and may occur as a pure variant or mixed with typical UC. These tumors typically stain positive for\n",
      "chromogranin A (which can also be measured in the peripheral blood) and synaptophysin (Figure 2.3).\n",
      "The cells have a high nucleus-to-cytoplasm ratio, and grow in sheets or nests of cells. This variant\n",
      "should be distinguished from undifferentiated UC, which is the least differentiated of the UCs\n",
      "Sarcomatoid bladder cancer is a rare variant, accounting for 0.3% of cases. It contains morphologic\n",
      "features of epithelial elements expressing cytokeratin (which may be urothelial, squamous,\n",
      "neuroendocrine or adenocarcinoma) and malignant mesenchymal 'sarcoma' elements (leiomyosarcoma,\n",
      "chondrosarcoma, rhabdomyosarcoma, liposarcoma). It may be associated with past exposure to\n",
      "cyclophosphamide or radiation Lymphoepithelial-like bladder cancer accounts for 0.4-1.3% of bladder\n",
      "cancers. Morphologically, it resembles nasopharyngeal lymphoepithelioma, with syncytial sheets of\n",
      "undifferentiated tumor cells with minimal cytoplasm, prominent nucleoli, many mitoses and the\n",
      "presence of lymphocytes and reactive cells, including histiocytes, eosinophils and plasma cells. It\n",
      "does not stain for Epstein-Barr virus markers, distinguishing it from certain lymphomas.\n",
      "Immunohistochemical diagnosis includes identification of both lymphocyte and epithelial cell markers\n",
      "Plasmacytoid urothelial cancer, as the name suggests, resembles lymphoma or plasmacytoma. About 3%\n",
      "of bladder cancers contain this variant. Immunohistochemistry demonstrates expression of epithelial\n",
      "markers such as cytokeratins or epithelial membrane antigen, and plasma cell markers such as CD138.\n",
      "Expression of GATA3 can be useful to distinguish these lesions from plasmacytomas, particularly in\n",
      "the metastatic setting when the epithelial component might be missed Nested variant urothelial\n",
      "cancer is also rare, accounting for 0.3% of invasive cancers. It can be aggressive despite a\n",
      "relatively innocuous cellular morphology. Cells are usually only mildly atypical, although the deep\n",
      "interface with the stroma may show irregularity and infiltration, with more atypical cellular\n",
      "features at greater depth and evidence of retraction artifact. Nested variant is not associated with\n",
      "overlying CIS, and cannot be classified as high grade 'Field changes' of a probable premalignant\n",
      "nature are often found in association with bladder cancer, and range from atypia to mild or severe\n",
      "dysplasia. The term refers to the concept that the entire tissue is abnormal at some genetic level,\n",
      "even if there is no macroscopic evidence of disease. The recognition of such changes is important in\n",
      "determining the risk of recurrence and progression. Normal transitional epithelium has a superficial\n",
      "layer of large, flat umbrella cells, beneath which are 3-7 layers of regular cells (Figure 2.1a).\n",
      "These lie above a basement membrane that separates the mucosa from the underlying lamina propria.\n",
      "The World Health Organization (WHO) has recently reclassified urothelial neoplasms and recognizes\n",
      "hyperplasia as well as four types of atypia. These include dysplasia (low-grade intraurothelial\n",
      "neoplasia) and CIS (high-grade intraurothelial neoplasia, formerly classified as severe dysplasia).\n",
      "Atypia indicates the presence of an increased number of cell layers, with loss of polarity of a\n",
      "still-intact umbrella layer. Dysplasia refers to an increase in the size of nuclei that are basally\n",
      "located and exhibit loss of polarity but the cell layers are not increased in number Staging and\n",
      "grading Accurate staging and grading of UC is essential, as it determines the most effective\n",
      "treatment. Understaging and undergrading may lead to inappropriate decisions about primary treatment\n",
      "modalities or perioperative systemic chemotherapy, increasing the risk of adverse outcomes for the\n",
      "patient Staging. The tumor-nodes-metastases (TNM) staging of the American Joint Committee on Cancer\n",
      "is the system most widely used for bladder cancer, illustrated in Figures 2.4 and 2.5 The seventh\n",
      "edition of the TNM staging (introduced in January 2010) was replaced by the eighth edition from 1\n",
      "January 2018 (available from cancerstaging.org). The only material change in the staging of bladder\n",
      "cancer is the addition of invasion of seminal vesicles to the T4a stage Grading. The current grading\n",
      "system, introduced in 2004, stratifies bladder cancer into low and high grade, replacing the WHO\n",
      "1973 three-grade system, as illustrated in Figure 2.6. Approximately 40% of former grade 2 tumors\n",
      "are reclassified as high grade in the current system, and grade 1 tumors are stratified into\n",
      "papillary urothelial neoplasm of low malignant potential or low-grade cancers. Many pathologists\n",
      "will report according to both systems when a high-grade cancer has features of former grade 2, in\n",
      "order to give the treating physician greater understanding of the potential behavior of a particular\n",
      "cancer (Figure 2.6) Molecular phenotype Genomic profiling of non-muscle-invasive and muscle-invasive\n",
      "bladder cancer reveals substantial molecular diversity, suggesting that bladder cancer comprises\n",
      "multiple genomic phenotypes, reflecting the clinical and histological heterogeneity. Low-grade\n",
      "tumors are characterized by a high frequency of FGFR3 mutations, 9q loss of heterozygosity and\n",
      "alterations in PIK3CA and STAG2. High-grade cancers have frequent cell cycle alterations, with\n",
      "mutations in p53 and RB1 and 9p and 9q loss of heterozygosity. The Cancer Genome Atlas (TCGA)\n",
      "project recently reported comprehensive integrated genomic analysis of 412 muscle-invasive cancers.\n",
      "These cancers were characterized by a high somatic mutation rate, similar to that in lung cancer and\n",
      "melanoma, with 58 significantly mutated genes. The high mutation load was associated with APOBEC\n",
      "(apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) mutagenesis, and survival\n",
      "probability was associated with overall mutation burden and neoantigen load Analysis of mRNA\n",
      "expression clustering identified five luminal and basal subtypes, similar to those seen in breast\n",
      "cancer, that stratify outcomes, suggesting different strategies for the use of neoadjuvant\n",
      "chemotherapy, immunotherapy and targeted therapies. Several groups have described similar\n",
      "stratification using expression-based subtyping, as summarized in a recent review Molecular\n",
      "profiling is likely to provide useful information about the biology of bladder cancer, including\n",
      "clues to treatment selection and sequencing. For example, responses to atezolizumab are most common\n",
      "in TCGA cluster II cancers; potential driver mutations in FGFR3 are most common in TCGA cluster I;\n",
      "microsatellite instability, DNA repair defects and altered expression of specific genes such as\n",
      "APLNR loss may be important for response to immunotherapy. However, this information has yet to lead\n",
      "to changes in clinical practice Patterns of recurrence and spread Most Ta and T1 tumors can be\n",
      "completely resected cystoscopically and treated successfully without cystectomy. In approximately\n",
      "40% of patients with such tumors there is no recurrence after resection of the primary tumor;\n",
      "however, this subgroup of patients cannot be initially distinguished with certainty from those whose\n",
      "tumors will recur (stratification criteria are shown in Table 5.2). Among patients who do experience\n",
      "recurrence, 20-30% of tumors (usually high grade) may progress to a higher stage. Thus, vigilant\n",
      "surveillance is necessary, as is judicious use of intravesical agents (see page 45) to decrease the\n",
      "likelihood of recurrence and progression in high-risk patients (exempli gratia those with large or\n",
      "multiple tumors, high-grade tumors, or Ta or T1 tumors with associated CIS) Most recurrences occur\n",
      "in the bladder, although 4-10% of patients develop a tumor in the upper urinary tract (ureter and\n",
      "renal pelvis) and a similar number may develop a tumor in the prostatic urethra, which is lined by\n",
      "urothelium similar to that of the bladder. Conversely, 40% of patients who have an initial UC of the\n",
      "renal pelvis will subsequently develop a UC in the bladder CIS has a high rate of progression to\n",
      "muscle-invasive disease if it is not eradicated with intravesical therapy, usually bacillus\n",
      "Calmette-Guérin (BCG) On average, muscle-invasive disease is associated with regional lymph node\n",
      "metastases in 25% of patients. Hematogenous spread is most common to the lungs, liver and bones, and\n",
      "these are the most common sites of progression in patients who experience recurrence after\n",
      "definitive loco-regional therapy with radical cystectomy or chemoradiation. Distant metastases are\n",
      "present at initial diagnosis in 5% of patients Mortality due to UC is directly related to the\n",
      "pathological stage and grade of bladder cancer (Table 2.2). For those with low-grade Ta and T1\n",
      "tumors, 5-year disease-specific survival should exceed 95%, whereas reported 5-year survival may be\n",
      "as low as 50% for patients with high-grade T1 cancers or CIS without adjuvant therapy. Intravesical\n",
      "immunotherapy with BCG is associated with frequent complete response at 6 months following induction\n",
      "and initial maintenance, and 5-year survival should approach 80-85%. For patients with T2/T3aN0M0\n",
      "disease, the 5-year survival rate is 60-70%, despite radical cystectomy. Progression is often due to\n",
      "subclinical 'micrometastases' that were present at the time of cystectomy but were not\n",
      "radiologically detectable. In patients who experience disease progression, this occurs within 2-3\n",
      "years of cystectomy in about 80% of cases. Patients who are treated with peri-operative chemotherapy\n",
      "may experience late relapse (after 5 years), with metastases often occurring at unusual sites,\n",
      "including the central nervous system or intraperitoneally, presenting as bowel obstruction The\n",
      "5-year survival rate in patients with T4 UC is only 10-20%; survival of those with T4a disease is at\n",
      "the upper end of this range. The 5-year survival rate for individuals with para-aortic or distant\n",
      "lymph node metastases but no visceral disease is 20-40%, although occasionally cure is possible with\n",
      "chemotherapy. For patients with visceral metastases the 5-year survival rate, irrespective of\n",
      "chemotherapy, is only about 10%. Independent adverse prognostic determinants for patients with\n",
      "metastatic disease include poor performance status, weight loss and raised liver function test\n",
      "results and alkaline phosphatase levels. Sex and age are not independent prognostic variables\n",
      "Patients with adenocarcinoma or squamous carcinoma have a 5-year survival rate of more than 50%\n",
      "following radical cystectomy, provided that the lymph nodes are negative. Urachal adenocarcinoma is\n",
      "treated with partial cystectomy, and adjuvant therapy for locally advanced cancers is similar to the\n",
      "treatment for colon cancer. However, if metastases are present, the prognosis is grim (see page 62).\n",
      "Patients with small-cell neuroendocrine carcinoma may be cured with systemic chemotherapy and\n",
      "cystectomy or radiation if there is no residual small-cell carcinoma. The prognosis for bladder\n",
      "sarcomas is determined by histological subtype, extent of disease and performance status\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "al'sarcoma' elements (leiomyosarcoma, chondrosarcoma, rhabdomyosarcoma and liposarcoma). It may be\n",
      "associated with past exposure to cyclophosphamide or radiation, and may be associated with\n",
      "metastatic malignancies, such as bladder cancer, bladder cancer, and bladder\n",
      "cancer.Lymphoepithelial-like bladder cancer accounts for 0.4-1.3% of bladder cancers.\n",
      "Morphologically, it resembles nasopharyngeal lymphoepithelioma, with syncytial sheets of\n",
      "undifferentiated tumor cells with minimal cytoplasm, prominent nucleoli, many mitoses and the\n",
      "presence\n",
      "\n",
      "Reference:\n",
      "Urothelial carcinoma is the predominant histology of bladder cancer. Variant histology is common and\n",
      "is usually seen as a mixed pattern with conventional urothelial cancer. Low-grade non-muscle-\n",
      "invasive bladder tumors may recur but progression to muscle invasion occurs in < 5% of cases. High-\n",
      "grade non-muscle-invasive bladder cancer will progress if not adequately treated with resection and\n",
      "intravesical therapy. Carcinoma in situ, whether primary or associated with Ta or T1 papillary\n",
      "tumor, is a high-risk cancer. Up to 30% of patients with high-grade non-muscle-invasive tumors and\n",
      "up to 70% with muscle-invasive disease may die of bladder cancer.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781912776696, 'hh-5')\n",
      "Time to-event endpoints Many endpoints in oncology are time-to-event endpoints, id est the time\n",
      "until a specified event of interest occurs, such as death or the occurrence of disease. Typical\n",
      "examples are overall survival (OS) progression-free survival (PFS) disease-free survival (DFS)\n",
      "duration of response Often these endpoints are measured from the time the participants in a study\n",
      "are randomized into treatment groups. This is the case for OS, PFS and DFS, but duration of response\n",
      "is measured from the time point at which partial or complete response is achieved to disease\n",
      "progression Time-to-event analyses include information from both censored and uncensored\n",
      "observations (see below) Censoring is a common feature of all time-to-event endpoints. A subject's\n",
      "time to event is said to be censored if the event of interest (death, disease progression etc.) has\n",
      "not occurred in that patient by the end of the follow-up period. A censored observation can also\n",
      "occur when information on a subject is known for a limited duration only (exempli gratia if a person\n",
      "drops out of a study before the end and is lost to follow-up) Example 1. In a study with a fixed\n",
      "24-month follow-up, a subject who is still alive at month 24 will provide a censored value for OS.\n",
      "The OS for such a subject is considered to be at least as long as the duration of the study Example\n",
      "2. At the time of an interim analysis, some subjects may not have been in the study for very long.\n",
      "These subjects will provide censored values if the event of interest has not occurred during the\n",
      "limited follow-up Kaplan-Meier curves Kaplan-Meier curves provide a way of plotting the distribution\n",
      "of a time-to-event endpoint. In Figure 2.1 the dashed line shows that at 24 months' follow-up the\n",
      "estimated survival probability is 54% Kaplan-Meier survival curves are often used to compare the\n",
      "data between two groups of subjects. Figure 2.2 shows Kaplan-Meier curves for OS in a randomized\n",
      "study of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast\n",
      "cancer treated either with or without trastuzumab. The Kaplan-Meier curve steps down at time points\n",
      "at which deaths occur, while censored observations are denoted by notches on the curve. In this\n",
      "study, the follow-up period ranged from 3 months to 74 months The Kaplan-Meier curve plots the\n",
      "probability of being event free over time, with these probabilities being estimated from the data in\n",
      "the study. Note that the curve for patients who received trastuzumab is consistently above the curve\n",
      "for those who did not receive trastuzumab, indicating a higher survival probability in that group\n",
      "For the rest of this chapter, for simplicity, let us assume that the event of interest is death\n",
      "Median overall survival. The Kaplan-Meier curves can be used to obtain median survival times (Figure\n",
      "2.3). The median survival time is the time point at which 50% of patients are estimated to be alive,\n",
      "and this can be found by drawing a horizontal line at the 50% line on the y -axis Hazard ratio\n",
      "Treatment differences are usually expressed as a hazard ratio (HR). In order to understand what an\n",
      "HR is, it is necessary to understand what a hazard rate is Hazard rate is the probability that a\n",
      "subject will die within a given time interval among the subjects alive in that treatment group at\n",
      "the start of that interval. In a group of 1000 patients, suppose 10 die in month 1, 15 die in month\n",
      "2 and 12 die in month 3 The hazard rate for month 1 = 10/1000 The hazard rate for month 2 = 15/990\n",
      "The hazard rate for month 3 = 12/975 and so on In practice, hazard rates can be calculated for\n",
      "smaller time periods and the hazard rate can be considered as a continuous measure Figure 2.4 shows\n",
      "two hypothetical hazard rate curves that correspond to active (treatment) and control (placebo)\n",
      "groups. Although hazard rates are never constant over time, in many cases (at least approximately)\n",
      "the ratio of the hazard rates, id est the hazard rate for an event in the active group divided by\n",
      "the hazard rate for an event in the control group, will be approximately constant. When this is the\n",
      "case it is assigned a single value, the HR What do hazard ratios tell us? By convention, the hazard\n",
      "rate for the active group is divided by the hazard rate for the control group HR = 1: the hazard\n",
      "rate in the active group is identical to that in the control group HR < 1: the hazard rate in the\n",
      "active group is, on average, lower than that in the control group HR > 1: the hazard rate in the\n",
      "active group is, on average, higher than that in the control group It should be noted that the HR is\n",
      "a relative measure of effect between the treatment arms and does not give any information on the\n",
      "performance of the active treatment in absolute terms The HR for OS in the previous breast cancer\n",
      "example is 0.502 with a 95% confidence interval (CI) of 0.390 to 0.755. This means that the hazard\n",
      "rate for death for the patients who received trastuzumab was reduced by 49.8%, on average, over time\n",
      "compared with those who did not receive trastuzumab HRs are usually given in conjunction with a 95%\n",
      "CI, id est the range of values that is likely to include the true population value (see Chapter 1).\n",
      "This range can be used to measure the precision of the HR; the narrower the CI the more precise the\n",
      "HR estimate Logrank test While it is possible to compare the survival of patients in two different\n",
      "study groups at any given point in time on the Kaplan-Meier curves, this does not provide a\n",
      "comparison of the total survival experience of the two groups. The logrank test provides a p -value\n",
      "for the total survival experience of the treatment group compared with the control group by\n",
      "comparing the two Kaplan-Meier curves. It takes the whole follow-up period into account A\n",
      "significant p -value (probabilities lower than 0.05 are usually considered significant, see Chapter\n",
      "1) shows that there is sufficient evidence to declare treatment differences The logrank test\n",
      "implicitly assumes that the HR is fairly constant. This will not always be the case and when the HR\n",
      "is not constant the logrank test does not provide an appropriate comparison of the Kaplan-Meier\n",
      "curves. Note that a constant HR manifests itself as Kaplan-Meier curves that start together at time\n",
      "zero but then separate out gradually with time (see Figure 2.2 for an example where this is the\n",
      "case) Restricted mean survival time The restricted mean survival time (RMST) is the mean survival\n",
      "time up to a certain point of follow-up, for example 10 years. If the RMST is 7 years, this means\n",
      "that the mean survival time in the 10-year period from the point of randomization is estimated to be\n",
      "7 years. It is a straightforward statistic to calculate as it is the area under the curve (AUC) up\n",
      "to year 10 (Figure 2.5) Life expectancy difference. If the HR does not provide a suitable measure of\n",
      "treatment effect, for example if the HR is not constant, then a treatment difference can be\n",
      "expressed as the difference between two RMST values (the active RMST minus the control RMST). This\n",
      "is calculated as the area between the two Kaplan-Meier curves (Figure 2.6) Adjusting for baseline\n",
      "imbalances The principle of randomizing participants to two (or sometimes more) groups in a study is\n",
      "that, in theory, the two treatment groups are balanced in terms of factors that may influence the\n",
      "outcome. Any differences in outcomes between the two groups are then attributed to the difference in\n",
      "treatments. However, there are numerous baseline variables that may have a bearing on the outcome\n",
      "(exempli gratia patient characteristics such as age, sex and ethnicity, or stage or grade of tumor).\n",
      "It is therefore usually of value to adjust the analysis to account for any such differences in\n",
      "baseline factors There are two ways to make such adjustments for time-to-event endpoints. The\n",
      "stratified logrank test can adjust for a small number of factors, while the Cox proportional hazards\n",
      "model is a modeling approach that can, in theory, adjust for many more factors simultaneously\n",
      "Prognostic and predictive factors. It is becoming fairly standard practice in the oncology setting\n",
      "to use the term prognostic to refer to a baseline factor that affects the endpoint in some way. A\n",
      "prognostic factor can provide information on clinical outcome independent of therapy. In Table 2.1,\n",
      "the Eastern Cooperative Oncology Group (ECOG) performance status is prognostic for death - the\n",
      "greater the ECOG score, the poorer the prognosis The term predictive is used for a baseline factor\n",
      "that influences the magnitude of difference the treatment makes to the endpoint. In Table 2.2, ECOG\n",
      "performance status is both prognostic and predictive. As in Table 2.1, the higher the ECOG score,\n",
      "the poorer the prognosis. In addition, the lower the ECOG score, the greater the benefit of the\n",
      "treatment over placebo In the HER2-positive breast cancer study discussed previously, an analysis\n",
      "was carried out to see if the location of metastases had any influence on the outcome (Figure 2.7).\n",
      "In this example, visceral metastases is clearly a predictive factor for survival\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Time to-event endpoints are usually expressed as a hazard ratio (HR).Many endpoints in oncology are\n",
      "time-to-event endpoints, id est the time until a specified event of interest occurs, such as death\n",
      "or the occurrence of disease. Typical examples are:death-overall survival (OS) and death-\n",
      "progression-free survival (PFS) and death-disease-free survival (DFS) (Figure 2.1). The HR is\n",
      "measured as the time until death (duration of response) of the patient.Often these endpoints are\n",
      "measured from the time the participants in a study are randomized into treatment groups. This is the\n",
      "case for OS, PFS and DFS, but\n",
      "\n",
      "Reference:\n",
      "Typical examples of time-to-event analyses include overall survival, progression-free survival,\n",
      "disease-free survival and duration of response. Censoring is a common feature of all time-to-event\n",
      "endpoints. Observations are said to be censored when the event of interest has not happened by the\n",
      "end of the follow-up period. Kaplan-Meier curves plot the probability of being event free over time.\n",
      "The curves from different treatment groups can be plotted against each other to show the differences\n",
      "in outcome. Treatment differences are often expressed as a hazard ratio (HR). An HR of 1 means the\n",
      "risk in the two groups is the same. An HR > 1 means that the risk in one group is higher than the\n",
      "other, and vice versa. The logrank test compares the two Kaplan-Meier curves to provide a p -value\n",
      "for the difference in total survival experience of the two groups. This test can only be used if\n",
      "there is a constant HR, id est the Kaplan-Meier curves start together at time zero and then separate\n",
      "out gradually with time. If the HR is not constant, a treatment difference can be expressed as the\n",
      "difference between two restricted mean survival times (which is equal to the area between two\n",
      "Kaplan-Meier curves). The stratified logrank and the Cox proportional hazards model are two ways of\n",
      "adjusting for imbalances in baseline factors. Baseline variables that are important prognostic\n",
      "factors (exempli gratia age and stage of disease) should be taken into consideration in all\n",
      "statistical analyses, even in randomized studies.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9783318066241, 'ch8')\n",
      "8 Management of other local complications Abdominal compartment syndrome Intra-abdominal pressure\n",
      "(IAP) is the steady-state pressure maintained within the abdominal cavity. IAP is measured in\n",
      "patients in an intensive care unit setting via an indwelling urinary catheter (transbladder\n",
      "technique) and is usually 5-7 mmHg in critically ill adults Moderate-to-severe acute pancreatitis\n",
      "(AP) is associated with increased vascular permeability (resulting in interstitial edema),\n",
      "retroperitoneal inflammation and collections and with paralytic ileus; it may also be associated\n",
      "with ascites. These factors increase IAP and may result in intra-abdominal hypertension (a sustained\n",
      "IAP >= 12 mmHg). Patients with intra-abdominal hypertension are at risk of developing organ failure\n",
      "(OF), as increased pressure in the abdomen may collapse blood vessels, resulting in gastrointestinal\n",
      "tract and kidney ischemia and decreased cardiac output. OF can also arise from organ compression\n",
      "resulting, for example, in difficulties expanding the lungs and decreased chest compliance.\n",
      "Abdominal compartment syndrome (ACS) is defined as a sustained increase in IAP (> 20 mmHg) that is\n",
      "associated with new organ dysfunction/failure Very few randomized controlled trials (RCTs) have\n",
      "compared aggressive versus conservative treatment of pancreatitis-associated ACS. In critically ill\n",
      "patients with increasing IAP, some non-invasive measures may be useful. Nasogastric and colonic\n",
      "decompression via tubes should be used in cases of gastric or colonic dilatation. Neuromuscular\n",
      "blockade with artificial respiration decreases IAP by reducing abdominal musculature tone and\n",
      "increasing abdominal compliance. In cases of refractory intra-abdominal hypertension, and\n",
      "particularly in cases of organ dysfunction, percutaneous drainage of collections may decrease IAP\n",
      "and improve outcomes. Patients with no response can undergo abdominal decompression surgery (Figure\n",
      "8.1). The indications, timing and technique for decompression surgery are a matter of debate, as\n",
      "there is no good-quality evidence from RCTs. Currently, midline laparostomy seems to be the method\n",
      "of choice Disconnected tail syndrome A healthy pancreas produces 1-4 liters of pancreatic juice per\n",
      "day. central pancreatic gland necrosis may result in complete transection of the main pancreatic\n",
      "duct, causing pancreatic juice to leak into the retroperitoneum (Figure 8.2). This complication is\n",
      "called disconnected tail syndrome (DTS) or disconnected pancreatic duct syndrome. DTS is associated\n",
      "with bulky retroperitoneal collections, pancreatic ascites, pancreatic pleural effusion (Figure 8.3)\n",
      "and/or pancreaticocutaneous fistula. Fluid obtained from these complications is typically rich in\n",
      "amylase and lipase There are no good-quality RCTs addressing the management of DTS. The role of\n",
      "enteral or parenteral nutrition is unclear. Octreotide, a somatostatin analog that inhibits the\n",
      "secretion of pancreatic juice, does not seem to be useful in managing DTS. Endoscopic retrograde\n",
      "cholangiopancreatography together with pancreatic stenting of the disrupted duct will do little to\n",
      "solve the problem, as a necrotic collection is present and may become infected. In general, the\n",
      "recommended management is endoscopic transmural drainage of the necrotic collection if indicated\n",
      "(see page 67) using a long-term double-pigtail plastic stent. As discussed in Chapter 7 (see page\n",
      "69), lumen-apposing metal stents (LAMS) left in place for more than 4 weeks may be associated with\n",
      "bleeding or may become embedded. However, in cases of DTS, early removal of the stent will probably\n",
      "result in the collection relapsing, so the use of LAMS in this kind of endoscopic drainage is\n",
      "discouraged. In cases of partial main pancreatic duct disruption, retrospective data suggest that\n",
      "bridging of the disruption using a transpapillary pancreatic stent may improve outcomes. In\n",
      "refractory cases, distal pancreatectomy or pancreaticojejunostomy may be needed Pancreatic\n",
      "pseudoaneurysm AP results in local inflammation and may expose surrounding tissues to pancreatic\n",
      "enzymes. Visceral arteries exposed to inflammation and/or enzymes may develop arteritis and\n",
      "destruction of the vessel wall. The debilitated vessel wall may dilate to form a pseudoaneurysm, or\n",
      "the vessel may bleed into a pre-existing surrounding collection meaning that the wall of the\n",
      "collection becomes the new wall of the pseudoaneurysm (Figure 8.4). The most commonly affected\n",
      "vessels are the intrapancreatic arteries and the splenic and gastroduodenal artery. The eventual\n",
      "rupture of a pseudoaneurysm into the retroperitoneum, abdomen, gut, bile duct (hemobilia) or\n",
      "pancreatic duct (hemosuccus pancreaticus) may be associated with massive bleeding. A case series\n",
      "study found that, overall, 20% of patients diagnosed with a pseudoaneurysm due to acute or chronic\n",
      "pancreatitis died The treatment of choice for pseudoaneurysms due to acute or chronic pancreatitis\n",
      "is selective angiographic embolization. Percutaneous thrombin injection has been described as an\n",
      "alternative to angiography. Surgery is reserved for refractory cases Peripancreatic vein thrombosis\n",
      "Retrospective data suggest that almost 2% of patients overall, and almost 20% of patients with\n",
      "severe AP, develop peripancreatic vein thrombosis (PVT). A prospective study found that 3% of\n",
      "patients overall and 9% of patients with moderate-to-severe AP experienced this complication. PVT is\n",
      "associated with local complications of AP because inflammation and local compression of the veins\n",
      "are important prothrombotic factors. PVT is usually an incidental finding on a contrast-enhanced CT\n",
      "scan performed to look for or control pancreatic or peripancreatic collections and necrosis. The\n",
      "splenic vein is the most frequently affected (in 70% of cases), followed by the portal and superior\n",
      "mesenteric veins. Left-sided portal hypertension with collateral circulation on imaging is a\n",
      "frequent consequence of PVT if it is not promptly treated, but bleeding due to esophageal or gastric\n",
      "varices is uncommon, affecting 2.2% of patients with PVT according to a retrospective study Although\n",
      "there are no RCTs and the benefits have not been properly studied, patients with acute PVT\n",
      "(diagnosed during index admission) should begin anticoagulation therapy unless contraindicated,\n",
      "although a retrospective study reported no differences in recanalization. The authors' personal\n",
      "experience suggests that early anticoagulation, first (during hospital stay) with low-molecular-\n",
      "weight heparin and then oral anticoagulation for 3-6 months, is safe and may be effective in solving\n",
      "the thrombosis and avoiding left-sided portal hypertension. Patients with well-established PVT\n",
      "(exempli gratia PVT diagnosed in an ambulatory control CT scan after discharge, and showing\n",
      "collateral circulation) will show little response to anticoagulation\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "8 Management of other local complications of acute or chronic pancreatitis (ACS) is not\n",
      "recommended.Abdominal compartment syndrome (ACS) or acute pancreatitis (PVT) is a complication of\n",
      "acute and chronic pancreatitis. The treatment of choice for pseudoaneurysms due to chronic\n",
      "pancreatitis is selective angiographic embolization. Percutaneous thrombin injection has been\n",
      "described as an alternative to angiography. Surgery is reserved for refractory cases of acute\n",
      "pancreatitis.Peripancreatic vein thrombosis (PVT) may be associated with acute\n",
      "pancreatitis.Retrospective data suggest that almost 2% of patients overall, and almost 20% of\n",
      "patients with severe AP, develop\n",
      "\n",
      "Reference:\n",
      "Abdominal compartment syndrome (ACS) is defined as a sustained intra-abdominal pressure > 20 mmHg\n",
      "that is associated with new organ dysfunction/failure. When non-invasive measures fail in ACS,\n",
      "neuromuscular blockade with artificial respiration, percutaneous drainage or, finally, decompressive\n",
      "surgery may be indicated. Disconnected tail syndrome may be associated with bulky retroperitoneal\n",
      "collections, pancreatic ascites, pancreatic pleural effusion and/or pancreaticocutaneous fistula. If\n",
      "indicated, the treatment of choice for disconnected tail syndrome is long-term double-pigtail\n",
      "plastic stent drainage with or without transpapillary main pancreatic duct stenting. A pancreatic\n",
      "pseudoaneurysm should be treated with selective angiographic embolization. Although bleeding varices\n",
      "are uncommon, peripancreatic vein thrombosis should be diagnosed during the index hospital admission\n",
      "and patients should receive prompt anticoagulation therapy.\n",
      "\n",
      "####################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print_examples([\n",
    "    'allenai/led-base-16384'],\n",
    "    df_train)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "fSqOx7kdMoNJ"
   },
   "source": [
    "##### Print Val Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 7134,
     "status": "ok",
     "timestamp": 1610617100643,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "f7k8RzJgMoNK",
    "outputId": "34bc6750-7383-42d4-8a7a-f30b9e35a3bb",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(9781910797471, 'ch02')\n",
      "Pathophysiology and clinical stages Advances in the management of heart failure (HF) over the past\n",
      "20 years have been informed by a better understanding of its pathophysiology. There are few\n",
      "situations in cardiology where treatment has been as closely linked to an appreciation of the\n",
      "underlying science Vicious cycle of heart failure. HF is a disease of inappropriate adaptation to\n",
      "injury. The body has a limited range of compensatory responses to circulatory impairment, mainly\n",
      "vasoconstriction and sodium and water retention (see below). In general, however, these adjustments\n",
      "to hypovolemia are poorly suited to pump failure, and increases in the preload and afterload of the\n",
      "failing heart lead to worsening HF (Figure 2.1) Neurohormonal pathways activated in HF include the\n",
      "sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS) and the\n",
      "natriuretic peptide (NP) system. They play a significant role in the pathophysiology of HF, and\n",
      "pharmacological interventions have been developed accordingly (see Chapter 7) Sympathetic nervous\n",
      "system. Sympathetic activation of the adrenergic system leads to vasoconstriction, which increases\n",
      "the resistance to blood flow and helps to maintain arterial pressure in the early stages of HF when\n",
      "cardiac output is reduced. However, vasoconstriction also increases the afterload on the heart,\n",
      "leading to a worsening of HF (see Figure 2.1) Renin-angiotensin-aldosterone system. Enhanced\n",
      "sympathetic outflow also activates the RAAS (Figure 2.2). Renin release from the kidneys causes\n",
      "increased formation of angiotensin I from angiotensinogen and, via the action of angiotensin-\n",
      "converting enzyme (ACE), angiotensin II. Angiotensin II causes systemic vasoconstriction and acts on\n",
      "the adrenal cortex to produce aldosterone, leading to sodium and water retention. In addition,\n",
      "aldosterone (which may be released even in the setting of ACE inhibition) contributes to myocardial\n",
      "and vascular fibrosis. Sympathetic stimulation also releases antidiuretic hormone, which leads to\n",
      "retention of free water and contributes to dilutional hyponatremia Natriuretic peptide system. The\n",
      "natriuretic peptide family consists of A (atrial) and B (brain) type natriuretic peptides (ANP and\n",
      "BNP), which are produced by cardiomyocytes in response to atrial and ventricular stretch, and C type\n",
      "natriuretic peptide, which is secreted by endothelial and renal cells. NPs, mainly BNP, lead to\n",
      "increased sodium excretion and vasodilation, especially in the early phases of HF. BNP also has\n",
      "anti-remodeling properties. The biological action of BNP is mediated through membrane-bound\n",
      "natriuretic peptide receptors (NPRs) and the peptide is degraded by neutral endopeptidase (including\n",
      "neprilysin). It is postulated that HF is a state of relative BNP deficiency caused by both lack of\n",
      "biologically active peptide and resistance at a receptor level. In end-stage HF, the peptides may\n",
      "not be released because of myocyte loss Other pathways also reflect an inappropriate response to\n",
      "injury. Cytokine release is increased in HF, leading to a variety of consequences including\n",
      "apoptosis. The role of these as contributors to the progression of HF, rather than a correlate, is\n",
      "debated. Certainly, the failure of tumor necrosis factor (TNF) inhibitors to improve outcome argues\n",
      "against a causative role Remodeling of the myocardium. Global and local responses to maladaptive\n",
      "stimuli lead to myocardial remodeling, namely increased myocardial volume and mass and a net loss of\n",
      "myocytes. The heart has the ability to change the force of contraction, and therefore stroke volume,\n",
      "in response to changes in venous return (the Frank-Starling mechanism). A reduction in stroke volume\n",
      "due to myocardial injury can be overcome by left ventricular (LV) enlargement. This is not a\n",
      "response that can keep occurring indefinitely - eventually a loss of LV function will occur due to\n",
      "reduced interaction between contractile elements, caused by their separation LV hypertrophy (LVH)\n",
      "maintains wall stress as the LV enlarges. However, it is also eventually maladaptive as the\n",
      "hypertrophied myocardium exceeds the growth of its blood supply Autonomic reflexes. The increase of\n",
      "sympathetic tone associated with HF leads to disturbance of the autonomic reflexes. Persistent\n",
      "elevation of the heart rate is maladaptive in the ventricle: disturbances of LV relaxation are\n",
      "common, so the shortening of diastole that occurs with tachycardia (the duration of systole remains\n",
      "stable) is not well tolerated Insulin resistance is an important metabolic sequel to HF. It\n",
      "contributes to the disturbance of myocyte energy metabolism, leading to the description of the\n",
      "failing heart as 'an engine out of fuel'. Causes of insulin resistance include the underlying\n",
      "etiologies of HF (central obesity, diabetes mellitus) and loss of skeletal muscle (see below)\n",
      "Peripheral vasoconstriction, as described above, symptomatically may contribute to cold sensitivity\n",
      "Loss of skeletal muscle is an important manifestation of HF, reflecting inactivity, consequences of\n",
      "circulating substances such as tumor growth factor (TGF)-beta and reduced cardiac output. In its\n",
      "most advanced manifestation, loss of skeletal muscle may lead to cachexia. The consequences of this\n",
      "process include contributions to insulin resistance as well as loss of the skeletal muscle\n",
      "circulatory bed. The loss of this vasculature represents an additional decrement in the amount of\n",
      "vasculature that can undergo vasodilation (and therefore unload the LV) Cardiorenal interactions.\n",
      "Reduced renal perfusion in HF (due to reduced stroke volume and vasoconstriction) is an important\n",
      "contributor to sodium and fluid overload. The exact links between cardiac and renal function have\n",
      "yet to be resolved. More marked disturbances of renal function, leading to coexisting renal failure,\n",
      "may also occur and pose problems for volume control Clinical stages and functional classes The\n",
      "clinical syndrome of HF represents the final manifestation of advanced disease. Although progress\n",
      "has been made in the management of this entity, the greatest hope of avoiding the adverse outcome of\n",
      "HF is to intervene at an earlier subclinical stage, when there is more likelihood of reversing the\n",
      "process. The American Cardiology Association (ACC)/American Heart Association (AHA) guidelines\n",
      "divide progression of the disease into four preclinical and clinical stages (Table 2.1) It is\n",
      "important to distinguish these from functional classes, as described in the New York Heart\n",
      "Association (NYHA) classification system, which is based on severity of symptoms and exercise\n",
      "capacity and can be used to assess response to treatment (see Table 2.1) ACC/AHA stages A and B are\n",
      "preclinical; these patients fall into NYHA functional class I. ACC/AHA stage C reflects patients\n",
      "with symptoms or signs of HF, so these patients may be classified functionally in any of the NYHA\n",
      "classes I to III. The functional status of patients in ACC/AHA class D (with marked symptoms and\n",
      "signs of HF) is usually limited (NYHA class II to IV) The association between functional class,\n",
      "cardiac function (LVEF) and prognosis is discussed in more detail in Chapter 9\n",
      "\n",
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Pathophysiology and clinical stages of heart failure (HHF)Advances in the management of heart\n",
      "failure (HF) over the past 20 years have been informed by a better understanding of its\n",
      "pathophysiology. There are few situations in cardiology where treatment has been as closely linked\n",
      "to an appreciation of the underlying science of the disease as there is in the clinical stages of HF\n",
      "(see Figure 2.1).Vicious cycle of heart failure. HF is a disease of inappropriate adaptation to\n",
      "injury. The body has a limited range of compensatory responses to circulatory impairment, mainly\n",
      "vasoconstriction and sodium and water retention (see below). In general, however, these adjustments\n",
      "to hypovolemia are poorly suited to pump failure, and\n",
      "\n",
      "Reference:\n",
      "Heart failure (HF) is a disease of response to injury, which is initially appropriate and becomes\n",
      "inappropriate. Inappropriate non-cardiac responses include activation of a variety of hormonal\n",
      "reflexes (vasoconstriction, and sodium and water retention). Reversal of these inappropriate\n",
      "responses is critical to the management of HF. Remodeling is a cardiac response that is initially\n",
      "appropriate and becomes inappropriate as the heart enlarges excessively and hypertrophies. Symptoms\n",
      "develop in HF as a result of a complex web of interactions, involving not only the heart, hormonal\n",
      "changes and skeletal muscle, but also the vasculature (especially the endothelium), lungs and other\n",
      "organs. In addition to the classification of HF by clinical manifestation (acute vs chronic,\n",
      "systolic vs diastolic), etiology and precipitants (addressed in other chapters), HF can be\n",
      "classified by clinical stage (the course of the disease) and functional class (functional status\n",
      "based on symptom severity and exercise capacity).\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541086, 'ch_5')\n",
      "Etiology and pathogenesis The origins of eating disorders are widely seen as a complex combination\n",
      "of biological and environmental factors. Various genetic, developmental, psychological, familial and\n",
      "social variables have been suggested as risk factors Biological factors Genetic factors. The current\n",
      "state of the genetics of eating disorders is that while there is familial clustering of these\n",
      "syndromes, it is not at all clear that they are in their entirety genetically transmitted disorders.\n",
      "Whatever the genetic component to each one of them, it seems to be stronger for anorexia than\n",
      "bulimia. And granting even that, the current literature supports a polygenetic transmission of risk\n",
      "which needs substantial accumulation of environmental risk to have disorders come to the fore The\n",
      "most potent risk factor for eating disorders is female gender (see Chapter 2). This association is\n",
      "likely to reflect biological as well as psychosocial factors Family studies indicate that first-\n",
      "degree relatives of patients with anorexia have an increased prevalence of eating disorders (Table\n",
      "3.1), and that first-degree relatives of patients with bulimia or binge-eating disorder appear to be\n",
      "at increased risk of eating disorders, mood disorders and substance abuse. Twin studies of anorexia\n",
      "and bulimia suggest there is approximately a 50-80% genetic contribution to liability accounted for\n",
      "by additive genetic factors Candidate gene studies have initially focused on the serotonergic and\n",
      "other neurotransmitter system genes involved in bodyweight regulation, with hardly any unequivocally\n",
      "confirmed findings. Systematic genome-wide linkage scans based on families with at least two\n",
      "individuals with an eating disorder revealed initial linkage regions on chromosomes 1, 3, 4\n",
      "(anorexia) and 10p (bulimia). Ongoing international collaborations are working at pooling cases and\n",
      "using newer forms of analysis such as genome-wide associations Similar to other complex disorders,\n",
      "the eating disorders are likely to have a polygenic etiology, each gene having a relatively small\n",
      "effect Physiological factors. Both high and low premorbid body mass index (BMI) may predispose to\n",
      "anorexia. Being overweight or obese (with a high BMI) is a risk factor because of the likelihood of\n",
      "dieting, while low BMI may characterize individuals who are already prodromally ill with anorexia\n",
      "but who have not yet reached the weight criteria for definitive diagnosis Childhood obesity is a\n",
      "risk factor for bulimia and binge-eating disorder. A pear-shaped body and relatively high amounts of\n",
      "body fat may also predispose to eating disorders. People with one or both of these characteristics\n",
      "may have fat deposits that are hard to move by normal dieting; this may lead to the adoption of\n",
      "extreme weight-control measures Hormonal and neurohormonal influences. The study of the neurobiology\n",
      "of eating disorders has demonstrated large hormonal and neurohormonal differences in adult and late-\n",
      "adolescent patients who are acutely ill. Levels of histidyl-proline diketopiperazine, a hormone that\n",
      "is involved in the induction of satiety, are shown to increase as individuals with anorexia gain\n",
      "weight. This hormonal change may be responsible for premature feelings of satiation Around 20% of\n",
      "individuals with diabetes mellitus develop an eating disorder. Patients with type 1 diabetes are\n",
      "more likely to develop anorexia or bulimia, while patients with type 2 diabetes are more likely to\n",
      "develop binge-eating disorder. This suggests that insulin-glucagon systems may be involved in the\n",
      "predisposition for eating disorders. In addition, because energy requirements for weight\n",
      "rehabilitation and maintenance have been shown to differ in anorexic patients, bulimic patients and\n",
      "control populations, it is possible that premorbid metabolic abnormalities act as risk factors for\n",
      "eating disorders Neurobiological factors. Although many of the biological findings in eating\n",
      "disorders can be best understood as results of starvation and disturbed eating behaviors, some are\n",
      "causally linked as risk or maintaining factors. Considerable evidence suggests that altered brain\n",
      "serotonin function contributes to dysregulation of appetite, mood, and impulse control in eating\n",
      "disorders Dysregulation of the serotonergic system is usually secondary to weight changes. Studies\n",
      "have suggested that diminished serotonin activity may trigger some of the cognitive and mood\n",
      "disturbances associated with bulimia. The findings also indicated that chronic depletion of plasma\n",
      "tryptophan may be one of the mechanisms whereby persistent dieting can lead to the development of\n",
      "eating disorders in vulnerable individuals Brain monoamine function in eating disorders has been\n",
      "studied in both the acute state and after recovery, using specific ligands and positron emission\n",
      "tomography. There is a reduction in 5-HT 2A receptors and an increase in 5-HT 1A receptors in both\n",
      "the acute and recovered state, and dopamine receptors (DA) within the striatum are increased after\n",
      "recovery. Anomalies in the dopamine system could heighten food reward in bulimia and binge-eating\n",
      "disorder Abnormalities in both illness-related (food and body shape) and non-illness-related\n",
      "information processing have been detected with functional brain imaging studies. These functional\n",
      "abnormalities could maintain some of the eating disorder behaviors Environmental factors Family\n",
      "functioning. Historically, the role of dysfunctional styles of family interaction was put forward in\n",
      "theories of the development of eating disorders. Unfortunately and unfairly, this has led to some\n",
      "parenting styles being blamed for causing eating disorders in children. Still, the type of\n",
      "relationships that children and adolescents develop with food and body image, both healthy and\n",
      "unhealthy, is strongly influenced by parental attitudes toward eating, weight and body shape\n",
      "parental eating and weight-related behavior modeled in the home excessive parental control over a\n",
      "child's nutritional intake such that the child is unable to make independent food choices Perceived\n",
      "pressure to be thin, family criticism regarding weight, and maternal investment in slenderness\n",
      "predict eating disturbances in adolescents. Parents also have a strong influence over their\n",
      "children's internalization of the aesthetic ideal Anorexia. When compared with control families,\n",
      "those with an anorexic child tend to show more rigid organization, less clear interpersonal\n",
      "boundaries, and avoidance of open discussion of disagreements between parents and children. Patients\n",
      "with an eating disorder seem to be more likely than controls to experience attachment disturbances,\n",
      "such as insecure and anxious attachment styles and deactivating defensive strategies. Furthermore,\n",
      "families of individuals with anorexia tend to have a higher rate of parental eating disorders,\n",
      "family dieting and adverse comments from family members about eating, weight or appearance Bulimia.\n",
      "The families of individuals with bulimia are often more chaotic and conflicted. These families tend\n",
      "to have higher rates of alcoholism, substance misuse and affective disorders, as well as higher\n",
      "levels of perfectionism and a sense of ineffectiveness Societal influences. The preoccupation with\n",
      "body image and the drive to attain thinness that are characteristic of eating disorders relate to\n",
      "the idealized representation of the human figure within a given culture, and to the pressure to\n",
      "conform from peers and the media. In Western countries, the body dimensions of female cultural\n",
      "icons, such as fashion models and actresses, have become progressively thinner over the past\n",
      "decades, with a concomitant rise in disordered eating among women. Mounting evidence implicates the\n",
      "mass media in the promotion of body-image and eating disturbances, with the emphasis on dieting and\n",
      "other weight-control behaviors often targeted at women rather than men, thus paralleling the gender\n",
      "distribution of eating pathology. A longitudinal prospective study of ethnic Fijian adolescent girls\n",
      "demonstrated an increase in key indicators of disordered eating following novel prolonged television\n",
      "exposure to the aesthetic ideal The internalization of societal pressures has been shown to have a\n",
      "clear effect on body dissatisfaction and eating dysregulation in population samples. The first diet\n",
      "in adolescent girls is most frequently triggered by comparison with others' appearance and their own\n",
      "self-ideal. Societal influences and internalization of the thin ideal may lead directly to body\n",
      "dissatisfaction and unhealthy eating, or may be mediated by more general psychological processes\n",
      "such as intrapersonal (self-esteem, mood, personality) or interpersonal functioning and/or emotional\n",
      "regulation and coping Stressors and life events precipitate the onset of eating disorders in 70% of\n",
      "cases, and include parental neglect, abuse, indifference, loss and separation. In some studies, a\n",
      "high incidence of sexual abuse during childhood is reported by women with diagnosed eating\n",
      "disorders; rates of abuse are seemingly higher in bulimia than anorexia. In a US statewide\n",
      "representative sample, both sexual and physical abuse were strong independent risk factors for\n",
      "disordered eating in adolescent girls and boys. The nature of this relationship is difficult to\n",
      "assess because of differences in diagnostic criteria for abuse, a high base rate of sexual abuse in\n",
      "the general female population and a high rate of abuse associated with other psychiatric diagnoses.\n",
      "The issue is insufficiently explored in young people. Male university students who reported physical\n",
      "and sexual abuse in childhood were also at a greater risk for eating disorders A wide range of other\n",
      "childhood adversities and stressful life events has been associated with eating problems during\n",
      "adolescence. In one large referred population of patients with eating disorders, 55% reported recent\n",
      "stressful life events, most often separation (exempli gratia death of an important other, parental\n",
      "divorce, separation from close ones) or other changes in family or living conditions The effects of\n",
      "stress on eating are not uniform. Stress-induced hyperphagia (an abnormally increased appetite for,\n",
      "and consumption of, food) occurs more often in children and adults who are dietary-restrained eaters\n",
      "than in those who are not. Thus, for the vast majority of children and adults, the effects of\n",
      "current stress on food intake seem to be moderated by intermittent dietary restraint Developmental\n",
      "factors Life-stage risk factors have been identified at the major developmental phases of childhood\n",
      "and adolescence Preschool. It is still debatable whether there is a correlation between eating\n",
      "problems in early childhood and those in adolescence. The demographics of early feeding problems\n",
      "suggest no association, because boys are more likely to exhibit disordered eating in early\n",
      "childhood, whereas girls are at greater risk in adolescence. However, early childhood feeding and\n",
      "eating problems, such as pica, picky eating, digestive problems, as well as eating conflicts,\n",
      "struggles around meals, and unpleasant meals, have been found to predict eating disorders in\n",
      "adolescence or young adulthood. Mothers of patients with eating disorders have reported reliance on\n",
      "scheduled feeding and prematurely introduced solids more frequently than controls. However, these\n",
      "practices were also used with siblings who did not become ill, suggesting that other factors are\n",
      "likely to be involved in the pathogenesis of eating disorders In one study, six eating behaviors\n",
      "were evaluated at three time points over 2.5 years by maternal interview in two different\n",
      "overlapping cohorts (aged 0-10 and 9-18 years). Early maladaptive eating patterns were associated\n",
      "with a greater likelihood of problems later in life. Picky eating and digestive problems predicted\n",
      "preanorexic behavior. Early eating problems were also a predictor of the future onset of bulimia\n",
      "School-age children. In elementary school (7-12 years), significant numbers of children want to be\n",
      "thinner than they are. Studies indicate that 37% try some form of weight loss, and 6.9% score in the\n",
      "pathological range on an adapted version of the Eating Attitudes Test (see Table 4.8). There are few\n",
      "significant differences between boys and girls. Body-image distortions in this age group are\n",
      "associated with dieting and weight concerns. Food refusal, ritualistic behavior during meals, phobic\n",
      "behavior and elevated internalizing behaviors such as depression and anxiety have all been described\n",
      "in school-age children who eventually suffer from an eating disorder Prepuberty and adolescence.\n",
      "Studies have also confirmed that eating problems emerge in response to pubertal change, especially\n",
      "fat accumulation. Girls who feel most negatively about their bodies at puberty are at a higher risk\n",
      "of developing eating difficulties. Several studies have identified associations between disturbed\n",
      "eating in adolescents and anxious attachment weight concerns deficient self-regulation affective\n",
      "lability concerns about current body shape Contextual risk factors during this developmental phase\n",
      "include teasing by peers discomfort about discussing problems with parents maternal preoccupation\n",
      "with diets acculturation to Western values in immigrants First-generation immigrants, for example,\n",
      "are less likely to develop anorexia than the second and later generations Interestingly, homosexual\n",
      "boys (12-20 years) have a far greater frequency of disordered eating and weight concerns than\n",
      "heterosexual boys, for complex reasons that are currently not well understood Anorexia seems to\n",
      "occur at a precise timepoint in adolescent development, possibly reflecting the young person's\n",
      "inability to manage the developmental demands of adolescence. Adolescence is also a time marked by\n",
      "an increase in fat deposition for girls, and an unease and unhappiness with bodily appearance. In a\n",
      "sample of 808 girls (12-14 years) with no clinical symptoms, 34% stated a strong desire to lose\n",
      "weight; of these, 34% had a body mass index (BMI) of less than 20 (id est in the normal or thin\n",
      "range). Furthermore, 24% restricted their food intake to influence their weight and shape, 5%\n",
      "engaged in 8-hour fasting for more than half of each week and 38% undertook vigorous exercise to\n",
      "control their weight The biological changes of puberty certainly contribute to the onset of eating\n",
      "disorders. In girls, the peripubertal rise in estrogens affects mood and appetite regulation,\n",
      "because estrogens modulate serotonergic function via a variety of mechanisms, including changes in\n",
      "serotonin receptor number, serotonin synthesis and metabolism. Interestingly, dieting, a common\n",
      "factor that precipitates binge-eating behavior, alters brain serotonin function more markedly in\n",
      "women than in men. Estrogens also enhance stress responsiveness through downregulation of the\n",
      "hypothalamo-pituitary-adrenocortical axis In girls, an association between early pubertal timing and\n",
      "eating-disorder symptoms as well as diagnosis has been observed in a number of studies Individual\n",
      "variables Intrapersonal factors. Affective disturbances have been proposed as underlying disorders\n",
      "for bulimia, and a similar relationship has been proposed between anorexia and obsessive-compulsive\n",
      "disorders Depression is one of the most salient psychiatric comorbidities in both men and women with\n",
      "eating disorders. Dysregulation in serotonin, a neurotransmitter involved in the regulation of both\n",
      "mood and satiety, has been implicated as a causal factor in depression and eating disorders.\n",
      "Antidepressants that selectively block serotonin reuptake are effective in the treatment of both\n",
      "depression and bulimia or binge-eating disorder Anxiety and obsessive-compulsive behavior.\n",
      "Similarly, increased levels of anxiety and obsessiveness have been described in young people and\n",
      "adults with eating disorders. Premorbid overanxious disorder and obsessive-compulsive tendencies are\n",
      "seen significantly more often in patients with anorexia than in controls. Similarly, the risk for\n",
      "bulimia is increased by the presence of overanxious disorder or social phobia relative to controls.\n",
      "However, longitudinal studies in other fields indicate that premorbid anxiety disorders and negative\n",
      "affectivity are also risk factors for the development of other psychiatric conditions such as\n",
      "affective disorders and substance abuse Anger. Clinicians have described internalized anger and rage\n",
      "as primary emotions in patients with eating disorders. Researchers have found higher levels of\n",
      "perceived external control, lower assertiveness, lower self-esteem and more self-directed hostility\n",
      "in individuals with anorexia and bulimia than in controls Body-image disturbance is a well-known\n",
      "risk factor for clinical and subclinical levels of eating disorders. It has been related to indices\n",
      "of global psychological functioning, such as self-esteem, anxiety, depression and negative\n",
      "affectivity. However, body-image disturbance seems to be more closely related to restricted eating,\n",
      "and global psychological functioning more closely related to bulimia Body dissatisfaction is not\n",
      "only a defining characteristic of eating disorders but also a contributing factor in their\n",
      "development and maintenance. The unhealthy weight-control behaviors that characterize eating\n",
      "disorders, such as strict dieting, excessive exercise or laxative/diuretic abuse, are used to\n",
      "compensate for negative perceptions of body size, shape or weight. In a Canadian study of middle-\n",
      "school adolescents (early teens), negative perception of physical appearance and high importance of\n",
      "social acceptance correlated significantly with high levels of disordered eating Personality traits.\n",
      "Girls and women with anorexia tend to be anxious, inhibited and controlled, while those with bulimia\n",
      "tend to be more affectively labile and impulsive Negative self-evaluation, perfectionism and\n",
      "obsessive-compulsive behavior are all psychological traits that promote dieting behavior and are\n",
      "more commonly found in those with anorexia than in those with other psychiatric disturbances. A\n",
      "desire to avoid conflict predisposes the anorexic to focus on the more easily controllable domain of\n",
      "the body and weight. Being a perfectionist and a self-disciplinarian allows a person to maintain the\n",
      "strict diet and exercise regimen necessary for the sustainment of the disorder Psychological risk\n",
      "factors associated with bulimia include negative self-evaluation, shyness, a lack of close friends,\n",
      "missing school, perfectionism and mood lability Interpersonal functioning. Girls have been described\n",
      "as different from boys in their self-perceptions, emotions and behaviors pertaining to interpersonal\n",
      "relationships. Numerous studies have been conducted on the influence of peers on eating behavior and\n",
      "body image. Pressure to be thin from friends or weight-based teasing from peers has been associated\n",
      "with subclinical eating disturbances in high-school girls and with full-blown eating disorders in\n",
      "college-age women. Negative social feedback, in the form of teasing a person about their appearance,\n",
      "has been indicated as a possible etiologic factor in the development of disordered eating Impulse\n",
      "behaviors and substance abuse. Bulimic patients have a history of impulsive behaviors, including\n",
      "alcohol and drug misuse, suicidal behaviors and shoplifting. These problematic behaviors are often\n",
      "overlooked on initial contact. The preoccupation with food often impairs patients' functioning in\n",
      "social-, school- and work-related activities. The pattern of impulsive behaviors associated with\n",
      "bulimia is not common in those with anorexia A review of the literature on the comorbidity of eating\n",
      "disorders and substance abuse reveals an association between the two, especially among bulimics 17%\n",
      "of bulimics report a current or past history of drug, substance or alcohol abuse and/or dependence,\n",
      "or treatment for any of the above 20% of drug abusers report a current or past history of bulimia or\n",
      "bulimic behaviors Among bulimics, the family history studies show alcoholism rates of 39%, and drug\n",
      "or substance use rates of 19% When treating a patient with either an eating disorder or a substance-\n",
      "abuse problem, the clinician should always consider the possibility of a comorbid substance-abuse or\n",
      "eating problem Several psychological and biological mechanisms have been proposed to explain the\n",
      "comorbidity of eating disorders and substance abuse Psychological factors include the hypothesis of\n",
      "an addictive personality that predisposes individuals to becoming addicted to substances, viewing\n",
      "food and drugs as functional equivalents. Another explanation, which has received empirical support,\n",
      "is that the initial development of an addiction fosters psychological and behavioral patterns that\n",
      "enable individuals to develop other addictions. Another mechanism is the self-medication hypothesis,\n",
      "which states that individuals with an eating disorder turn to alcohol and drugs in order to cope\n",
      "with, or treat, their eating problems. The same has been said about depression - afflicted\n",
      "individuals turn to food or drugs to treat their depression Biological factors have been\n",
      "investigated in terms of the genetic contributions to alcoholism, drug abuse and eating disorders.\n",
      "Similarities in the process of these disorders suggest biological mechanisms underlying the\n",
      "addiction\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Etiology and pathogenesis of eating disorders. The study of eating disorders in the United States\n",
      "has found that there is a strong association between eating disorders and the development of eating\n",
      "disorders.The study of eating disorders has found that eating disorders have been associated with a\n",
      "complex combination of biological and environmental factors. Various genetic, developmental,\n",
      "psychological, familial and social variables have been suggested as risk factors for eating\n",
      "disorders.Biological factors and psychosocial factors.Biological factors. The current state of the\n",
      "genetics of eating disorders is that while there is familial clustering of these syndromes, it is\n",
      "not at all clear that they are in their entirety genetically transmitted disorders. Whatever the\n",
      "genetic component to each one of them, it seems to be stronger\n",
      "\n",
      "Reference:\n",
      "Clinicians and patients are best served by considering eating disorders from a bio-psycho-social\n",
      "perspective, unified in a framework of developmental psychopathology. All components are present,\n",
      "and interact to increase the risk for disorder as development proceeds. Disorder represents the\n",
      "crystallization of these interactions into syndromes which, in this case, are a developmental\n",
      "outcome, not simply the burgeoning of a latent biological deficit, as reductionist models of\n",
      "psychopathology would have it. Eating problems usually emerge in the context of pubertal change.\n",
      "Parental attitudes and behaviors towards eating, weight and body shape have a strong influence on\n",
      "the development of a child's relationship with food and body image, both healthy and unhealthy.\n",
      "Stressors and life events, such as childhood abuse, separations or bereavement, may precipitate the\n",
      "onset of eating disorders. Psychiatric comorbidities in both men and women with eating disorders\n",
      "include depression, anxiety, obsessive behavior and body-image disturbance. When treating a patient\n",
      "with either an eating disorder or substance-abuse problem, clinicians should always consider the\n",
      "possibility of comorbidity.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797457, 'chp1')\n",
      "Epidemiology and pathophysiology Prostate cancer is the most common malignancy to affect men of\n",
      "middle age and beyond in most developed countries and, increasingly in developing countries, it is\n",
      "second only to lung cancer as a cause of cancer deaths in men. The lifetime risk of developing\n",
      "clinical prostate cancer in western countries is about 1 in 8. Approximately 80% of men aged 80\n",
      "years have prostate cancer at autopsy. However, many of these cancers grow slowly and the risk of\n",
      "developing clinically detectable cancer is about 13%; the lifetime risk of actually dying from\n",
      "prostate cancer is approximately 3% Worldwide, there has been a steady increase in the incidence of\n",
      "clinically significant prostate cancer, although in the USA the number of incidental diagnoses of\n",
      "prostate cancer has fallen by 28% since the US Preventive Task Force issued a draft guideline in\n",
      "2011 (which became a final recommendation 2012) discouraging prostate-specific antigen (PSA)-based\n",
      "screening in all men (Figure 1.1) However, prostate cancer primarily affects men over the age of 50\n",
      "years, so the number of men diagnosed with prostate cancer is predicted to increase substantially\n",
      "over the next two decades as a result of the worldwide trend towards an aging population. The debate\n",
      "around measurement of PSA is discussed in detail in Chapter 3 (pages 36 -) Mortality from prostate\n",
      "cancer in Europe rose to a peak in 1993, reached a plateau, and has now started to decrease.\n",
      "Mortality in the USA has also shown similar trends (see Figure 1.1); the rate of decline has\n",
      "increased significantly in recent years and is now four times faster than in the UK. Some have\n",
      "attributed this drop to the efforts made in North America to detect and treat prostate cancer early\n",
      "through PSA testing a decade or two earlier, although several other factors may also have\n",
      "contributed, such as changes in lifestyle and better treatment outcomes Risk factors Despite the\n",
      "high incidence of prostate cancer, relatively little is known about the underlying causes. However,\n",
      "several risk factors have been identified (Table 1.1) Age is the greatest factor that influences the\n",
      "development of prostate cancer. Clinical disease is rare in men under the age of 50 years but the\n",
      "incidence increases markedly over 60 years of age Race. Marked geographic and racial variations are\n",
      "seen in the incidence of clinical prostate cancer (Table 1.2). The risk is highest in North America\n",
      "and northern European countries, and lowest in the Far East. In the USA, the risk is higher in black\n",
      "men than in white men, and black men also appear to develop more aggressive disease earlier. The\n",
      "incidence of prostate cancer is lowest in Chinese and Japanese races, although the prevalence is now\n",
      "increasing in both. The incidence of latent (clinically insignificant) disease is similar in all\n",
      "populations studied. The incidence of prostate cancer in men who emigrate from a low- to a high-risk\n",
      "area increases to that of the local population within two generations. This suggests that\n",
      "environmental influences such as diet and lifestyle factors may have a profound effect on the\n",
      "development of prostate cancer and on the progression of latent to clinically detectable cancer\n",
      "Family history/genetic risk. Epidemiology studies show that heritable factors account for a small\n",
      "proportion of prostate cancer risk but a higher proportion of early-onset disease. However, a host\n",
      "of studies have suggested the existence of prostate cancer susceptibility genes. Family history is a\n",
      "strong risk factor for prostate cancer: the risk of a man developing prostate cancer is increased\n",
      "approximately 2.5-fold if he has a first-degree relative who is affected. The relative risks for\n",
      "developing prostate cancer based on family history are shown in Table 1.3 The high incidence of\n",
      "familial prostate cancer prompted a search for germline mutations. Early linkage analyses suggested\n",
      "the human prostate cancer 1 gene (HPC1) located at 1q24-25, and studies in men with familial\n",
      "prostate cancer but without male to male transmission led to the identification of the X-linked\n",
      "human prostate cancer X gene (HPCX) at Xq27-28. Further loci have also been identified on\n",
      "chromosomes 2, 3, 5, 6, 8, 10, 11, 13, 15, 17, 19, 20 and 22. Familial prostate cancer is a far more\n",
      "heterogenous condition than familial breast cancer, with contributions from many more gene loci. The\n",
      "predictive value of any one allele is low; hence, a clinically useful genetic test has not yet been\n",
      "identified The strongest evidence for direct causality comes from families who develop cancer\n",
      "syndromes such as Lynch syndrome - the risk of developing prostate cancer is elevated twofold for\n",
      "those carrying the abnormal gene Mutations in the BRCA2 breast cancer susceptibility gene are rare\n",
      "in men with prostate cancer but appear to be associated with earlier diagnosis and more aggressive\n",
      "disease, such as higher Gleason score (see pages 14 -) and higher PSA level and tumor stage and/or\n",
      "grade at diagnosis. Furthermore, carriers of BRCA2 mutations may have lower overall survival (OS)\n",
      "and prostate cancer-specific survival compared with non-carriers. Knowledge of a man's BRCA2 status\n",
      "therefore has prognostic value. The US National Cancer Institute web pages on the genetics of\n",
      "prostate cancer provide a thorough review of the current status of this fast-changing field and are\n",
      "updated regularly (www.cancer.gov/types/prostate/hp/prostate-genetics-pdq) Hormones. Testosterone\n",
      "and its more potent metabolite dihydrotestosterone (DHT) are essential for normal prostate growth\n",
      "and also play a role in the development of prostate cancer (Figure 1.2). Prostate cancer almost\n",
      "never develops in the rare case of men who are for some reason castrated before puberty, or in men\n",
      "deficient in 5alpha-reductase - the enzyme with type I and II isoforms that converts testosterone to\n",
      "DHT. Trials have shown that the type II 5alpha-reductase inhibitors finasteride and dutasteride\n",
      "reduce the development of prostate cancer by about 25%, suggesting a key role for DHT. However, the\n",
      "incidence of prostate cancer increases with age, while serum testosterone levels decrease. In\n",
      "addition, men diagnosed with advanced prostate cancer often have a lower average testosterone level\n",
      "than men of a similar age who do not have prostate cancer Obesity. Early studies showed an increased\n",
      "risk of prostate cancer in obese men whereas more recent studies indicate that levels of detected\n",
      "prostate cancer are in fact lower in obese men. This may be because they have lower levels of PSA\n",
      "and androgens, such that fewer obese men underwent biopsy and were diagnosed with prostate cancer in\n",
      "the PSA era. A recently published study on risk factors for prostate cancer reported that being\n",
      "obese was associated with a 44% increase in the risk of prostate cancer diagnosis. Prostate cancer\n",
      "mortality is significantly higher in men who are obese. The mechanism by which obesity increases the\n",
      "likelihood of death from prostate cancer is not known but may be through the activation of pro-\n",
      "carcinogenic pathways such as the insulin-like growth factor (IGF) axis Western diets tend to be\n",
      "high in animal fat, protein, meat and processed carbohydrates, and low in plant foods. A number of\n",
      "studies support links between the intake of saturated fat and red and processed meats in particular\n",
      "and the development of prostate cancer. There is also some evidence that alpha-linoleic acid, an\n",
      "omega-3 polyunsaturated fatty acid, increases the risk of prostate cancer and of developing advanced\n",
      "disease, which may be the result of oxidative stress and subsequent DNA damage or the development of\n",
      "obesity. Omega-3 fatty acids from marine sources may, however, decrease the risk of developing\n",
      "prostate cancer Sun exposure and vitamin D. The risk of dying from prostate cancer is related\n",
      "geographically to ultraviolet (UV) light exposure, and men with prostate cancer have lower levels of\n",
      "vitamin D. Vitamin D levels are determined by dietary intake and conversion in the skin by UV light;\n",
      "however, the mechanism by which vitamin D levels protect against prostate cancer is not known, and\n",
      "vitamin D supplementation doe not decrease the risk. Calcitriol (vitamin D) has been used in the\n",
      "treatment of advanced prostate cancer but evidence of efficacy is lacking Histological features Most\n",
      "prostate cancers are adenocarcinomas. The majority (> 70%) appear to arise in the peripheral zone of\n",
      "the gland (Figure 1.3); 5-15% arise in the central zone and the remainder from the transition zone,\n",
      "which is where benign prostatic hyperplasia (BPH) also develops Microscopic foci of 'latent'\n",
      "prostate cancer are a common autopsy finding and may appear very early in life: approximately 30% of\n",
      "men over 50 years of age have evidence of latent disease. However, these microscopic tumors often\n",
      "grow very slowly, and many never progress to clinical disease. Beyond a certain size, however, these\n",
      "lesions progressively de-differentiate, probably as a result of clonal selection, and become\n",
      "increasingly invasive. A tumor with a volume greater than 0.5 cm or that is anything other than well\n",
      "differentiated is generally regarded as clinically significant The Gleason grading system is widely\n",
      "used for grading prostate cancer (Figure 1.4). In this system, the tumor is first graded 1-5\n",
      "according to aggressiveness; the numbers of the two most widely represented grades are then summed\n",
      "to produce the Gleason score. More recently, the grouping of Gleason scores has been introduced,\n",
      "more accurately conveying the risk/aggressiveness of a cancer and allowing better counseling of\n",
      "patients. The system is described in more detail below Because prostate cancers are often\n",
      "heterogeneous, the numbers of the two most widely represented grades are added to produce the\n",
      "Gleason score (exempli gratia 3 + 4), which provides useful prognostic information. Occasionally,\n",
      "more than two grades are observed in prostatectomy or biopsy specimens, the least common being known\n",
      "as the tertiary grade. If the tertiary grade has a high score (4 or 5), the patient has increased\n",
      "risk of disease progression even if the primary and secondary grades are lower, and the tertiary\n",
      "rather than the secondary grade informs the score In 2015, a consensus conference of the\n",
      "International Society of Uropathology proposed a new Gleason grade grouping, which ranges from 1 to\n",
      "5, 1 being the most indolent and 5 the most aggressive. Table 1.4 shows the allocation of the scores\n",
      "to the grade groups. The higher the Gleason grade group, the greater the likelihood that primary\n",
      "treatment with radical prostatectomy will fail, validating this method of reporting prostate cancer\n",
      "grade (Figure 1.5) Patterns of disease spread Prostate cancer is also classified according to the\n",
      "spread of the disease, using the American Joint Committee on Cancer tumor-nodes-metastasis (TNM)\n",
      "system (Table 1.5). The tumor stage (T1-T4) describes the pathological development of the tumor T1\n",
      "represents 'incidental' status, in which the tumor is discovered after transurethral resection of\n",
      "the prostate (TURP) or, more commonly, by PSA testing, and is not detectable by palpation or\n",
      "ultrasonography T2 represents a cancer that is palpable but still confined to the prostate gland T3\n",
      "represents a cancer that has extended through the prostate capsule into the surrounding fat or\n",
      "seminal vesicles T4 represents advanced disease, where the tumor has invaded neighboring organs\n",
      "(Figure 1.6) The nodal stages (N0-N1) and metastatic stages (M0-M1c) reflect the clinical\n",
      "progression of the disease. Metastases are most common in the lymph nodes (N1) and bones (M1b); the\n",
      "lungs and other soft tissues are less commonly involved It is not currently possible to distinguish\n",
      "unambiguously between tumors that will remain latent throughout the patient's life and those that\n",
      "will definitely progress to clinical disease. Studies of incidental carcinomas diagnosed after TURP\n",
      "suggest that the median time to progression for T1b tumors (high-volume: moderately or poorly\n",
      "differentiated) is 4.75 years, compared with 13.5 years for T1a tumors (low-volume; well-\n",
      "differentiated) (Figure 1.7). Thus, elderly men with T1a tumors are most appropriately managed by\n",
      "active surveillance alone (see page 60), whereas for younger men with T1b disease, options for more\n",
      "aggressive, potentially curative, therapy can be discussed\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Prostate cancer has prognostic value. The US National Cancer Institute web pages on the genetics of\n",
      "prostate cancer provide a thorough review of the current status of this fast-changing field and are\n",
      "updated regularly (www.cancer.gov/types/prostate/hp/prostate-genetics-pdq) and are updated\n",
      "regularly.Prostate cancer is classified according to the incidence of prostate cancer. The incidence\n",
      "of prostate cancer is highest in men over 50 years of age. The prevalence of prostate cancer is\n",
      "higher in men under 50 years of age than in men over 60 years of age.The prevalence of prostate\n",
      "cancer in men over 50 year of age is estimated to be about 1 in 8. Approximately 80% of men aged 80\n",
      "years have\n",
      "\n",
      "Reference:\n",
      "Prostate cancer is soon likely to supersede lung cancer as the most common cause of cancer death in\n",
      "men in western countries, as fewer men smoke and the population is aging. Age is the greatest risk\n",
      "factor but race, family history, western-style diet and obesity also have an effect. Most prostate\n",
      "cancers are adenocarcinomas arising in the peripheral zone of the gland. Prostate cancers are graded\n",
      "according to the Gleason system, which carries prognostic significance.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541796, 'chapter5')\n",
      "5 Aggressive B-cell lymphomas The aggressive B-cell lymphomas (also known as high-grade B-cell\n",
      "lymphomas) include diffuse large B-cell lymphoma (DLBCL), mediastinal large B-cell lymphoma, Burkitt\n",
      "lymphoma, and lymphoblastic lymphoma or acute lymphoblastic leukemia (see page 80). It can sometimes\n",
      "be difficult for pathologists to distinguish DLBCL from Burkitt lymphoma. Another subtype of\n",
      "lymphoma has therefore been identified, known for now as 'aggressive B-cell lymphoma with features\n",
      "intermediate between DLBCL and Burkitt lymphoma'. Other terms sometimes used for particularly\n",
      "aggressive types of DLBCL include ' c-Myc -positive DLBCL' and 'double hit' and 'triple hit'\n",
      "lymphomas, depending on the number of BCL2 and MYC translocations. Left untreated, these tumors can\n",
      "rapidly be fatal. Treatment aims to provide a cure. Relapse is associated with a poor prognosis\n",
      "Diffuse large B-cell lymphoma The most common aggressive lymphoma is DLBCL, which accounts for\n",
      "approximately 30% of all cases of non-Hodgkin lymphoma (NHL). Typically, the cells are large (Figure\n",
      "5.1) and express B-cell markers. While there are a few recurring cytogenetic and molecular\n",
      "abnormalities, they are not particularly helpful diagnostically (Table 5.1). Importantly for\n",
      "treatment, most DLBCL express CD20, which is the target for rituximab. The condition may present at\n",
      "any age, but is increasingly common in later life Pathology. The most common finding is sheets of\n",
      "large cells, which stain with the B-cell markers CD19, CD79a and CD20. Molecular profiling using\n",
      "expression microarrays (see page 37) has identified two main types of DLBCL, namely those derived\n",
      "from germinal-center B cells (GCB subtype) and those derived from a more differentiated stage in the\n",
      "B-cell life cycle - activated B-cell (ABC) type In accordance with their germinal-center derivation,\n",
      "BCL-6 and CD10 are expressed in about 50% of GCB subtype DLBCL. There is substantial evidence that\n",
      "the molecular subtype has prognostic significance. The ABC subtype has been found to confer a worse\n",
      "prognosis Clinical presentation. Clinically, there are some important considerations About 50% of\n",
      "all cases involve extranodal sites Approximately 30% of patients have underlying indolent B-cell\n",
      "lymphomas DLBCLs are aggressive, but approximately 50% are curable with combination chemotherapy 5%\n",
      "will relapse in the central nervous system (CNS) Management of DLBCL, as with all lymphomas, starts\n",
      "with staging (see Chapter 4). Although outcome is partly dependent on the extent of disease at\n",
      "presentation, treatment is usually with combination chemotherapy, such as R-CHOP, regardless of\n",
      "clinical stage. Staging is, however, crucial, because it is important to identify all the sites\n",
      "involved so that response during therapy can be properly assessed Staging investigations include\n",
      "PET/CT scans of chest, abdomen and pelvis; extranodal sites may need to be reimaged if not\n",
      "adequately visualized bone-marrow biopsy complete blood count, renal and liver profile, and\n",
      "immunoglobulins lactate dehydrogenase (LDH) virology, which should include hepatitis C, hepatitis B\n",
      "and HIV Prognosis can be usefully predicted using the International Prognostic Index (IPI). Patients\n",
      "are divided into four outcome groups depending on their score (Table 5.2) low risk low-intermediate\n",
      "risk high-intermediate risk high risk Clinical trials are under way to determine whether more\n",
      "intensive initial chemotherapy will improve the outcome in the poor prognostic groups; however,\n",
      "retrospective data already exist to describe the impact of rituximab on outcome, and a revised IPI\n",
      "has been proposed - the R-IPI. This defines three prognostic groups (Table 5.3). Prospective\n",
      "confirmation of these data is awaited Treatment. The standard treatment for DLBCL is six courses of\n",
      "R-CHOP given every 21 days. GELA (Groupe d'Etude des Lymphomes de l'Adulte) demonstrated an overall\n",
      "survival advantage by adding rituximab to CHOP in the elderly. Stratified analysis showed the\n",
      "significant superiority of R-CHOP over CHOP in terms of overall survival in low-risk patients (80%\n",
      "vs 62% at 5 years; P=0.023). However, the difference in high-risk patients was only of borderline\n",
      "significance (48% vs 39%; P=0.062). Subsequent trials extended this observation to younger patients\n",
      "Early-stage DLBCL is best managed with abbreviated R-CHOP (id est a total of four courses). Some\n",
      "centers will use adjunctive radiotherapy Refractory disease. Those patients who do not achieve\n",
      "complete remission by the completion of their fourth course of R-CHOP may be considered to have\n",
      "refractory disease in this setting, and the possibility of using salvage regimens should be\n",
      "discussed Treatment according to subtype. Emerging data suggest that different treatment approaches\n",
      "should be considered depending on the molecular subtype of DLBCL. Although still the subject of\n",
      "clinical trials, the evidence to date indicates that some drugs, for example those that target the\n",
      "B-cell receptor pathway (including fostamatinib, a spleen tyrosine kinase [SYK] inhibitor, and\n",
      "ibrutinib, a Bruton's tyrosine kinase [BTK] inhibitor), are more effective for ABC subtypes of DLBCL\n",
      "than GCB subtypes Patients with aggressive subtypes of DLBCL such as c-Myc -positive DLBCL, which\n",
      "has a high cell proliferation rate, tend to fare poorly with standard treatment compared with those\n",
      "who have c-Myc -negative disease. Regimens administered as continuous infusions, such as dose-\n",
      "adjusted EPOCH-R (EPOCH plus rituximab), are being evaluated as potentially more active treatments\n",
      "in these cases Follow-up. Patients who are in complete remission can be followed up in an outpatient\n",
      "clinic. Most centers see their patients every few months during the first 2 years when the chance of\n",
      "relapse is highest. Patients can probably be seen less often after 2 years provided they remain free\n",
      "of disease. Many centers now discharge patients after 5 years Relapse or progressive disease. The\n",
      "prognosis for patients who relapse after treatment is generally poor, with only 20-30% of patients\n",
      "rescued with salvage/relapse protocols. Most patients destined to relapse will do so in the first 2\n",
      "years after initial treatment. Salvage protocols vary, but are usually based on regimens containing\n",
      "platinum. The key consideration is response, because patients achieving a satisfactory response may\n",
      "then benefit from high-dose therapy and peripheral stem-cell rescue (Figure 5.2). The following\n",
      "salvage/relapse regimens are used R-DHAP and R-ESHAP are similar regimens given by infusion over 5\n",
      "days. R-ESHAP is an excellent stem-cell mobilizer, but has a long-term survival rate (over 5 years)\n",
      "of only 20% when used as the sole therapeutic agent (id est without subsequent high-dose therapy)\n",
      "R-ICE is given as an infusion over 3-4 days; like R-ESHAP, it is a good stem-cell mobilizer As\n",
      "suggested above, patients who have relapsed do better if they are able to receive high-dose therapy\n",
      "(see page 115), as long as they achieved a satisfactory response to the initial salvage\n",
      "chemotherapy. Patients who do not respond to initial salvage therapy have chemorefractory disease\n",
      "and are best either entered into clinical trials of novel agents or given palliative care.\n",
      "Occasionally, radiotherapy provides excellent symptomatic relief for localized disease Central\n",
      "nervous system prophylaxis. CNS involvement is a rare but devastating complication of DLBCL.\n",
      "Patients with involvement of two or more extranodal sites together with a raised LDH are at\n",
      "particular risk of relapse in the CNS. Furthermore, certain anatomic sites may confer risk, such as\n",
      "involvement of the bone marrow, testis, breast, tonsil and paraspinal territory. or disease that\n",
      "involves the facial bones and surrounding structures This area of lymphoma management is\n",
      "controversial, but most centers invoke some form of prophylaxis for patients thought to be at risk\n",
      "of CNS involvement. Chemotherapy (exempli gratia methotrexate and cytosine arabinoside) delivered\n",
      "directly into the cerebrospinal fluid by lumbar puncture is one such strategy. An alternative is\n",
      "administration of a sufficiently high dose of systemic drugs to pass the blood-brain barrier\n",
      "(exempli gratia high-dose methotrexate and high-dose cytosine arabinoside) Burkitt lymphoma Burkitt\n",
      "lymphoma is a rare and important disease with a distinctive immunophenotype and cytogenetics. It can\n",
      "often be cured with aggressive sequential chemotherapy. Burkitt lymphoma is probably the most\n",
      "aggressive tumor affecting humans. Every cell is undergoing cell division, leading to potentially\n",
      "devastating presentations with huge tumor burdens. There are three main types endemic Burkitt\n",
      "lymphoma, which is almost always associated with Epstein-Barr virus (EBV) infection sporadic Burkitt\n",
      "lymphoma, which occurs more often in Western Europe and the USA, is not as frequently associated\n",
      "with EBV and requires aggressive chemotherapy (Table 5.4) Burkitt lymphoma associated with HIV\n",
      "Pathology. Biopsy of an affected lymph node or other involved tissue will show sheets of small- to\n",
      "medium-sized lymphoid cells with a so-called 'starry-sky' appearance caused by the presence of\n",
      "phagocytic macrophages dotted about within the tumor (Figure 5.3). A characteristic feature of\n",
      "Burkitt lymphoma is a very high proliferation rate, usually close to a 100%. Occasional cases of\n",
      "DLBLC will exhibit a similar high rate so this finding is not in itself diagnostic. The\n",
      "immunophenotype is one of a mature GCB phenotype expressing CD19, CD20 and CD10. The extreme mitotic\n",
      "rate is, in part, due to overexpression of the MYC oncogene, which forces the cell to proliferate.\n",
      "The gene is located on chromosome 8 and can translocate to one of three immunoglobulin genes located\n",
      "on chromosomes 14, 22 and 2 (t[8;14], t[8;22] or t[2;8]). This places MYC under the control of the\n",
      "immunoglobulin gene enhancer, which drives expression Clinical presentation. Many patients present\n",
      "with rapidly enlarging lymph nodes, but the disease is almost always widespread and should be\n",
      "treated as such. Extranodal involvement is very common; extensive bone-marrow infiltration, and CNS,\n",
      "ovarian, gastrointestinal and breast involvement are all well recognized. Occasionally, patients\n",
      "will present with florid leukemia. The large tumor bulk often seen in these patients is reflected in\n",
      "very high levels of LDH in some cases. Full staging is mandatory and should include analysis of the\n",
      "cerebrospinal fluid Treatment. Burkitt lymphoma requires treatment with high-dose sequential\n",
      "chemotherapy. Effective treatment regimens expose the malignant and rapidly dividing cells to longer\n",
      "periods of chemotherapy than would be achieved with simple CHOP. Another important component of\n",
      "therapy is CNS-directed treatment, usually in the form of high-dose methotrexate or high-dose\n",
      "cytosine arabinoside. Cure rates of 65-80% can be achieved when sequential chemotherapy is delivered\n",
      "such as CODOX-M or, for higher-risk patients (high LDH and advanced stage) CODOX-M/IVAC. These\n",
      "regimens contain high-dose methotrexate and/or high-dose cytosine arabinoside to protect or treat\n",
      "the CNS Because of the large bulk at presentation and the rapid response to chemotherapy, steps must\n",
      "be taken to avoid the clinical consequences of killing tumor cells too quickly (tumor lysis\n",
      "syndrome): adequate hydration of the patient with careful recording of fluid balance is essential,\n",
      "along with regular monitoring of renal and cardiac function and electrolytes, and administration of\n",
      "an agent to prevent deposition of uric acid, such as rasburicase (recombinant uric acid oxidase), in\n",
      "the kidneys Primary mediastinal (thymic) large B-cell lymphoma Primary mediastinal (thymic) large\n",
      "B-cell lymphoma is a rare aggressive locally invasive lymphoma that presents in young adults and\n",
      "more commonly in women. It was once considered a variant of DLBCL, but it is now listed as a\n",
      "separate entity in the WHO classification (see page 131) Pathology. Mediastinal large B-cell\n",
      "lymphoma is thought to arise from thymic B cells and is characterized by the presence of medium or\n",
      "large lymphoma cells with clear cytoplasm enmeshed in a variable amount of reactive fibrosis (Figure\n",
      "5.4, Table 5.5). Mediastinal large B-cell lymphoma presents a fairly distinct immunophenotype. The\n",
      "cells express the B-cell antigens CD20, CD19 and CD79a, and may also express CD30, which is better\n",
      "known as a marker of Hodgkin lymphoma. Characteristically, the cells do not express surface\n",
      "immunoglobulin, CD10 or human leukocyte antigen class I molecules. Furthermore, unlike DLBCL,\n",
      "primary B-cell mediastinal lymphomas do not show rearrangements of either the BCL2 or BCL6 genes.\n",
      "Interestingly, gene-expression microarray studies show that the signature of mediastinal large\n",
      "B-cell lymphoma is more like that of classic Hodgkin lymphoma than that of DLBCL Cytogenetics of\n",
      "mediastinal large B-cell lymphoma show a characteristic pattern of genomic aberrations with gains on\n",
      "the short arm of chromosomes 9 and 2 (involving the JAK2 and REL [also known as C-REL ] genes,\n",
      "respectively) Clinical presentation reflects the fact that this tumor tends to remain localized to\n",
      "the upper anterior mediastinum (Figure 5.5), is aggressive and will invade local structures.\n",
      "Obstruction of the superior vena cava causing cough, dyspnea and stridor is a relatively common\n",
      "clinical presentation. Phrenic nerve palsy or recurrent laryngeal nerve palsy may occur as a direct\n",
      "result of local tissue invasion Treatment. Studies have found that primary mediastinal large B-cell\n",
      "lymphoma has a favorable outcome compared with DLBCL. Most centers treat mediastinal large B-cell\n",
      "lymphoma using a DLBCL protocol (R-CHOP), though others may use infusional regimens based on the\n",
      "excellent outcome data with dose-adjusted EPOCH-R. Whether the addition of radiotherapy to the\n",
      "mediastinum at the completion of chemotherapy confers survival advantage is controversial. Some\n",
      "centers routinely administer radiotherapy to residual masses, while others reserve radiotherapy for\n",
      "treatment at relapse or progression after salvage and high-dose therapy\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "' appearance caused by the presence of phagocytic macrophages dotted about within the tumor (Figure\n",
      "5.3). A characteristic feature of Burkitt lymphoma is a very high proliferation rate, usually close\n",
      "to a 100%. Occasional cases of DLBLC will exhibit a similar high rate so this finding is not in\n",
      "itself diagnostic. The immunophenotype is one of a mature GCB phenotype expressing CD19, CD20 and\n",
      "CD10. The extreme mitotic rate is, in part, due to overexpression of the MYC oncogene, which forces\n",
      "the cell to proliferate. Other terms sometimes used for particularly aggressive types of DLBCL\n",
      "include'c-Myc -positive DLBCL' and '\n",
      "\n",
      "Reference:\n",
      "The commonest aggressive B-cell lymphoma is diffuse large B-cell lymphoma (DLBCL). Most DLBCL\n",
      "express CD20, which is the target for rituximab; approximately 50% of DLBCL are curable with R-CHOP.\n",
      "Patients who relapse require salvage chemotherapy and, if chemosensitive, will benefit from high-\n",
      "dose chemotherapy and stem-cell rescue. Burkitt lymphoma and the c-Myc -positive DLBCL subtype have\n",
      "high proliferation rates and should be treated with sequential chemotherapy incorporating central\n",
      "nervous system prophylaxis.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541024, 'ch_5')\n",
      "Brain metastases Improvements in therapy for systemic cancer have increased the number of patients\n",
      "living long enough to develop symptomatic brain metastases. Indeed, brain metastases are the most\n",
      "common intracranial tumor. In particular, human epidermal growth factor receptor-2-positive (Her2+)\n",
      "breast cancer patients with systemic disease controlled with trastuzumab appear to have an increased\n",
      "risk of developing brain metastases. Thus, the development of new strategies to prevent and treat\n",
      "brain metastases is increasingly important Approximately 1 in 4 patients with cancer will develop a\n",
      "brain metastasis; patients with melanoma, lung or breast cancer are at the greatest risk (Table\n",
      "4.1). Most patients present with headaches or focal neurological deficits; 20% or more present with\n",
      "or develop seizures. Radiographically, metastases are ring-enhancing lesions, most often located at\n",
      "the gray-white matter junction. There is often significant surrounding edema. About half are single\n",
      "lesions (Figure 4.1), with the remainder being multiple lesions (Figures 4.2 and 4.3). Skull and\n",
      "dural metastases are most commonly seen in association with prostate and breast cancer Patients with\n",
      "a new diagnosis of brain metastasis should be systemically restaged as appropriate for their primary\n",
      "tumor. The Radiation Therapy Oncology Group (RTOG) has delineated specific prognostic categories for\n",
      "patients with newly diagnosed brain metastases (Table 4.2). These may be helpful in determining\n",
      "appropriate treatment options and long-term plans (exempli gratia hospice care) for individual\n",
      "patients. A treatment algorithm for newly diagnosed brain metastasis is shown in Figure 4.4\n",
      "Symptomatic management Symptomatic management can result in a significant improvement in quality of\n",
      "life for patients with brain metastases. Vigilance for less common complications of brain\n",
      "metastases, such as the syndrome of inappropriate antidiuretic hormone secretion (SIADH), is\n",
      "critical Vasogenic edema secondary to metastases typically responds to treatment with\n",
      "corticosteroids within a matter of hours. Dexamethasone is the corticosteroid most often used. For\n",
      "initial symptom control, it can be administered in two, three or four daily doses, with each dose\n",
      "between 4 mg and 20 mg. Unfortunately, there are significant side effects associated with\n",
      "corticosteroids including, but not limited to, myopathy, hyperglycemia, edema, weight gain,\n",
      "avascular necrosis and psychosis. All patients on prolonged corticosteroids should receive\n",
      "prophylactic therapy for Pneumocystis carinii pneumonia. Steroids should be tapered as rapidly as\n",
      "possible (decreasing the dose every 3 days, as tolerated) to minimize side effects. Eliminating\n",
      "doses given late in the day and minimizing multiple daily doses may help to limit the side effects\n",
      "Anticonvulsants are indicated for any patient presenting with a seizure. Prophylactic\n",
      "anticonvulsants have not been shown to be effective and therefore only complicate patient\n",
      "management, increasing the risk of medication-related side effects. Non-convulsive status\n",
      "epilepticus should be considered in any patient with an altered level of consciousness (see Fast\n",
      "Facts: Epilepsy) Radiotherapy and surgery Standard therapy for a patient with newly diagnosed brain\n",
      "metastasis remains whole-brain radiotherapy. A total dose of 3000 cGy is administered in ten daily\n",
      "doses of 300 cGy. Prognosis following standard therapy is poor, with an average survival of 3-4\n",
      "months. About 50% of patients die from progressive neurological disease; the remainder die as a\n",
      "result of systemic tumor progression Aggressive focused management of brain metastases may improve\n",
      "the prognosis for some patients. Those with a single brain metastasis located in a surgically\n",
      "accessible region clearly benefit from a combination of surgical resection and whole-brain\n",
      "radiotherapy. Stereotactic radiosurgery may also be helpful. In this patient group, the median\n",
      "survival with either of these approaches is 8-9 months. These results, while encouraging, have been\n",
      "obtained in highly selected patient populations, most of whom had a high Karnofsky performance\n",
      "status, limited systemic tumor burden and small brain metastases. Such patients have an inherently\n",
      "better prognosis, and consequently these results may not be easily extrapolated to all patients.\n",
      "(The Karnofsky performance status is scored from 0 to 100, with higher scores meaning a patient is\n",
      "better able to carry out daily activities.) Controversy still surrounds several specific issues.\n",
      "First, there is no consensus on the number and size of lesions that are appropriate to treat with\n",
      "stereotactic radiosurgery. In general, it is reasonable to treat up to three individual metastases\n",
      "that are smaller than 3 cm at the largest diameter. Second, the optimal timing of whole-brain\n",
      "radiotherapy following surgical resection or stereotactic radiosurgery is unclear. While early\n",
      "whole-brain radiotherapy improves local control, there is no clear survival benefit. As a result,\n",
      "many practitioners are inclined to defer whole-brain radiotherapy until there is progressive disease\n",
      "in the brain. This strategy may minimize treatment-related neurocognitive deficits and permit much\n",
      "needed palliation at a future time Use of chemotherapy in the treatment of brain metastases is\n",
      "generally disappointing. Unfortunately, by the time most patients develop brain metastases, they\n",
      "have already been exposed to the most effective chemotherapeutic agents and the metastatic clones\n",
      "are relatively chemoresistant. Although the blood-brain barrier is focally disrupted, water-soluble\n",
      "chemotherapy may not penetrate sufficiently to reach a therapeutic concentration In spite of this,\n",
      "chemotherapy may be useful in treating some individuals with brain metastases. Newly diagnosed\n",
      "patients who are chemotherapy naïve and neurologically asymptomatic may respond favorably to\n",
      "systemic chemotherapy. They should be followed closely with serial MRI and neurological examinations\n",
      "to monitor their response to treatment. In particular, patients with brain metastases from small-\n",
      "cell lung cancer, breast cancer, testicular cancer or choriocarcinoma may have a better than average\n",
      "response to chemotherapy Chemotherapy or radiosensitizing agents may be combined with whole-brain\n",
      "radiotherapy in an attempt to improve the outcome compared with either modality alone. A European\n",
      "Organization for Research on Treatment of Cancer (EORTC) study found a significant survival\n",
      "advantage for patients with small-cell lung cancer treated with teniposide in combination with\n",
      "whole-brain radiotherapy, when compared with teniposide alone. Similarly, a significant improvement\n",
      "in radiographic response was seen in patients with newly diagnosed brain metastases who were treated\n",
      "with temozolomide in combination with whole-brain radiotherapy, when compared with whole-brain\n",
      "radiotherapy alone Finally, chemotherapy may be useful in the setting of recurrent brain metastases.\n",
      "At recurrence, most patients have multiple lesions that are not amenable to radiosurgery or focal\n",
      "therapy. Furthermore, the majority have active and often symptomatic systemic tumors. This clinical\n",
      "scenario makes palliative chemotherapy an appropriate intervention\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Brain metastases are the most common intracranial tumor in the U.S. and the majority of patients\n",
      "with metastatic brain metastases are at the greatest risk of developing brain\n",
      "metastases.Improvements in therapy for systemic cancer have increased the number of patients living\n",
      "long enough to develop symptomatic brain metastases. Indeed, brain metastases are generally\n",
      "disappointing. Unfortunately, by the time most patients develop brain metastases, they have already\n",
      "been exposed to the most effective chemotherapeutic agents and the metastatic clones are relatively\n",
      "chemoresistant. Although the blood-brain barrier is focally disrupted, water-soluble chemotherapy\n",
      "may not penetrate sufficiently to reach a therapeutic concentration. In addition, patients with\n",
      "metastatic tumors are at the greatest\n",
      "\n",
      "Reference:\n",
      "Improvements in therapy for systemic cancer have resulted in an increase in the number of patients\n",
      "living long enough to develop symptomatic brain metastasis. It is likely that this trend will\n",
      "continue. Therefore, new strategies to prevent and treat brain metastases will become increasingly\n",
      "important. Patients with a new diagnosis of brain metastasis should be systemically restaged as\n",
      "appropriate for their primary tumor. Although the average prognosis for an individual with brain\n",
      "metastasis is poor, selected patients will benefit significantly from aggressive local therapy or\n",
      "judicious use of chemotherapy.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797662, 'ch07')\n",
      "Management of advanced and metastatic disease A core principle in the management of solid tumors is\n",
      "to consider control of both the primary and metastatic disease. Several clinical scenarios occur in\n",
      "bladder cancer Cancers that are clearly confined to the bladder can potentially be cured if the\n",
      "primary tumor can be removed or ablated, through surgery, radiation therapy or multimodality\n",
      "approaches, and there is no metastatic disease; 5-year survival rates are about 70%. Management of\n",
      "these cancers is discussed in chapter on 'Management of non-muscle-invasive disease' Locally\n",
      "advanced cancers and tumors that have spread to loco-regional lymph nodes are associated with an\n",
      "increased risk of local relapse and a higher risk of micrometastatic disease at diagnosis. Five-year\n",
      "survival is about 35%. Lymph node involvement is identified through lymph node dissection or\n",
      "accurate imaging. The primary cancer may still be amenable to local therapy, and is potentially\n",
      "curable in the absence of distant metastases. Optimum systemic therapy with cisplatin-based\n",
      "chemotherapy is standard of care for patients with adequate renal function who are suitable for\n",
      "chemotherapy Cancers predominantly involving the bladder but where there is small-volume overt\n",
      "metastatic disease are unlikely to be cured with currently available modalities; treatment is\n",
      "therefore palliative in intent, which must be clearly understood from the outset. Five-year survival\n",
      "for patients with metastatic disease is approximately 5%, although this varies depending on the bulk\n",
      "of disease, response to therapy and patient factors, including comorbidities. The mainstay of\n",
      "therapy is systemic treatment to control the progression of metastatic disease although management\n",
      "of the primary cancer may be necessary to alleviate symptoms and to prevent future complications\n",
      "such as pain, intractable hematuria and upper urinary tract obstruction. Surgery or radiation\n",
      "therapy may therefore be necessary for management of the primary tumor, and sometimes for management\n",
      "of metastatic disease Cancers where the bulk of disease is metastatic are currently incurable; the\n",
      "intention of treatment is therefore palliative. Ablative local therapies such as surgery or\n",
      "radiation therapy should only be used to ameliorate current and potential issues that compromise\n",
      "quality of life All these strategies are predicated on whether the patient is able to tolerate the\n",
      "proposed treatment, and other factors such as comorbidities may require modification of the\n",
      "treatment plan. Treatment decisions usually require multidisciplinary input. A key component of such\n",
      "discussions should be whether participation in a clinical trial is possible and an appropriate\n",
      "option for the patient to consider This chapter summarizes current clinical recommendations for the\n",
      "systemic therapy of loco-regional advanced or metastatic disease. The treatment landscape and\n",
      "resulting recommendations are likely to change over the next few years as clinical trials are\n",
      "completed, particularly those of immunotherapies (see page 71) Systemic therapy for metastatic\n",
      "bladder cancer The activity of various cytotoxic drugs such as doxorubicin (Adriamycin),\n",
      "methotrexate, vinblastine and cisplatin against urothelial bladder cancer has been recognized since\n",
      "the 1970s. Response rates with cisplatin monotherapy were initially reported to be as high as 40%,\n",
      "although subsequent studies showed that response rates of 10-15% were more realistic. Other drugs\n",
      "such as paclitaxel and gemcitabine were also subsequently shown to have activity as monotherapies\n",
      "The first combination chemotherapy regimen to be widely used in clinical practice was cisplatin,\n",
      "methotrexate and vinblastine (CMV), which showed an overall response rate of 56% in a small single-\n",
      "arm study, half of which were complete remissions (notably in the era before computed tomography).\n",
      "MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) was shown to be superior to single-agent\n",
      "cisplatin for relevant endpoints of tumor response, duration of remission and overall survival (OS).\n",
      "CMV and MVAC have been the mainstay of chemotherapy for metastatic urothelial bladder cancer for\n",
      "many years. Unfortunately, however, both regimens are difficult to deliver safely and are associated\n",
      "with substantial toxicity, including bone marrow suppression, neutropenic sepsis, mucositis,\n",
      "neuropathy, ototoxicity, nausea and vomiting, requiring frequent hospitalization, and sometimes\n",
      "leading to treatment-related death. These cytotoxic regimens can now be used in a broader range of\n",
      "patients since the development of supportive care measures such as antiemetics and colony-\n",
      "stimulating factors; previously, only the fittest patients were able to tolerate these cytotoxic\n",
      "regimens The treatment of metastatic bladder cancer was transformed following publication of a\n",
      "randomized Phase III trial comparing MVAC versus gemcitabine and cisplatin (GC)., The study was\n",
      "somewhat ambitiously designed to demonstrate a 33% improvement in OS with GC, rather than as an\n",
      "equivalence or non-inferiority study. The survival curves for the two regimens were similar, and the\n",
      "trial did not meet its primary endpoint. However, GC was found to be better tolerated than MVAC and\n",
      "was adopted as standard of care for the treatment of metastatic disease. GC has become the de facto\n",
      "standard for trials in other settings, even though this is not supported by high-level evidence.\n",
      "Modifications to the regimen are frequently made (often with little supporting evidence), such as\n",
      "splitting the dose of cisplatin, dropping treatment weeks or shortening treatment cycles, modifying\n",
      "the gemcitabine dosage, or substitution with drugs such as carboplatin. It is important to recognize\n",
      "when and how far we should go beyond high-level evidence when making treatment decisions with\n",
      "patients Improvements in supportive care have led to renewed interest in older chemotherapy\n",
      "combinations. One new approach is the intensification of treatment, such as accelerated or high-dose\n",
      "MVAC, with granulocyte colony-stimulating factor support. These regimens are generally much better\n",
      "tolerated than the original MVAC regimen and outcomes are at least comparable to those with GC, and\n",
      "perhaps numerically superior, although this has been difficult to prove statistically and remains\n",
      "controversial. Further modifications such as the addition of a taxane to GC increased the toxicity\n",
      "without substantially improving outcomes and therefore are not recommended. Chemotherapy regimens in\n",
      "common use for the first-line treatment of metastatic bladder cancer are summarized in Table 7.1 The\n",
      "dosing and scheduling details of cytotoxic chemotherapy regimens for advanced or metastatic bladder\n",
      "cancer are summarized in Table 7.2. Useful reviews of chemotherapy have been published by Yafi and\n",
      "colleagues and Oing and colleagues Recent clinical trials have targeted a so-called 'cisplatin-\n",
      "ineligible' population. The criteria for this designation are rather soft and can include Eastern\n",
      "Cooperative Oncology Group performance status (PS) 2 or worse glomerular filtration rate (GFR) less\n",
      "than 60 mL/min pre-existing neuropathy or ototoxicity increased risk for neuropathy or ototoxicity\n",
      "(exempli gratia diabetes, alcohol misuse, occupational noise exposure) congestive cardiac failure or\n",
      "other inability to manage a fluid load However, not all these factors indicate unsuitability for\n",
      "cisplatin. Many 'cisplatin-ineligible' patients who enter trials have only one of these criteria,\n",
      "most commonly poor PS or reduced GFR, which means that many of these trials are not generalizable to\n",
      "real-world practice. While poor PS and reduced GFR are both relative contraindications to cisplatin,\n",
      "PS may be compromised by other conditions that will be unaffected by cisplatin, or may improve if\n",
      "symptoms are due to a tumor that subsequently responds to cisplatin. Patients with GFR of 40-60\n",
      "mL/min can often be managed safely by splitting the cisplatin dose over 2 weeks (although there is\n",
      "little evidence to support this approach). In addition, it may be possible to improve renal function\n",
      "through the use of percutaneous nephrostomy tubes or ureteric stents if hydronephrosis or\n",
      "hydroureter are contributory factors. These points need to be considered when deciding whether\n",
      "cisplatin is appropriate for a specific patient, and when designing clinical trials Second and\n",
      "subsequent lines of chemotherapy Tumors that have progressed after first-line chemotherapy cannot be\n",
      "cured with chemotherapy, and response rates are typically lower than with first-line setting. It is\n",
      "important to reiterate at this stage that the intent of treatment is palliative, which can often be\n",
      "an uncomfortable conversation Chemotherapy may still be a reasonable palliative option as long as\n",
      "all other palliative objectives are addressed and quality of life is not impaired by treatment. The\n",
      "literature contains many examples of small studies in the post-first-line setting, for both\n",
      "cisplatin-eligible and cisplatin-ineligible patients. Response rates with active agents range from\n",
      "20% to 80%. Use of complex regimens such as doublets or triplets does not seem to improve outcomes,\n",
      "and toxicity is substantially worse with combinations than with monotherapy. Patients who have had\n",
      "good responses previously may sometimes respond well to re-challenge with the same agents. Example\n",
      "regimens are shown in Table 7.2 (noting that not all drugs will be available in all regions) General\n",
      "principles of treatment The general principles of chemotherapy for advanced or metastatic disease\n",
      "are summarized in Table 7.3 Palliation and best supportive care Patients with incurable disease must\n",
      "be managed with palliative intent. Any treatment must provide some possibility of benefit, and this\n",
      "benefit should outweigh the predicted risks. Early involvement of a broad multidisciplinary\n",
      "management team is important and should include palliative care, nursing and allied health\n",
      "professionals Active treatment may still be appropriate, particularly if symptoms are amenable to\n",
      "such therapies and the patient is well enough to tolerate them. It is therefore reasonable to\n",
      "consider surgery, radiation therapy, cytotoxic chemotherapy or other active approaches within the\n",
      "context of supportive care and palliative intent. Practitioners delivering these therapies must be\n",
      "experienced and fully aware of the benefits and limitations of what they offer, bearing in mind the\n",
      "wellbeing of the patient and their broader social situation, including effects on family and carers.\n",
      "The financial implications of treatment may also require consideration Many symptoms can be treated\n",
      "with simple and non-invasive measures, for example optimal pain management, possibly involving a\n",
      "specialist pain management team detection and management of urinary tract infections modification of\n",
      "other treatments (such as cessation of antiplatelet drugs in a patient with intractable hematuria)\n",
      "blood transfusion (with defined stopping points) radiation therapy for symptomatic metastatic\n",
      "disease management of other symptoms of metastatic disease\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Management of advanced and metastatic disease is the primary endpoint. However, GC was found to be\n",
      "better tolerated than MVAC and was adopted as standard of care for the treatment of metastatic\n",
      "disease. Several clinical scenarios occur in bladder cancer. These include:Cancers that are clearly\n",
      "confined to the bladder can potentially be cured if the primary tumor can be removed or ablated,\n",
      "through surgery, radiation therapy or multimodality approaches, and there is no metastatic disease;\n",
      "5-year survival rates are about 70%. Management of these cancers is discussed in chapter on\n",
      "'Management of non-muscle-invasive disease' and in chapter on 'Patient management of metastatic\n",
      "disease' and 'Management of metastatic disease'.Management of metastatic\n",
      "\n",
      "Reference:\n",
      "Management of patients with advanced or metastatic disease is complex and requires a\n",
      "multidisciplinary approach. Management of both local and distant metastatic disease should be\n",
      "considered. The intent of treatment for patients with metastatic disease is optimal palliation\n",
      "(improved quality of life with or without prolonging survival). The benefits of any treatment must\n",
      "outweigh the risks. Perioperative chemotherapy should be considered for suitable patients with high-\n",
      "risk bladder-confined disease, but preoperative chemotherapy is preferred where possible.\n",
      "Combination chemoradiotherapy can be an alternative to cystectomy for the management of locally\n",
      "advanced disease. Cisplatin-based chemotherapy can provide excellent outcomes for some patients with\n",
      "advanced or metastatic disease. Radiation therapy to the primary or appropriate metastatic sites can\n",
      "provide useful palliation. Combination chemoradiotherapy to the bladder is best reserved for\n",
      "patients being treated with curative intent.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781912776726, 'ch3')\n",
      "Morphological features The initial step in the diagnosis of glioblastoma is morphological assessment\n",
      "of the tumor. High-grade gliomas are highly cellular, with varied nuclear morphology (Figure 3.1;\n",
      "also see Figure 1.3). Mitotic activity is usually noticeable, although its absence does not preclude\n",
      "malignant biological or clinical behavior. The matrix of these tumors is fibrillary, formed by\n",
      "processes of tumor cells and often involving underlying central nervous system (CNS) tissue that is\n",
      "overrun by tumor cells. The cytoplasm of tumor cells varies - some forms of high-grade astrocytic\n",
      "tumors show abundant eosinophilic cytoplasm, whereas others show a scanty perinuclear rim of\n",
      "cytoplasm Overtly high-grade astrocytic tumors also have vessels with hyperplastic and often\n",
      "multilayered endothelium, termed microvascular proliferations. These vessels are formed by the\n",
      "underlying CNS tissue and respond to vascular growth stimuli, rather than being a neoplastic element\n",
      "of the tumors themselves A further characteristic feature of high-grade gliomas is the presence of\n",
      "necrotic tumor cells of varying form and shape. Palisading necrosis is typical in glioblastoma, but\n",
      "larger areas of sharply demarcated necrotic tumor are also commonly seen When assessing gliomas, it\n",
      "must be borne in mind that some tumors with the molecular profile of a glioblastoma (see below) may\n",
      "not have all high-grade features. It is increasingly apparent that diffuse infiltrating gliomas may\n",
      "not have high-grade features when diagnosed early. Likewise, the histone H3.3 K27M-mutant gliomas\n",
      "may not have any histological high-grade features but are defined as WHO grade IV. This is why a\n",
      "multidisciplinary approach is so important for the optimal diagnosis of patients with glioblastoma -\n",
      "the molecular analysis ensures a more robust classification Identification of molecular subgroups\n",
      "Following the initial histological assessment, a set of markers is used to identify molecular\n",
      "subgroups of high-grade gliomas (see Table 1.1) or, indeed, to refine the diagnosis where both low-\n",
      "and high-grade histology is present Mutation-specific antibodies can be used to identify IDH1 R132H,\n",
      "histone H3.3 K27M and BRAF V600E. Staining can be used to identify loss of expression of ATRX,\n",
      "SMARCA4 or SMARCB1 (INI1). Some tumors can be robustly diagnosed with these antibodies alone,\n",
      "particularly tumors with IDH and ATRX mutations and H3.3 K27M mutated tumors Other markers. As\n",
      "antibodies are not available for all known mutations (exempli gratia in the IDH1 and IDH2 genes),\n",
      "other methods, such as Sanger sequencing, next-generation sequencing or multiplex ligation-dependent\n",
      "probe amplification, are required. Other mutations, such as in the TERT promoter, require\n",
      "sequencing, and copy number assays are necessary to detect chromosome loss or gain (exempli gratia\n",
      "7p gain and 10q loss in IDH wild-type glioblastoma; 1p/19q co-deletion in oligodendroglioma) or gene\n",
      "amplifications (exempli gratia EGFR, MYC) or deletions (exempli gratia CDKN2A/B; see Figure 1.3)\n",
      "Epigenetic changes. Many high-grade gliomas can be classified by a selection of the markers\n",
      "described above. However, some remain unclassifiable because of a lack of distinctive mutation\n",
      "patterns. Thus, a method has been developed that looks at epigenetic changes caused by a combination\n",
      "of mutations and the cell of origin. These epigenetic changes are identified from methylation\n",
      "patterns (which are a result of driver mutations), using a publicly accessible algorithm\n",
      "(www.molecularneuropathology.org). This method is widely used in the diagnosis of brain tumors with\n",
      "unusual or ambiguous histology and when conventional molecular testing is not diagnostically\n",
      "informative. A diagnostically useful copy number profile is also generated, which elucidates\n",
      "chromosomal changes and gene amplifications or losses (see Figure 1.3) Imaging is performed at the\n",
      "time of presentation to localize and characterize mass lesions and to define the disease extent.\n",
      "This chapter focuses on the diagnostic use of imaging in patients with suspected\n",
      "glioma/glioblastoma. The role of imaging in the management of patients with glioblastoma is\n",
      "discussed in Chapter 4 Computed tomography has a low soft tissue contrast, therefore its role in\n",
      "diagnosing glioma is limited. However, it remains the most rapid and widely accessible imaging\n",
      "modality for patients with brain tumors in the emergency setting. CT is commonly the first imaging\n",
      "test to be carried out when patients newly present with symptoms of glioblastoma; it is often\n",
      "sufficient to exclude the need for immediate neurosurgical intervention In many cases, CT will\n",
      "permit the distinction between a cortical ischemic infarct (cytotoxic edema) and a mass lesion\n",
      "(vasogenic edema). The accurate characterization of brain masses, however, requires MRI, as CT\n",
      "neither captures the lesion extent nor its morphology sufficiently Of note, calcification on CT in\n",
      "an untreated tumor is rare in primary (IDH wild-type) glioblastoma and should prompt consideration\n",
      "of an alternative diagnosis (exempli gratia oligodendroglioma) Anatomic magnetic resonance imaging.\n",
      "All patients with suspected or confirmed glioblastoma should have an MRI scan. Clinical glioma MRI\n",
      "sequences almost always comprise T2-weighted, T2-FLAIR (fluid-attenuated inversion recovery) and\n",
      "T1-weighted pre- and post-contrast sequences. T2-weighted and FLAIR images are most valuable for\n",
      "estimating macroscopic tumor boundaries: FLAIR increases the overall contrast between the tumor and\n",
      "normal brain tissue, and may thus facilitate lesion detection, while the loss of grey-white matter\n",
      "detail, indicative of tumor, is well delineated on T2 images. For this reason, T2 imaging should\n",
      "always be reviewed when assessing the extent of glioma infiltration Compared to IDH -mutant lower-\n",
      "grade gliomas, early (IDH wild-type) glioblastomas are variably smaller tumors that may manifest\n",
      "only as subtle signal abnormalities on T2/FLAIR imaging. Microscopic tumor infiltration, which is a\n",
      "typical feature of glioblastoma, remains occult on anatomic MRI. Similarly, imaging cannot reliably\n",
      "differentiate between peritumoral edema and infiltration The typical post-contrast appearance of\n",
      "glioblastoma on MRI is that of a (usually large) nodular rim-enhancing mass surrounding a central\n",
      "necrotic core. However, the diagnosis of glioblastoma can be complex, as any type of enhancement\n",
      "pattern can occur, including solid-patchy enhancement, thin rim enhancement resembling a cyst or,\n",
      "indeed, a total lack of enhancement (Figure 3.2). Because the early stages of primary glioblastoma\n",
      "are frequently non-enhancing, radiological descriptions of non-enhancing gliomas as 'low grade' can\n",
      "be misleading and are best avoided given that the WHO 2016 classification is now based on an\n",
      "integrated diagnosis Intratumoral susceptibility signals representing petechial hemorrhages are\n",
      "thought to be common in glioblastoma, so the inclusion of T2* or susceptibility weighted imaging\n",
      "(SWI) can be useful. SWI can also help delineate biopsy tracts Numerous anatomic imaging features\n",
      "have been explored as biomarkers of glioma subtype, specifically glioblastoma. For example, the\n",
      "Visually Accessible Rembrandt (VASARI) criteria use a set of well-defined visual features (exempli\n",
      "gratia enhancement, necrosis, peritumoral edema) to provide an objective description of gliomas.\n",
      "However, the accuracy and reproducibility of such systems for glioma grading and genotyping are\n",
      "limited because of the many qualitative features that cannot be so readily incorporated As mentioned\n",
      "in previous chapters, the location of the tumor can support the diagnosis, as it indicates the\n",
      "likelihood of certain genotypes. For example, multifocality is thought to be more common in IDH\n",
      "wild-type gliomas than IDH -mutant low-grade gliomas. Given the propensity of glioblastoma for rapid\n",
      "spread along white matter tracts, it is often considered to be a multifocal disease, even though\n",
      "this is not consistently visible on imaging. Distant metastases, however, are virtually non-\n",
      "existent, so staging can be achieved from brain imaging only. Although spinal dissemination of\n",
      "glioblastoma is uncommon, if spinal drop metastases are suspected (exempli gratia on discovery of\n",
      "intracranial leptomeningeal disease), post-gadolinium spine imaging from the skull base to the\n",
      "sacrum (id est along the entire vertebral canal) should be considered as part of the diagnostic\n",
      "work-up Distinguishing glioblastoma from other diseases is often, but not always, straightforward\n",
      "(Figure 3.3). Anatomic MRI is essential for the diagnosis of glioblastoma, but it has limited\n",
      "sensitivity and specificity for the characterization of morphologically atypical lesions; for\n",
      "example, CNS lymphoma with central necrosis or with solitary metastases. In these cases, body\n",
      "imaging is usually requested before brain biopsy Perfusion imaging techniques. The recommendations\n",
      "for performing advanced imaging techniques are less prescriptive than anatomic MRI, as there is a\n",
      "lack of high-level evidence for many of the more complex modalities. However, to improve the\n",
      "identification of malignant gliomas, recent European guidance recommends the addition of perfusion\n",
      "imaging for newly diagnosed non-gadolinium-enhancing masses. Perfusion MRI aims to identify\n",
      "neovascularization in brain tumors by analyzing (contrast-enhanced) blood flow through a volume of\n",
      "tissue over time. Several perfusion methods exist (Table 3.1) ASL, arterial spin labeling; CBF,\n",
      "cerebral blood flow; DCE, dynamic T1-weighted contrast-enhanced (perfusion); DSC, dynamic\n",
      "susceptibility contrast-enhanced (perfusion); Ktrans, volume transfer constant; rCBV, relative\n",
      "cerebral blood volume; Ve, interstitial volume; Vp, plasma volume Dynamic susceptibility contrast\n",
      "(DSC, T2*) perfusion is the most widely used and established technique. After obtaining a baseline\n",
      "image volume, gadolinium contrast is rapidly injected and the same image volume is repeatedly\n",
      "acquired at short (1-2 second) intervals for 1-2 minutes. The measured target parameter is relative\n",
      "cerebral blood volume (rCBV), which has been comprehensively validated as a biomarker of\n",
      "vascularity. Relative means that CBV values have undergone mathematical correction for gadolinium\n",
      "leakage effects, which typically occur in areas where the blood-brain-barrier is disrupted. rCBV\n",
      "quantification can be optimized by using a preload contrast bolus before the perfusion injection and\n",
      "by choosing the most suitable MRI settings (exempli gratia flip angle). rCBV increases (< 1.75\n",
      "compared to normal white matter) in areas of neovascularization and is particularly elevated in\n",
      "glioblastoma. On T2-weighted imaging, intralesional flow voids may be inconsistently visible as a\n",
      "sign of (enlarged) tumor vessels, corresponding to high rCBV readings rCBV can be used broadly to\n",
      "grade IDH -mutant astrocytomas, where serial DSC may improve the identification of anaplastic\n",
      "elements as a sign of 'transformation'. Blood volume is typically raised in aggressive IDH wild-type\n",
      "gliomas, but small (exempli gratia early) glioblastomas can elicit false-negative perfusion results.\n",
      "Conversely, 1p19q co-deleted oligodendrogliomas often demonstrate moderately raised perfusion, even\n",
      "those with a low grade and a relatively favorable prognosis. Therefore, elevated rCBV does not equal\n",
      "malignancy. Structural features on imaging, particularly calcification, and younger patient age can\n",
      "support the identification of oligodendrogliomas (Figure 3.4) Other caveats to applying DSC\n",
      "perfusion are limited resolution and the inability to quantify rCBV in areas of susceptibility\n",
      "(hemorrhage, coarse calcification) Dynamic contrast-enhanced (DCE, T1) perfusion is an alternative\n",
      "technique, which is not confounded by susceptibility effects, but requires more complex mathematical\n",
      "modeling. The measured parameters of DCE include the volume transfer constant (Ktrans), plasma\n",
      "volume (Vp) and interstitial volume (Ve), as well as time signal intensity curves. Such curves\n",
      "typically differ between tumor (rapid contrast wash in and wash out) and necrotic tissue (delayed\n",
      "progressive contrast wash in). DCE is potentially useful for grading and differential diagnosis, but\n",
      "can be particularly valuable for follow-up after treatment if susceptibility effects hamper DSC\n",
      "assessment Arterial spin labeling (ASL) is a new and promising modality that does not require a\n",
      "contrast injection. Instead, ASL uses endogenously labeled blood to directly measure cerebral blood\n",
      "flow. It is not prone to leakage errors or susceptibility effects, but does require substantial\n",
      "post-processing expertise. ASL may support glioma characterization, but published data on its use\n",
      "for glioma genotyping and differential diagnosis are, to date, limited. Examples of magnetic\n",
      "resonance perfusion imaging in glioblastoma are shown in Figure 3.5 Diffusion-weighted imaging (DWI)\n",
      "should always be interpreted within the context of structural MRI features, as many other diseases\n",
      "(exempli gratia ischemia, abscess, demyelination) can restrict diffusion. DWI uses a minimum of two\n",
      "diffusion gradients (usually b0 and b1000 mm /s) in three orthogonal directions and is widely\n",
      "integrated into clinical MRI protocols, including brain tumor imaging From the b1000 image, an\n",
      "apparent diffusion coefficient (ADC) map is generated through mathematical subtraction of T2\n",
      "effects. DWI (b1000) and ADC must be interpreted in conjunction and are often assessed qualitatively\n",
      "in clinical practice by reporting the presence or absence of restricted diffusion as a tumor\n",
      "feature. In general, diffusion decreases as tissue cellularity increases. Diffusion restriction is\n",
      "defined as reduced diffusivity (ADC signal) compared to normal brain parenchyma. This feature can\n",
      "occur in glioblastoma, but malignant gliomas are more likely to exhibit diffusion values similar to\n",
      "or slightly greater than normal brain tissue.. Perilesional edema and infiltration may be seen as a\n",
      "focally increased ADC signal that makes the tumor core appear relatively darker, leading to\n",
      "overestimation of tumor restriction. This error can be avoided by quantifying ADC values (Figure\n",
      "3.6) Lower ADC values have been shown to correlate with higher glioma grades, corresponding to an\n",
      "increase in proliferative indices. Numerous studies have observed lower ADC values in IDH wild-type\n",
      "gliomas than IDH -mutant WHO grade II/III gliomas, specifically IDH -mutant 1p19q intact\n",
      "astrocytomas, which may show markedly increased ADC values ('facilitated diffusion') To a limited\n",
      "extent, ADC measurements may also be valuable for differential diagnosis; for example, primary\n",
      "central nervous system lymphoma typically has lower ADC values than glioblastoma, but results can\n",
      "overlap for individual tumors Other diffusion techniques. It remains unclear whether more elaborate\n",
      "diffusion techniques (exempli gratia diffusion kurtosis imaging, and multiexponential and\n",
      "compartmental diffusion models) could offer a diagnostic advantage over standard DWI for radiomic\n",
      "predictions Magnetic resonance spectroscopy (MRS) is a non-invasive modality that measures\n",
      "metabolites (including choline, N -acetyl aspartate, lactate, lipids) in a defined volume of brain\n",
      "tissue. Single voxel spectroscopy measures the average amount of metabolites within the chosen\n",
      "region. Multivoxel spectroscopy is technically more demanding but increasingly available for\n",
      "clinical use. MRS techniques, including chemical shift imaging, can depict intratumoral metabolite\n",
      "heterogeneity, which can be used for surgical targeting Alterations in the normal metabolite\n",
      "distribution are interpreted as markers of disease processes. For example, choline is a marker of\n",
      "cellular proliferation, which increases in neoplasms. Normally, the choline peak does not exceed the\n",
      "creatine peak (creatine is a relatively stable normal metabolite and thus suitable for comparison).\n",
      "N -acetyl aspartate is the principal marker of neuronal integrity, which non-specifically decreases\n",
      "in glioblastoma. Lactate is not present in normal tissues, but accumulates in rapidly proliferating\n",
      "tumors as an effect of tissue hypoxia (Figure 3.7). In general, the presence of lactate indicates a\n",
      "'high grade' neoplasm, but as a single measurement it is not entirely specific and may occasionally\n",
      "be observed in IDH -mutant low-grade astrocytomas and non-neoplastic conditions. Lipids are markers\n",
      "of necrosis, which can also (non-specifically) increase in glioblastoma MRS has limited accuracy for\n",
      "glioma grading and is preferentially used to distinguish tumors from non-neoplastic conditions\n",
      "Recently, interest has grown in the use of spectroscopy to identify the oncometabolite\n",
      "2-hydroxyglutarate (2HG), which is produced by IDH -mutant gliomas. A small number of institutions\n",
      "have published excellent results on 2HG-MRS, but false-positive and false-negative results have been\n",
      "reported Positron emission tomography (PET) imaging techniques involve the administration of a\n",
      "radionuclide tracer, which preferentially accumulates in the target tissue. The most widely used PET\n",
      "tracer is F-fluorodeoxyglucose (FDG); this has been investigated with partial success for brain\n",
      "imaging, its main limitation being the relatively high 'background' uptake of normal brain\n",
      "parenchyma. For this reason, FDG is not widely used in clinical glioma imaging. A variety of amino\n",
      "acid (non-FDG) tracers have been tested for glioblastoma imaging, including C-methyl- L -methionine\n",
      "(C-MET), 18 F-fluoroethyl- L -tyrosine (F-FET), F-fluorothymidine (F-FLT), F-fluorocholine (F-CHO),\n",
      "C-choline (C-CHO) and F-fluoro- L -dihydroxy-phenylalanine (F-DOPA). Currently, no single amino acid\n",
      "tracer has shown clear superiority; false-negative and false-positive results have been reported\n",
      "with most tracers, and their accessibility may vary geographically for short half-life compounds PET\n",
      "imaging is rarely indicated in clinical practice for untreated glioma characterization. It is mostly\n",
      "reserved for problem solving, specifically if advanced MRI techniques are unable to provide a clear\n",
      "distinction between recurrent glioblastoma and therapy effects (see page 50) Differential diagnosis\n",
      "The presentation of patients with glioblastoma overlaps with a range of other conditions.\n",
      "Histological diagnosis of glioblastoma is therefore mandatory and is usually obtained through\n",
      "stereotactic biopsy or after tumor resection. It is imperative that the histology is reviewed by an\n",
      "expert neuropathologist and that a multidisciplinary team, including a neuroradiologist, is involved\n",
      "in the diagnostic work-up Of the differential diagnoses that should be considered, listed in Table\n",
      "3.2, all may present with neurological symptoms. In addition, cerebral abscess, encephalitis and\n",
      "toxoplasmosis may present with a fever. Toxoplasmosis is often asymptomatic, but it can present with\n",
      "flu-like symptoms (body aches, swollen lymph nodes, fever) in some people If an infection is being\n",
      "considered as a cause of symptoms, then a full history and examination along with a septic work-up\n",
      "is advised, including, but not limited to, full blood count, blood cultures, lumbar puncture and\n",
      "imaging, as clinically appropriate\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "ology is reviewed by an expert neuropathologist and that a multidisciplinary team, including a\n",
      "neuroradiologist, is involved in the diagnostic work-up. This is done by a team of\n",
      "neuropathologists, including a neuropathologist and a neurosurgeon.In addition, a multidisciplinary\n",
      "approach is used to determine the extent of glioblastoma. In addition, it is possible to determine\n",
      "the extent and extent of glioma by using a variety of imaging techniques. For example, the following\n",
      "is a list of imaging techniques used to determine glioblastomas:Diagnosis of Glioblastoma is based\n",
      "on a variety of imaging methods.Diagnosis of glioma is based on\n",
      "\n",
      "Reference:\n",
      "It is important to recognize that gliomas that appear to be low-grade tumors histologically may\n",
      "carry mutations associated with higher-grade tumors. The use of methylation arrays can add\n",
      "diagnostic information to brain tumors that are otherwise diagnostically difficult, or where\n",
      "conventional molecular tests do not give informative results. A variety of MRI features characterize\n",
      "glioblastoma, including solid contrast uptake and absence of enhancement. Anatomic MRI is required\n",
      "for the identification, characterization and estimation of disease extent. Early glioblastoma can\n",
      "present as small, barely visible lesions. Advanced modalities such as diffusion and perfusion MRI\n",
      "and magnetic resonance spectroscopy can support the characterization of gliomas, with a view to\n",
      "grading, genotyping and differential diagnosis. Differential diagnoses may include metastatic\n",
      "disease, primary central nervous system lymphoma and therapy effects such as pseudoprogression\n",
      "and/or radiation necrosis.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541994, 'ch03')\n",
      "The diagnosis of acne involves taking a history and physical examination to determine the type of\n",
      "acne (see clinical features of the different types of acne below), an assessment of severity (see\n",
      "page 38), and an assessment of psychosocial effect (see Chapter 4). Other investigations are not\n",
      "normally necessary; however, occasionally an underlying endocrinological disorder may necessitate\n",
      "further tests (see Adult female acne, pages 26-9) Table 3.1 outlines the key elements in developing\n",
      "an accurate acne history Acne vulgaris Acne vulgaris is the most common type of acne. The individual\n",
      "lesions of acne vulgaris (Figure 3.1) can be characterized as non-inflammatory lesions inflammatory\n",
      "lesions postinflammatory erythema and/or pigmentary changes Most patients have a mixture of non-\n",
      "inflammatory and inflammatory lesions Non-inflammatory lesions are called comedones (see Chapter 2).\n",
      "Comedones may be microscopic (microcomedones) or visible as blackheads (open comedones) or\n",
      "whiteheads (closed comedones) (Figure 3.2). Microcomedones, the precursors of all acne lesions, may\n",
      "develop into whiteheads or blackheads Blackheads (open comedones) are of similar size and really\n",
      "need no description. The reason for the black appearance is the presence of the skin pigment\n",
      "melanin, which has undergone oxidation Whiteheads (closed comedones) are small spots ( around 1 mm)\n",
      "and are usually white or cream in color. Macrocomedones are large closed comedones (usually > 2 mm)\n",
      "and are usually white in color and palpable (Figure 3.3). In closed comedones, the contents of the\n",
      "pore cannot escape as easily as from an open comedone (as their external orifice is very small), so\n",
      "closed comedones, like microcomedones and macrocomedones, are more likely to become inflamed\n",
      "Inflammatory lesions may be superficial (papules, pustules) or deep (deep pustules or nodules)\n",
      "Papules are small raised red spots (< 5 mm) that persist for 7-10 days (Figure 3.4) Pustules (Figure\n",
      "3.5) are of a similar size to papules but are predominantly yellow Nodules (Figure 3.6) are larger\n",
      "lesions (> 5 mm) and persist much longer (2-3 weeks). They are often firm initially and may be\n",
      "tender; as inflammation develops they frequently soften Scars. Nodules are often associated with\n",
      "scarring, but more superficial inflammatory papules or pustules can lead to scars. Increased\n",
      "accumulation of dermal collagen may produce firm hypertrophic or keloid scars, especially on the\n",
      "angle of the jaw and the upper back and chest (see Figure 2.4, page 16) Hypertrophic scars do not\n",
      "extend beyond the initial area of inflammation, while keloid scars do. Loss of dermal tissue results\n",
      "in large atrophic scars - especially seen on the upper trunk - or smaller but deeper ice-pick scars,\n",
      "especially seen on the cheek (see Figure 2.3, page 16) The best solution to the problem of acne\n",
      "scarring is prevention, by instituting appropriate therapy early in the course of the condition\n",
      "Postinflammatory erythema and/or pigmentary changes. In some patients, particularly those with skin\n",
      "of color and Fitzpatrick skin types IV-VI, hyper- (Figure 3.7) or hypopigmented macules may persist\n",
      "following resolution of inflammatory acne lesions. Patients may think that these resolving lesions\n",
      "are active acne lesions and may have the erroneous impression that their acne is not improving. It\n",
      "is important to reassure patients that these dark areas are healing lesions and not active acne\n",
      "Postinflammatory hyperpigmentation generally resolves slowly with time but may take up to a year or\n",
      "longer in many cases. As with scarring, early appropriate therapy is the best means of avoiding this\n",
      "complication Other forms of acne Acne conglobata is a very severe form of inflammatory acne\n",
      "characterized by grouped comedones, cysts, abscesses, draining sinus tracts and scars (Figure 3.8).\n",
      "The majority of affected patients are males who present with lesions on the back, buttocks, chest\n",
      "and face. The axilla and inguinal areas can also be involved. The grouped comedones often have\n",
      "multiple openings. The inflammatory lesions are large, tender and red to violaceous in color; they\n",
      "often drain a serous or purulent material. Deep-seated sinus tracts often develop, as does keloidal\n",
      "scarring. Secondary infection with staphylococci or streptococci can occur, although many lesions\n",
      "are colonized by Propionibacterium acnes (P. acnes) only Patients with this very severe form of acne\n",
      "require expert care with oral isotretinoin, oral and intralesional corticosteroids and surgical\n",
      "excision of sinus tracts. Chronicity for many years is a feature, as is poor response to therapy\n",
      "Acne fulminans is a very severe form of inflammatory acne associated with systemic signs and\n",
      "symptoms, including fever, arthralgias and/or osteolytic lesions of the clavicles or ribs. It\n",
      "usually occurs in boys aged 13-18 years and can be very acute in its onset. Investigations\n",
      "frequently demonstrate leukocytosis, elevated erythrocyte sedimentation rate and/or proteinuria.\n",
      "Clinically, acne fulminans is characterized by multiple intensely inflamed nodules, cysts and\n",
      "plaques (Figure 3.9). Large nodules can ulcerate, drain and become necrotic. Hemorrhagic crusting is\n",
      "common. A polyarthritis of large joints such as the sacroiliac, hips, knees, shoulders, elbows and\n",
      "ankles may be present. The etiology of acne fulminans is unknown Patients with this disorder should\n",
      "be urgently referred to a dermatologist for management with oral corticosteroids and isotretinoin\n",
      "(Table 3.2) Acne with solid facial edema. In rare cases, acne can be accompanied by a firm non-\n",
      "pitting edema of the midportion of the face and forehead. The etiology of this phenomenon is unknown\n",
      "but may relate to lymphatic obstruction secondary to the inflammatory response associated with the\n",
      "acne. A primary hypoplastic abnormality of the lymphatics is the likely cause. This condition is\n",
      "unresponsive to oral antibiotics but has been treated successfully at times with oral isotretinoin\n",
      "and corticosteroids Adult female acne. Adult acne, particularly in women, is worthy of special note;\n",
      "many adults have a prolonged course of acne beyond teenage years and in some cases acne may present\n",
      "for the first time in adulthood. Although it is generally less severe than teenage acne, acne in\n",
      "adult women is challenging to treat. In some cases, this form of acne is characterized by tender\n",
      "inflammatory papules or nodules involving the lower third of the face and neck (Figure 3.10). There\n",
      "may also be comedonal acne involving the forehead or lateral margins of the face. In other cases,\n",
      "widespread disease may affect the trunk Hyperandrogenism. If an adult woman has sudden-onset severe\n",
      "acne, acne accompanied by signs of hyperandrogenism or acne that is refractory to conventional\n",
      "therapy, a medical history and physical examination directed towards eliciting symptoms or signs of\n",
      "hyperandrogenism should be performed. Investigations to rule out an underlying endocrine abnormality\n",
      "should also be carried out in these cases (Table 3.3); note, however, that most cases of adult\n",
      "female acne do not require an endocrine work-up Screening tests for hyperandrogenism include serum\n",
      "dehydroepiandrosterone sulfate (DHEAS), total testosterone, free testosterone, and luteinizing\n",
      "hormone and follicle-stimulating hormone. These tests should be obtained in the luteal phase of the\n",
      "menstrual cycle. Women should be advised not to take oral contraceptives for at least 1 month before\n",
      "laboratory testing, as these drugs can mask an underlying endocrine abnormality Excess androgens may\n",
      "be produced by either the adrenal gland or the ovary. Serum DHEAS can be used to screen for an\n",
      "adrenal source of excess androgen production. An ovarian source of excess androgens may be suspected\n",
      "if the serum total testosterone is elevated Women with hyperandrogenism may also have insulin\n",
      "resistance; they are at risk of developing diabetes and cardiovascular disease. It is therefore\n",
      "important for the long-term health of these patients to identify hyperandrogenism so that\n",
      "appropriate therapy from an endocrinologist or gynecologist can be initiated Childhood\n",
      "endocrinopathy. Acute onset, persistent or severe acne in the presence of virilization in children\n",
      "aged 1-7 years should always raise the possibility of an underlying endocrinopathy including\n",
      "premature adrenarche, precocious puberty, congenital adrenal hyperplasia due to 11beta-hydroxylase\n",
      "deficiency or the presence of an adrenocortical tumor. A focused history and examination for signs\n",
      "of accelerated growth, precocious puberty (Table 3.4) and hirsutism or other signs of\n",
      "hyperandrogenism should be adopted, and referral to a pediatric endocrinologist should be considered\n",
      "Follow up and anticipatory guidance is indicated in these children. In prepubertal acne, predictive\n",
      "factors for severity and persistence include a high number of comedones, mid-facial distribution and\n",
      "early development of comedones, high to normal levels of DHEAS and high total testosterone. Earlier\n",
      "menarche in girls has also been described as a predictive factor Acne excoriée (also known as acne\n",
      "excorie or 'acne de jeune filles') is described on pages 46-7 Acne mechanica. Repetitive rubbing or\n",
      "friction can sometimes exacerbate acne. This is most commonly observed with sports equipment such as\n",
      "football helmets, shoulder pads and chin straps. It can also occur in response to habits of rubbing\n",
      "the face or resting the head on the hands. Acne mechanica tends to occur in cases of moderate-to-\n",
      "severe inflammatory acne and less often in cases of mild acne. Treatment is aimed at controlling the\n",
      "underlying acne and minimizing the mechanical stress on the skin Occupational acne. Exposure to\n",
      "certain industrial agents can lead to the development of acne. Coal tar derivatives and insoluble\n",
      "cutting oils can produce an inflammatory acne characterized by large comedones, papules, pustules,\n",
      "cysts and nodules. Lesions are most commonly noted in areas covered by clothing that was saturated\n",
      "with the offending agent Chloracne is caused by exposure to halogenated hydrocarbons via ingestion,\n",
      "inhalation or contact with the skin. Most cases have been reported as a result of accidental\n",
      "industrial exposure, ingestion of contaminated food products, chemical warfare or exposure to\n",
      "herbicides. Implicated chemicals include polyhalogenated naphthalenes, biphenyls, dibenzofurans,\n",
      "dioxins and azobenzenes Chloracne is characterized by the development of dense collections of\n",
      "comedones (Figure 3.11) on the face, retroauricular skin, neck, axilla and scrotum. These comedones\n",
      "can eventually develop into tender inflamed cysts. Outbreaks of severe inflammatory lesions, which\n",
      "heal with scarring, can occur for years following exposure to the offending agent Treatments include\n",
      "topical tretinoin and oral isotretinoin; physical treatment with gentle cautery after application of\n",
      "local anesthesia can be particularly helpful Differential diagnosis The differential diagnosis of\n",
      "acne includes drug-induced acneiform eruptions, rosacea, pyoderma faciale, gram-negative\n",
      "folliculitis and perioral dermatitis Drug-induced acne. A number of drugs cause or worsen acne or\n",
      "can induce an acneiform eruption (Table 3.5). The latter account for about 1% of all drug-induced\n",
      "skin eruptions. A diagnosis of acne vulgaris is defined by the presence of closed comedones, papules\n",
      "and pustules. In contrast, most drug-induced 'acnes' represent acne-like eruptions embracing\n",
      "monomorphic inflammatory lesions in the absence of comedones, often presenting abruptly outside the\n",
      "most frequent age range for acne and extending over areas not commonly affected by acne. The face\n",
      "and upper trunk are most frequently affected The interval between the onset of the acneiform\n",
      "eruption and administration of the implicated drug depends very much on the agent provoking the\n",
      "response Psychotropic drugs. Rarely, some psychoactive drugs including lithium and amineptine, an\n",
      "atypical tricyclic antidepressant, may induce true acne. Lithium can worsen existing acne or cause\n",
      "acne de novo. The acne presents 2-3 months after starting therapy. Papules, pustules and nodules\n",
      "occur and severe forms such as acne conglobata have been described. Most reported cases involving\n",
      "amineptine have been in adult women Comedonal lesions are the most frequently seen lesions;\n",
      "inflammatory lesions are usually sparse. The mechanism has been postulated to be via a selective\n",
      "decrease in the uptake of dopamine followed by an inhibitory effect of elevated dopamine on\n",
      "prolactin, with a subsequent increase in testosterone output. If 'acne' is triggered the drug should\n",
      "be withdrawn; response is variable and systemic therapy and physical treatment of the comedones may\n",
      "be required Corticosteroids may provoke an acneiform reaction regardless of their route of\n",
      "administration. The precise mechanism is uncertain. Steroid acne is usually, but not invariably,\n",
      "more monomorphic than true acne vulgaris; however, both inflammatory and non-inflammatory lesions\n",
      "may be present on the face, back and chest (Figure 3.12) Abuse of androgenic anabolic steroids\n",
      "(AAS), synthetic derivatives of testosterone and testosterone salts by body builders and others can\n",
      "exacerbate true acne vulgaris and induce acne fulminans or acne conglobata. Usage is increasing in\n",
      "women. Induction of acne is due, at least in part, to androgen receptor binding leading to\n",
      "hypertrophy of the sebaceous glands with consequent increased sebum output and a concomitant\n",
      "increase in the population density of P. acnes. Estimates suggest that acne is a side effect in as\n",
      "many as 43% of users Progestins. Acne may be exacerbated by progestins and has been reported with\n",
      "use of the Mirena coil. Third-generation progestins in combined oral contraceptives have a lower\n",
      "androgenic effect Antiepileptic drugs, especially phenytoin, have been incriminated in case reports\n",
      "in the past Iodides and bromides commonly cause follicular pustules. Iodides may be found in non-\n",
      "prescription preparations for asthma, expectorants, kelp-containing substances and teas. Sedatives\n",
      "and cold remedies often contain bromides. Chloracne (see page 31) is caused by systemic poisoning,\n",
      "most frequently in occupational settings Vitamins B, B and B. Exacerbation or new onset of acne have\n",
      "been described with vitamin B, 5-10 mg/week. Women are almost exclusively affected, with acne\n",
      "developing within the first 2 weeks after the injection. The acne-inducing dose of vitamin B has not\n",
      "been established. Iodine is present in some ampules of vitamin B and may be the trigger. Recently, a\n",
      "study showed that vitamin B supplementation in P. acnes cultures promoted the production of\n",
      "porphyrins, providing a potential mechanism of action, as porphyrins induce inflammation in acne The\n",
      "eruption is monomorphic, consisting of small follicular papules and pustules on the face, especially\n",
      "the forehead and chin, as well as the upper arms and upper trunk. Conventional acne therapies are\n",
      "usually unsuccessful but the acneiform rash settles within 8-10 days of withdrawing the vitamin B\n",
      "therapy. The severity of the reaction also appears to correlate with the response to therapy EGFR\n",
      "inhibitors. A follicular acneiform eruption has been reported in patients with cancer who are\n",
      "treated with epidermal growth factor receptor (EGFR) inhibitors. The consistency of lesion\n",
      "morphology and timing following monotherapy with these agents suggests a direct biological effect of\n",
      "the antibody A drug-induced skin reaction occurs in more than 50% of patients, often within a few\n",
      "weeks of receiving therapy. The changes include follicular papules and sterile pustules on the face\n",
      "and upper trunk in a distribution similar to conventional acne, although in severe cases the limbs\n",
      "may be affected. Comedones are not seen. Most reports suggest that topical acne therapies, oral\n",
      "tetracyclines and topical or oral corticosteroids are effective. Oral isotretinoin has also been\n",
      "used with some success Rosacea is most common in adults with fair skin and light hair and eye color.\n",
      "Comedones are notably absent. It is characterized by facial flushing and erythema of the cheeks,\n",
      "nose, forehead and chin (Figure 3.13). Inflammatory papules and pustules can develop within the\n",
      "areas of erythema. In late stages of rosacea, a bulbous hypertrophy of the nose, termed rhinophyma,\n",
      "may occur (Figure 3.14) Pyoderma faciale (Figure 3.15), synonymous with rosacea fulminans, is deemed\n",
      "to be an explosive form of rosacea. This disorder is most common in young women, often in the\n",
      "context of stress, with a phenotype typical of rosacea patients. Treatment with oral isotretinoin\n",
      "and corticosteroids is indicated (see Table 3.2) Gram-negative folliculitis is characterized by the\n",
      "sudden development of superficial pustules in patients who have been treated for acne with\n",
      "antibiotics (Figure 3.16). It may seem to masquerade as a flare of the underlying acne, but it is\n",
      "actually a folliculitis caused by gram-negative bacteria including Pseudomonas species and\n",
      "Enterobacteriaceae. Cultures of pustules should be obtained. If gram-negative organisms are present\n",
      "the patient should be referred to a dermatologist for consultation regarding treatment with\n",
      "isotretinoin (see Table 3.2). High-dose trimethoprim has been used successfully but relapse rate is\n",
      "much higher than with oral isotretinoin Perioral (periorificial) dermatitis (Figure 3.17) is\n",
      "characterized by erythema, scaling and small papules and pustules, most commonly around the mouth\n",
      "and on the chin. It often occurs in adult women, especially in the context of stress. Topical\n",
      "corticosteroids can cause or exacerbate the condition and should be avoided. Oral tetracycline is\n",
      "the treatment of choice Assessing acne severity Defining acne severity helps with the selection of\n",
      "the most suitable initial therapy and enables response to treatment to be monitored. There are many\n",
      "scales available for assessing the severity of acne, but no consensus on a gold standard. Severity\n",
      "can be determined according to the type, number, distribution or location of lesions, or a\n",
      "combination of each of these. Acne can be classified as comedonal, mild, moderate or severe based on\n",
      "the type of lesions (Table 3.6). Alternatively, an assessment tool such as the Leeds Revised Acne\n",
      "Grading System allows grading of severity based on photographic comparisons of acne on the face\n",
      "(Figure 3.18), back and chest\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "ans is a very severe form of inflammatory acne associated with systemic signs and symptoms,\n",
      "including fever, arthralgias and/or osteolytic lesions of the clavicles or ribs. It usually occurs\n",
      "in boys aged 13-18 years and can be very acute in its onset. Investigations frequently demonstrate\n",
      "leukocytosis, elevated erythrocyte sedimentation rate and/or proteinuria. Clinically, acne fulminans\n",
      "is characterized by multiple intensely inflamed nodules, cysts and plaques (Figure 3.9). Large\n",
      "nodules can ulcerate, drain and become necrotic. Hemorrhagic crusting is common. A polyarthritis of\n",
      "large joints such as the sacroiliac\n",
      "\n",
      "Reference:\n",
      "Diagnosis is based on an accurate history, evaluation of clinical features, assessment of severity\n",
      "and recognition of psychological or social issues. Further investigations are rarely required. Acne\n",
      "presents with both inflammatory and comedonal lesions in most patients. Acne scarring is a very\n",
      "common sequel to acne. Postinflammatory hyperpigmentation may persist for many months in type IV-VI\n",
      "skins following the resolution of acne. Late-onset acne in females may relate to hyperandrogenism.\n",
      "Further investigations should be carried out to determine if there is an underlying endocrinological\n",
      "problem. Drugs, industrial agents and friction may all contribute to acne. Differential diagnoses of\n",
      "acne include drug-induced acneiform eruptions, rosacea, pyoderma faciale, gram-negative folliculitis\n",
      "and perioral dermatitis. Acne severity can be determined according to the type, number, distribution\n",
      "or location of lesions, or a combination of each of these. There are many scales available for this,\n",
      "but no gold standard at present.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797587, 'chp06')\n",
      "Principles of management Prevention versus treatment Current therapy of osteoarthritis (OA) largely\n",
      "aims to treat existing disease by controlling its major symptom - pain - and maintain or improve\n",
      "joint and limb function and improve quality of life. While there are numerous therapies targeted\n",
      "against symptoms, at present no treatments have been definitively shown to modify the structural\n",
      "progression of OA. Currently, the best advice we can give on preventing OA relates to the following\n",
      "lifestyle modifications avoid joint trauma avoid high-impact loading of joints (through sport or\n",
      "occupation) maintain a body mass index within the normal range for size maintain aerobic fitness,\n",
      "which aids periarticular muscle strength and weight control A healthy diet is important to aid\n",
      "weight control, but no diets or dietary supplements have been shown to prevent, or to modify the\n",
      "progression of, OA Management of OA There are many evidence-based guidelines from a variety of\n",
      "specialty societies for managing OA (see Key references, page 72). These guidelines agree on several\n",
      "main principles for the treatment of the disease People with OA should be involved in their own\n",
      "management, and should receive education about their condition and the range and safety of treatment\n",
      "options available Optimum treatment involves a combination of non-pharmacological and\n",
      "pharmacological approaches Therapies, particularly pharmacological ones, need to be tailored\n",
      "according to an individual person's comorbidities and risk factors Exercise and weight management\n",
      "should be recommended to all patients Table 6.1 summarizes the hierarchy of options that should be\n",
      "considered for managing individuals with OA In general, all non-pharmacological options should be\n",
      "considered early, with some sequence or 'step-up' when using pharmacological interventions.\n",
      "Remember, none of these therapies is mutually exclusive and patients who are not responding should\n",
      "be offered as many options as possible before surgery is considered. Therapies will need to be\n",
      "tailored according to an individual patient's comorbidities and preferences There are a few areas of\n",
      "controversy where guidelines diverge (discussed further in later chapters) glucosamine and\n",
      "chondroitin, alone or in combination (see Chapter 7) intra-articular therapy, particularly intra-\n",
      "articular hyaluronans (see Chapter 9) some surgical procedures (see Chapter 10) Very importantly, we\n",
      "should not confuse what clinicians advise or prescribe with how patients manage their own OA. There\n",
      "is little research on what patients actually do, but certainly compliance, perhaps more so with\n",
      "self-directed therapies, such as exercise, is often low. Clinicians therefore need to adapt the\n",
      "consultation to the needs of the individual patient to reach agreement on a suitable and sustainable\n",
      "management plan The subsequent chapters give an overview of the rationale, evidence and clinical\n",
      "hints for using a particular therapy. However, it is worth first reviewing some of the limitations\n",
      "of the evidence base Problems with interpreting the OA therapy literature The practicing clinician\n",
      "may well be overwhelmed at times with the number of publications on a given therapy. However, some\n",
      "critical analysis of trial data is important. Some of the common problems in interpreting OA trials\n",
      "include the use of different definitions (exempli gratia of OA) the use of different outcome\n",
      "measures unrealistic inclusion criteria the degree of clinical significance Different definitions.\n",
      "Studies use different definitions of OA, focusing on symptoms, clinical features, radiographic\n",
      "findings, or a combination of these. Inclusion of a wide range of pain severity (and presumably a\n",
      "wide range of structural pathology) means that the effects of a therapy on subgroups may be missed.\n",
      "For example, many studies of knee OA do not evaluate the patellofemoral joint, which is a common\n",
      "site of pain in OA of the knee, and few studies consider multiple joint involvement Use of different\n",
      "outcome measures. The Outcome Measures in Rheumatology Core Set (OMERACT) for OA recommends\n",
      "collecting data on pain, function and quality of life; however, there are many instruments for\n",
      "measuring these domains, and they have different performance metrics. For example, modern studies\n",
      "use patient-reported generic pain visual analog or numeric rating scales, or the more responsive\n",
      "disease-specific multi-domain instruments such as the Western Ontario MacMaster questionnaire\n",
      "(commonly known as WOMAC). As these tools may be used as averaged daily measures or at single time\n",
      "points, care needs to be taken when comparing studies Non-generalizable inclusion criteria. Most\n",
      "trials (of drugs in particular) tend to include relatively healthy patients and do not reflect the\n",
      "usual older OA population with a high frequency of comorbidities. In addition, trial participants\n",
      "may have only one painful joint, whereas large community samples suggest that, in practice, patients\n",
      "over 55 years of age may have an average of four painful joints Degree of clinical significance.\n",
      "Many studies have reported a statistically significant difference between two trial therapies\n",
      "without reporting whether the result is important clinically. This may sometimes be expressed as the\n",
      "minimal clinically important difference (MCID). The MCID may vary depending on the measure used to\n",
      "estimate a patient's symptoms. Although the reader should look at specific data for individual\n",
      "outcome measures, in general, a treatment effect of at least 20% is desirable Structured care\n",
      "pathways With the massive rise of symptomatic OA due to the aging 'baby boomer' population and the\n",
      "increasing prevalence of obesity, healthcare systems are being placed under increasing stress to\n",
      "manage OA. In the UK, Department of Health directives for the planning of appropriate care pathways\n",
      "are in place, based on patient self-management with aid from primary care physicians and physical\n",
      "therapists, with much smaller numbers of patients expected to use secondary care and surgical\n",
      "interventions if managed appropriately. Similarly, in the USA, a number of initiatives, supported by\n",
      "the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention, are\n",
      "addressing the rising burden of OA at the public health level. Certainly, public and private systems\n",
      "will increasingly look at the structure and cost-effectiveness of OA care regimens\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Principles of management of OAPrevention versus treatment of OACurrent therapy of osteoarthritis\n",
      "(OA) largely aims to treat existing disease by controlling its major symptom - pain - and maintain\n",
      "or improve joint and limb function and improve quality of life. While there are numerous therapies\n",
      "targeted against symptoms, at present no treatments have been definitively shown to modify the\n",
      "structural progression of OA. Currently, the best advice we can give on preventing OA relates to the\n",
      "following lifestyle modifications:avoid joint trauma, such as osteoporosis, and prevent\n",
      "osteoporosisavoid high-impact loading of joints (through sport or occupation)avoid high-impact load\n",
      "of joints (through exercise or occupation)avoid low-impact loading of the joints\n",
      "\n",
      "Reference:\n",
      "Prevention currently means advice to avoid trauma and high-impact repetitive loading of joints.\n",
      "Essential management requires involving and educating the person and choosing a range of non-\n",
      "pharmacological and pharmacological therapies. Muscle strengthening, aerobic exercise and weight\n",
      "loss are a good starting point for management.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797556, 'chp2')\n",
      "2 Pathophysiology and classification Normal neuromuscular transmission At the normal neuromuscular\n",
      "junction (NMJ), acetylcholine (ACh) is released from the motor neuron terminal, diffuses across the\n",
      "synaptic space and binds to ACh receptors (AChR), which are densely clustered on the folded endplate\n",
      "membrane of the muscle fiber. The high concentration of AChRs is crucial for efficient neuromuscular\n",
      "transmission. The ACh depolarizes the muscle endplate region, ultimately causing the muscle to\n",
      "contract (Figure 2.1) Myasthenia gravis (MG) is the best characterized autoimmune disorder of the\n",
      "nervous system. The immune-mediated nature of MG was suspected as early as the 1960s when it was\n",
      "speculated to be caused by a dysregulated immune response, with antibodies directed against skeletal\n",
      "muscle Acetylcholine receptor antibodies. A series of animal and human experiments in the 1970s\n",
      "confirmed the above hypothesis, and elevated titers of antibodies against the acetylcholine receptor\n",
      "(AChR) were ultimately discovered in the serum of patients with MG. Loss of AChRs results in\n",
      "impaired neuromuscular transmission and muscle weakness Multiple pathological processes cause loss\n",
      "of functional AChRs in MG complement-mediated lysis accelerated internalization and degradation of\n",
      "AChRs direct blockade of AChRs by antibodies Complement-mediated lysis is thought to be the most\n",
      "important mode of loss of AChR, but the actual process that initiates the aberrant immune attack on\n",
      "the AChR is unknown. Both the immunoglobulin (Ig) G antibody and complement have been localized to\n",
      "the motor endplate in myasthenia models, indicating that circulating IgG antibodies directed against\n",
      "the AChR bind to the postsynaptic membrane and activate the terminal complement sequence (C5b-9), or\n",
      "membrane attack complex (MAC). This results in lysis of the postsynaptic membrane, causing loss of\n",
      "the AChR (Figure 2.2). In fact, elevated MAC levels have been demonstrated in the plasma of patients\n",
      "with MG. 'Binding' antibodies are the most common type found in patients with MG Accelerated\n",
      "internalization and degradation of acetylcholine receptors. A key mechanism of disease pathology in\n",
      "MG is the modulation, internalization and eventual destruction of AChRs at the NMJ by the\n",
      "crosslinking of AChR-specific autoantibodies (Figure 2.3). This process is known as antigenic\n",
      "modulation Direct blockade of acetylcholine receptors by antibodies. 'Blocking' antibodies are the\n",
      "second most common type found in patients with MG. These antibodies block the binding of ACh to\n",
      "AChRs on the muscle endplate (Figure 2.4) Impaired neuromuscular transmission. As a result of the\n",
      "pathological processes described above, the postsynaptic membrane becomes simplified, with a\n",
      "reduction in the number of AChRs and junctional folds and a reduced safety factor in neuromuscular\n",
      "transmission, ultimately leading to impaired neuromuscular transmission Muscle-specific receptor\n",
      "tyrosine kinase antibodies. Although most patients with generalized MG have antibodies to AChR (see\n",
      "below), a minority of patients without AChR antibodies have antibodies to the muscle-specific\n",
      "receptor tyrosine kinase (MuSK). As discussed in Chapter 1, a higher percentage of patients with\n",
      "treatment-refractory MG have been found to have MuSK antibodies than those who respond to treatment.\n",
      "The disease can be particularly severe in patients with MuSK antibodies (see below) At present it is\n",
      "unclear how MuSK antibodies cause MG, but it is possible that MuSK antibodies alter AChR density or\n",
      "number. MuSK signaling is crucial for the development, long-term maintenance and stabilization of\n",
      "the postsynaptic portion of the NMJ. The antibodies in MuSK MG are largely of the IgG4 subclass and\n",
      "have been demonstrated in vitro to block the assembly and activation of MuSK. In animal models,\n",
      "administration of MuSK antibodies has resulted in reduced postsynaptic AChRs, disturbed synaptic\n",
      "alignment, reduced synaptic potentials and impaired muscle activation Role of the thymus.\n",
      "Approximately 75% of patients who undergo thymectomy are found to have thymic pathology. Of these,\n",
      "15% are discovered to have thymoma, and the remainder have evidence of lymphoid hyperplasia. Myoid\n",
      "cells are located in the thymus gland, and thymus tissue from patients with MG has been found to be\n",
      "enriched with AChR-reactive T cells. The close interaction between lymphocytes and myoid cells in\n",
      "the thymus, together with a yet-to-be-discovered stimulus that disrupts normal immune tolerance, may\n",
      "lead to the autoimmune response triggering MG MG can be classified in a variety of ways by disease\n",
      "type by antibody status by disease severity Classification by disease type. Ocular MG, which causes\n",
      "only ptosis and/or diplopia, occurs in approximately 15% of cases; generalized disease occurs in the\n",
      "remainder Classification by antibody status Antibodies to AChR. As noted above, MG is most often\n",
      "caused by antibodies to the AChR. This is the case for 85% of cases of generalized disease and\n",
      "approximately 50% of cases of purely ocular MG. Antibodies to AChR may be of the binding, blocking\n",
      "or modulating type, with binding being the most common. AChR antibodies are highly specific for the\n",
      "diagnosis of MG, although the degree of elevation in titers has never been found to correlate with\n",
      "the severity of disease. Antibody titers may decline with immunosuppressive treatment within an\n",
      "individual, although the reliability of determining treatment effect is less robust Antibodies to\n",
      "muscle receptor tyrosine kinase (MuSK) occur in about 7% of cases of generalized MG but are rarely\n",
      "reported in isolated ocular disease. MuSK-antibody-positive MG is a distinct clinical subset of the\n",
      "disease, almost always seen in adults, more frequently in women, and never in conjunction with\n",
      "thymic disease. There is predominant involvement of the bulbar muscles, often with concurrent neck\n",
      "and respiratory muscle weakness. Ocular and limb muscle weakness is less common than in AChR-\n",
      "antibody-related disease but is certainly seen in this population. Most patients can actually worsen\n",
      "on treatment with acetylcholinesterase inhibitors such as pyridostigmine In general, treatment-\n",
      "refractory MG and myasthenic crises are more common in this subset of the disease Seronegative for\n",
      "AChR or MuSK antibodies. When AChR or MuSK antibodies are not detected, patients are diagnosed with\n",
      "MG by clinical or electrodiagnostic means (typically with repetitive nerve stimulation or single\n",
      "fiber electromyography; see page 25 -) and are classified as 'double seronegative' or\n",
      "'seronegative'. Included in this group are a small percentage of patients with antibodies only to\n",
      "'clustered' AChRs. These antibodies can only be detected using cell-based assays, which, in contrast\n",
      "to standard diagnostic antibody tests, allow for the detection of antibodies that bind to AChRs that\n",
      "are clustered in a natural membrane environment, as they are at the NMJ. These patients are more\n",
      "likely to be younger and have milder disease than other patients with MG Other antibodies.\n",
      "Antibodies to lipoprotein-related protein 4 (LRP4), agrin and cortactin have recently been found in\n",
      "a small percentage of patients with MG. - Further discovery of pathogenic antibodies and\n",
      "improvements in antibody detection are likely to decrease the percentage of patients who are\n",
      "ultimately diagnosed with seronegative MG Classification by disease severity. Osserman was the first\n",
      "to classify patients with MG according to disease severity. The most commonly used modification of\n",
      "the original classification scheme is as follows Group I - ocular Group IIA - mild generalized Group\n",
      "IIB - moderate-to-severe generalized Group III - acute, severe, developing over weeks to months\n",
      "Group IV - late, severe, with marked bulbar involvement This classification has several notable\n",
      "limitations, including the indistinct descriptive wording and lack of clear distinctions between\n",
      "groups. This classification system also fails to include a category for patients in clinical\n",
      "remission or those in crisis A task force of the Myasthenia Gravis Foundation of America (MGFA)\n",
      "subsequently developed a refined classification system (Table 2.1) that is more clinically\n",
      "descriptive and provides a clearer distinction between groups\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "/or diplopia, occurs in approximately 15% of cases; generalized disease occurs in the remainder of\n",
      "the cases.Classification by antibody status:Antibodies to AChR. As noted above, MG is most often\n",
      "caused by antibodies to the AChR. This is the case for 85% of cases of generalized disease and\n",
      "approximately 50% of cases of purely ocular MG. Antibodies to ACHR may be of the binding, blocking\n",
      "or modulating type, with binding being the most common. AChR antibodies are highly specific for the\n",
      "diagnosis of MG, although the degree of elevation in titers has never been found to correlate with\n",
      "the severity of disease. Antibody titers may decline with immunos\n",
      "\n",
      "Reference:\n",
      "In myasthenia gravis (MG), pathogenic antibodies against acetylcholine receptors (AChRs) or muscle-\n",
      "specific receptor tyrosine kinase (MuSK) are responsible for the abnormal neuromuscular junction\n",
      "transmission leading to muscle weakness. Antibodies to AChRs reduce the number of AChRs by several\n",
      "pathological mechanisms including complement-activated damage, antigenic modulation leading to\n",
      "accelerated endocytosis and degradation of the AChR, and direct blockade of the receptor. Abnormal\n",
      "thymic pathology is associated with AChR-antibody-positive MG, particularly late-onset disease.\n",
      "About 7% of cases of generalized MG have antibodies to MuSK. This is a distinct clinical subset of\n",
      "the disease, which is generally more severe than AChR-antibody-positive MG, not associated with\n",
      "thymic pathology and more likely to be refractory to treatment.\n",
      "\n",
      "####################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print_examples([\n",
    "    'allenai/led-base-16384'],\n",
    "    df_val)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "UTUY8QgQa2WM"
   },
   "source": [
    "##### Print Test Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 7745,
     "status": "ok",
     "timestamp": 1610617121036,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "D9rpcejOa2WO",
    "outputId": "c86cf9ed-eca7-4f92-ce7a-91f8661fdd29",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(9781910797105, 'ch05')\n",
      "Developmental theories and environmental factors Is schizophrenia a degenerative brain disorder, as\n",
      "originally thought by Kraepelin, or is it better viewed as non-progressive? During the 1990s, much\n",
      "attention was given to the 'neurodevelopmental hypothesis' of schizophrenia. On the basis of the\n",
      "range of observations outlined in Table 5.1, it was suggested that a static lesion, either genetic\n",
      "or environmental in origin during brain development, expressed its effects as a function of the\n",
      "maturational stage of the brain. In schizophrenia, the characteristic symptoms emerge only during\n",
      "the final stages of brain development in adolescence, when normal 'pruning' or elimination of excess\n",
      "synapses takes place. It is now known that schizophrenia results in part from a developmentally\n",
      "regulated disconnection of higher order association areas, through alterations in neuronal\n",
      "migration, synapse formation and myelination Neurodevelopmental risk factors Some established risk\n",
      "factors act early in life (Table 5.2). Obstetric complications generally appear to increase the risk\n",
      "of schizophrenia. During pregnancy, risk factors include rubella and influenza infections in the\n",
      "first or second trimester and antepartum bleeding. Asphyxia and low birth weight, especially with\n",
      "intrauterine growth retardation, are risk factors at birth, as are certain brain insults and\n",
      "infections in childhood Early developmental delays Longitudinal follow-up studies of large birth\n",
      "cohorts have shown that the 1-2% of the sample who go on to develop adult schizophrenia show slight\n",
      "delays in motor, speech and intellectual milestones compared with the rest of the cohort. These\n",
      "differences are subtle, such as walking being delayed by 1-2 months. Certain problems, such as\n",
      "developmental receptive language disorders, are particularly linked to later schizophrenia. These\n",
      "developmental delays do not occur in bipolar disorder Secondary schizophrenias The so-called\n",
      "secondary schizophrenias fit less easily into the neurodevelopmental formulation. The psychotic\n",
      "symptoms in these cases appear to be caused by a primary organic disorder, either a known physical\n",
      "disorder or a clinically unsuspected brain lesion Table 5.3 lists those medical conditions in which\n",
      "a clear or possible association with schizophrenia-like disorders has been reported. Antineuronal\n",
      "cell surface antibody disorders involving the N -methyl- D -aspartate (NMDA) receptor can present\n",
      "with psychosis, which responds to immunotherapy. These disorders are more common than previously\n",
      "realized, accounting for perhaps 2-3% of first-onset cases Clinically recommended screening\n",
      "investigations for first-episode schizophrenia are outlined in Table 5.4 Street-drug use Use of\n",
      "cannabis and amphetamine-like drugs has long been known to be an important trigger of relapse, but\n",
      "had not been thought to directly cause the onset of illness. However, several cohort studies since\n",
      "2000 have shown that use of cannabis doubles the risk of developing schizophrenia The risk is\n",
      "further increased if minor psychotic symptoms pre-exist and if cannabis use starts early in\n",
      "adolescence. Research suggests that this effect of cannabis may be mediated by a particular gene.\n",
      "Those with a specific version of the catechol- O -methyltransferase (COMT) gene, carried by about a\n",
      "quarter of the general population, appear to be especially prone to psychosis after cannabis use.\n",
      "Delta-9-THC, the active component of cannabis, disrupts learning and recall in schizophrenia\n",
      "Psychosocial risk factors There is emerging evidence for the role of non-biological risk factors in\n",
      "schizophrenia, such as the effects of urban upbringing and of ethnicity, as noted in Chapter 3\n",
      "\n",
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Developmental theories and environmental factors in schizophrenia [ edit ]Is schizophrenia a\n",
      "degenerative brain disorder, as originally thought by Kraepelin, or is it better viewed as non-\n",
      "progressive? [ edit ]During the 1990s, much attention was given to the 'neurodevelopmental\n",
      "hypothesis' of schizophrenia. On the basis of the range of observations outlined in Table 5.1, it\n",
      "was suggested that a static lesion, either genetic or environmental in origin during brain\n",
      "development, expressed its effects as a function of the maturational stage of the brain. In\n",
      "schizophrenia, the characteristic symptoms emerge only during the final stages of brain development\n",
      "in adolescence, when normal 'pruning' or elimination of excess synapses takes place. It is now\n",
      "\n",
      "Reference:\n",
      "Early neurodevelopmental, non-genetic risk factors exist for schizophrenia. Like genetic factors,\n",
      "environmental factors are many and varied. Birth complications increase the child's risk of\n",
      "schizophrenia in later life fourfold. Psychosocial risk factors are being re-established as\n",
      "important risk factors. Cannabis use increases the risk of schizophrenia as well as relapse.\n",
      "Evidence for specific gene-environment interactions is beginning to emerge.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797433, 'ch05')\n",
      "Surgery is the cornerstone of management for both early and advanced ovarian cancer, although the\n",
      "aims are different in each case In patients with presumed early disease, the aim of surgery is to\n",
      "remove the primary tumor, along with adequate peritoneal and lymphogenic staging In advanced\n",
      "disease, the aim is to achieve maximal cytoreduction and tumor reduction Surgery for primary ovarian\n",
      "cancer Surgical management of primary ovarian cancer may involve non-fertility-sparing and\n",
      "fertility-sparing approaches (Figure 5.1) Non-fertility-sparing surgery consists of cytological\n",
      "staging, removal of the ovaries, fallopian tubes and uterus, peritoneal biopsies and lymph node\n",
      "dissection (Table 5.1). In addition, appendicectomy should be considered in patients with mucinous\n",
      "histology, or if the appendix appears abnormal Depending on the histological grade and tumor\n",
      "subtype, up to 30% of patients with apparently early epithelial ovarian cancer will be upstaged\n",
      "after comprehensive peritoneal and lymph node staging. - The only prospective randomized trial to\n",
      "have compared lymph node sampling alone with systematic lymph node dissection found that 13% of\n",
      "patients with lymph node involvement would be missed with lymph node sampling alone; this clearly\n",
      "has important implications for tumor staging and choice of adjuvant treatment. However, in this\n",
      "study, systematic lymph node dissection was not associated with a significant survival benefit\n",
      "compared with sampling alone, partly because of a lack of statistical power but also because of\n",
      "common use of chemotherapy in the sampling arm, which seemed to potentially compensate for the less\n",
      "radical dissection. Increasing evidence shows that the prevalence of positive lymph nodes in stage\n",
      "IA mucinous cancer is extremely low, and that there is no value in performing surgery that can lead\n",
      "to unnecessary morbidity Fertility-sparing surgery should be considered and discussed in younger\n",
      "patients and those with early-stage disease. Patients should be informed about the risks and\n",
      "benefits of such an approach, and the potentially higher risk of local relapse, which depends on\n",
      "their individual risk profile Patients with stage IA ovarian cancer and favorable histology (low-\n",
      "grade mucinous, serous, endometrioid or mixed histology) have been shown to have a lower risk after\n",
      "fertility-preserving surgery than patients with a higher disease stage or tumor grade. In large\n",
      "retrospective analyses, women with grade 3 disease or stage IC3 with clear cell histology had a\n",
      "higher risk of recurrence (Figure 5.2), which was mainly related to the higher incidence of extra-\n",
      "ovarian spread in grade 3 tumors rather than to a higher relapse rate in the preserved ovary. In\n",
      "retrospective studies, the risk of positive contralateral pelvic lymph nodes in women with\n",
      "unilateral disease despite negative ipsilateral nodes was as high as 11%., For this reason, staging\n",
      "of pelvic lymph nodes should be bilateral In advanced stages, maximal cytoreduction aimed at\n",
      "achieving complete tumor clearance has been shown to be associated with significant increases in\n",
      "both overall and progression-free survival. - A meta-analysis of 53 studies and 6885 patients, from\n",
      "1989 to 1998, showed that every 10% reduction in tumor was associated with a 6.3% prolongation of\n",
      "median overall survival Resection techniques In order to achieve total macroscopic tumor clearance\n",
      "in peritoneally disseminated disease, a maximal surgical effort is required, incorporating\n",
      "multivisceral resection techniques such as extensive peritoneal stripping full thickness\n",
      "diaphragmatic resection removal of bulky pelvic/para-aortic lymph nodes bowel resection Extra-\n",
      "abdominal cytoreductive procedures are increasingly being used to achieve complete tumor clearance\n",
      "outside the abdominal cavity. Techniques such as cardiophrenic/paracardiac lymph node dissection,\n",
      "pleurectomy, and supraclavicular and axillary lymph node dissection may be applied. Surgical\n",
      "expertise and training, with continuous audit of surgical outcome, morbidity and survival, have been\n",
      "proven to be important tools in making such extensive surgery safe for the patient without\n",
      "unnecessarily increasing morbidity. For this reason, there is an increasing trend toward the use of\n",
      "such procedures only in specialized centers with adequate infrastructure, resources and training\n",
      "Pelvic and para-aortic lymph node dissection is part of the debulking procedure in patients with\n",
      "bulky lymph nodes. In a randomized Phase III trial, the removal of these nodes only, compared with\n",
      "systematic lymph node dissection, was associated with a reduction in 5-year progression-free\n",
      "survival rates (21.6% versus 31.2%, respectively), with no significant difference in overall\n",
      "survival. Systematic pelvic and para-aortic lymphadenectomy offers no benefit in advanced disease in\n",
      "the absence of bulky lymph nodes Timing of surgery Cytoreductive surgery for ovarian cancer is\n",
      "generally performed at the time of diagnosis, when it is referred to as primary cytoreduction. It is\n",
      "also performed during primary chemotherapy, when it is referred to as interval cytoreduction, and\n",
      "after disease recurrence, which is called secondary or tertiary cytoreduction The optimal timing of\n",
      "surgery in relation to first-line chemotherapy is still under debate. Two prospective randomized\n",
      "trials, have reported lower surgical morbidity and comparable survival when neoadjuvant therapy was\n",
      "given, compared with upfront surgery, but whether these findings can be generalized to patients with\n",
      "good performance status treated in specialized centers is unclear Ongoing trials (TRUST, AGO OVAR OP\n",
      "7) are investigating the optimal timing of surgery, and will also address issues such as the optimal\n",
      "management of fragile patients Surgery for relapsed ovarian cancer Despite the established value of\n",
      "cytoreduction in the primary tumor setting, the value of tumor debulking surgery for recurrent\n",
      "epithelial ovarian cancer is not well defined. These patients have a chronic condition and hence\n",
      "quality of life needs to be carefully balanced with the surgical risks Secondary cytoreduction. The\n",
      "DESKTOP I trial retrospectively evaluated the survival benefit of secondary debulking in patients\n",
      "with ovarian cancer, sensitive to platinum chemotherapy. Complete tumor resection increased\n",
      "survival, compared with those with residual tumor (median 45.2 versus 19.7 months; hazard ratio [HR]\n",
      "3.71, 95% confidence interval [CI] 2.27-6.05, p < 0.0001). Using these data, the Arbeitsgemeinschaft\n",
      "Gynaekologische Onkologie (AGO) determined that complete tumor resection was feasible in patients\n",
      "with recurrent disease provided they had good performance status complete resection at primary\n",
      "surgery, or early FIGO stage (I/II) absence of gross ascites at relapse Patients that met all three\n",
      "of these criteria were given a positive AGO score An exploratory analysis of the DESKTOP results to\n",
      "evaluate the role of peritoneal carcinomatosis in recurrent epithelial ovarian cancer clearly showed\n",
      "that, even though peritoneal carcinomatosis was a negative predictor for complete resection in\n",
      "patients with recurrent disease, it appeared to have no independent negative impact on survival if\n",
      "total macroscopic clearance could be achieved The prospective, multicenter DESKTOP II trial,\n",
      "subsequently validated the AGO score, confirming its usefulness and reliability for predicting the\n",
      "benefit of complete tumor resection in more than two-thirds of patients with platinum-sensitive\n",
      "relapsed epithelial ovarian cancer. Of 516 patients screened over 19 months, 261 (51%) were\n",
      "classified as AGO score-positive and 129 of them with first relapse underwent secondary tumor\n",
      "debulking. The rate of complete resection was 76%. Interestingly, there was a poor correlation\n",
      "between imaging findings and intraoperative findings, both in terms of the number of lesions and\n",
      "localization of the tumor Perioperative morbidity and mortality appeared to be acceptable in the\n",
      "DESKTOP studies, with 0.8% mortality, 11% re-laparotomy (mainly due to bowel leakage or fistula in\n",
      "7% of patients) and 2% deep vein thrombosis; 52% of patients required postoperative treatment in\n",
      "intensive care (median 2 days, range 1-20) Similar findings have been reported in other patient\n",
      "series. A meta-analysis of data from 40 patients with recurrent epithelial ovarian cancer, spanning\n",
      "24 years, showed that after controlling for all other disease-related factors, every 10% increase in\n",
      "the proportion of patients undergoing complete cytoreductive surgery was associated with a 3-month\n",
      "increase in median cohort survival time Tertiary cytoreduction. The largest multicenter analysis of\n",
      "tertiary cytoreductive surgery evaluated 406 patients (median age 55 years; range 16-80) who\n",
      "underwent surgery between 1997 and 2011 in 12 centers across Europe, the USA and Asia. Most of the\n",
      "patients had initial FIGO stage III/IV disease (69%), peritoneal carcinomatosis (51.7%) and absence\n",
      "of ascites (72.2%). The most frequent tumor dissemination site was the pelvis (73%). In total, 224\n",
      "patients (54.1%) underwent complete tumor resection. This study confirmed that - even in the\n",
      "tertiary setting - complete macroscopic tumor clearance is a significant predictor of both overall\n",
      "and progression-free survival. Median overall survival for patients without residual tumor was 49\n",
      "months (95% CI 42.5-56.4) compared with 12 months (95% CI 9.3-14.7) in patients with residual tumor\n",
      "(p < 0.001). By contrast, peritoneal carcinomatosis was not prognostic for survival after\n",
      "controlling for residual tumor status. Importantly, common clinicopathological characteristics such\n",
      "as tumor stage, age and histological subtype, which have been shown to be significant predictors of\n",
      "survival at initial presentation, did not appear to be of any prognostic significance at the\n",
      "tertiary stage. Multivariate analysis identified platinum resistance, residual tumor at secondary\n",
      "surgery and peritoneal carcinomatosis to be of predictive significance for complete tumor resection,\n",
      "while residual tumor at secondary and tertiary surgery, decreasing time to second relapse, ascites,\n",
      "upper abdominal tumor involvement and non-platinum third-line chemotherapy significantly affected\n",
      "overall survival A further clinically relevant finding was the significant impact of third-line\n",
      "postoperative systemic chemotherapy on overall survival, emphasizing the importance of a combination\n",
      "of systemic chemotherapy and surgical intervention, even in this heavily pretreated patient\n",
      "population. (This may reflect a selection bias, because those patients who were fit enough and able\n",
      "to tolerate chemotherapy following radical surgery may theoretically have had more favorable\n",
      "survival rates than patients who were too weak to tolerate any systemic treatment or in whom\n",
      "chemotherapy was contraindicated.) Major operative morbidity and 30-day mortality rates were 25.9%\n",
      "and 3.2%, respectively; these are slightly higher than the equivalent data in the DESKTOP studies in\n",
      "the secondary treatment setting, but it should be noted that the study included both platinum-\n",
      "sensitive patients in whom cytoreduction was intended and symptomatic patients who underwent\n",
      "palliative surgery aimed at ameliorating their symptoms. The most common complication was\n",
      "infection/sepsis in 13% of patients; the re-laparotomy rate was 4.4%, but this was not associated\n",
      "with an increased risk of thromboembolic events (2.5%) As in all surgical treatment for ovarian\n",
      "cancer, appropriate patient selection is crucial to minimize morbidity and maximize benefit from\n",
      "this radical approach\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Surgery is the cornerstone of management for both early and advanced ovarian cancer, although the\n",
      "aims are different in each case.The optimal timing of surgery in relation to first-line chemotherapy\n",
      "is still under debate. Two prospective randomized trials, have reported lower surgical morbidity and\n",
      "comparable survival when neoadjuvant therapy was given, compared with upfront surgery, but whether\n",
      "these findings can be generalized to patients with good performance status treated in specialized\n",
      "centers is unclear.Surgery for primary ovarian cancer is considered the cornerstone of management of\n",
      "primary ovarian cancer.Surgery for secondary ovarian cancer is considered to be the cornerstone of\n",
      "management.Surgical management of primary and secondary ovarian cancer may involve non-fertility-\n",
      "sparing and fertility-sparing approaches (Figure 5\n",
      "\n",
      "Reference:\n",
      "Surgery is one of the cornerstones of treatment for ovarian cancer. The key aims of surgery are\n",
      "tumor removal and accurate staging. Multivisceral surgery is needed to achieve complete tumor\n",
      "resection. Surgery for relapsed disease is associated with significant prolongation of progression-\n",
      "free survival in prospective studies; data for overall survival are not yet mature, but in\n",
      "retrospective series patients who are tumor free after surgery at relapse have significantly longer\n",
      "overall survival than those with residual tumor. Peritoneal carcinomatosis is associated with lower\n",
      "complete debulking rates at relapse, but not with inferior overall survival in tumor-free patients\n",
      "who undergo surgery.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797617, 'chp1')\n",
      "Epidemiology, pathophysiology and etiology Acute myeloid leukemia (AML) is a hematologic malignancy\n",
      "that affects the blood and bone marrow. The build up of abnormal white blood cells interferes with\n",
      "the production of red blood cells, platelets and white blood cells, and indirectly leads to leukemic\n",
      "complications of infection, fatigue and hemorrhage. Complications also arise directly from the\n",
      "proliferation and accumulation of immature leukemia cells, which can affect blood flow or infiltrate\n",
      "other organs. The pathogenesis is described in more detail on page 9 Incidence data specific for AML\n",
      "worldwide are limited, as AML is usually included within the broader category of leukemia in\n",
      "epidemiology registries such as GLOBOCAN. The incidence of AML in the USA is 4.2 per 100 000 per\n",
      "year, with an estimated 21 380 new cases in 2017. AML accounts for about 1.3% of all new cancer\n",
      "cases and 31% of all new leukemia cases. In the UK in 2014, there were 3072 new cases of AML (fewer\n",
      "than 1% of all new cancer cases); there the incidence has risen by 28% since the early 1990s. Annual\n",
      "incidence rates differ little between large datasets from the USA (Surveillance, Epidemiology, and\n",
      "End Results), the UK (Cancer Research UK), and Sweden (Swedish Acute Leukemia Registry). Data from\n",
      "developing countries are sparse. AML is rare compared with other cancers, but is the most common\n",
      "acute leukemia in adults Age, sex and ethnicity. While AML affects all age groups, the incidence\n",
      "increases with advancing age (Figure 1.1), presenting at a median age of 67-69 years. AML is\n",
      "slightly more common in men than women, particularly in the older age groups. It is more commonly\n",
      "diagnosed in developed countries and is more common in white than in other populations Survival. AML\n",
      "is universally fatal if untreated. Even with treatment, patients seldom survive long term: according\n",
      "to US registry data, only 27% of patients survive 5 years from diagnosis. Survival is particularly\n",
      "poor in older patients, with fewer than 10% surviving 5 years. This is attributed to a marked\n",
      "increase in intrinsic chemoresistance with age and a greater number of comorbidities that compromise\n",
      "tolerance to chemotherapy. Some older patients do not receive treatment for AML because of these\n",
      "concerns, although data from the Swedish Acute Leukemia Registry demonstrate that this population\n",
      "benefits from treatment instead of purely palliative care., Figure 1.2 shows overall survival\n",
      "estimates by age group for patients in the Swedish registry AML is a hematologic malignancy arising\n",
      "from hematopoietic progenitor (stem) cells in the bone marrow (Figure 1.3). Clonal immature myeloid\n",
      "progenitor cells accumulate in the blood, bone marrow and, occasionally, extramedullary tissues.\n",
      "While these cells can divide and proliferate, they do not differentiate (mature) into functional\n",
      "cells (id est neutrophils) As noted above, patients experience complications directly from the\n",
      "accumulation of abnormal immature myeloblasts (or myeloid blasts) and indirectly from the reduction\n",
      "in functional myeloid cells and other mature hematopoietic elements. The leukemic involvement of the\n",
      "bone marrow often results in pancytopenia - patients may present with cytopenias in all\n",
      "hematopoietic cell lineages. Patients typically require transfusions of red blood cells and\n",
      "platelets and are at risk of life-threatening infectious complications due to neutropenia. Most\n",
      "patients with AML die from infection or, to a lesser extent, hemorrhage The role of genetics\n",
      "Advances in genetics have dramatically improved our understanding of the pathophysiology of AML.\n",
      "Although in-depth understanding of the relationship between a specific genetic mutation and a\n",
      "specific pathophysiological or clinical feature is clear in only a few cases, this is slowly\n",
      "changing. One such example is the association of the PML-RARA fusion gene with acute promyelocytic\n",
      "leukemia (APL), which is a subtype of AML (see Tables 2.2 and 2.3). The PML-RARA fusion gene is\n",
      "typically detected as a chromosomal rearrangement: t(15;17)(q22;q21) Patients with APL have a high\n",
      "risk for fatal hemorrhage due to disseminated intravascular coagulation (DIC), the consequence of a\n",
      "halt in myeloid differentiation that is mediated by the PML-RARA fusion gene. The PML-RARA fusion\n",
      "gene encodes a chimeric protein that disrupts various cellular processes, including nuclear body\n",
      "formation and apoptosis, adversely affecting normal myeloid development. In normal cells, RARA\n",
      "encodes a member of the nuclear hormone receptor family of transcription factors; PML is important\n",
      "in controlling proliferation and apoptosis, among other processes. The PML-RARA fusion protein\n",
      "suppresses gene transcription and blocks differentiation beyond the promyelocyte stage, resulting in\n",
      "the accumulation of malignant promyelocytes seen in APL. Degranulation of promyelocytes contributes\n",
      "to the development of DIC in patients with APL, putting them at risk for hemorrhage. The complex\n",
      "role of the PML-RARA fusion protein in modulating cellular functions is largely, and remarkably,\n",
      "understood. Treatment of APL is unique and ultimately capitalizes on these unique pathophysiological\n",
      "findings (though clinical advances preceded genetic understanding in this case; see pages 49-50 for\n",
      "the treatment of APL) Our understanding of the relationships between other genetic lesions and the\n",
      "pathophysiology of AML is limited but growing rapidly; it is hoped that understanding these\n",
      "relationships will identify new drug targets and enable novel therapies to be developed (exempli\n",
      "gratia midostaurin and enasidenib, see Chapter 3) Genetic sequencing studies suggest that most cases\n",
      "of AML arise from a limited number of mutations that accumulate with age. For example, The Cancer\n",
      "Genome Atlas (TCGA) (cancergenome.nih.gov) and other databases have shown that up to 5-6% of healthy\n",
      "individuals over 70 years of age have blood cells that contain potentially 'premalignant' mutations\n",
      "that are associated with clonal expansion (reviewed in TCGA Research Network 2013). However, the\n",
      "final insults that subsequently direct premalignant blood cells to become leukemic are many and\n",
      "remain poorly understood Sequencing data demonstrate the surprising finding that AML is associated\n",
      "with far fewer mutations than most other adult cancers: adults with AML have an average of 13\n",
      "genetic mutations, in stark contrast to melanoma and non-small-cell lung cancer, which typically\n",
      "have several hundred, as illustrated in Figure 1.4 TCGA has also shown that, on average, only five\n",
      "of 13 mutations found in a typical patient with AML are in genes known to be frequently mutated in\n",
      "AML. Despite the relatively low number of known mutations, there is tremendous heterogeneity in the\n",
      "types of mutation found in patients with AML. Furthermore, genetic analysis of serial samples from\n",
      "patients suggests that the pathogenesis of the disease is (at least in most cases) not rooted in a\n",
      "single mutation but in complex relationships between the accumulated (but limited number of)\n",
      "mutations Several datasets have grouped mutations into categories in an attempt to understand these\n",
      "relationships. For example, TCGA reported that almost all samples had at least one mutation in one\n",
      "of nine categories defined according to biological function and that are thought to have a role in\n",
      "the pathogenesis of AML (Table 1.1) Figure 1.5 shows the frequency of mutation for the most commonly\n",
      "mutated genes, which include FLT3, NPM1, DNMT3A, IDH2 and IDH1, in a group of 200 patients with\n",
      "newly diagnosed AML The circos plot in Figure 1.6 shows the complex relationship between mutations\n",
      "in patients with AML. Some mutated genes are frequently (and typically) observed in the presence of\n",
      "other specific gene mutations, such as NPM1 with FLT3 (red ribbon); other gene mutations are\n",
      "mutually exclusive, such as IDH1, IDH2 and TET2 Even in a single patient, all AML cells are not\n",
      "equal. Genetic sequencing studies have shown that relevant genetic variation occurs within the bone\n",
      "marrow cells from an individual patient with AML. Each group of cells with a shared mutation profile\n",
      "is called a clone; typically patients have one dominant clone and several smaller subclones. The\n",
      "presence of genetically different clones and subclones of myeloid blasts helps explain why a single\n",
      "patient may achieve remission but then experience relapse with more-resistant disease - sensitive\n",
      "clones are eliminated by chemotherapy, whereas surviving clones are more resistant to further rounds\n",
      "of chemotherapy; this is illustrated conceptually in Figure 1.7. One clone may be eliminated over\n",
      "time (and following treatment), whereas another may persist or emerge with additional novel\n",
      "mutations. Figure 1.8 illustrates clonal evolution in an actual patient. Mutational analyses like\n",
      "these explain why patients with morphologically similar leukemias may experience vastly different\n",
      "clinical outcomes Sequencing studies suggest that the development of individualized therapies that\n",
      "target unique mutations in selected patients, rather than a 'one way fits all' chemotherapy approach\n",
      "(described in Chapter 3), may improve outcomes for patients with AML. Several recent successful\n",
      "examples of this treatment approach are discussed in detail in Chapter 3. However, it is\n",
      "increasingly recognized that, in most patients, several subclones (oligoclonal) rather than a single\n",
      "clone contribute to the leukemia. This genetic diversity, even in a single patient, may limit the\n",
      "effectiveness of monotherapy with targeted agents and calls for a multitargeted approaches,\n",
      "including combinations with conventional chemotherapy. The use of targeted therapies to improve\n",
      "disease control before the use of potentially curative immunologic and decidedly non-targeted\n",
      "therapy (exempli gratia allogeneic hematopoietic cell transplantation, see Chapter 3) is another\n",
      "area of ongoing research Most cases of AML are idiopathic, arising in previously healthy individuals\n",
      "with no (or unknown) genetic predisposition. Advancing age is the main risk factor for AML, as noted\n",
      "above and described by TCGA, but a number of other risk factors contribute to the development of AML\n",
      "in some patients. These include familial risk, environmental exposure to chemicals, drugs or\n",
      "ionizing radiation, and antecedent hematologic disorders such as myelodysplastic syndromes (MDS) or\n",
      "myeloproliferative neoplasms (MPN) Familial risk. Although most cases of AML are not familial, it is\n",
      "now clear that myeloid neoplasms with germline predisposition (exempli gratia an inherited risk) are\n",
      "more frequent than has been recognized previously. Myeloid neoplasms with germline predisposition -\n",
      "that is, AML and related disorders that arise in the setting of an inherited genetic mutation which\n",
      "puts the patient at increased risk for developing the disease - are an important component of the\n",
      "forthcoming revision to the World Health Organization classification of AML (see Table 2.3).\n",
      "Germline mutations associated with an increased risk of developing a myeloid neoplasm occur in the\n",
      "CEBPA, DDX41, RUNX1, ANKRD26, ETV6 and GATA2 genes, among others Myeloid neoplasms with germline\n",
      "predisposition are a feature of several well-described clinical syndromes, including disorders of\n",
      "bone marrow failure (exempli gratia Fanconi anemia, Shwachman-Diamond syndrome, Diamond-Blackfan\n",
      "anemia) and telomere biology (exempli gratia dyskeratosis congenita). Likewise, several genetic\n",
      "syndromes with aberrations of somatic cell chromosome complement, such as Down syndrome with trisomy\n",
      "21, are associated with an increased incidence of AML. Down syndrome-associated AML in young\n",
      "children (< 4 years) is typically of the acute megakaryocytic subtype (see Table 2.2 for the\n",
      "different morphologic subtypes) and is associated with a mutation in the GATA1 gene. Affected\n",
      "patients have favorable clinical outcomes but require lower doses of chemotherapy because of higher\n",
      "treatment-related toxicities. Inherited diseases with defective DNA repair (exempli gratia Fanconi\n",
      "anemia, Bloom syndrome and ataxia telangiectasia) are also associated with AML. Each of these\n",
      "syndromes has unique clinical features and atypical toxicities after chemotherapy, requiring expert\n",
      "care Chemical and environmental exposure. Anticancer drugs are the leading cause of therapy-\n",
      "associated AML. Leukemias associated with topoisomerase II inhibitors typically occur 1-3 years\n",
      "after exposure; AML blasts in affected patients have a particular morphologic appearance with\n",
      "monocytic features. Patients who develop monocytic AML after exposure to topoisomerase II inhibitors\n",
      "often also have a particular chromosomal abnormality that involves the long arm of chromosome 11\n",
      "(11q23 rearrangements occur in AML and may be seen with many other partner chromosomes) Alkylating\n",
      "agents may also cause leukemias, on average 4-6 years after exposure; affected individuals often\n",
      "have abnormalities in many cells lines (multilineage dysplasia) and monosomy/aberrations in\n",
      "chromosomes 5 and 7 Exposure to ionizing radiation, benzene, chloramphenicol, phenylbutazone and\n",
      "other drugs, although rare, may result in bone marrow failure that evolves into AML Myelodysplastic\n",
      "syndromes/myeloproliferative neoplasms. Several disorders of myeloid cells are related to AML and\n",
      "are broadly classified as MDS and MPN, with tremendous heterogeneity within each group. Detailed\n",
      "description of these disorders is beyond the scope of this book, but it is important to understand\n",
      "that MDS or MPN may progress to AML, a condition which is referred to as secondary AML or AML\n",
      "arising from an antecedent hematologic disorder. The risk of progression of MDS to AML can be\n",
      "estimated based on the proportion of blasts in the marrow (MDS is defined as < 20% blasts),\n",
      "cytopenias, karyotype and other factors. MPN are further subclassified into familiar terms of\n",
      "polycythemia vera, essential thrombocythemia and chronic myelogenous leukemia, as well as other\n",
      "disorders such as mastocytosis and eosinophilic disorders associated with abnormalities of PDGFA/B\n",
      "or FGFR1, among others\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "The role of genetics in the pathophysiology of AML is limited, as shown in Figure 1.1. The role of\n",
      "genetics is limited, as described by TCGA. The role of genes is limited, as noted above and\n",
      "described by TCGA, but a number of other risk factors contribute to the development of AML in some\n",
      "patients. These include familial risk, environmental exposure to chemicals, drugs or ionizing\n",
      "radiation, and antecedent hematologic disorders such as myelodysplastic syndromes (MDS) or\n",
      "myeloproliferative neoplasms (MPN) (Figure 1.1). The role of genetics in AML is limited and\n",
      "described in detail in Figure 1.2.\n",
      "\n",
      "Reference:\n",
      "Acute myeloid leukemia (AML) is a relatively rare cancer. It is due to proliferation of immature\n",
      "myeloid cells, which interfere with the production of normal red blood cells, white blood cells and\n",
      "platelets. Patients typically require transfusion support and are at risk for potentially fatal\n",
      "infection. AML is uniformly fatal without treatment. AML is the most common acute leukemia in older\n",
      "adults, with median age at diagnosis of 67-69 years. Long-term survival of patients with AML is\n",
      "poor: about a quarter of patients survive 5 years but only 10% of older patients. Our understanding\n",
      "of the genetic basis for AML is improving. A small number of mutations are seen in the typical AML\n",
      "patient; the mutation profile of an individual patient may change over time. Most cases of AML are\n",
      "idiopathic; however, prior exposure to topoisomerase II inhibitors and alkylating agents increases\n",
      "the risk of AML. Inherited risk is uncommon but is likely to be more frequent than is currently\n",
      "understood.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9783318066685, 'ch4')\n",
      "4 Gene therapies with proven clinical efficacy Several gene therapy drugs are now approved by the US\n",
      "Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA) to be marketed as\n",
      "medicines (Table 4.1). Others have shown strong efficacy in early clinical studies and are therefore\n",
      "being evaluated in Phase III trials. Examples of gene therapies with track records of clinical\n",
      "efficacy are described in the following sections and summarized in Table 4.2 Hereditary blindness\n",
      "Prior to gene therapy, no treatment was available for certain forms of hereditary blindness.\n",
      "However, the ability of adeno-associated virus (AAV) vectors to transduce retinal cells on\n",
      "subretinal administration has enabled the development of therapies for such diseases. This effort\n",
      "ultimately led to the first gene therapy drug approved by the FDA for the treatment of a genetic\n",
      "disease in late 2017 Leber congenital amaurosis In Leber congenital amaurosis type 2 (LCA2),\n",
      "mutations in the RPE65 gene prevent the expression of retinal pigment epithelium 65 kDa protein\n",
      "(RPE65), thereby impairing the process of visual photo-transduction and severely limiting vision.\n",
      "Inheritance is autosomal recessive. Affected infants typically already have decreased visual\n",
      "responsiveness at birth Initially, three independent clinical studies demonstrated that a single\n",
      "subretinal injection of AAV2 vector expressing the therapeutic RPE65 gene improved vision in treated\n",
      "regions of the retina. This improvement was stable for at least 3 years. One protocol was\n",
      "successfully expanded to pediatric patients. Importantly, early intervention substantially improved\n",
      "the potential for restoring vision. Patients showed an increase in pupillary light responses of 2\n",
      "log units or more, with one child gaining light sensitivity near to that of age-matched normal-\n",
      "sighted individuals As a safety precaution, patients participating in these early studies had\n",
      "received gene transfer to only one eye. Likely facilitated by the immune-privileged nature of the\n",
      "eye, subsequent vector administration to the contralateral eye was successful, with study\n",
      "participants demonstrating gradually improved sensitivity to dim light, activation of the visual\n",
      "cortex and improved navigational skills. Equally important, there were no adverse effects to their\n",
      "previously treated eye. As perhaps expected, functional gains from gene transfer to the second eye\n",
      "were more pronounced in younger patients. Children receiving the gene therapy experienced vast\n",
      "improvements in their quality of life, such as being able to attend school or participate in sports\n",
      "Success with LCA2 gene therapy has generated interest in developing gene therapy for other retinal\n",
      "diseases. For instance, successful outcomes of a gene therapy trial for choroideremia have been\n",
      "reported. In these patients, mutations in the X-linked CHM gene (which encodes Rab escort protein 1\n",
      "[REP-1]) cause slow and progressive degeneration of photoreceptors, choroid and retinal pigmented\n",
      "epithelium, typically leading to complete blindness by middle age. REP-1 has important functions\n",
      "related to intracellular protein trafficking. Thus, absence of functional REP-1 may lead to early\n",
      "cell death. Importantly, subretinal gene transfer with an AAV2 vector carrying the CHM gene\n",
      "substantially improved vision in two patients and increased retinal sensitivity in four more\n",
      "patients Neuromuscular disorder: spinal muscular atrophy Spinal muscular atrophy (SMA) is a genetic\n",
      "disease that causes death in infants. Loss of motor neurons leads to progressive muscle wasting,\n",
      "initially affecting arm, leg and respiratory muscles. The disease is caused by mutations in the SMN1\n",
      "gene, which is autosomal recessive and encodes survival of motor neuron 1, telomeric (SMN1), a\n",
      "protein necessary for motor neuron survival. The SMN1 protein is important for the biogenesis and\n",
      "assembly of small nuclear ribonucleic particles (snRNPs), which are critical in messenger (m)RNA\n",
      "splicing (spliceosome assembly and pre-mRNA splicing). While SMN1 is ubiquitously expressed, its\n",
      "loss is particularly detrimental to motor neurons. Without functional motor neurons, the central\n",
      "nervous system (CNS) is unable to send signals to skeletal muscles, and babies born with this defect\n",
      "gradually become paralyzed To correct this devastating defect, a gene therapy was developed based on\n",
      "systemic delivery of high doses of AAV9 expressing functional SMN1. This vector is capable of\n",
      "transducing motor neurons and effectively transduces the spinal cord after systemic administration.\n",
      "Moreover, it is also able to cross the blood-brain barrier and transduce cells in the brains of\n",
      "rhesus macaques, even in animals up to 3 years old. Nonetheless, it is thought that the most\n",
      "effective reversal of disease can be achieved early in life. Remarkably, all 15 babies treated by\n",
      "this gene therapy in the initial clinical trial are alive at age 20 months or older (these patients\n",
      "were expected to die within the first 2 years of life). Most can sit up, and some are even able to\n",
      "walk. The FDA has approved the systemic AAV gene therapy for SMN1-deficient children up to the age\n",
      "of 2 years Lysosomal storage disorder: metachromatic leukodystrophy Myelin-producing cells in\n",
      "infants born with deficiency in arylsulfatase A (ARSA) accumulate sulfatide (sulfated glycolipids),\n",
      "which leads to demyelination of the nervous system and thus severe motor and cognitive damage. The\n",
      "first signs of the disease (late infantile metachromatic leukodystrophy [MLD]) appear in the second\n",
      "year of life; life expectancy is less than a decade. It was hoped that restoration of enzymatic\n",
      "activity in macrophages or microglia could halt the disease, and that this could potentially be\n",
      "achieved with a bone marrow or hematopoietic stem cell (HSC) transplant. However, these treatments\n",
      "are only marginally effective in halting disease progression, especially with regard to motor neuron\n",
      "function. Overexpression of ARSA using gene-modified HSCs may overcome these limitations by\n",
      "delivering a level of ARSA to microglia that would correct neighboring cells and thus halt\n",
      "demyelination To test this hypothesis in the clinic, three pre-symptomatic individuals received mild\n",
      "bone marrow conditioning followed by transplant of lentivirally transduced autologous CD34+ HSCs.\n",
      "Engraftment of gene-corrected cells was successful in bone marrow and peripheral blood. At 2 years\n",
      "after gene transfer, these children continued to produce therapeutic levels of functional ARSA\n",
      "enzyme and showed normal motor and cognitive development without evidence of disease manifestation.\n",
      "Follow-up studies in a total of nine treated patients showed that the protocol indeed needs to be\n",
      "administered early during disease onset to obtain optimal results for motor and cognitive functions\n",
      "and prevention of CNS demyelination. Stable reconstitution of ARSA activity in the cerebrospinal\n",
      "fluid can be achieved within 6 months after gene therapy. How to reduce this lag in enzyme delivery\n",
      "to the CNS is still an open question to be addressed Primary immune deficiencies: severe combined\n",
      "immune deficiencies Children born with primary immune deficiency suffer from recurrent infections,\n",
      "which may become lethal. Life expectancy is typically just a few years unless an HLA-matched bone\n",
      "marrow transplant is performed. However, compatible donors are typically found for fewer than 20% of\n",
      "patients. Hence, gene therapies have been developed to correct autologous HSCs in children born with\n",
      "X-linked severe combined immunodeficiency (SCID-X1), adenosine deaminase deficiency-severe combined\n",
      "immunodeficiency (ADA-SCID), chronic granulomatous disease (CGD) and Wiskott-Aldrich syndrome. These\n",
      "therapies circumvent the need for HLA-matched donors and also avoid immune suppression and\n",
      "complications arising from graft versus host disease SCID-X1 accounts for 40% of cases of severe\n",
      "combined immune deficiency and is caused by a lack of the gamma chain (gammac) that is shared by\n",
      "multiple cytokine receptors. Therefore, T cells are absent, B-cell function is impaired and natural\n",
      "killer (NK) cells fail to develop. Retrovirally transduced HSCs effectively restore immune function.\n",
      "Because of the strong selective advantage of gene-corrected cells, there is no need for bone marrow\n",
      "conditioning. However, development of leukemia in six of the 20 patients studied emerged as a major\n",
      "setback in these trials. This prompted the development of self-inactivating (SIN) viral vectors,\n",
      "which are devoid of long terminal repeat (LTR) promoter/enhancer function, and of lentiviral vectors\n",
      "to replace first-generation murine gammaretroviral vectors. In SIN vectors, a deletion is introduced\n",
      "into one of the LTR sequences. One round of transcription and reverse transcription 'copies' the\n",
      "deletion onto the second LTR, a process termed 'self-inactivation' ADA-SCID represents another fatal\n",
      "primary immunodeficiency with impaired T, B and NK cell development. The disease is caused by\n",
      "mutations in the gene encoding adenosine deaminase (ADA), an enzyme required for the clearance of\n",
      "toxic purine metabolites from the body. Patients also experience various non-immune complications in\n",
      "the pulmonary, hematologic, gastrointestinal, neurological and skeletal systems. Partial correction\n",
      "can be achieved by enzyme replacement therapy (ERT). Interestingly, ADA-SCID was the target for the\n",
      "very first gene therapy trial in 1990. However, at that time gene transfer to stem cells was highly\n",
      "inefficient. In subsequent trials, patients received non-myeloablative conditioning (using low-dose\n",
      "busulfan), and ERT was discontinued before transplantation with gammaretrovirally transduced\n",
      "autologous HSCs expressing the ADA transgene (Figure 4.1). Remarkably, gene therapy essentially\n",
      "resulted in a cure, with gene correction in multiple cell lineages, ADA expression at normal levels\n",
      "and restoration of immune competence. A large number of patients with ADA-SCID have now been treated\n",
      "without developing leukemia or other noticeable genotoxicity. Hence, the gene therapy product for\n",
      "ADA-SCID obtained marketing approval from the EMA Nonetheless, SIN retroviral or lentiviral vectors\n",
      "may be the basis for future gene therapy drugs for ADA-SCID, adding another layer of safety. Here,\n",
      "transgene expression is controlled by an internal promoter instead of a functional LTR Additional\n",
      "insights emerged from the cumulative experience with gene therapy for ADA-SCID. ERT does not appear\n",
      "to reduce the selective advantage of gene-corrected cells and may have synergistic effects with gene\n",
      "transfer. For instance, ERT may partially correct the hypocellularity in the bone marrow, increase\n",
      "HSC mobilization in the blood, shorten the time period of lymphopenia until gene-corrected\n",
      "lymphocytes appear and prevent systemic organ toxicity. Despite all these advances in treatment,\n",
      "some neurological, auditory and behavioral problems may still be seen in patients. It is possible\n",
      "that, compared with the blood and other organs, ADA delivery to the brain is limited following gene\n",
      "therapy, or that some irreversible damage to the CNS has already occurred prior to gene therapy\n",
      "Hematologic disorder: hemophilia To stop bleeding on injury of a blood vessel, a series of enzymatic\n",
      "reactions needs to occur in the blood (the coagulation cascade) to form a clot that seals the\n",
      "vessel. One of these reactions is catalyzed by serine protease factor IX (FIX), working in concert\n",
      "with its co-factor, factor VIII (FVIII). Mutations in either of the X-linked genes encoding FVIII or\n",
      "FIX cause hemophilia, which occurs in 1 in 5000 male births worldwide. Disease severity correlates\n",
      "with residual coagulation activity. In individuals with severe disease (< 1% clotting activity), the\n",
      "resulting failure of the blood to clot causes spontaneous bleeds into joints and soft tissues;\n",
      "certain types of bleeds can be life-threatening. The current treatment of hemophilia is mostly based\n",
      "on intravenous infusion of recombinant or plasma-derived FVIII or FIX proteins, which is done in\n",
      "prophylactic treatment protocols three times per week to prevent bleeds. Recombinant factors with\n",
      "prolonged half-lives have been developed to reduce the frequency of injections The treatment of\n",
      "hemophilia is undergoing more revolutionary changes with the development of alternative molecular\n",
      "approaches. A major complication in factor-replacement therapy is the development of neutralizing\n",
      "antibodies ('inhibitors') against the therapeutic protein. This occurs in 20-30% of treated patients\n",
      "with hemophilia A (FVIII deficiency, the more common form of the disease - FIX deficiency is called\n",
      "hemophilia B). A bispecific antibody has been developed that mimics FVIII function and is effective\n",
      "in providing hemostasis even in the presence of an inhibitor. The antibody is given subcutaneously\n",
      "every 1-4 weeks, with minor differences in bleeding rates between regimens Nonetheless, lifelong\n",
      "treatment of hemophilia is burdensome and expensive and typically not available in developing\n",
      "countries. In contrast, gene therapy has the potential to be curative, lasting for many years after\n",
      "a single round of gene transfer (> 10 years in canine models) Both FVIII and FIX are normally made\n",
      "in the liver (FVIII in liver endothelial cells and FIX in hepatocytes). However, diverse cell types\n",
      "are capable of producing functional coagulation factors, and tight regulation of gene expression is\n",
      "not required as the therapeutic range is wide. For example, raising coagulation activity to above 5%\n",
      "changes the disease phenotype to mild, typically requiring few additional factor infusions A large\n",
      "number of approaches, utilizing different gene transfer vectors and cell types for transgene\n",
      "expression, were initially explored during the 1990s. Since then, in vivo gene transfer to\n",
      "hepatocytes using AAV vectors has emerged as the leading method, and this is being evaluated in\n",
      "three Phase III trials and multiple more Phase I/II trials (Table 4.3, Figure 4.2). Various viral\n",
      "capsids have been adapted that allow for the transduction of hepatocytes after injection into a\n",
      "peripheral vein, and tissue-specific promoters are employed to restrict transgene expression to\n",
      "hepatocytes The complementary (c)DNA encoding wild-type FVIII is too large to fit into an AAV\n",
      "vector. A B-domain-deleted version of FVIII (BDD-FVIII) is fully functional but still poses\n",
      "challenges for vector engineering, given its size of around 4.5 kb. Nonetheless, development of\n",
      "small yet potent hepatocyte-specific promoters and codon optimization (to avoid translational codons\n",
      "that are only rarely used in mammalian cells and therefore limit protein expression, among other\n",
      "changes in the coding sequence) led to greatly improved expression cassettes for BDD-FVIII Given the\n",
      "smaller size of the coding sequence for FIX (1.4 kb), it could even be incorporated into 'self-\n",
      "complementary' AAV vectors. These have a genome half the size of a conventional single-stranded\n",
      "vector but instantly become double-stranded DNA on uncoating, resulting in improved transduction\n",
      "Initial experience with hepatic AAV- FIX gene transfer revealed the potential to activate CD8+\n",
      "T-cell responses against the viral capsid, leading to hepatic injury and, in some cases, loss of\n",
      "transgene expression. This led to the incorporation of immune suppression in the clinical protocol.\n",
      "Steroid drugs are given as soon as a rise in liver enzyme levels is detected in the blood.\n",
      "Furthermore, vectors were designed with potentially immune stimulatory CpG motifs edited out of the\n",
      "DNA as much as possible, given that CD8+ T-cell activation has been linked to innate immune sensing\n",
      "of the viral DNA via toll-like receptor 9 (TLR9) After preclinical efficacy and long-term follow-up\n",
      "studies in hemophilic mice and dogs and in non-human primates, followed by a series of early Phase\n",
      "I/II clinical trials and further preclinical development, there are now several AAV vectors in\n",
      "advanced clinical development for hemophilia. They all utilize hepatocyte-specific promoters but\n",
      "differ in capsid and also utilize different methods for vector production (such as transient\n",
      "transfection of human cells or baculovirus infection of insect cells). For FIX production, efficacy\n",
      "has been further improved by incorporation of a naturally occurring variant (FIX-Padua) that has an\n",
      "approximately eightfold higher enzymatic activity. Such vectors raised coagulation activity in\n",
      "patients with severe disease to around 30-50% of usual levels, close to the lower limit of the\n",
      "normal range. Thus, patients typically no longer require factor infusions, and dramatic reductions\n",
      "in annual bleeding rates (mostly none) are reported. These therapeutic benefits have persisted for\n",
      "at least 3 years, with more follow-up data pending. Notably, patients treated in an earlier trial\n",
      "with an AAV vector expressing FIX without the Padua mutation reached levels above 5% of normal that\n",
      "were sustained for at least 8 years. Two products expressing FIX-Padua have been developed. These\n",
      "are now being evaluated in Phase III clinical trials. Differences include capsids, vector\n",
      "genomes/expression cassette design, manufacturing systems and reported vector doses An AAV5 vector\n",
      "expressing FVIII in patients with hemophilia A, when given at very high doses (up to 10 vector\n",
      "genomes/kg), was able to normalize coagulation levels. Patients no longer required factor infusions\n",
      "and did not experience bleeds (annual bleeding rate of zero in 3 years of follow-up in a total of 12\n",
      "patients). FVIII levels somewhat declined over time but were, on average, around 50% at the end of\n",
      "year 3. Mild elevation of liver enzymes occurred during the initial months after vector\n",
      "administration and, as a precaution, was countered by steroid administration; the underlying cause\n",
      "was not clear Several more vectors are being tested for hemophilia A and B, based on diverse\n",
      "capsids. One hope is that patients who are not eligible for a particular product because of pre-\n",
      "existing neutralizing antibodies will be able to receive a different product, based on a different\n",
      "capsid. Current gene therapies for hemophilia are exclusively for adults, and debate is ongoing\n",
      "whether gene transfer should also be offered to pediatric patients. AAV vector genomes tend to\n",
      "persist in episomal forms, so that there may be a dilution effect in a growing liver. Use of other\n",
      "vector systems or AAV combined with site-specific integration/ gene-editing technologies may solve\n",
      "this problem in the future. Alternatively, protocols for re-administration may become available, but\n",
      "these may require initial immune suppression. Interestingly, hepatic AAV gene transfer was able to\n",
      "induce immune tolerance to FVIII and FIX in different animal models, suggesting that gene therapy\n",
      "could also be used as a means to induce immune tolerance in patients who develop inhibitors during\n",
      "conventional factor-replacement therapy Cancer gene therapy CAR-T therapy for lymphoma and leukemia.\n",
      "Adoptive lymphocyte therapy using gene-modified autologous T cells is one of the technologies\n",
      "revolutionizing cancer therapy. T cells are harvested from the patient's blood and transduced with a\n",
      "chimeric antigen receptor (CAR) by ex vivo gene transfer using retroviral or lentiviral vectors\n",
      "(Figure 4.3). Early success has been shown with blood cancers. In pioneering work, CAR-T cells\n",
      "directed against the CD19 antigen were able to effectively kill lymphoma cells from patients\n",
      "refractory to conventional chemotherapy. CAR-T cells targeting CD19 are now approved by the FDA and\n",
      "the EMA for the treatment of several types of blood cancer. These include: relapsed or refractory\n",
      "B-cell acute lymphoblastic leukemia (B-ALL) in children and young adults; and relapsed or refractory\n",
      "diffuse large B-cell lymphoma (DLBCL) in adults CARs have a modular design and comprise an antibody-\n",
      "derived single-chain variable fragment (scFv, the extracellular binding domain that targets the\n",
      "intact tumor surface antigen), a hinge region, a transmembrane domain and intracellular signaling\n",
      "domains. Expression of the CAR re-directs the T cells to the tumor antigen and provides the signals\n",
      "required for T-cell activation on binding to the antigen. Importantly, targeting of the intact\n",
      "antigen via scFv binding is neither MHC restricted nor dependent on co-receptors or epitope\n",
      "processing. CARs are broadly classified by the number of co-stimulatory domains that have been\n",
      "incorporated into the intracellular portion of the molecule. First-generation CARs contained only\n",
      "CD3zed chain, while second- or third-generation CARs have CD3zed plus one or more co-stimulatory\n",
      "domains, respectively (Figure 4.4). Current commercial designs are based on second-generation CARs.\n",
      "Future (fourth) generation CARs are being developed with inducible signaling CAR-T cell therapy for\n",
      "B-ALL was approved in 2017 for children and young adults (up to age 25). The clinical study leading\n",
      "to approval demonstrated a complete remission rate of 60% and overall response rate of 81% in 75\n",
      "patients receiving the anti-CD19 CAR-T cells. The relapse-free survival rate for the first 6 months\n",
      "was 80%, and B-cell aplasia (low numbers or absence of B cells) persisted. CAR-T cells continued to\n",
      "be detected in peripheral blood with a median lifespan of 168 days. Three of four patients\n",
      "experienced severe adverse events related to treatment, and about half developed severe cytokine\n",
      "release syndrome (CRS; see page 50) Also in 2017, the first CAR-T cell therapy was approved for the\n",
      "treatment of DLBCL. In the trial supporting the approval, a complete remission rate of 58% and an\n",
      "overall response rate of 83% was achieved in 101 patients with refractory aggressive lymphoma.\n",
      "Compared with the B-ALL trial, the incidence of severe neurotoxicity (32%) was higher, while CRS was\n",
      "less common (11%). Interestingly, therapy was effective even in the face of histological findings\n",
      "that traditionally indicate poor prognosis. In a related trial, 40% of patients with DLBCL achieved\n",
      "complete and durable remission, leading to FDA approval for relapsed and refractory lymphoma in 2018\n",
      "More recent CAR-T cell therapies with potentially reduced toxicities are being evaluated in clinical\n",
      "trials. Further, other target antigens, such as CD22 for leukemia and B-cell maturation antigen in\n",
      "multiple myeloma, are being explored to expand the spectrum of CAR-T cell therapeutic applications\n",
      "Other cancer gene therapies Although not discussed here, oncolytic virotherapies against certain\n",
      "types of cancer are being developed. In the case of melanoma, these may be genetically engineered\n",
      "and thus can also be considered a type of gene therapy\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "stranded vector but instantly become double-stranded DNA on uncoating, resulting in improved\n",
      "transduction of the T cells, resulting in improved T-cell activation, and improved T-cell\n",
      "expression, resulting in reduced T-cell activation and reduced T-cell expression. The T-cell\n",
      "activation of the T-cell has been shown in clinical trials. The T cell activation of the T cell has\n",
      "been demonstrated in clinical trials. In clinical trials, T cell activation has been shown to\n",
      "increase T cell activation, while T cell activation has shown to decrease T cell activation. T cell\n",
      "activation is shown in clinical trials, but clinical trials have shown no evidence of T cell\n",
      "activation in clinical trials.T cell activation has been observed in clinical trials\n",
      "\n",
      "Reference:\n",
      "Gene therapy, using gene-modified cells or in vivo gene transfer, has now been successful for\n",
      "diverse diseases and modes of gene transfer. After initial setbacks, hematopoietic stem cell gene\n",
      "therapy, primarily based on lentiviral vectors, is being successfully developed for primary immune\n",
      "deficiencies and some lysosomal storage disorders. Globin disorders are a major next target for this\n",
      "approach. Adeno-associated virus (AAV) gene therapies for Leber congenital amaurosis and spinal\n",
      "muscular atrophy are now approved medicines in the USA and rely on in vivo injection to,\n",
      "respectively, the subretinal space and systemic circulation. Multiple gene therapies for hemophilia,\n",
      "based on hepatic AAV gene transfer, have elevated coagulation factor activities in patients to the\n",
      "normal or near normal range. These are now being evaluated in Phase III trials. Chimeric antigen\n",
      "receptor (CAR)-T cell therapies for blood cancers, targeting the CD19 antigen, are in use to treat\n",
      "relapsed or refractory diffuse large B-cell lymphoma in adults and B-cell acute lymphoblastic\n",
      "leukemia in children and young adults.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797211, 'ch04')\n",
      "Drug treatment The first drugs used to treat Parkinson's disease, in the 1860s, were the belladonna\n",
      "alkaloids. These were replaced by the synthetic anticholinergic drugs benzhexol and benztropine in\n",
      "the 1940s, although pharmacological treatment has been the mainstay of Parkinson's disease\n",
      "management since the 1920s when researchers were focused on the development of a vaccine that would\n",
      "prevent postencephalitic parkinsonism. In 1957, Dr Arvid Carlsson demonstrated that dopamine was a\n",
      "neurotransmitter in the brain and not just a precursor of norepinephrine, as was the prevailing view\n",
      "at that time. He went on to show that L-dopa, a precursor of dopamine, effectively treated the\n",
      "symptoms of Parkinsonism. In 2000, he was awarded the Nobel prize for the first description of\n",
      "levodopa therapy in Parkinson's disease. During the 1960s, Birkmayer and Hornykiewicz, Barbeau et\n",
      "al. and Cotzias et al. demonstrated the dramatic clinical effects of high-dose oral levodopa\n",
      "therapy, revolutionizing the treatment of Parkinson's disease Levodopa is a precursor of dopamine\n",
      "and restores the dopamine lost due to degeneration of striatonigral cells. It has improved the\n",
      "quality of patients' lives substantially, and appears to have led to a reduction in mortality.\n",
      "Levodopa is converted to dopamine by dopa decarboxylation in the brain (Figure 4.1), but this can\n",
      "also occur outside the blood-brain barrier, leading to side effects such as nausea and postural\n",
      "hypotension. The addition of a peripheral decarboxylase inhibitor that does not cross the blood-\n",
      "brain barrier, such as carbidopa or benserazide, inhibits dopa decarboxylase in the rest of the body\n",
      "and reduces side effects. The bioavailability of levodopa has been enhanced further by the emergence\n",
      "of drugs such as tolcapone and entacapone, which inhibit catechol- O -methyl transferase (COMT), the\n",
      "enzyme principally responsible for the breakdown of dopamine Expected response. Patients with\n",
      "typical Parkinson's disease respond to levodopa almost immediately, although in some cases a delayed\n",
      "effect is seen after prolonged treatment. The beneficial response to levodopa can often be assessed\n",
      "after a single test dose. However, there may be significant false-positive results, given that\n",
      "patients with Parkinson-plus syndromes such as multiple system atrophy (MSA) or progressive\n",
      "supranuclear palsy (PSP) may also respond to levodopa initially. In addition, the test does not\n",
      "allow for the delayed positive 'long-duration' effect of levodopa. In resistant cases, the maximum\n",
      "tolerated dose (up to 2 g/day) should be tried for at least 1 month before the patient is declared\n",
      "unresponsive Administration. Levodopa therapy should be started at the minimal effective dose\n",
      "(usually 50-100 mg/day), in combination with a decarboxylase inhibitor, given three times daily Is\n",
      "levodopa toxic? Results of experiments with cultured dopaminergic neurons and with rats previously\n",
      "suggested that levodopa may be toxic to dopamine neurons; it was postulated that levodopa is\n",
      "converted to toxic dopamine metabolites, which cause damage by the production of free radicals such\n",
      "as hydrogen peroxide. The substantia nigra was thought to be at risk because it contains high\n",
      "concentrations of catalysts, such as iron, for free-radical production, and low concentrations of\n",
      "free-radical scavengers. These concerns gave rise to 'levodopa phobia' in many patients, denying\n",
      "them the benefit of levodopa treatment However, there is no robust evidence to suggest that levodopa\n",
      "is toxic to the human nigrostriatal pathway and these fears have mostly been discredited. A\n",
      "postmortem study of 5 patients with essential tremor, who were mistakenly given sustained levodopa\n",
      "therapy, found no evidence of damage to nigral cells. In addition, patients who receive long-term\n",
      "levodopa for restless legs syndrome show no evidence of damage to the substantia nigra at autopsy.\n",
      "These findings should reassure patients receiving long-term levodopa Levodopa dyskinesia. Chronic\n",
      "therapy with levodopa, however, results in motor fluctuations and dyskinesias due to Parkinson's\n",
      "disease progression coupled with the short half-life of levodopa. The ELLDOPA study (see below) in\n",
      "patients with early Parkinson's disease suggests that a higher dosage of levodopa leads to a higher\n",
      "frequency of dyskinesia. The development of dyskinesias has been shown to adversely affect patients'\n",
      "and carers' quality of life, and to at least double the cost of care. In order to prevent/delay\n",
      "dyskinesia, several trials have examined initiating treatment with a dopamine agonist such as\n",
      "ropinirole, pramipexole, cabergoline or pergolide. Many trials have compared these dopamine agonists\n",
      "with levodopa in previously untreated patients over a 4-5 year period Caution is necessary when\n",
      "comparing results, owing to differences in the methods used, but all the studies have suggested that\n",
      "up to 50% fewer dyskinesias developed in those treated with a dopamine agonist rather than levodopa,\n",
      "which can be reserved for use when the effects of the dopamine agonist wear off The ELLDOPA study\n",
      "(Early versus Late LevoDOPA in Parkinson's disease) evaluated previously untreated patients\n",
      "randomized to three doses (150, 300 or 600 mg) of levodopa or placebo. Levodopa-treated patients\n",
      "showed a significant improvement in motor scores at all three doses compared with those receiving\n",
      "placebo. Single-photon emission computed tomography (SPECT) imaging suggested an increased rate of\n",
      "decline of striatal I-beta-CIT uptake in the levodopa-treated arm compared with placebo. This\n",
      "anomalous observation further deepens the confusion surrounding the use of imaging findings as\n",
      "surrogate markers, the link between imaging findings and clinical outcome, and whether in-vivo\n",
      "neuroprotection trials can really be performed Side effects, such as lightheadedness or nausea, may\n",
      "be relieved by taking medication with food or increasing the dose of decarboxylase inhibitor. Side\n",
      "effects usually settle but, if persistent, can be prevented by using a peripheral dopamine\n",
      "antagonist such as domperidone. Some complications may, however, persist in the long term (Table\n",
      "4.1) Levodopa formulations Controlled-release preparations of levodopa, 200 mg or 100 mg, have no\n",
      "significant advantages over immediate-release preparations apart from their use in treating\n",
      "nocturnal disabilities. Such preparations have reduced bioavailability, and many patients dislike\n",
      "the longer lead time before improvement. Combining controlled-release and shorter-acting\n",
      "preparations is not advisable because the effect is difficult to predict Addition of a catechol-O-\n",
      "methyl transferase (COMT) inhibitor such as entacapone to the traditional combination of levodopa\n",
      "and a decarboxylase inhibitor (carbidopa) is now licensed for the treatment of later-stage\n",
      "Parkinson's disease that is no longer stabilized on a levodopa/decarboxylase preparation The STRIDE-\n",
      "PD study was a prospective 134-week double-blind trial comparing the risk of developing dyskinesias\n",
      "in 747 Parkinson's disease patients randomized to either levodopa and carbidopa (LC) or levodopa,\n",
      "carbidopa and entacapone (LCE), administered four times daily at 3.5-hour intervals. LCE had a\n",
      "shorter time to onset and increased frequency of dyskinesia at week 134 (42% vs 32%; p < 0.02) than\n",
      "LC. The time to wearing off and motor scores were not significantly different, although there was a\n",
      "trend in favor of LCE Although the mean levodopa dose was comparable in the two groups, the LCE\n",
      "group had a 30% greater exposure to levodopa based on the pharmacokinetic effect of entacapone,\n",
      "which increases the plasma levodopa by 30%. LCE caused a significant increase in dyskinesia in\n",
      "patients who were taking dopamine agonists, but not in patients who were not taking dopamine\n",
      "agonists. Surprisingly, there was an increase in prostate cancer and myocardial infarctions in the\n",
      "LCE group. At present, LCE cannot be recommended as the initial levodopa formulation\n",
      "Intraduodenal/jejunal infusion of levodopa offers an alternative route of administration in very\n",
      "advanced Parkinson's disease when other treatments have failed, and in patients not suitable for\n",
      "deep brain stimulation (see Table 5.3) or apomorphine (see pages 73 -). Using a portable infusion\n",
      "pump the enteral gel is delivered continuously through a percutaneous endoscopic gastrostomy tube\n",
      "into the duodenum, where it is absorbed and produces a steady plasma level. Studies have shown that\n",
      "this infusion is effective in controlling motor fluctuations in advanced Parkinson's disease and\n",
      "reduces dyskinesias. It also enables the patient to discontinue oral dopaminergic treatment and\n",
      "apomorphine infusion. It is licensed in several countries as an 'orphan' drug Several other trials\n",
      "using intrajejunal levodopa are in progress or have been completed. These include the GLORIA and\n",
      "MONOTREAT studies (completed), and the DUOGLOBE (addressing non-motor symptoms, specifically sleep)\n",
      "and INSIGHTS studies (in progress) Carbidopa/levodopa extended release. A novel extended-release\n",
      "capsule formulation of carbidopa and levodopa in a 1:4 ratio (ER CD-LD, formerly known as IPX066),\n",
      "containing intermediate- and extended-release beads, has recently been licensed for the treatment of\n",
      "Parkinson's disease. The drug's enhanced pharmacokinetic profile offers reliable control of motor\n",
      "symptoms, including the reduction of 'off time' throughout the day. Three studies have investigated\n",
      "the efficacy of this formulation in patients with Parkinson's disease (see below); however, no sleep\n",
      "benefit has been found, and the long-term consequences of this dosing with levodopa is unknown The\n",
      "APEX-PD study, a phase 3 randomized double-blind fixed-dose placebo-controlled trial, investigated\n",
      "the safety and efficacy of ER CD-LD in levodopa-naïve patients with early Parkinson's disease.\n",
      "Patients were randomized to one of four treatments for 30 weeks: placebo or ER CD-LD, 145 mg, 245 mg\n",
      "or 390 mg, three times daily. All dosages were superior to placebo throughout the study and at 30\n",
      "weeks (p < 0.0001) with respect to the change from baseline in Unified Parkinson's Disease Rating\n",
      "Scale (UPDRS) part II and III scores. The most frequently reported adverse events were nausea,\n",
      "headache and dizziness, but there were no unexpected serious adverse events related to the drug. The\n",
      "trial showed that ER CD-LD is safe and efficacious in patients with early Parkinson's disease The\n",
      "ADVANCE-PD study, a double-blind active-control parallel-group randomized phase 3 study, compared\n",
      "the efficacy and safety of ER CD-LD with immediate-release (IR) CD-LD in patients with advanced\n",
      "Parkinson's disease with motor fluctuations. The primary endpoint of percentage of 'off time' during\n",
      "waking hours showed a significant decrease for ER CD-LD compared with IR CD-LD. ER CD-LD\n",
      "significantly improved the control of motor symptoms compared with IR CD-LD in several clinical\n",
      "measures including the UPDRS, Clinician Global Impression of Change (CGI), Patient Global Impression\n",
      "of Change (PGI), Parkinson's Disease Questionnaire (PDQ)-39 and modified Rankin test. ER CD-LD was\n",
      "generally well tolerated The ASCEND-PD study, a randomized double-blind two-period crossover trial,\n",
      "compared ER CD-LD with carbidopa-levodopa in combination with the COMT inhibitor entacapone (CD-\n",
      "LD-E) in patients with advanced Parkinson's disease with motor fluctuations. The primary outcome\n",
      "measure was the percentage of 'off time' during waking hours based on subjects' diaries. ER CD-LD\n",
      "improved motor symptoms compared with CD-LD-E, demonstrating that it may be a useful treatment\n",
      "option in these patients Dopamine agonists Dopamine agonists stimulate dopamine receptors directly\n",
      "and so bypass the degenerating presynaptic nigrostriatal neurons. Five types of dopamine receptors\n",
      "(D -D) have been identified so far, broadly divided into D -like receptors (D and D) - linked to\n",
      "adenylate cyclase D -like receptors (D, D and D) - not linked to adenylate cyclase Improvement in\n",
      "motor function is generally attributed to D and D receptors, which are densely concentrated in the\n",
      "striatum (caudate nucleus and putamen). D receptors are localized in the limbic regions that are\n",
      "important for regulation of behavior, mood and emotion. Ease of use, side effects and relative cost\n",
      "determine which dopamine agonist to choose (Table 4.2) Efficacy. Pergolide and cabergoline are no\n",
      "longer recommended or in widespread use because of studies showing an association with ergot-related\n",
      "cardiac valvular disease. If absolutely indicated, cabergoline can only be used after pre-treatment\n",
      "echocardiography (ECG), with regular monitoring by ECG and chest X-ray during treatment. Lung and\n",
      "cardiac function should also be regularly monitored In this respect, non-ergot dopamine agonists\n",
      "such as pramipexole, ropinirole and the rotigotine transdermal patch are preferable (see Table 4.2).\n",
      "Longer-acting agonists such as the rotigotine skin patch, and once-daily ropinirole and pramipexole\n",
      "may also be used for added convenience and adherence Comparative studies of the efficacy of these\n",
      "newer dopamine agonists are scarce. The longer half-life of some dopamine agonists, and also their\n",
      "receptor specificity, may help in the provision of a more sustained and selective motor effect with\n",
      "fewer side effects (Table 4.3) Continuous dopamine stimulation (CDS) is a relatively modern concept\n",
      "that has been shown to reduce the severity and incidence of dyskinesias based on the fact that\n",
      "pulsatile delivery of dopamine to the deafferented dopamine receptors in the striatum is likely to\n",
      "be dyskinesogenic CDS may prevent or reverse motor complications because it does not prime the basal\n",
      "ganglia for involuntary movements as much as agents that produce pulsatile stimulation. CDS may also\n",
      "improve some aspects of sleep in patients with Parkinson's disease. However, Nutt reinforced the\n",
      "idea that CDS remains a theoretical concept, and the effect of CDS on dyskinesias, to date, has\n",
      "never been tested in a robust randomized clinical trial. The STRIDE-PD study (see pages 66 -) with\n",
      "the drugs given orally every 3.5 hours probably failed to provide CDS In practice, dopamine agonists\n",
      "are also useful for smoothing the 'on/off' fluctuations secondary to levodopa, as well as the many\n",
      "theoretical advantages listed in Table 4.4 Ropinirole and pramipexole are well-established non-ergot\n",
      "dopamine agonists in widespread clinical use in early and advanced Parkinson's disease. Both are\n",
      "effective in early and late disease as monotherapy and adjunctive therapy. In addition, pramipexole\n",
      "has been investigated for its anti-anxiety and antidepressant effects in Parkinson's disease. A\n",
      "direct beneficial effect of pramipexole on depressive symptoms, accounting for 80% of total\n",
      "treatment effect, was found in a 12-week randomized double-blind placebo-controlled trial of the\n",
      "drug in 287 mild-to-moderate Parkinson's disease patients with depressive symptoms In the 1990s, 8\n",
      "patients with Parkinson's disease who were taking pramipexole or ropinirole were reported to have\n",
      "fallen asleep while driving, causing accidents. In Europe, this led to a driving ban for patients\n",
      "taking either of the two drugs, although the ban has now been lifted. Since then, similar episodes\n",
      "of unintended sleep have been reported in patients taking other dopaminergic drugs. Daytime\n",
      "sleepiness is likely to be a part of the disease process, which could be aggravated by the use of\n",
      "dopaminergic drugs. This important side effect is discussed in greater detail on pages 136 - (see\n",
      "Sleep disorders) Rotigotine is the first transdermally delivered non-ergot dopamine agonist shown to\n",
      "be effective in early and advanced Parkinson's disease. Unlike the other non-ergot dopamine agonists\n",
      "it is effective in a once-daily application, and provides a theoretically attractive option for CDS\n",
      "by achieving constant plasma levels over 24 hours. In parkinsonian primate and mouse models,\n",
      "treatment with rotigotine produces virtually no dyskinesias In addition to D activity, rotigotine\n",
      "also has considerable affinity for the D receptor, unlike the other non-ergot dopamine agonists\n",
      "pramipexole and ropinirole. This is theoretically important because D activity is thought to\n",
      "synergistically enhance the effect mediated via D -like receptors. Rotigotine appears to have no\n",
      "affinity for 5-HT 2b receptors, which have been implicated in the pathogenesis of fibrotic side\n",
      "effects associated with ergot dopamine agonists, particularly cardiac valvulopathy Transdermal\n",
      "delivery also offers the advantage of preventing interaction with food and the first-pass metabolism\n",
      "associated with oral drugs. Approximately 1200 patients were enrolled worldwide in phase 3 trials in\n",
      "which rotigotine provided effective relief from the symptoms of both early and advanced Parkinson's\n",
      "disease In clinical trials, a rotigotine patch was associated with a reaction at the site of\n",
      "application in 39-44% of patients, although only a small subset had a severe reaction. The risk is\n",
      "reduced by changing the application site on a daily basis Rotigotine patches were withdrawn from the\n",
      "US market because of a problem with crystallization, but were reintroduced in 2012. The licensed\n",
      "doses are different from those in the UK Apomorphine is a highly potent D and D agonist that also\n",
      "acts on D receptors but has no opioid properties. It has a short half-life and is usually\n",
      "administered subcutaneously, either as a 'rescue' injection or by an infusion pump over 12, 18 or 24\n",
      "hours. The effects of oral and rectal apomorphine are less reliable; delivery by transdermal\n",
      "iontophoresis, and the buccal, intranasal and rectal routes are under investigation. Occasionally,\n",
      "patients can stop taking levodopa, but most need regular doses in addition to apomorphine\n",
      "Apomorphine infusion benefits patients with refractory motor response fluctuations and diphasic\n",
      "dyskinesias. Continuous subcutaneous administration may be very useful in the later stages of the\n",
      "disease, producing a continuous antidyskinetic effect and smoothing 'on/off' fluctuations. In the\n",
      "case of injections, a response occurs after 10-15 minutes and lasts for 45-60 minutes. Self-\n",
      "injection, in a manner similar to the self-injection of insulin by people with diabetes, is ideal\n",
      "for 'rescuing' patients from disabling 'off' periods. The treatment can be labor-intensive and\n",
      "requires specialist nursing care. In the UK, where the treatment is well established, 'shared care'\n",
      "guidelines have been developed to help the delivery of apomorphine therapy, clearly setting out the\n",
      "shared responsibilities of primary and secondary care providers. This is not the case in the USA\n",
      "where apomorphine infusion is not yet licensed for use. Daily rotation of injection sites may\n",
      "prevent skin nodules, while local ultrasound therapy and skin massage can help to treat existing\n",
      "nodules Side effects of dopamine agonists Nausea. The antiemetic domperidone (not available in the\n",
      "USA) used to be recommended for use with all dopamine agonists to prevent nausea. However, this is\n",
      "no longer the case as it has been found to be associated with cardiac dysrrythmia related to\n",
      "prologation of the QT interval. As such, the Medicines and Healthcare Products Regulatory Agency\n",
      "(MHRA) has advised that domperidone, 10 mg three times daily, should only be used for a maximum of 1\n",
      "week. In the USA, alternative antiemetics such as trimethobenzamide, 250 mg three times daily, are\n",
      "used in conjunction with apomorphine to prevent nausea Sleep disorders. Unintended or abnormal\n",
      "sleepiness is a potentially dangerous adverse effect in patients taking dopaminergic agents. As well\n",
      "as the incidents reported in patients taking ropinirole and pramipexole (see page 71), similar\n",
      "episodes have been reported in patients taking pergolide, bromocriptine, cabergoline, apomorphine\n",
      "and levodopa. However, abnormal sleepiness has also been described in patients with Parkinson's\n",
      "disease at the time of diagnosis, when they are not yet receiving any dopamine-replacement therapy.\n",
      "Daytime sleepiness is, therefore, likely to be a combined effect of the disease process and\n",
      "dopaminergic drug treatment, and not a novel event related solely to the use of dopamine agonists A\n",
      "small percentage of patients with Parkinson's disease (possibly 0.5-1%) with excessive daytime\n",
      "sleepiness, may exhibit sudden onset of sleep resembling narcolepsy. For this reason, older patients\n",
      "receiving dopaminergic therapy should be assessed using both the Epworth Sleepiness Scale (for\n",
      "excessive daytime sleepiness) and the Parkinson's Disease Sleep Scale (PDSS). A pragmatic view is\n",
      "that those who score more than 10 out of 24 on the Epworth scale, or less than 5 on item 15 of the\n",
      "PDSS, should be advised to exercise caution when driving, or preferably not to drive at all during\n",
      "the titration phase of therapy Studies suggest that somnolence is at its worst when dopaminergic\n",
      "therapy, particularly treatment with dopamine agonists, is being initiated and titrated up. In\n",
      "'sleepy' patients, polysomnography may identify a subset of people with a phenotype similar to that\n",
      "for narcolepsy, or it may unearth sleep apnea as a cause of daytime sleepiness Dopamine\n",
      "dysregulation syndrome (DDS), which resembles addiction, has been described in mostly young male\n",
      "patients with Parkinson's disease. DDS is typically linked to levodopa therapy when doses are\n",
      "increased continuously and beyond the level required to treat motor disability. The emerging pattern\n",
      "is that of a compulsive medication overuse associated with cognitive and behavioral disturbances.\n",
      "Patients are also liable to develop impulse-control disorders or punding behavior. Patients crave\n",
      "the drug and have unpleasant 'off' periods. As a result, they increase the dose of drugs that have\n",
      "been prescribed 'as required' or increase doses for reported 'off' periods. Patients often seek\n",
      "alternative drug sources such as internet sites, and drug hoarding and hiding are common. The\n",
      "condition has been termed variously as homeostatic hedonistic dysregulation impulse dysregulation\n",
      "compulsive behavior syndrome reward-seeking behavior Punding may be seen in association with DDS or\n",
      "in isolation, and implies an intense fascination with repetitive tasks. These complex repetitive\n",
      "behaviors were first described in psychostimulant addicts, and the phenomenon is similar to that\n",
      "observed in animals with amphetamine-induced stereotyped behaviors. The behaviors may develop from\n",
      "pre-existing habits, depending on an individual's previous occupation and interests. Examples\n",
      "include hoarding, handling, labeling and sorting objects, spending excessive time on a computer,\n",
      "writing or drawing, and aimless walkabouts. In men, the manipulation or dismantling of machines and\n",
      "tools is often reported Impulse-control disorders. The American Psychiatric Association's DSM5\n",
      "(Diagnostic and Statistical Manual of Mental Disorders, 5th edition) defines impulse control\n",
      "disorders (ICDs) as the failure to resist an impulse, drive or temptation to perform an act that is\n",
      "harmful to the person or to others. These are increasingly reported in Parkinson's disease and\n",
      "include a range of compulsive disorders (Table 4.5). Typically, the syndrome is characterized by a\n",
      "combination of impulsivity, compulsivity and preoccupation with a behavior or mood state.\n",
      "Unrecognized, ICDs can have serious consequences, such as breakdowns in interpersonal relationships\n",
      "and financial distress. The lifetime prevalence of ICDs, as reported by patients attending\n",
      "specialized clinics, is between 3 and 8%, although the DOMINION study reported a higher rate of\n",
      "13.7% with ICDs, including problem/pathological gambling (5%), compulsive sexual behavior (3.5%),\n",
      "compulsive buying (5.7%) and binge-eating disorder (4.3%) Men with early-onset Parkinson's disease\n",
      "and a history of alcohol misuse, illicit drug use or affective disorders may be susceptible to this\n",
      "syndrome. Abnormal dopamine release in the nucleus accumbens in response to a reward has been\n",
      "postulated as a possible mechanism. The treatment is complex and requires slow withdrawal of\n",
      "dopamine agonists, use of atypical neuroleptics and/or antidepressants, counseling and input from a\n",
      "neuropsychiatrist Dopamine agonist withdrawal syndrome. Abrupt cessation of therapy with dopamine\n",
      "agonists can lead to a dopamine agonist withdrawal syndrome (DAWS). It can present with a wide range\n",
      "of symptoms including panic attacks, anxiety, social phobia, depression, vomiting and symptomatic\n",
      "orthostatic hypotension. It rarely responds to levodopa, antidepressants or anxiolytics. However, it\n",
      "may improve with cautious reintroduction of low-dose dopamine agonists Fibrosis. The risk of serosal\n",
      "fibrosis in relation to ergot-derived drugs was first described in 1966. There have been several\n",
      "reports of cardiac, retroperitoneal and pleuropulmonary fibrosis in patients taking ergot-derived\n",
      "dopamine agonists such as pergolide, cabergoline and bromocriptine. Serosal fibrosis is a serious\n",
      "complication that is often irreversible The increased affinity of ergot-derived dopamine agonists\n",
      "for 5-HT 2b receptors has been cited as a possible mechanism. In practice, given the availability of\n",
      "non-ergot agonists (see above), the use of ergot dopamine agonists is no longer recommended COMT\n",
      "metabolizes dopamine and levodopa, producing two inactive metabolites, 3- O -methyl-dopamine and 3-\n",
      "O -methyl-dopa. Two COMT inhibitors, tolcapone and entacapone, are available; they extend the plasma\n",
      "half-life of levodopa, thus increasing the concentrations of levodopa and dopamine within the brain\n",
      "(Table 4.6; Figure 4.2). COMT inhibition prolongs 'on' time by 30-60%, which may increase the\n",
      "duration of, but not worsen, peak-dose dyskinesias Tolcapone blocks COMT in both the peripheral and\n",
      "central nervous systems. In November 1998, the European Medical Evaluation Agency withdrew tolcapone\n",
      "in the EU because of three cases of fatal fulminant hepatitis; sales were also suspended in Canada\n",
      "and Australia. In the USA, the Food and Drug Administration (FDA) recommended that regular liver\n",
      "function tests be performed. Tolcapone was re-released in Europe, but now its use must be\n",
      "accompanied by regular blood tests to monitor liver function. The FDA advises that levels of alanine\n",
      "and aspartate transaminase (ALT/AST) should be determined at baseline, then every 2-4 weeks during\n",
      "the first 6 months of therapy and then at intervals deemed clinically relevant. In the USA,\n",
      "tolcapone should be discontinued if ALT or AST levels exceed two times the normal upper limit. The\n",
      "patient consent form has been replaced with a patient acknowledgment form. The usual starting dose\n",
      "is 100 mg/day, increasing to 200 mg three times daily. Dyskinesia and nausea are common side\n",
      "effects, but diarrhea is the most common reason for drug withdrawal. Patients should be warned that\n",
      "the drug may color their urine Entacapone, 200 mg with each dose of levodopa, acts only\n",
      "peripherally, unlike tolcapone. No hepatobiliary side effects have been reported, and routine liver\n",
      "function tests are not required. The incidence of diarrhea is also less frequent than with\n",
      "tolcapone. Other side effects include hypotension, sedation, headache and dyskinesias. Patients\n",
      "should be forewarned that the drug may turn urine a reddish-orange color A combined formulation of\n",
      "entacapone, decarboxylase inhibitor and levodopa has been licensed for use in the USA, Europe and\n",
      "certain parts of Asia; the drug should make adherence easier for patients taking entacapone and is\n",
      "likely to be administered for treatment of early 'wearing-off' symptoms. Its use may be refined with\n",
      "a new scale/questionnaire designed to assess 'wearing off', as described by Stacy et al Monoamine\n",
      "oxidase B inhibitors Selegiline, 10 mg once daily or 5 mg twice daily orally (or 1.25 mg once daily\n",
      "by buccal administration), is a selective irreversible blocker of intra- and extraneuronal MAOB, and\n",
      "reduces metabolism of dopamine (Figure 4.3). The sublingual form of selegiline (1.25-2.5 mg/day) can\n",
      "be administered as an adjunct to levodopa in patients with fluctuations In animal models, selegiline\n",
      "blocks the conversion of MPTP to MPP +, which is toxic to dopaminergic neurons (see Figure 2.4). On\n",
      "this basis, it was thought that MAOB inhibition with selegiline might slow the decline in human\n",
      "Parkinson's disease by neuroprotection. However, the double-blind prospective placebo-controlled\n",
      "DATATOP study (Deprenyl And Tocopherol Antioxidant Therapy for Parkinsonism) in 1993, failed to\n",
      "confirm the neuroprotective property of selegiline. Furthermore, in the mid-1990s a report by the\n",
      "Parkinson's Disease Research Group (UK) suggested a 60% increase in mortality among patients\n",
      "receiving continued selegiline therapy, although this has not been substantiated Side effects of\n",
      "MAOB inhibition include hallucinations, sleep disorders, agitation, postural hypotension and\n",
      "withdrawal problems. Although a lower-dose formulation of selegiline (2.5 mg) with a better safety\n",
      "profile is available, its clinical role remains unclear: it is not neuroprotective, and safety in\n",
      "older patients is uncertain. However, it can have a useful dopa-sparing effect and may stimulate\n",
      "drowsy patients (Table 4.7) Rasagiline is a second-generation irreversible selective MAOB inhibitor\n",
      "that is administered orally at a dosage of 0.5-1 mg once daily. Approved dosing of this drug varies\n",
      "in different countries: the approved dose in Europe is 1 mg, while both 0.5 mg and 1 mg doses are\n",
      "approved in the USA, so that adjunctive therapy initiated at 0.5 mg can be raised to 1 mg if\n",
      "effectiveness is insufficient at the lower dose. It is approximately five times more potent than\n",
      "selegiline, and, in animal models, rasagiline increased cellular antioxidant activity and\n",
      "antiapoptotic factors In clinical trials, patients started late on rasagiline appeared to have worse\n",
      "motor scores than those initiated on rasagiline, prompting some researchers to suggest that\n",
      "rasagiline may have a disease-modifying role in Parkinson's disease (see pages 89 -). Several\n",
      "randomized controlled trials have shown rasagiline's efficacy as monotherapy or as an adjunct to\n",
      "levodopa in Parkinson's disease Safinamide is a glutamate antagonist as well as a MAOB inhibitor and\n",
      "a partial dopamine agonist. Trials suggest that this agent may improve motor function and reduce\n",
      "dyskinesias in patients with Parkinson's disease, and may have some additional non-motor benefits.\n",
      "Safinamide has been approved in the EU (but is not yet licensed in the UK) as oral once-daily add-on\n",
      "therapy to levodopa alone or in combination with other treatments in patients with mid- to late-\n",
      "stage Parkinson's disease Phase 3 trials have shown that safinamide significantly improves motor\n",
      "function in early Parkinson's disease in patients taking a single dopamine agonist at a stable dose\n",
      "(MOTION study) and significantly improves motor fluctuations in patients with mid- to late-stage\n",
      "disease taking levodopa and other Parkinson's disease drugs at a stable dose (SETTLE study).\n",
      "Safinamide has also demonstrated statistically significant improvement in quality of life in the\n",
      "short (6 months) and long term (up to 2 years), as assessed by the Parkinson's Disease Quality of\n",
      "Life (PDQ-39) and/or the European Quality of Life (EuroQoL, EQ-5D) scales Anticholinergics block the\n",
      "action of acetylcholine against dopamine within the basal ganglia (Figure 4.4). Data on the\n",
      "comparative efficacies of the different anticholinergic drugs are not available Historically, these\n",
      "drugs were used as an adjunct to levodopa therapy, helping to control rest-tremor and dystonia.\n",
      "However, they are no longer recommended in modern practice, particularly in older parkinsonian\n",
      "patients because of the risk of inducing a confusional state and aggravating/accelerating dementia\n",
      "Side effects include urinary retention, constipation, blurred vision, precipitation of narrow-angle\n",
      "glaucoma, dry mouth, memory problems and confusion. If neuropsychiatric side effects necessitate\n",
      "withdrawal of anticholinergic therapy, this should be carried out slowly in order to avoid a\n",
      "withdrawal syndrome that itself includes a confusional state associated with akinesia and\n",
      "disorientation Other drugs Pardoprunox is a partial dopamine agonist (mainly at D and D receptors)\n",
      "and also a full 5-HT 1A receptor agonist. It is being investigated for use in levodopa-treated\n",
      "fluctuating patients and its effect on 'off' and 'on' times without troublesome dyskinesias\n",
      "Amantadine, 100-400 mg daily, is an antiviral agent with an antiparkinsonian effect. Its mechanisms\n",
      "of action include increased dopamine synthesis an amphetamine-like action releasing catecholamines\n",
      "from presynaptic stores blocking dopamine and noradrenaline reuptake mild anticholinergic action\n",
      "antiglutamate action by antagonism at the N -methyl-D-aspartate receptors The antiparkinsonian\n",
      "effect of amantadine is mild, and is useful in young patients to delay the introduction of levodopa.\n",
      "The effect is long-lasting, and patients may deteriorate markedly if the drug is withdrawn\n",
      "Amantadine should be given as a single dose in the morning to prevent sleep problems. At high doses,\n",
      "amantadine has an antidyskinetic action that may last up to 9 months, but high doses can cause\n",
      "visual hallucinations, confusion and agitation. Amantadine can cause a specific discoloration of the\n",
      "legs called livedo reticularis When to initiate treatment Precisely when to begin treatment is\n",
      "controversial (Table 4.8). Some experts advocate early treatment to provide maximum clinical benefit\n",
      "to patients, whereas others prefer to delay initiation of treatment in order to minimize the risk of\n",
      "medication-related side effects including levodopa-related motor complications. The misconception\n",
      "that the benefits of levodopa treatment are limited to a finite period of time has caused many\n",
      "physicians to inappropriately delay the introduction of symptomatic therapy. With the development of\n",
      "pharmaceutical agents that are safe and well tolerated, with the potential to influence disease\n",
      "outcomes, there has been a call to reconsider the potential value of early intervention PDLIFE\n",
      "study. The argument for treatment of Parkinson's disease at diagnosis has been strengthened by the\n",
      "publication of the UK's prospective PDLIFE study, a national audit of the quality of life of people\n",
      "with Parkinson's disease. Findings indicate a progressive and significant deterioration in the self-\n",
      "reported health status of patients with Parkinson's disease who are left untreated at diagnosis\n",
      "compared with those who are treated. The work has reignited the debate of whether to initiate\n",
      "treatment of the disease at diagnosis or whether to adopt a 'wait and watch' policy. If a\n",
      "neuroprotective agent became available it would be instituted as early as possible, even before the\n",
      "appearance of motor symptoms. Nevertheless, the issue of neuroprotection in Parkinson's disease\n",
      "remains controversial (see pages 89 -) Choice of treatment All patients with Parkinson's disease who\n",
      "require drug treatment should be given the opportunity to make an informed choice from the range of\n",
      "treatment options available, including dopamine agonists, other levodopa-sparing agents, levodopa\n",
      "and combination therapy. The main aims are to keep the drug regimen as simple as possible aid\n",
      "adherence reduce the likelihood of side effects Theoretically, attempts should be made to stick to a\n",
      "regimen that mimics CDS as much as possible. Long-acting agents, or continuous delivery systems such\n",
      "as the rotigotine transdermal patch, or controlled-release preparations of other non-ergot dopamine\n",
      "agonists may be particularly useful in this regard It is very important that the patient's\n",
      "lifestyle, amount of support at home and individual preferences are all taken into consideration,\n",
      "and that the different therapeutic options with their potential side effects and advantages are\n",
      "explained Modern management of Parkinson's disease is not possible without the support of a\n",
      "multidisciplinary care team. A typical multidisciplinary team should consist of a Parkinson's\n",
      "disease nurse specialist, a physiotherapist, occupational therapist, and an experienced speech and\n",
      "language therapist with access to neuropsychology and palliative care Current guidelines. Different\n",
      "international guidelines (NICE, AAN, EFNS/MDS-ES) all agree that there is no single universal first\n",
      "choice of drug for people with Parkinson's disease, particularly in the early stages of the\n",
      "condition. Individual choice of drug will be influenced, for example, by the degree of motor\n",
      "disability (if severe, the first choice is likely to be levodopa), occupational needs, the risk of\n",
      "motor complications (more common in younger patients, which would be delayed by agonists),\n",
      "neuropsychiatric complications (more common in older and cognitively impaired patients, so agonists\n",
      "should be avoided), patient/clinician preferences and adherence issues. For these reasons, many\n",
      "younger patients will choose a levodopa-sparing strategy, while older patients may prefer levodopa\n",
      "therapy (see below) Guidelines for the management of Parkinson's disease published in the UK by NICE\n",
      "in June 2006 offer evidence-based advice drawn up by a multidisciplinary panel. Key recommendations\n",
      "are that patients and their carers should be involved in deciding their treatment and care, and that\n",
      "the choice of treatment should suit the patient's needs and preferences. This guideline is currently\n",
      "being updated. The following key points were identified as priorities for implementation Any patient\n",
      "with a suspected diagnosis of Parkinson's disease should be seen by a specialist within 6 weeks\n",
      "after referral by the primary care physician. A specialist is defined as an individual with\n",
      "expertise in the differential diagnosis of Parkinson's disease The diagnosis of Parkinson's disease\n",
      "should be reviewed every 6-12 months. The apomorphine and levodopa challenge tests should not be\n",
      "used to differentiate Parkinson's disease from atypical parkinsonian syndromes Regular access to\n",
      "specialist nursing care, physiotherapy, occupational therapy, and speech and language therapy should\n",
      "be available to patients Patients and their carers should be given an opportunity to discuss\n",
      "palliative care issues. No specific agents could be identified as the treatment of choice in either\n",
      "early or advanced disease The guidelines also emphasize the need for considering non-motor symptoms\n",
      "at all stages of Parkinson's disease Guidelines for the management of Parkinson's disease in other\n",
      "countries are broadly similar to the NICE guidelines. They include those of the AAN, published in\n",
      "2002 and modified in 2006, and those issued by the joint task force of the EFNS and the Movement\n",
      "Disorder Society's European Section in 2006 More recent guidelines from the Scottish Intercollegiate\n",
      "Guidelines Network (SIGN) highlight the following issues as key to the modern 'holistic' treatment\n",
      "of Parkinson's disease communication throughout disease progression attitudes to drug treatment\n",
      "information needs in relation to multifaceted areas family carers' needs non-motor symptoms\n",
      "importance of multidisciplinary team working The SIGN's suggested scheme for therapy is shown in\n",
      "Figure 4.5 Dopamine agonist versus levodopa. In younger patients, the issues of neuroprotection and\n",
      "dyskinesias should be considered. The results of four controlled dopamine-agonist monotherapy trials\n",
      "have been published and suggest that initiation of treatment with an agonist is beneficial in the\n",
      "early stages of Parkinson's disease. However, the results of the PD Med study, a multicenter real-\n",
      "life pragmatic study, reporting on quality of life-related outcomes in both young and old patients\n",
      "with Parkinson's disease, is likely to generate considerable controversy regarding the use of\n",
      "dopamine agonists and the choice of initial therapy. In total, 1620 patients with early Parkinson's\n",
      "disease were recruited and given one of three initial treatment regimens levodopa formulation (528\n",
      "patients) levodopa-sparing strategy - dopamine agonist (632 patients) levodopa-sparing strategy -\n",
      "MAOB inhibitor (selegiline; 460 patients) The study started in 2000 with a median follow-up of 3\n",
      "years and maximum of 7 years. During this time the dopamine agonists varied, including ergot\n",
      "agonists that are no longer in widespread use. The randomization to levodopa or alternative regimens\n",
      "was at the discretion of the clinician and a large part of the study was conducted in centers for\n",
      "the care of the elderly. The findings suggest relatively small but persistent benefits of starting\n",
      "therapy with levodopa rather than the listed alternatives. Interestingly, initial treatment with a\n",
      "MAOB inhibitor appeared to be at least as effective as treatment with a dopamine agonist Patients\n",
      "assigned to the levodopa arm scored, on average, 1.8 points (95% CI 0.5-3.0) higher on the\n",
      "Parkinson's Disease Questionnaire-39 (PDQ-39) mobility subscale than those assigned to levodopa-\n",
      "sparing therapies; however, the effects on non-motor aspects of the scale are unclear. A cost-\n",
      "utility analysis of the study will be reported separately If levodopa is used and the dose is\n",
      "titrated to the response, most patients initially need 50-100 mg three times daily to produce a\n",
      "consistent effect without fluctuations. Within 2-3 years, most will need a more frequent dosage to\n",
      "avoid fluctuations; smaller, more frequent doses (every 2-3 hours) often lead to an overall increase\n",
      "in dose. COMT inhibitors or dopamine agonists can, however, be introduced instead of increasing the\n",
      "frequency of levodopa Monitoring. Scales for monitoring Parkinson's disease, and thus the response\n",
      "to treatment, include Movement Disorder Society's UPDRS Hoehn and Yahr Disease Staging Scale (Table\n",
      "4.9) Parkinson's Disease Questionnaire (long form - PDQ 39; short form - PDQ 8) EuroQol (patient-\n",
      "related quality of life) Carer Strain Index Epworth Sleepiness Scale Parkinson's Disease Sleep Scale\n",
      "Non-Motor Symptoms Questionnaire (NMSQuest; see Figure 3.5) Non-Motor Symptoms Scale (NMSS)\n",
      "Parkinson's Disease Fatigue Scale Neuroprotection is a concept whereby a treatment may affect the\n",
      "underlying pathophysiology of Parkinson's disease and slow or halt the inexorable progression of the\n",
      "condition. Neuroprotective therapies already investigated or under review include caffeine,\n",
      "minocycline, nicotine, estrogen, creatine, lazaroids, bioenergetics, antiapoptotic drugs (CEP-1347,\n",
      "TCH-346), GM-1 ganglioside and GPi-1485. MAOB inhibitors and dopamine agonists have been clinically\n",
      "evaluated for neuroprotective properties based on positive results in animal models In the early\n",
      "2000s, the CALM-PD study (Comparison of the Agonist pramipexole vs Levodopa on Motor complications\n",
      "in Parkinson's Disease) and the REAL-PET study (Ropinirole as EArly therapy versus Levodopa - PET\n",
      "study) generated speculation among researchers that dopamine agonists such as ropinirole and\n",
      "pramipexole may have a neuroprotective role. The results were reported as partially positive,\n",
      "although methodological and logistical problems with these studies have prevented recommendation of\n",
      "these drugs specifically for neuroprotection. The trial designs did not take non-motor symptoms into\n",
      "account and could not exclude the regulatory effect of drugs on the imaging findings. Furthermore,\n",
      "clinical rating scales showed that the patients who received levodopa had better outcomes than those\n",
      "who received the agonists Trials with CEP-1347 and TCH-346, and more recently smilagenin, have been\n",
      "negative. Coenzyme Q10 has demonstrated encouraging potential as a neuroprotective agent in large\n",
      "doses, but trial data have been negative. In the USA, small 'futility studies' are being supported\n",
      "by the National Institute of Neurological Disorders and Stroke (NINDS) and the Michael J Fox\n",
      "Foundation to investigate agents with the potential to slow progression of the disease. See Chapter\n",
      "9 (pages 155 -) for more information on emerging therapies in this area The ADAGIO study. Rasagiline\n",
      "has been studied in the delayed-start ADAGIO study (Attenuation of Disease progression with Azilect\n",
      "Once-daily), which comprised two phases, each lasting 36 weeks. In phase 1, patients were randomized\n",
      "to one of four groups: rasagiline, 1 mg or 2 mg/day (early-start group), or corresponding placebo.\n",
      "In phase 2, the subjects in the early-start group remained on the same regimen, while the subjects\n",
      "in the placebo group were switched to rasagiline 1 mg or 2 mg/day (delayed-start group). At the end\n",
      "of the study, the early-start group who had received rasagiline 1 mg/day for 72 weeks showed a\n",
      "positive result, but those who had received 2 mg/day for the full study period did not. The reasons\n",
      "for this discrepancy are unclear but may be partly explained by a more robust symptomatic benefit\n",
      "from the 2 mg dose that masked the disease-modifying effect. Post hoc subgroup analysis showed a\n",
      "positive result for both the 1 mg and 2 mg dose for those subjects who had the highest quartile\n",
      "scores on the UPDRS at baseline. Although this does not make the study positive, it does suggest the\n",
      "need for further research, id est larger and longer delayed-start studies using the 2 mg/day dose in\n",
      "patients with more advanced Parkinson's disease It should be noted that the difference in UPDRS\n",
      "between the early- and delayed-start groups was small (1.7 points) and its clinical significance is\n",
      "hard to ascertain. However, the object of this study was not to determine the clinical significance\n",
      "of a disease-modifying therapy, but to see if the benefit from therapy was secondary to disease\n",
      "modification, id est something more than symptomatic improvement The ADAGIO study is an important\n",
      "landmark clinical trial that suggests early treatment with rasagiline, 1 mg/day, confers benefits\n",
      "that are not duplicated by delayed treatment with the same agent. However, no 'definitive'\n",
      "recommendations or guidelines can be made from these results. Clinicians will have to decide on a\n",
      "case-by-case basis whether the patient would benefit from rasagiline. Cost, concomitant medications\n",
      "and a possible disease-modifying benefit will have to be factored into the decision-making process\n",
      "by the patient and the treating physician The ADAGIO Follow-Up (AFU) study investigated the long-\n",
      "term effect of rasagiline in ADAGIO study participants and the long-term benefits of early- versus\n",
      "delayed-start rasagiline treatment. Although clinically important improvements were seen in a\n",
      "substantial number of patients, the study failed to demonstrate significant differences between the\n",
      "original ADAGIO early- and delayed-start groups. However, these results should be interpreted with\n",
      "caution given the significant gap, and loss of participants, between the time of the ADAGIO and AFU\n",
      "studies The PROUD study (PRamipexole On Underlying Disease) is another delayed-start trial, which\n",
      "investigated the disease-modifying effect of pramipexole in early Parkinson's disease. In phase 1,\n",
      "535 patients were randomized to double-blind placebo or pramipexole, 1.5 mg/day for 6-9 months. In\n",
      "phase 2, all patients were administered pramipexole, 1.5 mg/day, for up to 15 months. The primary\n",
      "endpoint was a change from the baseline UPDRS total score after 15 months, and a substudy assessed\n",
      "the change in DaTSCAN uptake after 15 months. In total, 411 patients were included in the primary\n",
      "assessment. After 15 months there was no difference between the early- and delayed-start group and\n",
      "DaTSCAN uptake was also similar. The results did not support a disease-modifying effect of\n",
      "pramipexole Treatment of non-motor symptoms The AAN and MDS task force documents for managing non-\n",
      "motor symptoms of Parkinson's disease recognize the need for clinical studies in this area, as good\n",
      "quality trials providing a level 1 evidence base for the treatment of non-motor symptoms are few and\n",
      "far between. Table 4.10 summarizes the evidence base for the treatment of the small number of non-\n",
      "motor symptoms for which controlled trials have been conducted. The few randomized controlled\n",
      "studies that have addressed the non-motor aspects of Parkinson's disease are outlined below The\n",
      "RECOVER study (Randomized Evaluation of the 24-hour COVerage: Efficacy of Rotigotine) was a\n",
      "multinational double-blind placebo-controlled trial of 287 patients with Parkinson's disease who had\n",
      "unsatisfactory early-morning symptom control. Patients received either a rotigotine transdermal\n",
      "patch, 2-16 mg/day (n = 190), or placebo (n = 97). This was the first time an international clinical\n",
      "trial protocol included measures of non-motor symptoms, such as nocturnal sleep disturbance, along\n",
      "with early morning motor function as co-primary efficacy endpoints using the UPDRS Part III (motor\n",
      "examination) and the modified Parkinson's Disease Sleep Scale (PDSS-2). The overall effect on non-\n",
      "motor symptoms was also assessed using the Parkinson's disease non-motor scale (NMSS) As well as\n",
      "significant motor improvement with rotigotine patch therapy (p = 0.0002), there was highly\n",
      "significant improvement in the mean PDSS-2 total score (a decrease of −5.9 points with rotigotine vs\n",
      "−1.9 points with placebo, p < 0.0001). The NMSS score also registered a significant improvement in\n",
      "sleep and mood Detailed post hoc analysis of the RECOVER data has shown efficacy for mild to\n",
      "moderate pain in Parkinson's disease as well as sleep and mood. The rotigotine transdermal patch is\n",
      "now being investigated for pain in Parkinson's disease using the King's Parkinson disease pain scale\n",
      "PANDA was a multisite double-blind randomized placebo-controlled parallel-group study in male and\n",
      "female subjects with confirmed Parkinson's disease and severe pain, as assessed by a new pain\n",
      "classification system for Parkinson's disease. The study evaluated treatment with prolonged-release\n",
      "oxycodone combined with naloxone (OXN PR). Subjects were randomized to receive either OXN PR or\n",
      "placebo for up to 112 days. The primary endpoint of improvement of average 24-hour pain score after\n",
      "16 weeks was not met in the full analysis population but the per protocol population analysis\n",
      "revealed that adherence to OXN PR significantly improved average 24-hour pain scores at 16 weeks\n",
      "compared with placebo (p = 0.010). Furthermore, the results showed a significant improvement in the\n",
      "24-hour pain score after 4 weeks (p = 0.018), 8 weeks (p = 0.011) and 12 weeks (p = 0.021). This was\n",
      "the first ever randomized placebo-controlled study to assess Parkinson's-associated pain as a\n",
      "primary outcome measure The EuroInf study, an open-label prospective observational 6-month\n",
      "multicenter study, compared 43 patients on apomorphine with 44 on intrajejunal levodopa infusion\n",
      "(IJLI). It is the first study to consider non-motor symptom scores as the primary outcome. Patients\n",
      "treated with IJLI showed large improvement (effect size = 0.83) on the NMSS total score. Patients\n",
      "treated with apomorphine had moderate improvement (effect size = 0.53) on the NMSS total score with\n",
      "significantly more improvement in mood and apathy NMSS scores than IJLI Overall, health-related\n",
      "quality of life and non-motor symptoms improved in 75% of patients receiving IJLI; a similar\n",
      "proportion of patients receiving apomorphine showed improvement in health-related quality of life.\n",
      "Adverse effects included peritonitis with IJLI and skin nodules with apomorphine The IMPACT study, a\n",
      "non-randomized controlled trial, was conducted in six hospitals in the Netherlands to address the\n",
      "role of a multidisciplinary approach for the treatment of Parkinson's disease. The primary outcomes\n",
      "were activities of daily living measured with the Academic Medical Center linear disability score\n",
      "and quality of life measured with the Parkinson's disease quality of life questionnaire. Results\n",
      "were analysed at 4, 6 and 8 months. Secondary outcomes included motor functioning (measured by UPDRS\n",
      "part III at 4 months), and caregiver burden and costs (during the whole study period). The results\n",
      "showed that the multidisciplinary care approach conferred only small benefits compared with normal\n",
      "integrated care in the Netherlands. The study did not reach statistical significance. However, the\n",
      "authors concluded that alternative approaches need to be devised and explored to achieve more\n",
      "substantial health benefits\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      ", as well as the effects of levodopa on Parkinson's disease. In the US, there is no evidence that\n",
      "levodopa is effective in treating Parkinson's disease. However, there is evidence that it is\n",
      "effective in preventing Parkinson's disease.In the UK, there is evidence of levodopa being effective\n",
      "in Parkinson's disease. There is no evidence of Levodopa being effective for Parkinson's disease.\n",
      "Furthermore, there is evidence for levodopa being ineffective in Parkinson's disease, but there is\n",
      "no evidence of levodopamine being effective in Parkinson’s disease.There is evidence that\n",
      "levodopamine is effective in Parkinson's Disease. There is evidence that levadopa is effective for\n",
      "Parkinson's Disease.There\n",
      "\n",
      "Reference:\n",
      "Levodopa restores the dopamine lost due to degeneration of striatonigral cells; patients with\n",
      "typical Parkinson's disease respond to levodopa almost immediately. Fear over the toxicity of\n",
      "levodopa has resulted in levodopa phobia in some patients; however, there is no robust evidence to\n",
      "suggest that levodopa is toxic to the human nigrostriatal pathway and these fears have mostly been\n",
      "discredited. Dopamine agonists are useful for smoothing the 'on/off' fluctuations secondary to\n",
      "levodopa therapy; some, such as rotigotine, may offer continuous dopaminergic stimulation in\n",
      "practice and specifically offer night-time and early morning benefit. Treatment decisions should be\n",
      "based on the degree of disability, occupational needs, age, patient/clinician preference and\n",
      "adherence issues; neuroprotection remains a theoretical argument, while dyskinesias and wearing off\n",
      "are an important consideration in younger patients. Trial data indicate that treatment of\n",
      "Parkinson's disease could be initiated with levodopa, oral dopamine agonists or a monoamine oxidase\n",
      "B (MAOB) inhibitor. The PD MED study seems to suggest that initial therapy with levodopa offers a\n",
      "small but persistent benefit compared with the alternatives, and initial MAOB inhibitor treatment is\n",
      "at least as effective as a dopamine agonist. The findings of the PDLIFE study suggest that early\n",
      "initiation of treatment may be beneficial in terms of health-related quality of life. Impuse control\n",
      "disorders have emerged as a major complication of mostly dopamine agonist treatment, and monitoring\n",
      "is a must. The treatment of non-motor symptoms is important at all stages of Parkinson's disease.\n",
      "The results of the PANDA study may help people with Parkinson's-associated pain.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541680, 'ch_8')\n",
      "Management: behavioral therapy Behavioral therapy - the collective name for the various methods and\n",
      "strategies used to bring about changes in lifestyle - is universally credited as being one of the\n",
      "three main pillars of weight management, alongside dietary modification and increased physical\n",
      "activity (Chapters 5 and). Bringing about a change in behavior is an important part of clinical\n",
      "care; the ability to foster such change in patients is fundamental to the skill base of any health\n",
      "professional. Changing patients' habits and attitudes using cognitive behavioral therapy (CBT) is\n",
      "key to long-term obesity management Classic behavioral interventions for managing obese patients may\n",
      "last months or years, but complex behavioral therapy concepts can be introduced during a normal\n",
      "consultation. In fact, many clinicians do so without realizing, by simply providing good advice in a\n",
      "logical ordered fashion. For example, if the first thing an individual does when arriving home from\n",
      "a stressful day is to eat two biscuits, basic dietary and nutritional advice is simple: stop eating\n",
      "biscuits. Behavioral therapy, on the other hand, suggests how to avoid eating the biscuits: the\n",
      "answer could be simple - don't buy any biscuits; or more complex - avoid the stressful situation\n",
      "that triggered the desire to eat biscuits, which may mean changing jobs, or walking home instead of\n",
      "taking a crowded bus. Other suggestions might include putting the biscuits where they are difficult\n",
      "to reach, or to have healthy snacks readily accessible instead. Alternatively, there may be other\n",
      "ways to unwind: such as having a bath or going for a run Behavioral therapy produces disappointing\n",
      "results when used alone, but has much more profound effects when used in combination with other\n",
      "modalities. In short-term studies, it has been shown to induce weight loss of 10% or more but this\n",
      "was not sustained in the long term. However, a long-term support program that combines behavioral\n",
      "therapy with regular physical activity and dietary advice can be highly successful in improving\n",
      "adherence to lifestyle changes and sustaining weight loss 'Stage of change' theory An individual's\n",
      "likelihood of accepting any lifestyle advice depends on their 'stage of change', which refers to\n",
      "their state of mind and reflects how motivated they are to undergo management for their condition.\n",
      "Before starting treatment it is important to determine which stage the individual is at and to act\n",
      "accordingly; success is unlikely if the wrong approach is made at the wrong time. The six stages are\n",
      "shown in Figure 7.1 Elements of behavioral therapy Goal setting: the agreement of realistic weight-\n",
      "loss targets, at a realistic rate of improvement Self-monitoring: increasing self-awareness of\n",
      "eating patterns and physical activity behavior, which is an essential precursor for change Stimulus\n",
      "control: avoiding situations that lead to harmful behavior, and promoting situations that influence\n",
      "healthy activity Problem solving: how to avoid social and societal pressures that might result in\n",
      "straying from agreed goals and targets Cognitive restructuring: identifying and modifying self-\n",
      "defeating thoughts and ideas Many of these techniques are summarized in Table 7.1 Self-monitoring is\n",
      "a fundamental pillar of CBT; in its most basic form it constitutes a food and activity diary that\n",
      "records what is eaten where the food is eaten, and in what circumstances emotional feelings or\n",
      "triggers involved levels of activity A food and activity diary should clarify eating patterns and\n",
      "behaviors, particularly events that trigger eating, with a view to changing those patterns once they\n",
      "have been identified, for instance by planning ahead. Once the pattern of eating has been\n",
      "established, the diary can be used as part of the treatment plan, by recording progress towards\n",
      "dietary goals. Long-term weight management has been shown to improve when food records are used\n",
      "Stimulus control. Different stimuli (cues) for eating, only one of which is feeling physically\n",
      "hungry, must first be identified then managed. For example, eating chocolate biscuits on arriving\n",
      "home from work is more likely to be because of stress than hunger; the stimulus control is therefore\n",
      "to remove the biscuit or the stress. External cues include time (exempli gratia eating because its\n",
      "lunchtime) the presence of food (exempli gratia eating because food is available, or finishing a\n",
      "plateful because it is rude or wasteful not to [this can be a habit deeply ingrained from\n",
      "childhood]) social situations (exempli gratia eating cheese with port because everyone else is)\n",
      "Stimulus control might involve avoiding external cues, for instance taking a different route home\n",
      "that avoids passing the temptation of a fast-food outlet. Controlling eating at the last stage of\n",
      "the chain (id est when one is already looking at the menu in the window) is incredibly difficult,\n",
      "whereas taking action earlier in the chain, when the meal is less tangible, is easier. Avoiding\n",
      "shopping whilst hungry is another example of stimulus control. Internal cues include stress or\n",
      "emotional eating (discussed below) 'Learned self-control' becomes important when the only route home\n",
      "passes the fast-food outlet, making external temptation unavoidable. Learned self-control occurs\n",
      "with prolonged repetition of the external stimulus, without giving in and eating. After enough\n",
      "journeys home without buying food, the conditioned response will be reduced Problem solving therapy\n",
      "(PST) can be used during a consultation to implement strategies for the management of obesity. PST\n",
      "facilitates the development of a set of skills that enhance a patient's self-efficacy, and high\n",
      "levels of self-efficacy correlate with successful outcomes in obesity management programs. Patients\n",
      "are supported to develop the ability to recognize potential solutions to their problems rather than\n",
      "solutions being suggested by the patient's healthcare practitioner. The process is outlined in Table\n",
      "7.2; the skills developed are transferable to solving a range of problems 'Stress management' is\n",
      "self-explanatory; comfort eating is widely recognized as a reason for overeating. However, evidence\n",
      "for hyperphagia in a stressful environment is conflicting, as for some individuals stress causes\n",
      "loss of appetite. Many people indulge in 'emotional eating': eating at times of stress, pressure or\n",
      "negative emotional state to provide comfort. This amounts to eating without relying on the usual\n",
      "stimulus of hunger to govern when food is required. Such behavior may reflect childhood patterns,\n",
      "even breast-feeding, when eating and comfort were closely associated. Others admit to 'bingeing' on\n",
      "energy-dense foods when commonsense tells them to stop but they feel powerless to resist These\n",
      "phenomena may arise from common pathways in the brain that relate to satiety and mood; the\n",
      "underlying stress or depression must be confronted for weight loss to be successful Eating disorders\n",
      "Binge eating disorder (BED) is specifically recognized in its own right in the fifth edition of the\n",
      "Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the broadly accepted manual for\n",
      "mental illness classification, published by the American Psychiatric Association. Patients with BED\n",
      "display the features of bulimia nervosa but without the purging, abnormal exercise regimens or other\n",
      "compensatory behavior to induce weight loss (see also Fast Facts: Eating Disorders). The condition\n",
      "was largely ignored when it was first recognized in 1959 but has recently gained greater prominence\n",
      "Diagnostic criteria are loss of control of eating plus three of eating much more rapidly than normal\n",
      "eating until uncomfortably full eating large amounts when not physically hungry eating alone because\n",
      "of embarrassment of volume of consumption feeling disgusted, depressed or very guilty afterward Its\n",
      "features include recurrent episodes of eating objectively large amounts of food within a discrete\n",
      "period of time, a subjective sense of lack of control during each eating episode, binge eating at\n",
      "least 2 days a week on average for 6 months and no regular use of inappropriate compensatory\n",
      "behaviors, id est purging, fasting or excessive exercise. It is estimated that 2.5% of adult women\n",
      "and 1.1% of men have BED, most, but not all, of whom are obese. The prevalence among patients\n",
      "attending obesity clinics is 20-30%, emphasizing the importance of recognizing the condition without\n",
      "delay Treatment involves conventional weight management combined with CBT. Strict dietary regimens\n",
      "are likely to aggravate the condition and should be avoided. Depression and personality disorders\n",
      "have been linked with BED but it is unclear whether the abnormal eating pattern predates the\n",
      "emotional disorder or vice versa Night eating syndrome (NES) was recognized as an abnormal eating\n",
      "pattern in the 1950s by Albert Stunkard, as was its association with psychological and emotional\n",
      "factors. Individuals with NES tend to be moody, tense, anxious, nervous and depressed; NES is\n",
      "thought to be associated with abnormal reactions to stress and changes in the circadian rhythm, with\n",
      "a disruption of the hypothalamo-pituitary axis. Criteria are shown in Table 7.3 The prevalence of\n",
      "NES in the general population is 1-2%, rising to 10% of obese patients and as many as a quarter of\n",
      "grossly obese people. It is associated with obstructive sleep apnea and restless legs syndrome, but\n",
      "has no association with nocturnal sleep-related eating disorder, which is more of a sleep disorder\n",
      "than an eating disorder characterized by eating during sleep (rather like sleep walking). Patients\n",
      "with NES lack hunger before their episodes of night eating, display 'automaticity' of the behavior\n",
      "during waking intervals and varying levels of consciousness during eating Treatment is predominantly\n",
      "behavioral rather than dietary, initially by persuading patients to have an early substantial\n",
      "breakfast and to regain a normal eating pattern. The circadian rhythm should be reinforced by the\n",
      "appropriate amount of exercise during the day, with normal regular mealtimes and daily routines\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "Management: behavioral therapy is a fundamental pillar of CBT; in its most basic form it constitutes\n",
      "a food and activity diary that records the behavior of the individual.Behavioral therapy - the\n",
      "collective name for the various methods and strategies used to bring about changes in lifestyle - is\n",
      "universally credited as being one of the three main pillars of weight management, alongside dietary\n",
      "modification and increased physical activity (Chapters 5 and). Bringing about a change in behavior\n",
      "is an important part of clinical care; the ability to foster such change in patients is fundamental\n",
      "to the skill base of any health professional. Changing patients' habits and attitudes using\n",
      "cognitive behavioral therapy (CBT) is key to long-term obesity management.Cognitive behavioral\n",
      "therapy is an important pillar of CB\n",
      "\n",
      "Reference:\n",
      "Behavioral therapy, alongside diet and lifestyle advice, is one of the three key components of\n",
      "obesity management. A person's degree of motivation and expectations should be assessed. Techniques\n",
      "include goal setting, self-monitoring and stimulus control. Binge eating disorder and night eating\n",
      "syndrome are specific eating disorders and should be treated accordingly.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797907, 'chp6')\n",
      "Supportive treatment At present, the main focus of care for pyruvate kinase (PK) deficiency is with\n",
      "supportive therapies Red blood cell (RBC) transfusions are frequently used to support patients with\n",
      "PK deficiency, particularly during the first months of life. However, transfusion thresholds and\n",
      "guidelines used in other red cell disorders, such as thalassemia major or intermedia, do not\n",
      "necessarily apply to PK deficiency When to transfuse. There is no set standard with regard to\n",
      "transfusions for patients with PK deficiency because the degree of anemia and associated symptoms\n",
      "differ so much between affected individuals., The decision to opt for transfusion therapy is\n",
      "therefore based on a patient's tolerance of anemia rather than on an arbitrary level of hemoglobin.\n",
      "As explained in Chapter 1, an increase in red cell 2,3-diphosphoglycerate results in enhanced oxygen\n",
      "off-loading into the tissues. Consequently, patients may tolerate moderately severe anemia with few\n",
      "symptoms. When patients have a transfusion, the goal nadir hemoglobin level should also be based on\n",
      "symptoms rather than on a level extrapolated from guidelines used in other anemias Many patients\n",
      "with PK deficiency will never need a transfusion or will only require intermittent, or unplanned,\n",
      "transfusions during hemolytic crises due to infections or an aplastic crisis associated with\n",
      "parvovirus infection. Others may remain on regular transfusion therapy until splenectomy is\n",
      "considered Hemoglobin goals. During the first years of life, hemoglobin goals are those that allow\n",
      "for normal growth and development, and young children are often reliant on frequent transfusions to\n",
      "decrease symptoms and improve growth. As individuals age through adulthood, transfusion requirements\n",
      "may increase despite a stable hemoglobin, as a result of increased symptoms from the anemia, perhaps\n",
      "related to increased daily activity Complications. Transfusions are associated with iron loading,\n",
      "and chelation therapy is necessary in patients who receive regular transfusions (see Table 5.3) The\n",
      "hypoxic and glucose-restricted environment of the spleen poses a problem to PK-deficient\n",
      "reticulocytes, which rely on oxidative phosphorylation to produce adenosine triphosphate (ATP).\n",
      "Impaired ATP production leads to RBC destruction in the spleen. Severely PK-deficient reticulocytes\n",
      "are metabolically more stable in the absence of the spleen; therefore, a paradoxical, sustained,\n",
      "robust reticulocytosis follows splenectomy in this disorder Partial splenectomy has been performed\n",
      "in a few patients with PK deficiency, but has not been beneficial The benefits of splenectomy.\n",
      "Before splenectomy, the reticulocyte count may be inappropriately low or mildly to moderately\n",
      "increased (5-15%). After splenectomy, reticulocyte counts can be as high as 50-70% and, with the\n",
      "extended lifespan of PK-deficient reticulocytes in the absence of the spleen, hemoglobin levels\n",
      "increase by a median of 1.6 g/dL Splenectomy partially ameliorates the anemia in most patients and\n",
      "is beneficial in decreasing the need for transfusions in 90% of patients. In patients who received\n",
      "regular transfusions before splenectomy, approximately 80% can discontinue transfusions altogether\n",
      "following surgery. However, in almost all patients, an incompletely compensated hemolytic process\n",
      "persists, in which mild anemia, reticulocytosis and indirect hyperbilirubinemia continue Poor\n",
      "responders. Approximately 14% of patients on regular transfusions prior to splenectomy will have a\n",
      "poor response and will continue to require regular transfusions. In these cases, imaging to evaluate\n",
      "for a splenule or secondary spleen is indicated, but these are rarely found Patient selection.\n",
      "Preoperative assessment of red cell survival, splenic sequestration and/or spleen size is of no\n",
      "value in selecting patients for splenectomy. In part, this reflects the importance of the liver as a\n",
      "site of RBCl destruction. Low pre-splenectomy hemoglobin levels are associated with a poorer\n",
      "response to splenectomy in terms of the post-splenectomy hemoglobin rise and/or transfusion burden\n",
      "The burden of transfusions in PK deficiency varies between patients. The decision whether to have a\n",
      "splenectomy to improve the anemia of PK deficiency is complex and depends on both the physician's\n",
      "and the patient's perspective of the potential benefits and risks. Recent guidelines recommend\n",
      "splenectomy in patients who are reliant on regular transfusions or are severely anemic. Splenectomy\n",
      "should also be considered in patients who receive intermittent transfusions with every infectious\n",
      "illness or who have symptomatic anemia The timing of splenectomy is based on the risk-benefit\n",
      "assessment. Splenectomy in young children is associated with an increased risk of post-splenectomy\n",
      "sepsis, while a delay in splenectomy in patients who receive regular transfusions is associated with\n",
      "increased iron loading Post-splenectomy sepsis. Splenectomy increases susceptibility to serious\n",
      "bacterial infections with encapsulated organisms, such as Streptococcus pneumoniae, Haemophilus\n",
      "influenzae, Neisseria meningitidis and Capnocytophaga canimorsus. In the absence of a spleen,\n",
      "individuals are also at risk of severe babesiosis and malaria. With adequate vaccinations and\n",
      "prophylactic antibiotics, the absolute risk of a serious infection is very low. Nevertheless,\n",
      "because of these lifelong infectious risks, surgery should be avoided altogether or preferably\n",
      "delayed until at least 5 years of age. If splenectomy is needed at an earlier age, the benefits must\n",
      "be balanced against the risk of infection Vaccination. Since the spleen is the primary site for the\n",
      "production of immunoglobulin M antibodies, which are required for opsonization of encapsulated\n",
      "organisms, vaccination prior to splenectomy is much preferred. Vaccination schedules are frequently\n",
      "updated based on new information and vaccine development. Therefore, physicians should refer to an\n",
      "updated website rather than to articles or books for a list and schedule of vaccinations before\n",
      "splenectomy. A useful website is www.cdc.gov/vaccines/schedules/index.html. It is recommended that\n",
      "all vaccines are given at least 2 weeks before splenectomy Antibiotic prophylaxis. Oral antibiotics\n",
      "for infection prophylaxis are indicated after splenectomy. Strategies include daily antibiotic\n",
      "prophylaxis and empiric antibiotics administered for febrile illnesses. The ideal duration for\n",
      "prophylactic antibiotics is not clear, and practice varies by country. Some physicians recommend a\n",
      "lifetime of prophylactic antibiotics, while others recommend discontinuation after 1 year if\n",
      "patients live close to a medical center and agree to seek urgent medical care for all fevers Most\n",
      "physicians recommend that asplenic children receive daily prophylaxis with penicillin VK until at\n",
      "least 5 years of age and for at least 1 year following splenectomy Once splenectomized, if an\n",
      "individual has a fever of 38.5°C (101.5°F) or higher, they should be seen urgently for a blood\n",
      "culture and complete blood count and given intravenous or intramuscular broad-spectrum antibiotics\n",
      "Post-splenectomy thrombosis. Many studies demonstrate an overall increased risk of thrombosis after\n",
      "splenectomy, including in otherwise healthy individuals. After splenectomy, the overall risk of\n",
      "thrombosis in PK deficiency is approximately 10%, including portal vein thrombosis, deep vein\n",
      "thrombosis, pulmonary embolism and central nervous system thrombosis Although the etiology for the\n",
      "increased risk is not clear, some physicians recommend taking low-dose aspirin (acetylsalicylic\n",
      "acid) after splenectomy, particularly in patients with marked thrombocytosis, to potentially\n",
      "decrease this risk Folic acid With the reticulocytosis associated with PK deficiency, folic acid\n",
      "needs are increased. Supplemental folic acid may be needed, depending on the patient's dietary folic\n",
      "acid intake\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "is. Splenectomy increases susceptibility to serious bacterial infections with encapsulated\n",
      "organisms, such as Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and\n",
      "Capnocytophaga canimorsus. In the absence of a spleen, individuals are also at risk of severe\n",
      "babesiosis and malaria. With adequate vaccinations and prophylactic antibiotics, the absolute risk\n",
      "of a serious infection is very low. Nevertheless, because of these lifelong infectious risks,\n",
      "surgery should be avoided altogether or preferably delayed until at least 5 years of age. If\n",
      "splenectomy is needed at an earlier age, the benefits must be balanced against the risk of infection\n",
      "with encapsulated organisms.Vaccination\n",
      "\n",
      "Reference:\n",
      "The burden of transfusions in pyruvate kinase (PK) deficiency is quite variable and depends on both\n",
      "patient and provider factors. The decision for transfusion therapy relates to the patient's\n",
      "tolerance of anemia rather than an arbitrary level of hemoglobin. Some patients with PK deficiency\n",
      "may tolerate a lower level of hemoglobin than those with other anemias due to increased red cell\n",
      "2,3-diphosphoglycerate. Splenectomy is beneficial in increasing the hemoglobin level and decreasing\n",
      "the need for transfusions in most patients with PK deficiency. Given the potential risks associated\n",
      "with splenectomy, physicians should participate in shared decision making with their patients to\n",
      "determine whether to pursue splenectomy and at what age. The risk of post-splenectomy thrombosis in\n",
      "PK deficiency is similar (approximately 10%) to other non-malignant hematologic conditions.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541277, 'ch_6')\n",
      "The diagnosis of epilepsy relies on the correct classification of epileptic seizures and epilepsy\n",
      "syndromes (see Chapter 2), with consequent implications for prognosis and choice of therapy Epilepsy\n",
      "is not a single disease but an extensive collection of conditions with a wide range of underlying\n",
      "etiologies and pathologies, all sharing the common and fundamental characteristic of recurrent,\n",
      "usually unprovoked, seizures. Figure 3.1 shows some common etiologies in relation to age The\n",
      "diagnostic procedure aims to answer three key questions Is the episode an epileptic seizure? What is\n",
      "(are) the seizure type(s)? What is the epilepsy syndrome? Differential diagnosis A wide range of\n",
      "conditions can mimic epileptic seizures and must be considered in the differential diagnosis (Table\n",
      "3.1). For example, syncopal attacks, sometimes with clonic movements and incontinence, are commonly\n",
      "misdiagnosed as epileptic seizures. Furthermore, non-epileptic psychogenic seizures (also called\n",
      "pseudoseizures) are estimated to occur in up to 45% of patients referred to specialist centers with\n",
      "apparently refractory epilepsy. This misidentification of non-epileptic conditions as epilepsy can\n",
      "lead to unnecessary treatments that are potentially harmful, and can delay the start of appropriate\n",
      "therapy. The temptation to attach a label of 'epilepsy' should be resisted if there is any doubt\n",
      "about the diagnosis despite a thorough evaluation. Both the physician and patient must simply await\n",
      "the passage of time before coming to a firm conclusion. Further challenges of diagnosis and\n",
      "management may arise in patients in whom non-epileptic events coexist with epileptic seizures or\n",
      "develop as a substitute for epileptic seizures once the epilepsy is controlled Acute symptomatic\n",
      "seizures (also called provoked seizures) must be distinguished from unprovoked (epileptic) seizures.\n",
      "Acute symptomatic seizures occur in close temporal relationship (often arbitrarily defined as within\n",
      "1 week) with an acute insult of the central nervous system (CNS), which may be metabolic, toxic,\n",
      "structural, traumatic, infectious or inflammatory. Common examples include seizures during an acute\n",
      "stroke, encephalitis or electrolyte disturbance. It has been estimated that up to 50% of all\n",
      "seizures may be considered to be acute symptomatic. There should be an adequate effort to search for\n",
      "any underlying acute CNS insult which may require urgent treatment. Unlike epileptic seizures, acute\n",
      "symptomatic seizures are not necessarily characterized by a tendency for recurrence. Therefore, as a\n",
      "general rule, long-term therapy with antiepileptic drugs (AEDs) is not indicated for most\n",
      "individuals, although it may be warranted on a short-term basis until the acute condition is\n",
      "resolved Clinical evaluation Despite advances in investigational technologies, the diagnosis of\n",
      "epilepsy remains essentially clinical, and is based on a detailed description of the events\n",
      "experienced by the patient before, during and after a seizure. A witness's account of one or more of\n",
      "the episodes is an essential component of a confident diagnosis (Table 3.2).In addition to a full\n",
      "medical and social history, the patient should be asked about factors that may precipitate seizures\n",
      "by lowering the threshold for such an event (Table 3.3) Physical examination is often unremarkable,\n",
      "although there may be focal neurological signs that correspond to an underlying structural\n",
      "abnormality in the brain. Investigations aiming to unearth anything that acutely provokes seizures\n",
      "should be guided by the clinical scenario. Routine blood tests should include full blood count and\n",
      "electrolytes, and an electrocardiogram should be performed to detect cardiac arrhythmias and\n",
      "conduction abnormalities, particularly prolonged QT syndromes. Drug screening may be carried out\n",
      "when the history suggests drug abuse. Lumbar puncture for cerebrospinal fluid examination should be\n",
      "reserved for those suspected of having an acute CNS infection Investigational technologies\n",
      "Electroencephalography can support the clinical diagnosis of epilepsy and help with the\n",
      "classification of partial-onset or generalized seizures. It is important to give the\n",
      "electroencephalographer detailed information concerning the patient's age, seizure behavior and\n",
      "response to AEDs Routine EEGs are often insensitive - more than 50% of patients with epilepsy will\n",
      "have a normal trace. Activation techniques, including hyperventilation and photic stimulation\n",
      "(Figure 3.2),are helpful in uncovering abnormalities. Diagnostic yield can also be increased by\n",
      "repeat recordings. If the initial EEG is unremarkable and the diagnosis remains in doubt, a sleep-\n",
      "deprivation study is recommended Routine EEGs have a limited role in determining whether AED(s) can\n",
      "be safely tapered after a prolonged seizure-free interval. In a patient with suspected non-\n",
      "convulsive status epilepticus (see Chapter 7), an EEG can be diagnostic. An EEG can also immediately\n",
      "differentiate between epileptic and psychogenic convulsive status epilepticus Prolonged ambulatory\n",
      "recording. In cases of a negative routine EEG, better detection of interictal and ictal events may\n",
      "be achieved with a prolonged EEG recording using portable equipment. On the plus side, this allows\n",
      "recording to take place in the patient's usual environment, but technical faults are more likely and\n",
      "accurate correlation with simultaneous behaviors on video is available only with certain recording\n",
      "systems Video-EEG telemetry. Behavioral correlation can be achieved in inpatients by video\n",
      "monitoring during the EEG. This investigation is mandatory as part of the evaluation for epilepsy\n",
      "surgery, and may be the only way to distinguish epileptic from non-epileptic seizures\n",
      "Magnetoencephalography, in which the magnetic fields associated with the intracellular current flows\n",
      "within neurons are measured between seizures, has been the subject of recent research. In some\n",
      "situations, it usefully identifies candidates for surgery among patients with normal neuroimaging\n",
      "results EEG with functional MRI (fMRI). Advances in technology have allowed combined recording of\n",
      "EEG during fMRI, so that interictal EEG changes can be spatially localized. As a result,\n",
      "simultaneous EEG and fMRI provides the opportunity to better understand the spatiotemporal\n",
      "mechanisms of the generation of epileptiform activity in the brain. Its role in the clinical\n",
      "management of epilepsy, particularly in selection of surgical candidacy in the case of drug\n",
      "resistance, is an area of active research Brain imaging Structural imaging. Imaging studies of the\n",
      "brain to look for underlying structural abnormalities are essential for the appropriate diagnostic\n",
      "evaluation of most patients with epilepsy, particularly those presenting with partial-onset\n",
      "seizures. The imaging modality of choice is MRI. It has higher sensitivity and specificity than CT\n",
      "for identifying structural lesions such as malformations of cortical development (Figure 3.3a),\n",
      "hippocampal sclerosis, arteriovenous malformations, cavernous hemangioma (Figure 3.3b) and low-grade\n",
      "gliomas (Figure 3.3c). CT should be performed if MRI is unavailable and in patients for whom MRI is\n",
      "contraindicated (exempli gratia those with cardiac pacemakers, non-compatible aneurysm clips or\n",
      "severe claustrophobia) Typical pathological findings vary with age. In children, MRI is particularly\n",
      "useful in identifying congenital abnormalities, such as neuronal migration disorders and\n",
      "arteriovenous malformations. In young adults, frequently detected conditions are hippocampal\n",
      "sclerosis, sequelae of head trauma, congenital anomalies, brain tumors and vascular lesions. For\n",
      "patients in mid-life and beyond, scans are helpful in evaluating stroke and cerebral degeneration,\n",
      "and in identifying primary and secondary neoplasia Any patient with refractory epilepsy in whom the\n",
      "initial MRI scan is normal should have a high-resolution scan to exclude hippocampal atrophy and\n",
      "focal cortical dysplasia. The scan should be repeated periodically if there is one of the following\n",
      "suspicion of a tumor worsening in the patient's neurological or cognitive function increase in the\n",
      "frequency or severity of the seizures Functional imaging can identify focal abnormalities in\n",
      "cerebral physiology even when structural imaging results are normal. Single photon emission computed\n",
      "tomography (SPECT) can demonstrate increased blood flow in brain regions in association with seizure\n",
      "activity. Epileptogenic areas can be detected as hypometabolic regions interictally by positron\n",
      "emission tomography (Figure 3.4). Magnetic resonance spectroscopy can measure changes in chemical\n",
      "compounds in the brain associated with neuronal loss in certain epileptogenic pathologies.\n",
      "Functional neuroimaging techniques have a limited role in routine diagnostic evaluation, but are\n",
      "useful adjuncts in the work-up for epilepsy surgery\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      "The diagnosis of epilepsy relies on the correct classification of epileptic seizures and epilepsy\n",
      "syndromes (see Chapter 2), with consequent implications for prognosis and choice of therapy for\n",
      "patients with epilepsy.Video-EEG telemetry. Behavioral correlation can be achieved in inpatients by\n",
      "video monitoring during the EEG. This investigation is mandatory as part of the evaluation for\n",
      "epilepsy surgery, and may be the only way to distinguish epileptic from non-epileptic seizures.The\n",
      "diagnostic procedure aims to answer three key questions:Is the epileptic seizure causing the\n",
      "seizure?Is the seizure causing the seizure causing the epileptic seizure?Is the episode an epileptic\n",
      "seizure?Does the epileptic seizure cause the seizure?What is (are) the seizure\n",
      "\n",
      "Reference:\n",
      "Epilepsy has many underlying etiologies. A wide range of conditions can mimic epileptic seizures. A\n",
      "witness's account is essential for accurate diagnosis of epilepsy and classification of seizures.\n",
      "Electroencephalography can support diagnosis and help with the classification of seizures and\n",
      "syndromes. Structural brain imaging is essential in the diagnostic work-up for patients with\n",
      "seizures suspected of having a focal onset. MRI is the imaging modality of choice for detecting\n",
      "structural abnormalities in the brain. Functional neuroimaging techniques are mainly used as\n",
      "supplementary investigations in patients being considered for epilepsy surgery.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9783318068207, 'hh-5')\n",
      "The recent improvements in terms of available technologies and bioinformatics tools have allowed a\n",
      "better understanding of the pathobiology of different tumor types and the identification of several\n",
      "genomic alterations that may be targetable. CGP offers a complete evaluation of the genomic\n",
      "landscape of each tumor for both prognostic and predictive purposes, helping oncologists make\n",
      "decisions about cancer treatment The adoption of broad NGS gene panels (Table 3.1) may support the\n",
      "administration of immunotherapy drugs in patients harboring high TMB (see page 45). Another\n",
      "potentially valuable approach is hybrid capture-based CGP, an ultra-sensitive assay that can be used\n",
      "to detect variants even in specimens with low tumor purity (a low proportion of tumor cells). The\n",
      "implementation of CGP in clinical practice is, however, limited by issues such as costs, turnaround\n",
      "time, sensitivity, specificity and bioinformatics pipelines. Despite increasing knowledge of the\n",
      "cancer molecular landscape, the clinical and pathological significance of several molecular\n",
      "variants, including SNVs, CNVs and indels, remains unknown and unexplored As far as variants are\n",
      "concerned and, in particular, when rare or unknown mutations are reported, it is fundamentally\n",
      "important to define the association with the risk of cancer development and progression. In this\n",
      "setting, it is pivotal to predict the structure and the potential functional impact of the proteins\n",
      "generated to define the frequency of appearance in the healthy population identify the inheritance\n",
      "within a family when the same pathological condition is evidenced assess the statistical\n",
      "significance of the association with cancer when the same alteration is identified in independent\n",
      "cancer patients Single nucleotide variants in coding and intronic regions can significantly alter\n",
      "the functions of cancer-related genes. An interesting field of investigation regarding SNVs involves\n",
      "mutations that affect non-coding regions. Mutations in these sequences in 3'-untranslated regions\n",
      "(3'-UTRs) are frequently implicated in cancer-related oncogenes Copy number variants represent an\n",
      "important mechanism of activation and inactivation of oncogenes and tumor suppressor genes,\n",
      "respectively. However, the detection of CNVs is limited by exon-capturing methods that do not cover\n",
      "many recurrent CNV regions and by other computational biases. To overcome these biases, it is\n",
      "possible to define a CNV by the ratio of copies in cancer and normal DNA Indels present several\n",
      "issues: in particular, they are not always easy to compare using different variant callers\n",
      "(separating real variants from artifacts), because there are several correct ways of reporting them;\n",
      "this factor may significantly limit reproducibility among laboratories Microsatellite instability\n",
      "Microsatellites are repetitive, highly preserved DNA sequences that occur throughout the genome.\n",
      "Their nature makes them particularly prone to DNA-mismatching errors (MSI) that can occur during DNA\n",
      "replication Four genes are involved in the process of mismatch repair (MMR), which is the cell's\n",
      "method of overcoming these errors: MLH1, MSH2, MSH6 and PMS2. These genes encode four proteins, mutL\n",
      "homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6) and post-meiotic segregation\n",
      "increased 2 (PMS2), that form heterodimers: MLH1-PMS2 and MSH2-MSH6. These heterodimers work with\n",
      "other proteins to nick the strand around the mutation and repair the sequence. The inactivation of\n",
      "this system leads to a deficient MMR (dMMR) mechanism (Figure 3.1) Interestingly, only MLH1 and MSH2\n",
      "are necessary partners in the heterodimers: MSH6 and PMS2 can be replaced by other proteins (such as\n",
      "MSH3, MLH3 and PMS1). To determine the MMR status, both immunohistochemistry (IHC) and PCR-based\n",
      "techniques can be adopted Immunohistochemistry uses tagged antibodies to detect specific proteins -\n",
      "MLH1, MSH2, MSH6 and PMS2 in this instance - in tissue slices or samples. The European Society of\n",
      "Medical Oncology (ESMO) recommends IHC as the first-line test to assess MMR status in sporadic\n",
      "cancer belonging to the spectrum of Lynch syndrome (colorectal, endometrial, small intestine,\n",
      "urothelial, central nervous system and sebaceous gland; Table 3.2) As discussed above, MLH1\n",
      "mutations are related to loss on IHC of both MLH1 and PMS2; in the same way, mutations in MSH2\n",
      "relate to the loss of both MSH2 and MSH6 on IHC. Overall, it is necessary to adopt all four IHC\n",
      "antibodies to define MMR status. However, IHC can be affected by several issues - for example,\n",
      "false-negative results may relate to problems with tissue fixation. Where there are fixation issues,\n",
      "it is important to focus on positive internal controls (for example, immune cells) PCR-based\n",
      "techniques involve comparing the profiles of microsatellite loci generated by amplification from\n",
      "neoplastic samples and corresponding normal tissue material obtained from the same patient. If a\n",
      "locus reports a discordance between neoplastic and normal tissue samples, MSI is reported. Two\n",
      "different reference panels are used: one that considers two mononucleotide (BAT-25 and BAT-26) and\n",
      "three dinucleotide (D5S346, D2S123 and D17S250) repeats (an example is shown in Figure 3.2), and the\n",
      "other adopting five polyA mononucleotide repeats (BAT-25, BAT-26, NR-21, NR-24, NR-27)., This latter\n",
      "panel is associated with a higher sensitivity and specificity. MSI status is defined when two or\n",
      "more of five microsatellite loci are unstable In indeterminate IHC cases, PCR may be a reliable and\n",
      "highly specific and sensitive tool to define MSI status. ESMO guidance suggests that MSI-low (only\n",
      "one unstable locus) should be considered microsatellite stable (MSS) NGS may represent a valid\n",
      "alternative for MMR status assessment MSI as a predictive biomarker. Because of the development of\n",
      "several mutations, MSI-high (MSI-H) status is a predictive biomarker of response to immunotherapy.,\n",
      "In May 2017, the FDA approved the use of an immune checkpoint inhibitor (pembrolizumab) in advanced\n",
      "stage solid tumors with MSI-H (evaluated by PCR or NGS) or dMMR (evaluated by IHC) status. Other\n",
      "immune checkpoint inhibitors, such as nivolumab, are now also being used to treat some MSI-H cancers\n",
      "Tumor mutational burden TMB is the number of somatic, non-synonymous, coding base mutations that\n",
      "occur in a defined region of a tumor genome. The accumulation of a high number of mutations is able\n",
      "to generate several neoantigens that can potentially elicit a severe immune response against the\n",
      "tumor. In this setting, CGP may usefully detect advanced stage cancers with high TMB. Rizvi et al.\n",
      "have highlighted the responsiveness of patients with advanced stage non-small cell lung cancer\n",
      "(NSCLC) and high TMB to the anti-programmed cell death 1 (PD-1) antibody pembrolizumab. They\n",
      "emphasized that durable clinical benefit and progression-free survival (PFS) were higher in the\n",
      "cohort of patients with more than 200 mutations compared with patients with low TMB (< 200\n",
      "mutations) Snyder et al. found similar results using a WES approach in patients with melanoma. The\n",
      "responsiveness and overall survival of patients treated with the anti-cytotoxic T-lymphocyte antigen\n",
      "4 (CTLA-4) antibody ipilimumab was higher in the high TMB cohort. However, as WES is currently\n",
      "unfeasible in routine clinical practice, with its high costs and long turnaround time, several\n",
      "different approaches are now employed, based on wide NGS panels In the CheckMate 227 and 568\n",
      "clinical trials, TMB was evaluated using the FoundationOne CDx assay to support the administration\n",
      "of an immunotherapy combination (ipilimumab plus nivolumab) in advanced stage NSCLC. Patients were\n",
      "defined as having a high TMB when the tumor DNA harbored at least ten mutations per megabase\n",
      "Different gene panels are available to evaluate TMB status (see Table 3.1). For example, Rizvi et\n",
      "al. adopted three different versions of the MSK-IMPACT panel, covering 341, 410 and 468 genes, to\n",
      "assess TMB Data interpretation potentially limits the usefulness of TMB analysis, regardless of the\n",
      "approach adopted (WES versus wide gene panels) and gene panel employed. In terms of prediction of\n",
      "suitability for immunotherapeutic regimens, it is important to analyze not only the total number but\n",
      "also the type of the detected mutations. While Rizvi et al. underlined the positive predictive value\n",
      "for immunotherapy when mutations in genes involved in DNA repair and replication are identified,\n",
      "Skoulidis et al. demonstrated that mutations in STK11 (also known as LKB1) were associated with\n",
      "resistance to immunotherapeutic drugs Fusions and splice variants. RNA-based molecular approaches,\n",
      "such as reverse transcription PCR (RT-PCR), NGS and multiplex digital color-coded barcode\n",
      "technology, play a key role in identifying targetable gene fusions (Figure 3.3). These are chimeric\n",
      "genes generated from the fusion of two different genes belonging to the same or different\n",
      "chromosomes According to international guidelines, a person with advanced stage NSCLC is potentially\n",
      "eligible for tyrosine kinase inhibitor (TKI) therapy if they have a gene fusion involving ALK or\n",
      "ROS1. Other gene fusions have also been identified and are now the basis of therapeutic indications\n",
      "and/or are being explored in clinical trials (see Chapter 5) As well as a predictive role, the\n",
      "identification of gene fusions may also have a key diagnostic function for assessing risk of\n",
      "malignancy, such as in thyroid nodules with undetermined cytological diagnosis. In particular, PAX8\n",
      "/ PPARG and RET / CCDC6 gene fusions are more frequently associated with thyroid malignancies\n",
      "Another important field of application for RNA-based molecular approaches is the identification of\n",
      "splice variants. The variation occurs at the splice site between an exon and an intron. It leads to\n",
      "alternative RNA splicing, resulting from the loss of exons or the inclusion of introns, and the\n",
      "generation of a novel protein (Figure 3.4) As for gene fusions, the presence of a splice variant may\n",
      "have a predictive role for therapy. In advanced stage NSCLC, MET exon 14 skipping is associated with\n",
      "responsiveness to crizotinib and cabozantinib However, several issues affect RNA analysis. In\n",
      "particular, RNA is less stable than DNA, and for this reason careful attention must be paid to pre-\n",
      "analytic factors that could interfere with RNA stability. In particular, fixation procedures may\n",
      "significantly influence RNA integrity and stability. An alcohol-based fixative gives better results\n",
      "in terms of RNA quality and quantity than a formalin-based fixative When RT-PCR is used, careful\n",
      "attention should be paid to the design of primers. In particular, to minimize the risk of false-\n",
      "positive results or overestimation of gene expression, primers should be designed to lie on\n",
      "exon/exon junctions. As far as the complementary DNA (cDNA) input is concerned, the concentration\n",
      "should be between 10 pg and 1 μg An important limitation is that the RT-PCR method can only identify\n",
      "known alterations. This limitation can be overcome by NGS, which allows the identification of known\n",
      "and unknown gene alterations for different patients simultaneously. However, NGS suffers from\n",
      "several limitations related to high costs and, in particular, data interpretation (see Chapter 6).\n",
      "Strengthening automated data analysis with ad hoc information from the bioinformatics pipeline may\n",
      "reduce this issue The nCounter Analysis System is another approach. This is a multiplex digital\n",
      "color-coded barcode technology that can identify gene fusions and splice variants simultaneously.\n",
      "Only a small amount of RNA input is needed (25-250 ng) and the method has a short turnaround time\n",
      "for testing (about 3 working days). In addition, the nCounter technology is able to identify several\n",
      "gene fusions and splice variants, even when RNA is of low quality and target capture amplification\n",
      "fails The nCounter workflow is characterized by four main steps pairs of probes (reporter probe and\n",
      "capture probe), designed to be adjacent to one another along the target sequence of a transcript,\n",
      "are hybridized with mRNAs excess probes are removed and the hybridized complex is bound to the\n",
      "surface of the sample cartridge the probe/target complexes are aligned on the cartridge by an\n",
      "electric current and immobilized for data collection the sample cartridge is scanned by a digital\n",
      "analyzer, and each color code is counted and tabulated The nCounter system has a number of\n",
      "limitations, however. In particular, results generated by reading the color-coded barcodes are not\n",
      "directly usable for clinical purposes. Thus, additional data processing is required. Furthermore,\n",
      "careful attention needs to be paid to the design of the probe to avoid false-positive results\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (150 tok):\n",
      "\n",
      ", the identification of gene fusions may also have a key diagnostic function for assessing risk of\n",
      "malignancy, such as in thyroid nodules with undetermined cytological diagnosis. In particular, PAX8\n",
      "/ PPARG and RET / CCDC6 gene fusions are more frequently associated with thyroid malignancies\n",
      "(Figure 3.1).Another important field of application for RNA-based molecular approaches is the\n",
      "identification of splice variants. The variation occurs at the splice site between an exon and an\n",
      "intron. It leads to alternative RNA splicing, resulting from the loss of exons or the inclusion of\n",
      "introns, and the generation of a novel protein (Figure 3.4) that can be used to identify the splice\n",
      "\n",
      "Reference:\n",
      "Comprehensive genomic profiles offer a complete evaluation of the genomic landscape of each tumor.\n",
      "The interpretation of the different variants reported, with attention focused on their clinical\n",
      "significance and usefulness for cancer patients, can support oncologists to make informed cancer\n",
      "treatment decisions. The clinical and pathological significance of several molecular variants,\n",
      "including SNVs, CNVs and indels, remains unknown. Some therapies are indicated for MSI-H cancer, and\n",
      "others are in clinical trials. Careful attention should be paid to the accuracy of the MMR\n",
      "evaluation (IHC, PCR or NGS). WES or wide gene panels may be employed to assess TMB status to guide\n",
      "immunotherapy decisions. RNA-based molecular approaches play a pivotal role in the identification of\n",
      "targetable gene fusions and splice variants.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541277, 'ch_12')\n",
      "Quality of life Psychiatric comorbidities Nearly 1 in 3 patients reports significant concern about\n",
      "their mood. Not surprisingly then, mood states and psychiatric comorbidities substantially\n",
      "contribute to the quality of life of patients with epilepsy. The three most common psychiatric\n",
      "comorbidities in patients with epilepsy are depression, anxiety and psychosis Depression is the most\n",
      "prevalent psychiatric condition in patients with epilepsy - up to 55% of patients in some studies -\n",
      "and has a greater negative impact on quality of life than seizure-specific variables such as seizure\n",
      "frequency and severity Depression is under-recognized and, when diagnosed, often undertreated.\n",
      "Depression associated with epilepsy differs clinically from depressive disorders in non-epileptic\n",
      "patients. Accordingly, symptoms of depression in patients with epilepsy often fail to meet the\n",
      "diagnostic criteria for affective disorders set out in the American Psychiatric Association's\n",
      "Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV). Diagnosis may be\n",
      "further complicated if the patient minimizes their psychiatric symptoms, or if the clinician does\n",
      "not inquire about psychiatric symptoms or considers depression to be part of the normal adaptation\n",
      "to the diagnosis of epilepsy. Clinicians often inadequately treat depression because they are\n",
      "concerned that antidepressant therapy will increase seizure frequency. The consequence of\n",
      "underdiagnosis and undertreatment can be fatal. The overall suicide rate in depressed patients with\n",
      "epilepsy is five times higher than that in the general population and as much as 25 times higher in\n",
      "patients with complex partial seizures of temporal lobe origin Patients experience depression most\n",
      "often interictally as a chronic, waxing and waning disorder, usually in association with variable\n",
      "levels of irritability and emotionality. Some patients experience depression during a simple partial\n",
      "seizure (ictal depression) or during the postictal state Before therapy is initiated, iatrogenic\n",
      "causes should be excluded. Antiepileptic drug (AED) treatment can be contributory, especially\n",
      "phenobarbital (PB), primidone (PRM), vigabatrin (VGB), topiramate (TPM), levetiracetam (LEV) and\n",
      "zonisamide (ZNS). Conversely, depression that follows the discontinuation of an AED with mood-\n",
      "stabilizing properties (exempli gratia lamotrigine [LTG]) can also be treated by reinstituting the\n",
      "AED Few controlled trials of antidepressants have been conducted in patients with epilepsy and\n",
      "depression. Selective serotonin-reuptake inhibitors (SSRIs) are first-line treatments, especially\n",
      "citalopram and sertraline, which have minimal pharmacokinetic interactions with AEDs. Tricyclic\n",
      "antidepressants (TCAs) can be given as second-line therapy. Monoamine oxidase inhibitors and non-\n",
      "TCAs are probably best avoided. Clomipramine and lithium are more likely to worsen seizure frequency\n",
      "than other antidepressants. Electroconvulsive therapy is not absolutely contraindicated in patients\n",
      "with epilepsy but should be reserved for medication-resistant depression. In addition to\n",
      "antidepressants, contributing psychosocial factors should be sought and addressed by qualified\n",
      "professionals (see Fast Facts: Depression) Anxiety is the second most common psychiatric condition\n",
      "in patients with epilepsy, with a prevalence of up to 50% in some studies. Anxiety markedly\n",
      "compromises quality of life and psychosocial functioning, even more so than depression in one study.\n",
      "Ictal anxiety may be mistaken for a panic disorder. Patients experience anxiety most commonly\n",
      "interictally in the form of a generalized anxiety disorder. Severity of anxiety does not necessarily\n",
      "correlate with seizure frequency. SSRIs and benzodiazepines are most often used, though no\n",
      "controlled studies in patients with epilepsy have been reported. Some AEDs, such as sodium valproate\n",
      "(VPA), gabapentin (GBP) and pregabalin (PGB), have anti-anxiety properties (see Fast Facts: Anxiety,\n",
      "Panic and Phobias) Psychosis. The incidence of psychosis varies according to the epilepsy syndrome,\n",
      "from 3.3% in patients with idiopathic generalized epilepsy to 14% in patients with temporal lobe\n",
      "epilepsy. Additionally, it correlates with epilepsy severity: psychosis occurs in 0.6-7% of patients\n",
      "with epilepsy in the community and 19-27% of patients with epilepsy who require hospitalization\n",
      "Ictal psychosis presents as hallucinations or delusions. Symptoms are usually self-limiting and can\n",
      "be mistaken for schizophrenia or mania, but unlike a primary psychiatric disorder are associated\n",
      "with a pattern of non-convulsive status epilepticus on electroencephalogram (EEG) recording.\n",
      "Postictal psychosis generally begins years after the onset of epilepsy. The typical pattern is a\n",
      "cluster of complex partial seizures, followed by a lucid postictal period. In turn, this lucid\n",
      "period is followed by affective symptoms together with grandiose and religious delusions, as well as\n",
      "simple auditory hallucinations. Patients with bilateral seizure foci, bilateral limbic lesions and\n",
      "clusters of complex partial seizures are at particularly high risk Interictal psychosis manifests as\n",
      "delusions and hallucinations; disorganized behavior and thought disorders may also occur. Compared\n",
      "with patients with schizophrenia, patients with interictal psychosis have an absence of negative\n",
      "symptoms, better premorbid state, less deterioration of personality and better response to\n",
      "pharmacotherapy There are no controlled trials of antipsychotic or atypical antipsychotic\n",
      "medications in patients with epilepsy and psychosis. Haloperidol, molindone, fluphenazine,\n",
      "perphenazine and risperidone appear less likely to worsen seizure frequency than clozapine and\n",
      "loxapine. Some AEDs, such as TPM, VGB and LEV, can occasionally produce psychotic reactions in\n",
      "susceptible patients Drug interactions Selective serotonin-reuptake inhibitors, especially\n",
      "fluoxetine and paroxetine, may increase serum concentrations of carbamazepine (CBZ) and phenytoin\n",
      "(PHT). These drugs also elevate serum concentrations of TCAs Tricyclic antidepressants. Serum\n",
      "concentrations of TCAs (which are metabolized by the 2D6 hepatic isoenzyme) are generally reduced by\n",
      "hepatic enzyme-inducing AEDs such as CBZ, PHT, PB and PRM. Conversely, VPA inhibits the metabolism\n",
      "of TCAs and may increase their circulating concentrations Antipsychotics. Most antipsychotic drugs,\n",
      "including haloperidol, perphenazine, chlorpromazine, thioridazine, thiothixene and risperidone, are\n",
      "metabolized by the cytochrome P450 2D6 and/or 3A4 hepatic isoenzymes and therefore their serum\n",
      "concentrations are lowered by hepatic enzyme-inducing AEDs such as CBZ, PHT, PB and PRM, and\n",
      "increased by VPA Social aspects There are very few, if any, aspects of daily living that remain\n",
      "unaffected by the diagnosis of epilepsy. Restrictions on independence can be the most socially\n",
      "disabling - in particular the effects of epilepsy on employment, driving, life insurance and\n",
      "lifestyle There are very few, if any, aspects of daily living that remain unaffected by the\n",
      "diagnosis of epilepsy. Restrictions on independence can be the most socially disabling - in\n",
      "particular the effects of epilepsy on employment, driving, life insurance and lifestyle Employment\n",
      "is important for self-esteem, supporting an independent lifestyle, and affording health insurance\n",
      "and the costs of epilepsy treatment. Numerous surveys show that rates of unemployment and\n",
      "underemployment are much higher in patients with epilepsy than in the general population. Factors\n",
      "most often cited are lack of available transportation (particularly if seizures preclude driving),\n",
      "negative attitudes of employers and employees towards epilepsy, and lack of experience in the\n",
      "workplace. Patients whose education was interrupted by epilepsy-related complications may need\n",
      "additional vocational training before they seek employment Clinicians should encourage their\n",
      "patients to work whenever possible and to recommend they seek legal help if they encounter\n",
      "discrimination in the workplace. In the USA, the Americans with Disabilities Act, which was amended\n",
      "in 2008 to further protect the rights of persons with epilepsy, protects a person from being denied\n",
      "employment because of a medical condition if that person can perform the essential duties of that\n",
      "job. In the UK, in line with several other European countries, a similar Disabilities Discrimination\n",
      "Act was introduced in 1995 to protect people with disabilities from discrimination in employment.\n",
      "Whether patients should disclose their epilepsy before being hired is best dealt with on a case-by-\n",
      "case basis Driving is often viewed as essential to holding a job and living independently. However,\n",
      "as driving is a privilege, applicants must meet the requirements established by their state,\n",
      "province or country to qualify for a driver's license. With reference to epilepsy, these\n",
      "requirements usually specify a seizure-free interval necessary for driving, the obligations of the\n",
      "patient and the physician to notify the authorities of the patient's status, and allowances that are\n",
      "made under certain circumstances such as seizures that only occur during sleep or seizures that\n",
      "occur during a physician-prescribed AED taper. Clinicians should be thoroughly familiar with the\n",
      "applicable laws where they practice, and should clearly document their discussions with patients.\n",
      "Clinicians should also remember that side effects of AEDs, especially sedation, may interfere with a\n",
      "patient's ability to safely operate a vehicle, and should advise patients accordingly Life\n",
      "insurance. Patients with epilepsy may be unable to find affordable life insurance, particularly if\n",
      "applying for an individual policy. Most insurance companies ascribe a globally higher risk of\n",
      "mortality to people with seizures, irrespective of the applicant's frequency or severity of\n",
      "seizures. Patients who obtain life insurance through their place of employment generally do not have\n",
      "a problem Lifestyle considerations. Clinicians should counsel patients on lifestyle modifications\n",
      "that reduce the risk of provoking seizures and help maintain overall health without unduly limiting\n",
      "activities that bring enjoyment and fulfillment. Reducing or eliminating the consumption of alcohol,\n",
      "engaging in stress-reducing behaviors, eating regularly and getting adequate sleep may help to\n",
      "reduce seizure frequency. Regular aerobic exercise, especially conducted in such a way that having a\n",
      "seizure would not pose a safety risk, is important for general maintenance of health as well as bone\n",
      "health. Participation in organized sports is generally possible, though the possibility of\n",
      "concussion should be minimized and athletes should consider discussing their condition with team\n",
      "trainers and doctors in advance\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Prediction\n",
      "allenai/led-base-16384 (47 tok):\n",
      "\n",
      ", is important for general maintenance of health as well as bone health. Participation in organized\n",
      "sports is generally possible, though the possibility of concussion should be minimized and athletes\n",
      "should consider discussing their condition with team trainers and doctors in advance\n",
      "\n",
      "Reference:\n",
      "Depression and anxiety are common in patients with epilepsy, and have a significantly negative\n",
      "impact on quality of life. The potential benefit of treating depression and anxiety\n",
      "pharmacologically outweighs the risk of increased seizures. Psychosis is uncommon in patients with\n",
      "epilepsy, and generally occurs following a cluster of complex partial seizures. When psychotropic\n",
      "medications and antiepileptic drugs are coadministered, dosages may need to be adjusted because of\n",
      "potential pharmacokinetic interactions. Patients should be encouraged to work whenever possible, and\n",
      "to seek legal help if they encounter discrimination in the workplace. Legal restrictions on driving\n",
      "for people with epilepsy vary; clinicians should be aware of the relevant laws in their place of\n",
      "practice, and must clearly document their discussion with patients. Patients with epilepsy may have\n",
      "difficulty in finding affordable life insurance. Patients should be counseled on lifestyle\n",
      "modifications that reduce the risk of provoking seizures without unduly limiting activities.\n",
      "\n",
      "####################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print_examples([\n",
    "    'allenai/led-base-16384'],\n",
    "    df_test)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "bKYnUXhvMszX"
   },
   "source": [
    "##### Summarize Test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "executionInfo": {
     "elapsed": 771,
     "status": "ok",
     "timestamp": 1610617165073,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "t3EV4tDfQ1hM"
   },
   "outputs": [],
   "source": [
    "def summarize(model_name_or_path, df, batch_size):\n",
    "    model, tokenizer = import_model_tok(model_name_or_path)\n",
    "    model = model.to(device)\n",
    "    \n",
    "    model.config.max_length = 512\n",
    "    model.config.min_length = 90\n",
    "    \n",
    "    input_ids = tokenizer(df.text.tolist(),\n",
    "        return_tensors='pt',\n",
    "        padding='max_length',\n",
    "        max_length=8192,\n",
    "        truncation=True).input_ids\n",
    "    input_ids = input_ids.split(batch_size)\n",
    "\n",
    "    summs = []\n",
    "\n",
    "    pbar = tqdm(total=len(input_ids), \n",
    "                position=0,\n",
    "                leave=True,\n",
    "                file=sys.stdout)\n",
    "    for batch in input_ids:\n",
    "\n",
    "        summ_enc = model.generate(\n",
    "            batch.to(device),\n",
    "            length_penalty = 2,\n",
    "            num_beams = config.NUM_BEAMS,\n",
    "            no_repeat_ngram_size = config.NO_REPEAT_NGRAM_SIZE,\n",
    "            early_stopping = True)\n",
    "        summ = tokenizer.batch_decode(summ_enc, skip_special_tokens=True)\n",
    "        summs += summ\n",
    "\n",
    "        pbar.update(1)\n",
    "    pbar.close()\n",
    "\n",
    "    df['summary_'+model_name_or_path] = summs\n",
    "\n",
    "    return df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 89831,
     "status": "ok",
     "timestamp": 1610617255307,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "xQ0KCVkXMszZ",
    "outputId": "d55a74ed-6e68-4e49-8577-9e6125282fb5"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "100%|██████████| 46/46 [1:18:53<00:00, 102.91s/it]\n"
     ]
    }
   ],
   "source": [
    "df_test = summarize('allenai/led-base-16384', df_test, 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6089476507b84185b6f681d21e055075",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=1839633783.0, style=ProgressStyle(descr…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "34e32ab37e274f4391c89d1cd3a29ad4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=898822.0, style=ProgressStyle(descripti…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1c4dd1e183c847fb931dcc0ed5741785",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=456318.0, style=ProgressStyle(descripti…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "143bdb1d58ce4feaafd0fdf814edbe66",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=772.0, style=ProgressStyle(description_…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "283162e5d3b34ccf9db824763ddcb850",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=27.0, style=ProgressStyle(description_w…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "100%|██████████| 46/46 [3:39:31<00:00, 286.33s/it]  \n"
     ]
    }
   ],
   "source": [
    "df_test = summarize('allenai/led-large-16384', df_test, 1)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "xoxYNE9nOSYL"
   },
   "source": [
    "### **Evaluation**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 34,
     "referenced_widgets": [
      "a77961a700f2489f8af86af7aecb7a36"
     ]
    },
    "executionInfo": {
     "elapsed": 2055,
     "status": "ok",
     "timestamp": 1610618117862,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "1d6eIfp0OWYh",
    "outputId": "e85b66fd-c178-41a6-a465-394c29fa4ac8"
   },
   "outputs": [],
   "source": [
    "from datasets import load_metric\n",
    "\n",
    "metric = load_metric(\"rouge\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "mIcAg1ss4qIR"
   },
   "source": [
    "#### Evaluate summaries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "executionInfo": {
     "elapsed": 1296,
     "status": "ok",
     "timestamp": 1610618120072,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "NN-p4XvvxPLi"
   },
   "outputs": [],
   "source": [
    "def evaluate_model(df, model_name_or_path):\n",
    "    df_eval = df.groupby(['book', 'chapter'], sort=False).agg({\n",
    "        'text': lambda t: ' '.join(list(t)),\n",
    "        'bullets': lambda b: ' '.join(list(b)),\n",
    "        'summary_'+model_name_or_path: lambda s: ' '.join(list(s))})\n",
    "    \n",
    "    rouge_res =\\\n",
    "        df_eval[['bullets', 'summary_'+model_name_or_path]]\\\n",
    "        .apply(lambda row:\n",
    "        metric.compute(\n",
    "            predictions = [row[1]],\n",
    "            references = [row[0]],\n",
    "            rouge_types = config.ROUGE_TYPES,\n",
    "            use_agregator = False), axis=1)\n",
    "\n",
    "    for r in config.ROUGE_TYPES:\n",
    "        for i, prf in enumerate(['precision', 'recall', 'fmeasure']):\n",
    "            df_eval[r+'_'+prf+'_'+model_name_or_path] =\\\n",
    "                rouge_res.map(lambda score: score[r][0][i])\n",
    "            \n",
    "    df_eval.to_csv(OUTPUT_PATH+model_name_or_path.replace('/', '?')+'.csv')\n",
    "    \n",
    "    return df_eval"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "executionInfo": {
     "elapsed": 2058,
     "status": "ok",
     "timestamp": 1610618121921,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "mCx3f697SXPm"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>bullets</th>\n",
       "      <th>summary_allenai/led-base-16384</th>\n",
       "      <th>rouge1_precision_allenai/led-base-16384</th>\n",
       "      <th>rouge1_recall_allenai/led-base-16384</th>\n",
       "      <th>rouge1_fmeasure_allenai/led-base-16384</th>\n",
       "      <th>rouge2_precision_allenai/led-base-16384</th>\n",
       "      <th>rouge2_recall_allenai/led-base-16384</th>\n",
       "      <th>rouge2_fmeasure_allenai/led-base-16384</th>\n",
       "      <th>rougeL_precision_allenai/led-base-16384</th>\n",
       "      <th>rougeL_recall_allenai/led-base-16384</th>\n",
       "      <th>rougeL_fmeasure_allenai/led-base-16384</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>book</th>\n",
       "      <th>chapter</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>9783318068207</th>\n",
       "      <th>hh-7</th>\n",
       "      <td>Non-small cell lung cancer\\nLung cancer is the...</td>\n",
       "      <td>The molecular status of, at least, EGFR, ALK, ...</td>\n",
       "      <td>. Current ESMO and ASCO guidelines do not reco...</td>\n",
       "      <td>0.289941</td>\n",
       "      <td>0.319218</td>\n",
       "      <td>0.303876</td>\n",
       "      <td>0.053412</td>\n",
       "      <td>0.058824</td>\n",
       "      <td>0.055988</td>\n",
       "      <td>0.142012</td>\n",
       "      <td>0.156352</td>\n",
       "      <td>0.148837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797631</th>\n",
       "      <th>chp6</th>\n",
       "      <td>Prevention and management\\nBy far the most res...</td>\n",
       "      <td>The treatment rather than the prevention of de...</td>\n",
       "      <td>Prevention and management of depression. There...</td>\n",
       "      <td>0.203540</td>\n",
       "      <td>0.534884</td>\n",
       "      <td>0.294872</td>\n",
       "      <td>0.053215</td>\n",
       "      <td>0.140351</td>\n",
       "      <td>0.077170</td>\n",
       "      <td>0.108407</td>\n",
       "      <td>0.284884</td>\n",
       "      <td>0.157051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797426</th>\n",
       "      <th>ch03</th>\n",
       "      <td>Diseases of the gallbladder\\nEtiology and path...</td>\n",
       "      <td>The prevalence of gallstones is greater in peo...</td>\n",
       "      <td>ubin and transaminases may be present in the g...</td>\n",
       "      <td>0.182635</td>\n",
       "      <td>0.476562</td>\n",
       "      <td>0.264069</td>\n",
       "      <td>0.066066</td>\n",
       "      <td>0.173228</td>\n",
       "      <td>0.095652</td>\n",
       "      <td>0.107784</td>\n",
       "      <td>0.281250</td>\n",
       "      <td>0.155844</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541277</th>\n",
       "      <th>ch_12</th>\n",
       "      <td>Quality of life\\nPsychiatric comorbidities\\nNe...</td>\n",
       "      <td>Depression and anxiety are common in patients ...</td>\n",
       "      <td>, is important for general maintenance of heal...</td>\n",
       "      <td>0.224242</td>\n",
       "      <td>0.496644</td>\n",
       "      <td>0.308977</td>\n",
       "      <td>0.051672</td>\n",
       "      <td>0.114865</td>\n",
       "      <td>0.071279</td>\n",
       "      <td>0.130303</td>\n",
       "      <td>0.288591</td>\n",
       "      <td>0.179541</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797907</th>\n",
       "      <th>chp6</th>\n",
       "      <td>Supportive treatment\\nAt present, the main foc...</td>\n",
       "      <td>The burden of transfusions in pyruvate kinase ...</td>\n",
       "      <td>is. Splenectomy increases susceptibility to se...</td>\n",
       "      <td>0.205962</td>\n",
       "      <td>0.580153</td>\n",
       "      <td>0.304000</td>\n",
       "      <td>0.040761</td>\n",
       "      <td>0.115385</td>\n",
       "      <td>0.060241</td>\n",
       "      <td>0.084011</td>\n",
       "      <td>0.236641</td>\n",
       "      <td>0.124000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541277</th>\n",
       "      <th>ch_8</th>\n",
       "      <td>Antiepileptic drugs\\nEstablished antiepileptic...</td>\n",
       "      <td>Sixteen new antiepileptic drugs (AEDs) have be...</td>\n",
       "      <td>Antiepileptic drugs have been shown to be effe...</td>\n",
       "      <td>0.063131</td>\n",
       "      <td>0.480769</td>\n",
       "      <td>0.111607</td>\n",
       "      <td>0.017722</td>\n",
       "      <td>0.137255</td>\n",
       "      <td>0.031390</td>\n",
       "      <td>0.055556</td>\n",
       "      <td>0.423077</td>\n",
       "      <td>0.098214</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797006</th>\n",
       "      <th>ch08</th>\n",
       "      <td>Acute exacerbations\\nAcute exacerbations of ch...</td>\n",
       "      <td>Acute exacerbations of COPD are common and pla...</td>\n",
       "      <td>Acute exacerbations of COPD can be treated wit...</td>\n",
       "      <td>0.141414</td>\n",
       "      <td>0.629213</td>\n",
       "      <td>0.230928</td>\n",
       "      <td>0.045570</td>\n",
       "      <td>0.204545</td>\n",
       "      <td>0.074534</td>\n",
       "      <td>0.073232</td>\n",
       "      <td>0.325843</td>\n",
       "      <td>0.119588</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch06</th>\n",
       "      <td>Neuroanatomy and structural imaging\\nOur knowl...</td>\n",
       "      <td>People with schizophrenia exhibit gray matter ...</td>\n",
       "      <td>Neuroanatomy and structural imaging. Neuropsyc...</td>\n",
       "      <td>0.173554</td>\n",
       "      <td>0.611650</td>\n",
       "      <td>0.270386</td>\n",
       "      <td>0.077348</td>\n",
       "      <td>0.274510</td>\n",
       "      <td>0.120690</td>\n",
       "      <td>0.110193</td>\n",
       "      <td>0.388350</td>\n",
       "      <td>0.171674</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9783318068207</th>\n",
       "      <th>hh-5</th>\n",
       "      <td>The recent improvements in terms of available ...</td>\n",
       "      <td>Comprehensive genomic profiles offer a complet...</td>\n",
       "      <td>, the identification of gene fusions may also ...</td>\n",
       "      <td>0.167095</td>\n",
       "      <td>0.532787</td>\n",
       "      <td>0.254403</td>\n",
       "      <td>0.038660</td>\n",
       "      <td>0.123967</td>\n",
       "      <td>0.058939</td>\n",
       "      <td>0.089974</td>\n",
       "      <td>0.286885</td>\n",
       "      <td>0.136986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch04</th>\n",
       "      <td>The biggest single clue we have about the caus...</td>\n",
       "      <td>Having a close relative with schizophrenia inc...</td>\n",
       "      <td>) are a more recent discovery and involve dupl...</td>\n",
       "      <td>0.090426</td>\n",
       "      <td>0.478873</td>\n",
       "      <td>0.152125</td>\n",
       "      <td>0.018667</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>0.031461</td>\n",
       "      <td>0.061170</td>\n",
       "      <td>0.323944</td>\n",
       "      <td>0.102908</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797006</th>\n",
       "      <th>ch03</th>\n",
       "      <td>Clinical features\\nThe characteristic symptom ...</td>\n",
       "      <td>COPD occurs, though less commonly, in those wh...</td>\n",
       "      <td>, the airflow limitation of COPD is a common c...</td>\n",
       "      <td>0.199430</td>\n",
       "      <td>0.404624</td>\n",
       "      <td>0.267176</td>\n",
       "      <td>0.054286</td>\n",
       "      <td>0.110465</td>\n",
       "      <td>0.072797</td>\n",
       "      <td>0.096866</td>\n",
       "      <td>0.196532</td>\n",
       "      <td>0.129771</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541406</th>\n",
       "      <th>ch_6</th>\n",
       "      <td>Platelet disorders\\nPlatelet function defects\\...</td>\n",
       "      <td>Thrombocytopenia may occur with some inherited...</td>\n",
       "      <td>Platelet disorders are usually associated with...</td>\n",
       "      <td>0.133172</td>\n",
       "      <td>0.491071</td>\n",
       "      <td>0.209524</td>\n",
       "      <td>0.041262</td>\n",
       "      <td>0.153153</td>\n",
       "      <td>0.065010</td>\n",
       "      <td>0.082324</td>\n",
       "      <td>0.303571</td>\n",
       "      <td>0.129524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541277</th>\n",
       "      <th>ch_6</th>\n",
       "      <td>The diagnosis of epilepsy relies on the correc...</td>\n",
       "      <td>Epilepsy has many underlying etiologies.\\nA wi...</td>\n",
       "      <td>The diagnosis of epilepsy relies on the correc...</td>\n",
       "      <td>0.183333</td>\n",
       "      <td>0.717391</td>\n",
       "      <td>0.292035</td>\n",
       "      <td>0.077994</td>\n",
       "      <td>0.307692</td>\n",
       "      <td>0.124444</td>\n",
       "      <td>0.097222</td>\n",
       "      <td>0.380435</td>\n",
       "      <td>0.154867</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797815</th>\n",
       "      <th>chp3</th>\n",
       "      <td>Diagnosis and disease burden\\nAccurate diagnos...</td>\n",
       "      <td>The World Health Organization diagnostic crite...</td>\n",
       "      <td>However, each of these symptoms was significan...</td>\n",
       "      <td>0.311429</td>\n",
       "      <td>0.630058</td>\n",
       "      <td>0.416826</td>\n",
       "      <td>0.097421</td>\n",
       "      <td>0.197674</td>\n",
       "      <td>0.130518</td>\n",
       "      <td>0.108571</td>\n",
       "      <td>0.219653</td>\n",
       "      <td>0.145315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797310</th>\n",
       "      <th>chp3</th>\n",
       "      <td>Staging and surgery\\nIlaria Onorati MD and Ola...</td>\n",
       "      <td>Better subclassification of early-stage NSCLC ...</td>\n",
       "      <td>), and T4 tumors without mediastinal nodal met...</td>\n",
       "      <td>0.143251</td>\n",
       "      <td>0.611765</td>\n",
       "      <td>0.232143</td>\n",
       "      <td>0.044199</td>\n",
       "      <td>0.190476</td>\n",
       "      <td>0.071749</td>\n",
       "      <td>0.093664</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.151786</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797426</th>\n",
       "      <th>ch12</th>\n",
       "      <td>Unusual tumors of the pancreas and ampulla of ...</td>\n",
       "      <td>Tumor types that occur in the ampullary and pe...</td>\n",
       "      <td>Unusual tumors of the pancreas and ampulla of ...</td>\n",
       "      <td>0.170000</td>\n",
       "      <td>0.579545</td>\n",
       "      <td>0.262887</td>\n",
       "      <td>0.040134</td>\n",
       "      <td>0.137931</td>\n",
       "      <td>0.062176</td>\n",
       "      <td>0.076667</td>\n",
       "      <td>0.261364</td>\n",
       "      <td>0.118557</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541024</th>\n",
       "      <th>ch_13</th>\n",
       "      <td>Geriatric neuro-oncology\\nAlthough half of all...</td>\n",
       "      <td>Pathological diagnosis is critical to select a...</td>\n",
       "      <td>Geriatric neuro-oncology is an area that has r...</td>\n",
       "      <td>0.117347</td>\n",
       "      <td>0.741935</td>\n",
       "      <td>0.202643</td>\n",
       "      <td>0.033248</td>\n",
       "      <td>0.213115</td>\n",
       "      <td>0.057522</td>\n",
       "      <td>0.068878</td>\n",
       "      <td>0.435484</td>\n",
       "      <td>0.118943</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797617</th>\n",
       "      <th>chp6</th>\n",
       "      <td>Research directions\\nThe expanded genetic char...</td>\n",
       "      <td>A wide range of targeted agencies for the trea...</td>\n",
       "      <td>because of age or comorbidities). A Phase II s...</td>\n",
       "      <td>0.230137</td>\n",
       "      <td>0.474576</td>\n",
       "      <td>0.309963</td>\n",
       "      <td>0.057692</td>\n",
       "      <td>0.119318</td>\n",
       "      <td>0.077778</td>\n",
       "      <td>0.115068</td>\n",
       "      <td>0.237288</td>\n",
       "      <td>0.154982</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541994</th>\n",
       "      <th>ch02</th>\n",
       "      <td>Pathophysiology, etiology and modifying factor...</td>\n",
       "      <td>Acne is a hormonally mediated disease.\\nFour m...</td>\n",
       "      <td>Pathophysiology, etiology and modifying factor...</td>\n",
       "      <td>0.089783</td>\n",
       "      <td>0.527273</td>\n",
       "      <td>0.153439</td>\n",
       "      <td>0.034161</td>\n",
       "      <td>0.203704</td>\n",
       "      <td>0.058511</td>\n",
       "      <td>0.061920</td>\n",
       "      <td>0.363636</td>\n",
       "      <td>0.105820</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797471</th>\n",
       "      <th>ch05</th>\n",
       "      <td>Case history\\nA 67-year-old man with diabetes ...</td>\n",
       "      <td>Assessment of functional class, based on exerc...</td>\n",
       "      <td>A 67-year-old man with diabetes mellitus, pulm...</td>\n",
       "      <td>0.177112</td>\n",
       "      <td>0.515873</td>\n",
       "      <td>0.263692</td>\n",
       "      <td>0.038251</td>\n",
       "      <td>0.112000</td>\n",
       "      <td>0.057026</td>\n",
       "      <td>0.087193</td>\n",
       "      <td>0.253968</td>\n",
       "      <td>0.129817</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch08</th>\n",
       "      <td>Neurochemical abnormalities, including changes...</td>\n",
       "      <td>The dopamine hypothesis remains the major neur...</td>\n",
       "      <td>The roles of other serotonergic receptors have...</td>\n",
       "      <td>0.118598</td>\n",
       "      <td>0.602740</td>\n",
       "      <td>0.198198</td>\n",
       "      <td>0.032432</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.054299</td>\n",
       "      <td>0.064690</td>\n",
       "      <td>0.328767</td>\n",
       "      <td>0.108108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781912776207</th>\n",
       "      <th>ch4</th>\n",
       "      <td>Accurate diagnosis and subtyping of PTCL is ch...</td>\n",
       "      <td>Many patients with aggressive T-cell lymphomas...</td>\n",
       "      <td>ivariate analysis identified four independent ...</td>\n",
       "      <td>0.065574</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.109589</td>\n",
       "      <td>0.009868</td>\n",
       "      <td>0.050847</td>\n",
       "      <td>0.016529</td>\n",
       "      <td>0.039344</td>\n",
       "      <td>0.200000</td>\n",
       "      <td>0.065753</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797495</th>\n",
       "      <th>chp12</th>\n",
       "      <td>Headache is a common complaint in the general ...</td>\n",
       "      <td>In patients without history of chronic headach...</td>\n",
       "      <td>Headache is a common complaint in the general ...</td>\n",
       "      <td>0.104859</td>\n",
       "      <td>0.455556</td>\n",
       "      <td>0.170478</td>\n",
       "      <td>0.028205</td>\n",
       "      <td>0.123596</td>\n",
       "      <td>0.045929</td>\n",
       "      <td>0.066496</td>\n",
       "      <td>0.288889</td>\n",
       "      <td>0.108108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781912776726</th>\n",
       "      <th>ch2</th>\n",
       "      <td>Clinical presentation\\nMost patients with glio...</td>\n",
       "      <td>The signs and symptoms of glioblastoma result ...</td>\n",
       "      <td>Clinical presentation and clinical history of ...</td>\n",
       "      <td>0.260000</td>\n",
       "      <td>0.590909</td>\n",
       "      <td>0.361111</td>\n",
       "      <td>0.105263</td>\n",
       "      <td>0.240000</td>\n",
       "      <td>0.146341</td>\n",
       "      <td>0.142500</td>\n",
       "      <td>0.323864</td>\n",
       "      <td>0.197917</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797815</th>\n",
       "      <th>chp2</th>\n",
       "      <td>The myeloproliferative neoplasms (MPNs) are ra...</td>\n",
       "      <td>The incidence of the myeloproliferative neopla...</td>\n",
       "      <td>The myeloproliferative neoplasms (MPNs) are ra...</td>\n",
       "      <td>0.218579</td>\n",
       "      <td>0.661157</td>\n",
       "      <td>0.328542</td>\n",
       "      <td>0.112329</td>\n",
       "      <td>0.341667</td>\n",
       "      <td>0.169072</td>\n",
       "      <td>0.122951</td>\n",
       "      <td>0.371901</td>\n",
       "      <td>0.184805</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797433</th>\n",
       "      <th>ch05</th>\n",
       "      <td>Surgery is the cornerstone of management for b...</td>\n",
       "      <td>Surgery is one of the cornerstones of treatmen...</td>\n",
       "      <td>Surgery is the cornerstone of management for b...</td>\n",
       "      <td>0.157333</td>\n",
       "      <td>0.578431</td>\n",
       "      <td>0.247379</td>\n",
       "      <td>0.029412</td>\n",
       "      <td>0.108911</td>\n",
       "      <td>0.046316</td>\n",
       "      <td>0.088000</td>\n",
       "      <td>0.323529</td>\n",
       "      <td>0.138365</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797617</th>\n",
       "      <th>chp1</th>\n",
       "      <td>Epidemiology, pathophysiology and etiology\\nAc...</td>\n",
       "      <td>Acute myeloid leukemia (AML) is a relatively r...</td>\n",
       "      <td>The role of genetics in the pathophysiology of...</td>\n",
       "      <td>0.227882</td>\n",
       "      <td>0.521472</td>\n",
       "      <td>0.317164</td>\n",
       "      <td>0.064516</td>\n",
       "      <td>0.148148</td>\n",
       "      <td>0.089888</td>\n",
       "      <td>0.104558</td>\n",
       "      <td>0.239264</td>\n",
       "      <td>0.145522</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541963</th>\n",
       "      <th>chapter3</th>\n",
       "      <td>Alcoholic liver disease\\nAlcoholic liver disea...</td>\n",
       "      <td>Alcoholic liver disease (ALD) is a common caus...</td>\n",
       "      <td>Alcoholic liver disease (ALD) is a common caus...</td>\n",
       "      <td>0.123209</td>\n",
       "      <td>0.693548</td>\n",
       "      <td>0.209246</td>\n",
       "      <td>0.063218</td>\n",
       "      <td>0.360656</td>\n",
       "      <td>0.107579</td>\n",
       "      <td>0.085960</td>\n",
       "      <td>0.483871</td>\n",
       "      <td>0.145985</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541796</th>\n",
       "      <th>chapter1</th>\n",
       "      <td>Lymphoma is a malignancy of lymphocytes and th...</td>\n",
       "      <td>The epidemiology of lymphoma is difficult to s...</td>\n",
       "      <td>Lymphoma is a malignancy of lymphocytes and th...</td>\n",
       "      <td>0.163539</td>\n",
       "      <td>0.491935</td>\n",
       "      <td>0.245473</td>\n",
       "      <td>0.053763</td>\n",
       "      <td>0.162602</td>\n",
       "      <td>0.080808</td>\n",
       "      <td>0.096515</td>\n",
       "      <td>0.290323</td>\n",
       "      <td>0.144869</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541963</th>\n",
       "      <th>chapter5</th>\n",
       "      <td>Autoimmune liver diseases\\nThree liver disease...</td>\n",
       "      <td>Autoimmune liver disease can target the hepato...</td>\n",
       "      <td>Autoimmune liver diseases are classified as au...</td>\n",
       "      <td>0.166205</td>\n",
       "      <td>0.722892</td>\n",
       "      <td>0.270270</td>\n",
       "      <td>0.061111</td>\n",
       "      <td>0.268293</td>\n",
       "      <td>0.099548</td>\n",
       "      <td>0.091413</td>\n",
       "      <td>0.397590</td>\n",
       "      <td>0.148649</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797907</th>\n",
       "      <th>chp2</th>\n",
       "      <td>Epidemiology and etiology\\nDespite being the b...</td>\n",
       "      <td>Gaps remain in our understanding of the epidem...</td>\n",
       "      <td>Epidemiology and etiology of pyruvate kinase d...</td>\n",
       "      <td>0.128713</td>\n",
       "      <td>0.702703</td>\n",
       "      <td>0.217573</td>\n",
       "      <td>0.052109</td>\n",
       "      <td>0.287671</td>\n",
       "      <td>0.088235</td>\n",
       "      <td>0.079208</td>\n",
       "      <td>0.432432</td>\n",
       "      <td>0.133891</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541666</th>\n",
       "      <th>ch_13</th>\n",
       "      <td>Pregnancy and diabetes\\nDiabetic pregnancy is ...</td>\n",
       "      <td>Diabetic pregnancy is associated with fetal mo...</td>\n",
       "      <td>Pregnancy and diabetes in the United States.Di...</td>\n",
       "      <td>0.156250</td>\n",
       "      <td>0.731707</td>\n",
       "      <td>0.257511</td>\n",
       "      <td>0.065274</td>\n",
       "      <td>0.308642</td>\n",
       "      <td>0.107759</td>\n",
       "      <td>0.083333</td>\n",
       "      <td>0.390244</td>\n",
       "      <td>0.137339</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781912776153</th>\n",
       "      <th>chp3</th>\n",
       "      <td>Syncope is a significant healthcare problem, r...</td>\n",
       "      <td>Syncope is defined as a total loss of consciou...</td>\n",
       "      <td>Syncope is a significant healthcare problem, r...</td>\n",
       "      <td>0.280928</td>\n",
       "      <td>0.622857</td>\n",
       "      <td>0.387211</td>\n",
       "      <td>0.126615</td>\n",
       "      <td>0.281609</td>\n",
       "      <td>0.174688</td>\n",
       "      <td>0.146907</td>\n",
       "      <td>0.325714</td>\n",
       "      <td>0.202487</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541468</th>\n",
       "      <th>ch_14</th>\n",
       "      <td>Renal replacement therapy and transplantation\\...</td>\n",
       "      <td>Not all patients with end-stage kidney disease...</td>\n",
       "      <td>Renal replacement therapy and transplantation ...</td>\n",
       "      <td>0.156164</td>\n",
       "      <td>0.527778</td>\n",
       "      <td>0.241015</td>\n",
       "      <td>0.049451</td>\n",
       "      <td>0.168224</td>\n",
       "      <td>0.076433</td>\n",
       "      <td>0.087671</td>\n",
       "      <td>0.296296</td>\n",
       "      <td>0.135307</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797662</th>\n",
       "      <th>ch09</th>\n",
       "      <td>Future trends\\nThe mortality and morbidity of ...</td>\n",
       "      <td>Public health preventative measures are likely...</td>\n",
       "      <td>Future trends in the treatment of bladder canc...</td>\n",
       "      <td>0.120853</td>\n",
       "      <td>0.515152</td>\n",
       "      <td>0.195777</td>\n",
       "      <td>0.016627</td>\n",
       "      <td>0.071429</td>\n",
       "      <td>0.026975</td>\n",
       "      <td>0.066351</td>\n",
       "      <td>0.282828</td>\n",
       "      <td>0.107486</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797211</th>\n",
       "      <th>ch04</th>\n",
       "      <td>Drug treatment\\nThe first drugs used to treat ...</td>\n",
       "      <td>Levodopa restores the dopamine lost due to deg...</td>\n",
       "      <td>Drug treatment for Parkinson's disease has bee...</td>\n",
       "      <td>0.343750</td>\n",
       "      <td>0.505747</td>\n",
       "      <td>0.409302</td>\n",
       "      <td>0.060052</td>\n",
       "      <td>0.088462</td>\n",
       "      <td>0.071540</td>\n",
       "      <td>0.140625</td>\n",
       "      <td>0.206897</td>\n",
       "      <td>0.167442</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541727</th>\n",
       "      <th>ch03</th>\n",
       "      <td>Blurred vision\\nThe most common causes of blur...</td>\n",
       "      <td>Most patients with blurred vision have benign,...</td>\n",
       "      <td>Blurred vision is the most common cause of gla...</td>\n",
       "      <td>0.206030</td>\n",
       "      <td>0.594203</td>\n",
       "      <td>0.305970</td>\n",
       "      <td>0.073048</td>\n",
       "      <td>0.211679</td>\n",
       "      <td>0.108614</td>\n",
       "      <td>0.100503</td>\n",
       "      <td>0.289855</td>\n",
       "      <td>0.149254</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9783318068207</th>\n",
       "      <th>hh-8</th>\n",
       "      <td>Preparing high-quality samples\\nIn the era of ...</td>\n",
       "      <td>Different sample types (histological or cytolo...</td>\n",
       "      <td>Preparing high-quality samples for molecular a...</td>\n",
       "      <td>0.089947</td>\n",
       "      <td>0.607143</td>\n",
       "      <td>0.156682</td>\n",
       "      <td>0.018568</td>\n",
       "      <td>0.127273</td>\n",
       "      <td>0.032407</td>\n",
       "      <td>0.047619</td>\n",
       "      <td>0.321429</td>\n",
       "      <td>0.082949</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541024</th>\n",
       "      <th>ch_12</th>\n",
       "      <td>Brain tumor syndromes and tumor-like cysts\\nFa...</td>\n",
       "      <td>There are several syndromes associated with an...</td>\n",
       "      <td>Brain tumor syndromes and tumor-like cysts hav...</td>\n",
       "      <td>0.221893</td>\n",
       "      <td>0.551471</td>\n",
       "      <td>0.316456</td>\n",
       "      <td>0.047478</td>\n",
       "      <td>0.118519</td>\n",
       "      <td>0.067797</td>\n",
       "      <td>0.097633</td>\n",
       "      <td>0.242647</td>\n",
       "      <td>0.139241</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch05</th>\n",
       "      <td>Developmental theories and environmental facto...</td>\n",
       "      <td>Early neurodevelopmental, non-genetic risk fac...</td>\n",
       "      <td>Developmental theories and environmental facto...</td>\n",
       "      <td>0.101036</td>\n",
       "      <td>0.619048</td>\n",
       "      <td>0.173719</td>\n",
       "      <td>0.025974</td>\n",
       "      <td>0.161290</td>\n",
       "      <td>0.044743</td>\n",
       "      <td>0.056995</td>\n",
       "      <td>0.349206</td>\n",
       "      <td>0.097996</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541420</th>\n",
       "      <th>ch_6</th>\n",
       "      <td>Successful asthma management will achieve both...</td>\n",
       "      <td>Drugs used in the management of asthma can be ...</td>\n",
       "      <td>osteroid needs to be minimized, although exist...</td>\n",
       "      <td>0.090426</td>\n",
       "      <td>0.290598</td>\n",
       "      <td>0.137931</td>\n",
       "      <td>0.021333</td>\n",
       "      <td>0.068966</td>\n",
       "      <td>0.032587</td>\n",
       "      <td>0.058511</td>\n",
       "      <td>0.188034</td>\n",
       "      <td>0.089249</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541680</th>\n",
       "      <th>ch_8</th>\n",
       "      <td>Management: behavioral therapy\\nBehavioral the...</td>\n",
       "      <td>Behavioral therapy, alongside diet and lifesty...</td>\n",
       "      <td>Management: behavioral therapy is a fundamenta...</td>\n",
       "      <td>0.073113</td>\n",
       "      <td>0.584906</td>\n",
       "      <td>0.129979</td>\n",
       "      <td>0.021277</td>\n",
       "      <td>0.173077</td>\n",
       "      <td>0.037895</td>\n",
       "      <td>0.054245</td>\n",
       "      <td>0.433962</td>\n",
       "      <td>0.096436</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797457</th>\n",
       "      <th>chp8</th>\n",
       "      <td>Management of castrate-resistant prostate canc...</td>\n",
       "      <td>After an initial response to androgen ablation...</td>\n",
       "      <td>/day, improved survival in men with metastatic...</td>\n",
       "      <td>0.167123</td>\n",
       "      <td>0.386076</td>\n",
       "      <td>0.233270</td>\n",
       "      <td>0.038462</td>\n",
       "      <td>0.089172</td>\n",
       "      <td>0.053743</td>\n",
       "      <td>0.082192</td>\n",
       "      <td>0.189873</td>\n",
       "      <td>0.114723</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797815</th>\n",
       "      <th>chp7</th>\n",
       "      <td>New treatments for myeloproliferative neoplasm...</td>\n",
       "      <td>A variety of new therapies directed against di...</td>\n",
       "      <td>New treatments for myeloproliferative neoplasm...</td>\n",
       "      <td>0.100890</td>\n",
       "      <td>0.478873</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.023810</td>\n",
       "      <td>0.114286</td>\n",
       "      <td>0.039409</td>\n",
       "      <td>0.065282</td>\n",
       "      <td>0.309859</td>\n",
       "      <td>0.107843</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9783318066685</th>\n",
       "      <th>ch4</th>\n",
       "      <td>4 Gene therapies with proven clinical efficacy...</td>\n",
       "      <td>Gene therapy, using gene-modified cells or in ...</td>\n",
       "      <td>stranded vector but instantly become double-st...</td>\n",
       "      <td>0.093677</td>\n",
       "      <td>0.238095</td>\n",
       "      <td>0.134454</td>\n",
       "      <td>0.009390</td>\n",
       "      <td>0.023952</td>\n",
       "      <td>0.013491</td>\n",
       "      <td>0.063232</td>\n",
       "      <td>0.160714</td>\n",
       "      <td>0.090756</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541680</th>\n",
       "      <th>ch_4</th>\n",
       "      <td>Cardiometabolic consequences\\nOverweight/obesi...</td>\n",
       "      <td>Obesity significantly affects cardiometabolic ...</td>\n",
       "      <td>Cardiometabolic consequences of obesity and di...</td>\n",
       "      <td>0.080128</td>\n",
       "      <td>0.304878</td>\n",
       "      <td>0.126904</td>\n",
       "      <td>0.016077</td>\n",
       "      <td>0.061728</td>\n",
       "      <td>0.025510</td>\n",
       "      <td>0.057692</td>\n",
       "      <td>0.219512</td>\n",
       "      <td>0.091371</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                     text  \\\n",
       "book          chapter                                                       \n",
       "9783318068207 hh-7      Non-small cell lung cancer\\nLung cancer is the...   \n",
       "9781910797631 chp6      Prevention and management\\nBy far the most res...   \n",
       "9781910797426 ch03      Diseases of the gallbladder\\nEtiology and path...   \n",
       "9781908541277 ch_12     Quality of life\\nPsychiatric comorbidities\\nNe...   \n",
       "9781910797907 chp6      Supportive treatment\\nAt present, the main foc...   \n",
       "9781908541277 ch_8      Antiepileptic drugs\\nEstablished antiepileptic...   \n",
       "9781910797006 ch08      Acute exacerbations\\nAcute exacerbations of ch...   \n",
       "9781910797105 ch06      Neuroanatomy and structural imaging\\nOur knowl...   \n",
       "9783318068207 hh-5      The recent improvements in terms of available ...   \n",
       "9781910797105 ch04      The biggest single clue we have about the caus...   \n",
       "9781910797006 ch03      Clinical features\\nThe characteristic symptom ...   \n",
       "9781908541406 ch_6      Platelet disorders\\nPlatelet function defects\\...   \n",
       "9781908541277 ch_6      The diagnosis of epilepsy relies on the correc...   \n",
       "9781910797815 chp3      Diagnosis and disease burden\\nAccurate diagnos...   \n",
       "9781910797310 chp3      Staging and surgery\\nIlaria Onorati MD and Ola...   \n",
       "9781910797426 ch12      Unusual tumors of the pancreas and ampulla of ...   \n",
       "9781908541024 ch_13     Geriatric neuro-oncology\\nAlthough half of all...   \n",
       "9781910797617 chp6      Research directions\\nThe expanded genetic char...   \n",
       "9781908541994 ch02      Pathophysiology, etiology and modifying factor...   \n",
       "9781910797471 ch05      Case history\\nA 67-year-old man with diabetes ...   \n",
       "9781910797105 ch08      Neurochemical abnormalities, including changes...   \n",
       "9781912776207 ch4       Accurate diagnosis and subtyping of PTCL is ch...   \n",
       "9781910797495 chp12     Headache is a common complaint in the general ...   \n",
       "9781912776726 ch2       Clinical presentation\\nMost patients with glio...   \n",
       "9781910797815 chp2      The myeloproliferative neoplasms (MPNs) are ra...   \n",
       "9781910797433 ch05      Surgery is the cornerstone of management for b...   \n",
       "9781910797617 chp1      Epidemiology, pathophysiology and etiology\\nAc...   \n",
       "9781908541963 chapter3  Alcoholic liver disease\\nAlcoholic liver disea...   \n",
       "9781908541796 chapter1  Lymphoma is a malignancy of lymphocytes and th...   \n",
       "9781908541963 chapter5  Autoimmune liver diseases\\nThree liver disease...   \n",
       "9781910797907 chp2      Epidemiology and etiology\\nDespite being the b...   \n",
       "9781908541666 ch_13     Pregnancy and diabetes\\nDiabetic pregnancy is ...   \n",
       "9781912776153 chp3      Syncope is a significant healthcare problem, r...   \n",
       "9781908541468 ch_14     Renal replacement therapy and transplantation\\...   \n",
       "9781910797662 ch09      Future trends\\nThe mortality and morbidity of ...   \n",
       "9781910797211 ch04      Drug treatment\\nThe first drugs used to treat ...   \n",
       "9781908541727 ch03      Blurred vision\\nThe most common causes of blur...   \n",
       "9783318068207 hh-8      Preparing high-quality samples\\nIn the era of ...   \n",
       "9781908541024 ch_12     Brain tumor syndromes and tumor-like cysts\\nFa...   \n",
       "9781910797105 ch05      Developmental theories and environmental facto...   \n",
       "9781908541420 ch_6      Successful asthma management will achieve both...   \n",
       "9781908541680 ch_8      Management: behavioral therapy\\nBehavioral the...   \n",
       "9781910797457 chp8      Management of castrate-resistant prostate canc...   \n",
       "9781910797815 chp7      New treatments for myeloproliferative neoplasm...   \n",
       "9783318066685 ch4       4 Gene therapies with proven clinical efficacy...   \n",
       "9781908541680 ch_4      Cardiometabolic consequences\\nOverweight/obesi...   \n",
       "\n",
       "                                                                  bullets  \\\n",
       "book          chapter                                                       \n",
       "9783318068207 hh-7      The molecular status of, at least, EGFR, ALK, ...   \n",
       "9781910797631 chp6      The treatment rather than the prevention of de...   \n",
       "9781910797426 ch03      The prevalence of gallstones is greater in peo...   \n",
       "9781908541277 ch_12     Depression and anxiety are common in patients ...   \n",
       "9781910797907 chp6      The burden of transfusions in pyruvate kinase ...   \n",
       "9781908541277 ch_8      Sixteen new antiepileptic drugs (AEDs) have be...   \n",
       "9781910797006 ch08      Acute exacerbations of COPD are common and pla...   \n",
       "9781910797105 ch06      People with schizophrenia exhibit gray matter ...   \n",
       "9783318068207 hh-5      Comprehensive genomic profiles offer a complet...   \n",
       "9781910797105 ch04      Having a close relative with schizophrenia inc...   \n",
       "9781910797006 ch03      COPD occurs, though less commonly, in those wh...   \n",
       "9781908541406 ch_6      Thrombocytopenia may occur with some inherited...   \n",
       "9781908541277 ch_6      Epilepsy has many underlying etiologies.\\nA wi...   \n",
       "9781910797815 chp3      The World Health Organization diagnostic crite...   \n",
       "9781910797310 chp3      Better subclassification of early-stage NSCLC ...   \n",
       "9781910797426 ch12      Tumor types that occur in the ampullary and pe...   \n",
       "9781908541024 ch_13     Pathological diagnosis is critical to select a...   \n",
       "9781910797617 chp6      A wide range of targeted agencies for the trea...   \n",
       "9781908541994 ch02      Acne is a hormonally mediated disease.\\nFour m...   \n",
       "9781910797471 ch05      Assessment of functional class, based on exerc...   \n",
       "9781910797105 ch08      The dopamine hypothesis remains the major neur...   \n",
       "9781912776207 ch4       Many patients with aggressive T-cell lymphomas...   \n",
       "9781910797495 chp12     In patients without history of chronic headach...   \n",
       "9781912776726 ch2       The signs and symptoms of glioblastoma result ...   \n",
       "9781910797815 chp2      The incidence of the myeloproliferative neopla...   \n",
       "9781910797433 ch05      Surgery is one of the cornerstones of treatmen...   \n",
       "9781910797617 chp1      Acute myeloid leukemia (AML) is a relatively r...   \n",
       "9781908541963 chapter3  Alcoholic liver disease (ALD) is a common caus...   \n",
       "9781908541796 chapter1  The epidemiology of lymphoma is difficult to s...   \n",
       "9781908541963 chapter5  Autoimmune liver disease can target the hepato...   \n",
       "9781910797907 chp2      Gaps remain in our understanding of the epidem...   \n",
       "9781908541666 ch_13     Diabetic pregnancy is associated with fetal mo...   \n",
       "9781912776153 chp3      Syncope is defined as a total loss of consciou...   \n",
       "9781908541468 ch_14     Not all patients with end-stage kidney disease...   \n",
       "9781910797662 ch09      Public health preventative measures are likely...   \n",
       "9781910797211 ch04      Levodopa restores the dopamine lost due to deg...   \n",
       "9781908541727 ch03      Most patients with blurred vision have benign,...   \n",
       "9783318068207 hh-8      Different sample types (histological or cytolo...   \n",
       "9781908541024 ch_12     There are several syndromes associated with an...   \n",
       "9781910797105 ch05      Early neurodevelopmental, non-genetic risk fac...   \n",
       "9781908541420 ch_6      Drugs used in the management of asthma can be ...   \n",
       "9781908541680 ch_8      Behavioral therapy, alongside diet and lifesty...   \n",
       "9781910797457 chp8      After an initial response to androgen ablation...   \n",
       "9781910797815 chp7      A variety of new therapies directed against di...   \n",
       "9783318066685 ch4       Gene therapy, using gene-modified cells or in ...   \n",
       "9781908541680 ch_4      Obesity significantly affects cardiometabolic ...   \n",
       "\n",
       "                                           summary_allenai/led-base-16384  \\\n",
       "book          chapter                                                       \n",
       "9783318068207 hh-7      . Current ESMO and ASCO guidelines do not reco...   \n",
       "9781910797631 chp6      Prevention and management of depression. There...   \n",
       "9781910797426 ch03      ubin and transaminases may be present in the g...   \n",
       "9781908541277 ch_12     , is important for general maintenance of heal...   \n",
       "9781910797907 chp6      is. Splenectomy increases susceptibility to se...   \n",
       "9781908541277 ch_8      Antiepileptic drugs have been shown to be effe...   \n",
       "9781910797006 ch08      Acute exacerbations of COPD can be treated wit...   \n",
       "9781910797105 ch06      Neuroanatomy and structural imaging. Neuropsyc...   \n",
       "9783318068207 hh-5      , the identification of gene fusions may also ...   \n",
       "9781910797105 ch04      ) are a more recent discovery and involve dupl...   \n",
       "9781910797006 ch03      , the airflow limitation of COPD is a common c...   \n",
       "9781908541406 ch_6      Platelet disorders are usually associated with...   \n",
       "9781908541277 ch_6      The diagnosis of epilepsy relies on the correc...   \n",
       "9781910797815 chp3      However, each of these symptoms was significan...   \n",
       "9781910797310 chp3      ), and T4 tumors without mediastinal nodal met...   \n",
       "9781910797426 ch12      Unusual tumors of the pancreas and ampulla of ...   \n",
       "9781908541024 ch_13     Geriatric neuro-oncology is an area that has r...   \n",
       "9781910797617 chp6      because of age or comorbidities). A Phase II s...   \n",
       "9781908541994 ch02      Pathophysiology, etiology and modifying factor...   \n",
       "9781910797471 ch05      A 67-year-old man with diabetes mellitus, pulm...   \n",
       "9781910797105 ch08      The roles of other serotonergic receptors have...   \n",
       "9781912776207 ch4       ivariate analysis identified four independent ...   \n",
       "9781910797495 chp12     Headache is a common complaint in the general ...   \n",
       "9781912776726 ch2       Clinical presentation and clinical history of ...   \n",
       "9781910797815 chp2      The myeloproliferative neoplasms (MPNs) are ra...   \n",
       "9781910797433 ch05      Surgery is the cornerstone of management for b...   \n",
       "9781910797617 chp1      The role of genetics in the pathophysiology of...   \n",
       "9781908541963 chapter3  Alcoholic liver disease (ALD) is a common caus...   \n",
       "9781908541796 chapter1  Lymphoma is a malignancy of lymphocytes and th...   \n",
       "9781908541963 chapter5  Autoimmune liver diseases are classified as au...   \n",
       "9781910797907 chp2      Epidemiology and etiology of pyruvate kinase d...   \n",
       "9781908541666 ch_13     Pregnancy and diabetes in the United States.Di...   \n",
       "9781912776153 chp3      Syncope is a significant healthcare problem, r...   \n",
       "9781908541468 ch_14     Renal replacement therapy and transplantation ...   \n",
       "9781910797662 ch09      Future trends in the treatment of bladder canc...   \n",
       "9781910797211 ch04      Drug treatment for Parkinson's disease has bee...   \n",
       "9781908541727 ch03      Blurred vision is the most common cause of gla...   \n",
       "9783318068207 hh-8      Preparing high-quality samples for molecular a...   \n",
       "9781908541024 ch_12     Brain tumor syndromes and tumor-like cysts hav...   \n",
       "9781910797105 ch05      Developmental theories and environmental facto...   \n",
       "9781908541420 ch_6      osteroid needs to be minimized, although exist...   \n",
       "9781908541680 ch_8      Management: behavioral therapy is a fundamenta...   \n",
       "9781910797457 chp8      /day, improved survival in men with metastatic...   \n",
       "9781910797815 chp7      New treatments for myeloproliferative neoplasm...   \n",
       "9783318066685 ch4       stranded vector but instantly become double-st...   \n",
       "9781908541680 ch_4      Cardiometabolic consequences of obesity and di...   \n",
       "\n",
       "                        rouge1_precision_allenai/led-base-16384  \\\n",
       "book          chapter                                             \n",
       "9783318068207 hh-7                                     0.289941   \n",
       "9781910797631 chp6                                     0.203540   \n",
       "9781910797426 ch03                                     0.182635   \n",
       "9781908541277 ch_12                                    0.224242   \n",
       "9781910797907 chp6                                     0.205962   \n",
       "9781908541277 ch_8                                     0.063131   \n",
       "9781910797006 ch08                                     0.141414   \n",
       "9781910797105 ch06                                     0.173554   \n",
       "9783318068207 hh-5                                     0.167095   \n",
       "9781910797105 ch04                                     0.090426   \n",
       "9781910797006 ch03                                     0.199430   \n",
       "9781908541406 ch_6                                     0.133172   \n",
       "9781908541277 ch_6                                     0.183333   \n",
       "9781910797815 chp3                                     0.311429   \n",
       "9781910797310 chp3                                     0.143251   \n",
       "9781910797426 ch12                                     0.170000   \n",
       "9781908541024 ch_13                                    0.117347   \n",
       "9781910797617 chp6                                     0.230137   \n",
       "9781908541994 ch02                                     0.089783   \n",
       "9781910797471 ch05                                     0.177112   \n",
       "9781910797105 ch08                                     0.118598   \n",
       "9781912776207 ch4                                      0.065574   \n",
       "9781910797495 chp12                                    0.104859   \n",
       "9781912776726 ch2                                      0.260000   \n",
       "9781910797815 chp2                                     0.218579   \n",
       "9781910797433 ch05                                     0.157333   \n",
       "9781910797617 chp1                                     0.227882   \n",
       "9781908541963 chapter3                                 0.123209   \n",
       "9781908541796 chapter1                                 0.163539   \n",
       "9781908541963 chapter5                                 0.166205   \n",
       "9781910797907 chp2                                     0.128713   \n",
       "9781908541666 ch_13                                    0.156250   \n",
       "9781912776153 chp3                                     0.280928   \n",
       "9781908541468 ch_14                                    0.156164   \n",
       "9781910797662 ch09                                     0.120853   \n",
       "9781910797211 ch04                                     0.343750   \n",
       "9781908541727 ch03                                     0.206030   \n",
       "9783318068207 hh-8                                     0.089947   \n",
       "9781908541024 ch_12                                    0.221893   \n",
       "9781910797105 ch05                                     0.101036   \n",
       "9781908541420 ch_6                                     0.090426   \n",
       "9781908541680 ch_8                                     0.073113   \n",
       "9781910797457 chp8                                     0.167123   \n",
       "9781910797815 chp7                                     0.100890   \n",
       "9783318066685 ch4                                      0.093677   \n",
       "9781908541680 ch_4                                     0.080128   \n",
       "\n",
       "                        rouge1_recall_allenai/led-base-16384  \\\n",
       "book          chapter                                          \n",
       "9783318068207 hh-7                                  0.319218   \n",
       "9781910797631 chp6                                  0.534884   \n",
       "9781910797426 ch03                                  0.476562   \n",
       "9781908541277 ch_12                                 0.496644   \n",
       "9781910797907 chp6                                  0.580153   \n",
       "9781908541277 ch_8                                  0.480769   \n",
       "9781910797006 ch08                                  0.629213   \n",
       "9781910797105 ch06                                  0.611650   \n",
       "9783318068207 hh-5                                  0.532787   \n",
       "9781910797105 ch04                                  0.478873   \n",
       "9781910797006 ch03                                  0.404624   \n",
       "9781908541406 ch_6                                  0.491071   \n",
       "9781908541277 ch_6                                  0.717391   \n",
       "9781910797815 chp3                                  0.630058   \n",
       "9781910797310 chp3                                  0.611765   \n",
       "9781910797426 ch12                                  0.579545   \n",
       "9781908541024 ch_13                                 0.741935   \n",
       "9781910797617 chp6                                  0.474576   \n",
       "9781908541994 ch02                                  0.527273   \n",
       "9781910797471 ch05                                  0.515873   \n",
       "9781910797105 ch08                                  0.602740   \n",
       "9781912776207 ch4                                   0.333333   \n",
       "9781910797495 chp12                                 0.455556   \n",
       "9781912776726 ch2                                   0.590909   \n",
       "9781910797815 chp2                                  0.661157   \n",
       "9781910797433 ch05                                  0.578431   \n",
       "9781910797617 chp1                                  0.521472   \n",
       "9781908541963 chapter3                              0.693548   \n",
       "9781908541796 chapter1                              0.491935   \n",
       "9781908541963 chapter5                              0.722892   \n",
       "9781910797907 chp2                                  0.702703   \n",
       "9781908541666 ch_13                                 0.731707   \n",
       "9781912776153 chp3                                  0.622857   \n",
       "9781908541468 ch_14                                 0.527778   \n",
       "9781910797662 ch09                                  0.515152   \n",
       "9781910797211 ch04                                  0.505747   \n",
       "9781908541727 ch03                                  0.594203   \n",
       "9783318068207 hh-8                                  0.607143   \n",
       "9781908541024 ch_12                                 0.551471   \n",
       "9781910797105 ch05                                  0.619048   \n",
       "9781908541420 ch_6                                  0.290598   \n",
       "9781908541680 ch_8                                  0.584906   \n",
       "9781910797457 chp8                                  0.386076   \n",
       "9781910797815 chp7                                  0.478873   \n",
       "9783318066685 ch4                                   0.238095   \n",
       "9781908541680 ch_4                                  0.304878   \n",
       "\n",
       "                        rouge1_fmeasure_allenai/led-base-16384  \\\n",
       "book          chapter                                            \n",
       "9783318068207 hh-7                                    0.303876   \n",
       "9781910797631 chp6                                    0.294872   \n",
       "9781910797426 ch03                                    0.264069   \n",
       "9781908541277 ch_12                                   0.308977   \n",
       "9781910797907 chp6                                    0.304000   \n",
       "9781908541277 ch_8                                    0.111607   \n",
       "9781910797006 ch08                                    0.230928   \n",
       "9781910797105 ch06                                    0.270386   \n",
       "9783318068207 hh-5                                    0.254403   \n",
       "9781910797105 ch04                                    0.152125   \n",
       "9781910797006 ch03                                    0.267176   \n",
       "9781908541406 ch_6                                    0.209524   \n",
       "9781908541277 ch_6                                    0.292035   \n",
       "9781910797815 chp3                                    0.416826   \n",
       "9781910797310 chp3                                    0.232143   \n",
       "9781910797426 ch12                                    0.262887   \n",
       "9781908541024 ch_13                                   0.202643   \n",
       "9781910797617 chp6                                    0.309963   \n",
       "9781908541994 ch02                                    0.153439   \n",
       "9781910797471 ch05                                    0.263692   \n",
       "9781910797105 ch08                                    0.198198   \n",
       "9781912776207 ch4                                     0.109589   \n",
       "9781910797495 chp12                                   0.170478   \n",
       "9781912776726 ch2                                     0.361111   \n",
       "9781910797815 chp2                                    0.328542   \n",
       "9781910797433 ch05                                    0.247379   \n",
       "9781910797617 chp1                                    0.317164   \n",
       "9781908541963 chapter3                                0.209246   \n",
       "9781908541796 chapter1                                0.245473   \n",
       "9781908541963 chapter5                                0.270270   \n",
       "9781910797907 chp2                                    0.217573   \n",
       "9781908541666 ch_13                                   0.257511   \n",
       "9781912776153 chp3                                    0.387211   \n",
       "9781908541468 ch_14                                   0.241015   \n",
       "9781910797662 ch09                                    0.195777   \n",
       "9781910797211 ch04                                    0.409302   \n",
       "9781908541727 ch03                                    0.305970   \n",
       "9783318068207 hh-8                                    0.156682   \n",
       "9781908541024 ch_12                                   0.316456   \n",
       "9781910797105 ch05                                    0.173719   \n",
       "9781908541420 ch_6                                    0.137931   \n",
       "9781908541680 ch_8                                    0.129979   \n",
       "9781910797457 chp8                                    0.233270   \n",
       "9781910797815 chp7                                    0.166667   \n",
       "9783318066685 ch4                                     0.134454   \n",
       "9781908541680 ch_4                                    0.126904   \n",
       "\n",
       "                        rouge2_precision_allenai/led-base-16384  \\\n",
       "book          chapter                                             \n",
       "9783318068207 hh-7                                     0.053412   \n",
       "9781910797631 chp6                                     0.053215   \n",
       "9781910797426 ch03                                     0.066066   \n",
       "9781908541277 ch_12                                    0.051672   \n",
       "9781910797907 chp6                                     0.040761   \n",
       "9781908541277 ch_8                                     0.017722   \n",
       "9781910797006 ch08                                     0.045570   \n",
       "9781910797105 ch06                                     0.077348   \n",
       "9783318068207 hh-5                                     0.038660   \n",
       "9781910797105 ch04                                     0.018667   \n",
       "9781910797006 ch03                                     0.054286   \n",
       "9781908541406 ch_6                                     0.041262   \n",
       "9781908541277 ch_6                                     0.077994   \n",
       "9781910797815 chp3                                     0.097421   \n",
       "9781910797310 chp3                                     0.044199   \n",
       "9781910797426 ch12                                     0.040134   \n",
       "9781908541024 ch_13                                    0.033248   \n",
       "9781910797617 chp6                                     0.057692   \n",
       "9781908541994 ch02                                     0.034161   \n",
       "9781910797471 ch05                                     0.038251   \n",
       "9781910797105 ch08                                     0.032432   \n",
       "9781912776207 ch4                                      0.009868   \n",
       "9781910797495 chp12                                    0.028205   \n",
       "9781912776726 ch2                                      0.105263   \n",
       "9781910797815 chp2                                     0.112329   \n",
       "9781910797433 ch05                                     0.029412   \n",
       "9781910797617 chp1                                     0.064516   \n",
       "9781908541963 chapter3                                 0.063218   \n",
       "9781908541796 chapter1                                 0.053763   \n",
       "9781908541963 chapter5                                 0.061111   \n",
       "9781910797907 chp2                                     0.052109   \n",
       "9781908541666 ch_13                                    0.065274   \n",
       "9781912776153 chp3                                     0.126615   \n",
       "9781908541468 ch_14                                    0.049451   \n",
       "9781910797662 ch09                                     0.016627   \n",
       "9781910797211 ch04                                     0.060052   \n",
       "9781908541727 ch03                                     0.073048   \n",
       "9783318068207 hh-8                                     0.018568   \n",
       "9781908541024 ch_12                                    0.047478   \n",
       "9781910797105 ch05                                     0.025974   \n",
       "9781908541420 ch_6                                     0.021333   \n",
       "9781908541680 ch_8                                     0.021277   \n",
       "9781910797457 chp8                                     0.038462   \n",
       "9781910797815 chp7                                     0.023810   \n",
       "9783318066685 ch4                                      0.009390   \n",
       "9781908541680 ch_4                                     0.016077   \n",
       "\n",
       "                        rouge2_recall_allenai/led-base-16384  \\\n",
       "book          chapter                                          \n",
       "9783318068207 hh-7                                  0.058824   \n",
       "9781910797631 chp6                                  0.140351   \n",
       "9781910797426 ch03                                  0.173228   \n",
       "9781908541277 ch_12                                 0.114865   \n",
       "9781910797907 chp6                                  0.115385   \n",
       "9781908541277 ch_8                                  0.137255   \n",
       "9781910797006 ch08                                  0.204545   \n",
       "9781910797105 ch06                                  0.274510   \n",
       "9783318068207 hh-5                                  0.123967   \n",
       "9781910797105 ch04                                  0.100000   \n",
       "9781910797006 ch03                                  0.110465   \n",
       "9781908541406 ch_6                                  0.153153   \n",
       "9781908541277 ch_6                                  0.307692   \n",
       "9781910797815 chp3                                  0.197674   \n",
       "9781910797310 chp3                                  0.190476   \n",
       "9781910797426 ch12                                  0.137931   \n",
       "9781908541024 ch_13                                 0.213115   \n",
       "9781910797617 chp6                                  0.119318   \n",
       "9781908541994 ch02                                  0.203704   \n",
       "9781910797471 ch05                                  0.112000   \n",
       "9781910797105 ch08                                  0.166667   \n",
       "9781912776207 ch4                                   0.050847   \n",
       "9781910797495 chp12                                 0.123596   \n",
       "9781912776726 ch2                                   0.240000   \n",
       "9781910797815 chp2                                  0.341667   \n",
       "9781910797433 ch05                                  0.108911   \n",
       "9781910797617 chp1                                  0.148148   \n",
       "9781908541963 chapter3                              0.360656   \n",
       "9781908541796 chapter1                              0.162602   \n",
       "9781908541963 chapter5                              0.268293   \n",
       "9781910797907 chp2                                  0.287671   \n",
       "9781908541666 ch_13                                 0.308642   \n",
       "9781912776153 chp3                                  0.281609   \n",
       "9781908541468 ch_14                                 0.168224   \n",
       "9781910797662 ch09                                  0.071429   \n",
       "9781910797211 ch04                                  0.088462   \n",
       "9781908541727 ch03                                  0.211679   \n",
       "9783318068207 hh-8                                  0.127273   \n",
       "9781908541024 ch_12                                 0.118519   \n",
       "9781910797105 ch05                                  0.161290   \n",
       "9781908541420 ch_6                                  0.068966   \n",
       "9781908541680 ch_8                                  0.173077   \n",
       "9781910797457 chp8                                  0.089172   \n",
       "9781910797815 chp7                                  0.114286   \n",
       "9783318066685 ch4                                   0.023952   \n",
       "9781908541680 ch_4                                  0.061728   \n",
       "\n",
       "                        rouge2_fmeasure_allenai/led-base-16384  \\\n",
       "book          chapter                                            \n",
       "9783318068207 hh-7                                    0.055988   \n",
       "9781910797631 chp6                                    0.077170   \n",
       "9781910797426 ch03                                    0.095652   \n",
       "9781908541277 ch_12                                   0.071279   \n",
       "9781910797907 chp6                                    0.060241   \n",
       "9781908541277 ch_8                                    0.031390   \n",
       "9781910797006 ch08                                    0.074534   \n",
       "9781910797105 ch06                                    0.120690   \n",
       "9783318068207 hh-5                                    0.058939   \n",
       "9781910797105 ch04                                    0.031461   \n",
       "9781910797006 ch03                                    0.072797   \n",
       "9781908541406 ch_6                                    0.065010   \n",
       "9781908541277 ch_6                                    0.124444   \n",
       "9781910797815 chp3                                    0.130518   \n",
       "9781910797310 chp3                                    0.071749   \n",
       "9781910797426 ch12                                    0.062176   \n",
       "9781908541024 ch_13                                   0.057522   \n",
       "9781910797617 chp6                                    0.077778   \n",
       "9781908541994 ch02                                    0.058511   \n",
       "9781910797471 ch05                                    0.057026   \n",
       "9781910797105 ch08                                    0.054299   \n",
       "9781912776207 ch4                                     0.016529   \n",
       "9781910797495 chp12                                   0.045929   \n",
       "9781912776726 ch2                                     0.146341   \n",
       "9781910797815 chp2                                    0.169072   \n",
       "9781910797433 ch05                                    0.046316   \n",
       "9781910797617 chp1                                    0.089888   \n",
       "9781908541963 chapter3                                0.107579   \n",
       "9781908541796 chapter1                                0.080808   \n",
       "9781908541963 chapter5                                0.099548   \n",
       "9781910797907 chp2                                    0.088235   \n",
       "9781908541666 ch_13                                   0.107759   \n",
       "9781912776153 chp3                                    0.174688   \n",
       "9781908541468 ch_14                                   0.076433   \n",
       "9781910797662 ch09                                    0.026975   \n",
       "9781910797211 ch04                                    0.071540   \n",
       "9781908541727 ch03                                    0.108614   \n",
       "9783318068207 hh-8                                    0.032407   \n",
       "9781908541024 ch_12                                   0.067797   \n",
       "9781910797105 ch05                                    0.044743   \n",
       "9781908541420 ch_6                                    0.032587   \n",
       "9781908541680 ch_8                                    0.037895   \n",
       "9781910797457 chp8                                    0.053743   \n",
       "9781910797815 chp7                                    0.039409   \n",
       "9783318066685 ch4                                     0.013491   \n",
       "9781908541680 ch_4                                    0.025510   \n",
       "\n",
       "                        rougeL_precision_allenai/led-base-16384  \\\n",
       "book          chapter                                             \n",
       "9783318068207 hh-7                                     0.142012   \n",
       "9781910797631 chp6                                     0.108407   \n",
       "9781910797426 ch03                                     0.107784   \n",
       "9781908541277 ch_12                                    0.130303   \n",
       "9781910797907 chp6                                     0.084011   \n",
       "9781908541277 ch_8                                     0.055556   \n",
       "9781910797006 ch08                                     0.073232   \n",
       "9781910797105 ch06                                     0.110193   \n",
       "9783318068207 hh-5                                     0.089974   \n",
       "9781910797105 ch04                                     0.061170   \n",
       "9781910797006 ch03                                     0.096866   \n",
       "9781908541406 ch_6                                     0.082324   \n",
       "9781908541277 ch_6                                     0.097222   \n",
       "9781910797815 chp3                                     0.108571   \n",
       "9781910797310 chp3                                     0.093664   \n",
       "9781910797426 ch12                                     0.076667   \n",
       "9781908541024 ch_13                                    0.068878   \n",
       "9781910797617 chp6                                     0.115068   \n",
       "9781908541994 ch02                                     0.061920   \n",
       "9781910797471 ch05                                     0.087193   \n",
       "9781910797105 ch08                                     0.064690   \n",
       "9781912776207 ch4                                      0.039344   \n",
       "9781910797495 chp12                                    0.066496   \n",
       "9781912776726 ch2                                      0.142500   \n",
       "9781910797815 chp2                                     0.122951   \n",
       "9781910797433 ch05                                     0.088000   \n",
       "9781910797617 chp1                                     0.104558   \n",
       "9781908541963 chapter3                                 0.085960   \n",
       "9781908541796 chapter1                                 0.096515   \n",
       "9781908541963 chapter5                                 0.091413   \n",
       "9781910797907 chp2                                     0.079208   \n",
       "9781908541666 ch_13                                    0.083333   \n",
       "9781912776153 chp3                                     0.146907   \n",
       "9781908541468 ch_14                                    0.087671   \n",
       "9781910797662 ch09                                     0.066351   \n",
       "9781910797211 ch04                                     0.140625   \n",
       "9781908541727 ch03                                     0.100503   \n",
       "9783318068207 hh-8                                     0.047619   \n",
       "9781908541024 ch_12                                    0.097633   \n",
       "9781910797105 ch05                                     0.056995   \n",
       "9781908541420 ch_6                                     0.058511   \n",
       "9781908541680 ch_8                                     0.054245   \n",
       "9781910797457 chp8                                     0.082192   \n",
       "9781910797815 chp7                                     0.065282   \n",
       "9783318066685 ch4                                      0.063232   \n",
       "9781908541680 ch_4                                     0.057692   \n",
       "\n",
       "                        rougeL_recall_allenai/led-base-16384  \\\n",
       "book          chapter                                          \n",
       "9783318068207 hh-7                                  0.156352   \n",
       "9781910797631 chp6                                  0.284884   \n",
       "9781910797426 ch03                                  0.281250   \n",
       "9781908541277 ch_12                                 0.288591   \n",
       "9781910797907 chp6                                  0.236641   \n",
       "9781908541277 ch_8                                  0.423077   \n",
       "9781910797006 ch08                                  0.325843   \n",
       "9781910797105 ch06                                  0.388350   \n",
       "9783318068207 hh-5                                  0.286885   \n",
       "9781910797105 ch04                                  0.323944   \n",
       "9781910797006 ch03                                  0.196532   \n",
       "9781908541406 ch_6                                  0.303571   \n",
       "9781908541277 ch_6                                  0.380435   \n",
       "9781910797815 chp3                                  0.219653   \n",
       "9781910797310 chp3                                  0.400000   \n",
       "9781910797426 ch12                                  0.261364   \n",
       "9781908541024 ch_13                                 0.435484   \n",
       "9781910797617 chp6                                  0.237288   \n",
       "9781908541994 ch02                                  0.363636   \n",
       "9781910797471 ch05                                  0.253968   \n",
       "9781910797105 ch08                                  0.328767   \n",
       "9781912776207 ch4                                   0.200000   \n",
       "9781910797495 chp12                                 0.288889   \n",
       "9781912776726 ch2                                   0.323864   \n",
       "9781910797815 chp2                                  0.371901   \n",
       "9781910797433 ch05                                  0.323529   \n",
       "9781910797617 chp1                                  0.239264   \n",
       "9781908541963 chapter3                              0.483871   \n",
       "9781908541796 chapter1                              0.290323   \n",
       "9781908541963 chapter5                              0.397590   \n",
       "9781910797907 chp2                                  0.432432   \n",
       "9781908541666 ch_13                                 0.390244   \n",
       "9781912776153 chp3                                  0.325714   \n",
       "9781908541468 ch_14                                 0.296296   \n",
       "9781910797662 ch09                                  0.282828   \n",
       "9781910797211 ch04                                  0.206897   \n",
       "9781908541727 ch03                                  0.289855   \n",
       "9783318068207 hh-8                                  0.321429   \n",
       "9781908541024 ch_12                                 0.242647   \n",
       "9781910797105 ch05                                  0.349206   \n",
       "9781908541420 ch_6                                  0.188034   \n",
       "9781908541680 ch_8                                  0.433962   \n",
       "9781910797457 chp8                                  0.189873   \n",
       "9781910797815 chp7                                  0.309859   \n",
       "9783318066685 ch4                                   0.160714   \n",
       "9781908541680 ch_4                                  0.219512   \n",
       "\n",
       "                        rougeL_fmeasure_allenai/led-base-16384  \n",
       "book          chapter                                           \n",
       "9783318068207 hh-7                                    0.148837  \n",
       "9781910797631 chp6                                    0.157051  \n",
       "9781910797426 ch03                                    0.155844  \n",
       "9781908541277 ch_12                                   0.179541  \n",
       "9781910797907 chp6                                    0.124000  \n",
       "9781908541277 ch_8                                    0.098214  \n",
       "9781910797006 ch08                                    0.119588  \n",
       "9781910797105 ch06                                    0.171674  \n",
       "9783318068207 hh-5                                    0.136986  \n",
       "9781910797105 ch04                                    0.102908  \n",
       "9781910797006 ch03                                    0.129771  \n",
       "9781908541406 ch_6                                    0.129524  \n",
       "9781908541277 ch_6                                    0.154867  \n",
       "9781910797815 chp3                                    0.145315  \n",
       "9781910797310 chp3                                    0.151786  \n",
       "9781910797426 ch12                                    0.118557  \n",
       "9781908541024 ch_13                                   0.118943  \n",
       "9781910797617 chp6                                    0.154982  \n",
       "9781908541994 ch02                                    0.105820  \n",
       "9781910797471 ch05                                    0.129817  \n",
       "9781910797105 ch08                                    0.108108  \n",
       "9781912776207 ch4                                     0.065753  \n",
       "9781910797495 chp12                                   0.108108  \n",
       "9781912776726 ch2                                     0.197917  \n",
       "9781910797815 chp2                                    0.184805  \n",
       "9781910797433 ch05                                    0.138365  \n",
       "9781910797617 chp1                                    0.145522  \n",
       "9781908541963 chapter3                                0.145985  \n",
       "9781908541796 chapter1                                0.144869  \n",
       "9781908541963 chapter5                                0.148649  \n",
       "9781910797907 chp2                                    0.133891  \n",
       "9781908541666 ch_13                                   0.137339  \n",
       "9781912776153 chp3                                    0.202487  \n",
       "9781908541468 ch_14                                   0.135307  \n",
       "9781910797662 ch09                                    0.107486  \n",
       "9781910797211 ch04                                    0.167442  \n",
       "9781908541727 ch03                                    0.149254  \n",
       "9783318068207 hh-8                                    0.082949  \n",
       "9781908541024 ch_12                                   0.139241  \n",
       "9781910797105 ch05                                    0.097996  \n",
       "9781908541420 ch_6                                    0.089249  \n",
       "9781908541680 ch_8                                    0.096436  \n",
       "9781910797457 chp8                                    0.114723  \n",
       "9781910797815 chp7                                    0.107843  \n",
       "9783318066685 ch4                                     0.090756  \n",
       "9781908541680 ch_4                                    0.091371  "
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evaluate_model(df_test, 'allenai/led-base-16384')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>bullets</th>\n",
       "      <th>summary_allenai/led-large-16384</th>\n",
       "      <th>rouge1_precision_allenai/led-large-16384</th>\n",
       "      <th>rouge1_recall_allenai/led-large-16384</th>\n",
       "      <th>rouge1_fmeasure_allenai/led-large-16384</th>\n",
       "      <th>rouge2_precision_allenai/led-large-16384</th>\n",
       "      <th>rouge2_recall_allenai/led-large-16384</th>\n",
       "      <th>rouge2_fmeasure_allenai/led-large-16384</th>\n",
       "      <th>rougeL_precision_allenai/led-large-16384</th>\n",
       "      <th>rougeL_recall_allenai/led-large-16384</th>\n",
       "      <th>rougeL_fmeasure_allenai/led-large-16384</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>book</th>\n",
       "      <th>chapter</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>9783318068207</th>\n",
       "      <th>hh-7</th>\n",
       "      <td>Non-small cell lung cancer\\nLung cancer is the...</td>\n",
       "      <td>The molecular status of, at least, EGFR, ALK, ...</td>\n",
       "      <td>asease. A high number of mutations. A mutation...</td>\n",
       "      <td>0.397260</td>\n",
       "      <td>0.094463</td>\n",
       "      <td>0.152632</td>\n",
       "      <td>0.041667</td>\n",
       "      <td>0.009804</td>\n",
       "      <td>0.015873</td>\n",
       "      <td>0.232877</td>\n",
       "      <td>0.055375</td>\n",
       "      <td>0.089474</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797631</th>\n",
       "      <th>chp6</th>\n",
       "      <td>Prevention and management\\nBy far the most res...</td>\n",
       "      <td>The treatment rather than the prevention of de...</td>\n",
       "      <td>--- I I I I I and I I, I I I I ( I,,,,s, I,,-,...</td>\n",
       "      <td>0.130531</td>\n",
       "      <td>0.343023</td>\n",
       "      <td>0.189103</td>\n",
       "      <td>0.028825</td>\n",
       "      <td>0.076023</td>\n",
       "      <td>0.041801</td>\n",
       "      <td>0.101770</td>\n",
       "      <td>0.267442</td>\n",
       "      <td>0.147436</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797426</th>\n",
       "      <th>ch03</th>\n",
       "      <td>Diseases of the gallbladder\\nEtiology and path...</td>\n",
       "      <td>The prevalence of gallstones is greater in peo...</td>\n",
       "      <td>DDiagnosis and treatment. Acalculous and progn...</td>\n",
       "      <td>0.239554</td>\n",
       "      <td>0.671875</td>\n",
       "      <td>0.353183</td>\n",
       "      <td>0.097765</td>\n",
       "      <td>0.275591</td>\n",
       "      <td>0.144330</td>\n",
       "      <td>0.130919</td>\n",
       "      <td>0.367188</td>\n",
       "      <td>0.193018</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541277</th>\n",
       "      <th>ch_12</th>\n",
       "      <td>Quality of life\\nPsychiatric comorbidities\\nNe...</td>\n",
       "      <td>Depression and anxiety are common in patients ...</td>\n",
       "      <td>QualityQuality of lifeHygiene HygieneHygieneHy...</td>\n",
       "      <td>0.014286</td>\n",
       "      <td>0.006711</td>\n",
       "      <td>0.009132</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.014286</td>\n",
       "      <td>0.006711</td>\n",
       "      <td>0.009132</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797907</th>\n",
       "      <th>chp6</th>\n",
       "      <td>Supportive treatment\\nAt present, the main foc...</td>\n",
       "      <td>The burden of transfusions in pyruvate kinase ...</td>\n",
       "      <td>Support. In these cases, the risk of splenecto...</td>\n",
       "      <td>0.229917</td>\n",
       "      <td>0.633588</td>\n",
       "      <td>0.337398</td>\n",
       "      <td>0.072222</td>\n",
       "      <td>0.200000</td>\n",
       "      <td>0.106122</td>\n",
       "      <td>0.119114</td>\n",
       "      <td>0.328244</td>\n",
       "      <td>0.174797</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541277</th>\n",
       "      <th>ch_8</th>\n",
       "      <td>Antiepileptic drugs\\nEstablished antiepileptic...</td>\n",
       "      <td>Sixteen new antiepileptic drugs (AEDs) have be...</td>\n",
       "      <td>DDosage. Dosing should be increased and the am...</td>\n",
       "      <td>0.063830</td>\n",
       "      <td>0.461538</td>\n",
       "      <td>0.112150</td>\n",
       "      <td>0.010667</td>\n",
       "      <td>0.078431</td>\n",
       "      <td>0.018779</td>\n",
       "      <td>0.039894</td>\n",
       "      <td>0.288462</td>\n",
       "      <td>0.070093</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797006</th>\n",
       "      <th>ch08</th>\n",
       "      <td>Acute exacerbations\\nAcute exacerbations of ch...</td>\n",
       "      <td>Acute exacerbations of COPD are common and pla...</td>\n",
       "      <td>Ac exacerbations of COPD exacerbations in COPD...</td>\n",
       "      <td>0.134211</td>\n",
       "      <td>0.573034</td>\n",
       "      <td>0.217484</td>\n",
       "      <td>0.052770</td>\n",
       "      <td>0.227273</td>\n",
       "      <td>0.085653</td>\n",
       "      <td>0.071053</td>\n",
       "      <td>0.303371</td>\n",
       "      <td>0.115139</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch06</th>\n",
       "      <td>Neuroanatomy and structural imaging\\nOur knowl...</td>\n",
       "      <td>People with schizophrenia exhibit gray matter ...</td>\n",
       "      <td>NeNeveNeveNevevevevevegevevevevegstststststtst...</td>\n",
       "      <td>0.164706</td>\n",
       "      <td>0.543689</td>\n",
       "      <td>0.252822</td>\n",
       "      <td>0.056047</td>\n",
       "      <td>0.186275</td>\n",
       "      <td>0.086168</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>0.330097</td>\n",
       "      <td>0.153499</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9783318068207</th>\n",
       "      <th>hh-5</th>\n",
       "      <td>The recent improvements in terms of available ...</td>\n",
       "      <td>Comprehensive genomic profiles offer a complet...</td>\n",
       "      <td>,, the number of nucleotide and the number and...</td>\n",
       "      <td>0.183463</td>\n",
       "      <td>0.581967</td>\n",
       "      <td>0.278978</td>\n",
       "      <td>0.049223</td>\n",
       "      <td>0.157025</td>\n",
       "      <td>0.074951</td>\n",
       "      <td>0.090439</td>\n",
       "      <td>0.286885</td>\n",
       "      <td>0.137525</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch04</th>\n",
       "      <td>The biggest single clue we have about the caus...</td>\n",
       "      <td>Having a close relative with schizophrenia inc...</td>\n",
       "      <td>TheAnd so on.How to look for genes in the gene...</td>\n",
       "      <td>0.085919</td>\n",
       "      <td>0.507042</td>\n",
       "      <td>0.146939</td>\n",
       "      <td>0.009569</td>\n",
       "      <td>0.057143</td>\n",
       "      <td>0.016393</td>\n",
       "      <td>0.045346</td>\n",
       "      <td>0.267606</td>\n",
       "      <td>0.077551</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797006</th>\n",
       "      <th>ch03</th>\n",
       "      <td>Clinical features\\nThe characteristic symptom ...</td>\n",
       "      <td>COPD occurs, though less commonly, in those wh...</td>\n",
       "      <td>,, and the presence of the presence of these s...</td>\n",
       "      <td>0.209756</td>\n",
       "      <td>0.497110</td>\n",
       "      <td>0.295026</td>\n",
       "      <td>0.053790</td>\n",
       "      <td>0.127907</td>\n",
       "      <td>0.075731</td>\n",
       "      <td>0.090244</td>\n",
       "      <td>0.213873</td>\n",
       "      <td>0.126930</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541406</th>\n",
       "      <th>ch_6</th>\n",
       "      <td>Platelet disorders\\nPlatelet function defects\\...</td>\n",
       "      <td>Thrombocytopenia may occur with some inherited...</td>\n",
       "      <td>DiDiagnosis. The diagnosis of the platelet cou...</td>\n",
       "      <td>0.169184</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.252822</td>\n",
       "      <td>0.054545</td>\n",
       "      <td>0.162162</td>\n",
       "      <td>0.081633</td>\n",
       "      <td>0.087613</td>\n",
       "      <td>0.258929</td>\n",
       "      <td>0.130926</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541277</th>\n",
       "      <th>ch_6</th>\n",
       "      <td>The diagnosis of epilepsy relies on the correc...</td>\n",
       "      <td>Epilepsy has many underlying etiologies.\\nA wi...</td>\n",
       "      <td>Theatheatheatheatheatheveeveveeveeveveveveevev...</td>\n",
       "      <td>0.042553</td>\n",
       "      <td>0.108696</td>\n",
       "      <td>0.061162</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.038298</td>\n",
       "      <td>0.097826</td>\n",
       "      <td>0.055046</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797815</th>\n",
       "      <th>chp3</th>\n",
       "      <td>Diagnosis and disease burden\\nAccurate diagnos...</td>\n",
       "      <td>The World Health Organization diagnostic crite...</td>\n",
       "      <td>DiDi.Diagnosis.Diagnosis and prognosis of MPNs...</td>\n",
       "      <td>0.311170</td>\n",
       "      <td>0.676301</td>\n",
       "      <td>0.426230</td>\n",
       "      <td>0.168000</td>\n",
       "      <td>0.366279</td>\n",
       "      <td>0.230347</td>\n",
       "      <td>0.167553</td>\n",
       "      <td>0.364162</td>\n",
       "      <td>0.229508</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797310</th>\n",
       "      <th>chp3</th>\n",
       "      <td>Staging and surgery\\nIlaria Onorati MD and Ola...</td>\n",
       "      <td>Better subclassification of early-stage NSCLC ...</td>\n",
       "      <td>StStaging and prognosis of lung cancer and pro...</td>\n",
       "      <td>0.099715</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>0.160550</td>\n",
       "      <td>0.017143</td>\n",
       "      <td>0.071429</td>\n",
       "      <td>0.027650</td>\n",
       "      <td>0.059829</td>\n",
       "      <td>0.247059</td>\n",
       "      <td>0.096330</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797426</th>\n",
       "      <th>ch12</th>\n",
       "      <td>Unusual tumors of the pancreas and ampulla of ...</td>\n",
       "      <td>Tumor types that occur in the ampullary and pe...</td>\n",
       "      <td>al cystic cystic pancreatic neoplasms. The ris...</td>\n",
       "      <td>0.149701</td>\n",
       "      <td>0.568182</td>\n",
       "      <td>0.236967</td>\n",
       "      <td>0.051051</td>\n",
       "      <td>0.195402</td>\n",
       "      <td>0.080952</td>\n",
       "      <td>0.074850</td>\n",
       "      <td>0.284091</td>\n",
       "      <td>0.118483</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541024</th>\n",
       "      <th>ch_13</th>\n",
       "      <td>Geriatric neuro-oncology\\nAlthough half of all...</td>\n",
       "      <td>Pathological diagnosis is critical to select a...</td>\n",
       "      <td>GerGlioblastoma. Several studies have shown th...</td>\n",
       "      <td>0.120205</td>\n",
       "      <td>0.758065</td>\n",
       "      <td>0.207506</td>\n",
       "      <td>0.046154</td>\n",
       "      <td>0.295082</td>\n",
       "      <td>0.079823</td>\n",
       "      <td>0.066496</td>\n",
       "      <td>0.419355</td>\n",
       "      <td>0.114790</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797617</th>\n",
       "      <th>chp6</th>\n",
       "      <td>Research directions\\nThe expanded genetic char...</td>\n",
       "      <td>A wide range of targeted agencies for the trea...</td>\n",
       "      <td>becausebecause of a new era for clinical trial...</td>\n",
       "      <td>0.261324</td>\n",
       "      <td>0.423729</td>\n",
       "      <td>0.323276</td>\n",
       "      <td>0.052448</td>\n",
       "      <td>0.085227</td>\n",
       "      <td>0.064935</td>\n",
       "      <td>0.114983</td>\n",
       "      <td>0.186441</td>\n",
       "      <td>0.142241</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541994</th>\n",
       "      <th>ch02</th>\n",
       "      <td>Pathophysiology, etiology and modifying factor...</td>\n",
       "      <td>Acne is a hormonally mediated disease.\\nFour m...</td>\n",
       "      <td>PathPathophysiologyFollicular hyperkeratinizat...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797471</th>\n",
       "      <th>ch05</th>\n",
       "      <td>Case history\\nA 67-year-old man with diabetes ...</td>\n",
       "      <td>Assessment of functional class, based on exerc...</td>\n",
       "      <td>TableTable 5.1 provides an overview of the evi...</td>\n",
       "      <td>0.178571</td>\n",
       "      <td>0.515873</td>\n",
       "      <td>0.265306</td>\n",
       "      <td>0.041322</td>\n",
       "      <td>0.120000</td>\n",
       "      <td>0.061475</td>\n",
       "      <td>0.096154</td>\n",
       "      <td>0.277778</td>\n",
       "      <td>0.142857</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch08</th>\n",
       "      <td>Neurochemical abnormalities, including changes...</td>\n",
       "      <td>The dopamine hypothesis remains the major neur...</td>\n",
       "      <td>NeDopamine. Glutamate is the major excitatory ...</td>\n",
       "      <td>0.120513</td>\n",
       "      <td>0.643836</td>\n",
       "      <td>0.203024</td>\n",
       "      <td>0.053985</td>\n",
       "      <td>0.291667</td>\n",
       "      <td>0.091106</td>\n",
       "      <td>0.087179</td>\n",
       "      <td>0.465753</td>\n",
       "      <td>0.146868</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781912776207</th>\n",
       "      <th>ch4</th>\n",
       "      <td>Accurate diagnosis and subtyping of PTCL is ch...</td>\n",
       "      <td>Many patients with aggressive T-cell lymphomas...</td>\n",
       "      <td>DiDiDiDiDiGiGiGiGiGiDiGiGiGiGGiGiGiGiGiGiGiGiG...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797495</th>\n",
       "      <th>chp12</th>\n",
       "      <td>Headache is a common complaint in the general ...</td>\n",
       "      <td>In patients without history of chronic headach...</td>\n",
       "      <td>Headache and neck and neck and head and head a...</td>\n",
       "      <td>0.107500</td>\n",
       "      <td>0.477778</td>\n",
       "      <td>0.175510</td>\n",
       "      <td>0.025063</td>\n",
       "      <td>0.112360</td>\n",
       "      <td>0.040984</td>\n",
       "      <td>0.072500</td>\n",
       "      <td>0.322222</td>\n",
       "      <td>0.118367</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781912776726</th>\n",
       "      <th>ch2</th>\n",
       "      <td>Clinical presentation\\nMost patients with glio...</td>\n",
       "      <td>The signs and symptoms of glioblastoma result ...</td>\n",
       "      <td>ClClinical presentation.Clinical presentation ...</td>\n",
       "      <td>0.290323</td>\n",
       "      <td>0.613636</td>\n",
       "      <td>0.394161</td>\n",
       "      <td>0.080863</td>\n",
       "      <td>0.171429</td>\n",
       "      <td>0.109890</td>\n",
       "      <td>0.120968</td>\n",
       "      <td>0.255682</td>\n",
       "      <td>0.164234</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797815</th>\n",
       "      <th>chp2</th>\n",
       "      <td>The myeloproliferative neoplasms (MPNs) are ra...</td>\n",
       "      <td>The incidence of the myeloproliferative neopla...</td>\n",
       "      <td>TheThe myeloproliferative neoplasms (,,,, to,,...</td>\n",
       "      <td>0.072046</td>\n",
       "      <td>0.206612</td>\n",
       "      <td>0.106838</td>\n",
       "      <td>0.008671</td>\n",
       "      <td>0.025000</td>\n",
       "      <td>0.012876</td>\n",
       "      <td>0.051873</td>\n",
       "      <td>0.148760</td>\n",
       "      <td>0.076923</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797433</th>\n",
       "      <th>ch05</th>\n",
       "      <td>Surgery is the cornerstone of management for b...</td>\n",
       "      <td>Surgery is one of the cornerstones of treatmen...</td>\n",
       "      <td>Sur. The largest multicenter analysis of terti...</td>\n",
       "      <td>0.176020</td>\n",
       "      <td>0.676471</td>\n",
       "      <td>0.279352</td>\n",
       "      <td>0.043478</td>\n",
       "      <td>0.168317</td>\n",
       "      <td>0.069106</td>\n",
       "      <td>0.091837</td>\n",
       "      <td>0.352941</td>\n",
       "      <td>0.145749</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797617</th>\n",
       "      <th>chp1</th>\n",
       "      <td>Epidemiology, pathophysiology and etiology\\nAc...</td>\n",
       "      <td>Acute myeloid leukemia (AML) is a relatively r...</td>\n",
       "      <td>EpEp.Epidemiology and pathophysiology of AML i...</td>\n",
       "      <td>0.247368</td>\n",
       "      <td>0.576687</td>\n",
       "      <td>0.346225</td>\n",
       "      <td>0.089710</td>\n",
       "      <td>0.209877</td>\n",
       "      <td>0.125693</td>\n",
       "      <td>0.113158</td>\n",
       "      <td>0.263804</td>\n",
       "      <td>0.158379</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541963</th>\n",
       "      <th>chapter3</th>\n",
       "      <td>Alcoholic liver disease\\nAlcoholic liver disea...</td>\n",
       "      <td>Alcoholic liver disease (ALD) is a common caus...</td>\n",
       "      <td>Al. Diagnosis and treatment for patients with ...</td>\n",
       "      <td>0.092417</td>\n",
       "      <td>0.629032</td>\n",
       "      <td>0.161157</td>\n",
       "      <td>0.021378</td>\n",
       "      <td>0.147541</td>\n",
       "      <td>0.037344</td>\n",
       "      <td>0.056872</td>\n",
       "      <td>0.387097</td>\n",
       "      <td>0.099174</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541796</th>\n",
       "      <th>chapter1</th>\n",
       "      <td>Lymphoma is a malignancy of lymphocytes and th...</td>\n",
       "      <td>The epidemiology of lymphoma is difficult to s...</td>\n",
       "      <td>LLymphoma.Lymphoma is the most common form of ...</td>\n",
       "      <td>0.102837</td>\n",
       "      <td>0.233871</td>\n",
       "      <td>0.142857</td>\n",
       "      <td>0.021352</td>\n",
       "      <td>0.048780</td>\n",
       "      <td>0.029703</td>\n",
       "      <td>0.088652</td>\n",
       "      <td>0.201613</td>\n",
       "      <td>0.123153</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541963</th>\n",
       "      <th>chapter5</th>\n",
       "      <td>Autoimmune liver diseases\\nThree liver disease...</td>\n",
       "      <td>Autoimmune liver disease can target the hepato...</td>\n",
       "      <td>Autoimmune. The characteristic autoantibodies ...</td>\n",
       "      <td>0.141643</td>\n",
       "      <td>0.602410</td>\n",
       "      <td>0.229358</td>\n",
       "      <td>0.039773</td>\n",
       "      <td>0.170732</td>\n",
       "      <td>0.064516</td>\n",
       "      <td>0.076487</td>\n",
       "      <td>0.325301</td>\n",
       "      <td>0.123853</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797907</th>\n",
       "      <th>chp2</th>\n",
       "      <td>Epidemiology and etiology\\nDespite being the b...</td>\n",
       "      <td>Gaps remain in our understanding of the epidem...</td>\n",
       "      <td>EpEp.Ep.Ep---h.Ep--h. Ep--h.m.Ep-h.1-h.1.1.1) ...</td>\n",
       "      <td>0.004854</td>\n",
       "      <td>0.013514</td>\n",
       "      <td>0.007143</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.004854</td>\n",
       "      <td>0.013514</td>\n",
       "      <td>0.007143</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541666</th>\n",
       "      <th>ch_13</th>\n",
       "      <td>Pregnancy and diabetes\\nDiabetic pregnancy is ...</td>\n",
       "      <td>Diabetic pregnancy is associated with fetal mo...</td>\n",
       "      <td>P. Pregnancy may be diagnosed in the first wee...</td>\n",
       "      <td>0.094527</td>\n",
       "      <td>0.463415</td>\n",
       "      <td>0.157025</td>\n",
       "      <td>0.012469</td>\n",
       "      <td>0.061728</td>\n",
       "      <td>0.020747</td>\n",
       "      <td>0.052239</td>\n",
       "      <td>0.256098</td>\n",
       "      <td>0.086777</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781912776153</th>\n",
       "      <th>chp3</th>\n",
       "      <td>Syncope is a significant healthcare problem, r...</td>\n",
       "      <td>Syncope is defined as a total loss of consciou...</td>\n",
       "      <td>Syncope is defined as a total loss of consciou...</td>\n",
       "      <td>0.273657</td>\n",
       "      <td>0.611429</td>\n",
       "      <td>0.378092</td>\n",
       "      <td>0.130769</td>\n",
       "      <td>0.293103</td>\n",
       "      <td>0.180851</td>\n",
       "      <td>0.184143</td>\n",
       "      <td>0.411429</td>\n",
       "      <td>0.254417</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541468</th>\n",
       "      <th>ch_14</th>\n",
       "      <td>Renal replacement therapy and transplantation\\...</td>\n",
       "      <td>Not all patients with end-stage kidney disease...</td>\n",
       "      <td>Dialysis is the most common method of peritone...</td>\n",
       "      <td>0.114286</td>\n",
       "      <td>0.407407</td>\n",
       "      <td>0.178499</td>\n",
       "      <td>0.020833</td>\n",
       "      <td>0.074766</td>\n",
       "      <td>0.032587</td>\n",
       "      <td>0.054545</td>\n",
       "      <td>0.194444</td>\n",
       "      <td>0.085193</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797662</th>\n",
       "      <th>ch09</th>\n",
       "      <td>Future trends\\nThe mortality and morbidity of ...</td>\n",
       "      <td>Public health preventative measures are likely...</td>\n",
       "      <td>Future developments in this area will be based...</td>\n",
       "      <td>0.146520</td>\n",
       "      <td>0.404040</td>\n",
       "      <td>0.215054</td>\n",
       "      <td>0.014706</td>\n",
       "      <td>0.040816</td>\n",
       "      <td>0.021622</td>\n",
       "      <td>0.091575</td>\n",
       "      <td>0.252525</td>\n",
       "      <td>0.134409</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797211</th>\n",
       "      <th>ch04</th>\n",
       "      <td>Drug treatment\\nThe first drugs used to treat ...</td>\n",
       "      <td>Levodopa restores the dopamine lost due to deg...</td>\n",
       "      <td>DDopopopopoponoponopoponopinoponopopinopinopin...</td>\n",
       "      <td>0.326409</td>\n",
       "      <td>0.421456</td>\n",
       "      <td>0.367893</td>\n",
       "      <td>0.080357</td>\n",
       "      <td>0.103846</td>\n",
       "      <td>0.090604</td>\n",
       "      <td>0.139466</td>\n",
       "      <td>0.180077</td>\n",
       "      <td>0.157191</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541727</th>\n",
       "      <th>ch03</th>\n",
       "      <td>Blurred vision\\nThe most common causes of blur...</td>\n",
       "      <td>Most patients with blurred vision have benign,...</td>\n",
       "      <td>BlBlurred vision. Patients complain of sudden ...</td>\n",
       "      <td>0.178571</td>\n",
       "      <td>0.507246</td>\n",
       "      <td>0.264151</td>\n",
       "      <td>0.061381</td>\n",
       "      <td>0.175182</td>\n",
       "      <td>0.090909</td>\n",
       "      <td>0.081633</td>\n",
       "      <td>0.231884</td>\n",
       "      <td>0.120755</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9783318068207</th>\n",
       "      <th>hh-8</th>\n",
       "      <td>Preparing high-quality samples\\nIn the era of ...</td>\n",
       "      <td>Different sample types (histological or cytolo...</td>\n",
       "      <td>Prep. In this setting, NGS NGS analysis should...</td>\n",
       "      <td>0.067751</td>\n",
       "      <td>0.446429</td>\n",
       "      <td>0.117647</td>\n",
       "      <td>0.005435</td>\n",
       "      <td>0.036364</td>\n",
       "      <td>0.009456</td>\n",
       "      <td>0.040650</td>\n",
       "      <td>0.267857</td>\n",
       "      <td>0.070588</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541024</th>\n",
       "      <th>ch_12</th>\n",
       "      <td>Brain tumor syndromes and tumor-like cysts\\nFa...</td>\n",
       "      <td>There are several syndromes associated with an...</td>\n",
       "      <td>11.1)¯¯¯¯Neurofibromatosis is an autosomal dom...</td>\n",
       "      <td>0.195402</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.280992</td>\n",
       "      <td>0.031700</td>\n",
       "      <td>0.081481</td>\n",
       "      <td>0.045643</td>\n",
       "      <td>0.097701</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.140496</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797105</th>\n",
       "      <th>ch05</th>\n",
       "      <td>Developmental theories and environmental facto...</td>\n",
       "      <td>Early neurodevelopmental, non-genetic risk fac...</td>\n",
       "      <td>Develop. Delta-9-9-THC, the active component o...</td>\n",
       "      <td>0.112299</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.192220</td>\n",
       "      <td>0.029491</td>\n",
       "      <td>0.177419</td>\n",
       "      <td>0.050575</td>\n",
       "      <td>0.053476</td>\n",
       "      <td>0.317460</td>\n",
       "      <td>0.091533</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541420</th>\n",
       "      <th>ch_6</th>\n",
       "      <td>Successful asthma management will achieve both...</td>\n",
       "      <td>Drugs used in the management of asthma can be ...</td>\n",
       "      <td>oconobserve. The use of inhaled corticosteroid...</td>\n",
       "      <td>0.172872</td>\n",
       "      <td>0.555556</td>\n",
       "      <td>0.263692</td>\n",
       "      <td>0.050667</td>\n",
       "      <td>0.163793</td>\n",
       "      <td>0.077393</td>\n",
       "      <td>0.077128</td>\n",
       "      <td>0.247863</td>\n",
       "      <td>0.117647</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541680</th>\n",
       "      <th>ch_8</th>\n",
       "      <td>Management: behavioral therapy\\nBehavioral the...</td>\n",
       "      <td>Behavioral therapy, alongside diet and lifesty...</td>\n",
       "      <td>Management of the management of the condition ...</td>\n",
       "      <td>0.070423</td>\n",
       "      <td>0.566038</td>\n",
       "      <td>0.125261</td>\n",
       "      <td>0.018824</td>\n",
       "      <td>0.153846</td>\n",
       "      <td>0.033543</td>\n",
       "      <td>0.046948</td>\n",
       "      <td>0.377358</td>\n",
       "      <td>0.083507</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797457</th>\n",
       "      <th>chp8</th>\n",
       "      <td>Management of castrate-resistant prostate canc...</td>\n",
       "      <td>After an initial response to androgen ablation...</td>\n",
       "      <td>Management of CRPC. Hormone-naïve CRPC. Treatm...</td>\n",
       "      <td>0.240437</td>\n",
       "      <td>0.556962</td>\n",
       "      <td>0.335878</td>\n",
       "      <td>0.052055</td>\n",
       "      <td>0.121019</td>\n",
       "      <td>0.072797</td>\n",
       "      <td>0.090164</td>\n",
       "      <td>0.208861</td>\n",
       "      <td>0.125954</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781910797815</th>\n",
       "      <th>chp7</th>\n",
       "      <td>New treatments for myeloproliferative neoplasm...</td>\n",
       "      <td>A variety of new therapies directed against di...</td>\n",
       "      <td>NewNew-New-New-Mammalgamalgamalgamatic-mammalg...</td>\n",
       "      <td>0.109718</td>\n",
       "      <td>0.492958</td>\n",
       "      <td>0.179487</td>\n",
       "      <td>0.031447</td>\n",
       "      <td>0.142857</td>\n",
       "      <td>0.051546</td>\n",
       "      <td>0.062696</td>\n",
       "      <td>0.281690</td>\n",
       "      <td>0.102564</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9783318066685</th>\n",
       "      <th>ch4</th>\n",
       "      <td>4 Gene therapies with proven clinical efficacy...</td>\n",
       "      <td>Gene therapy, using gene-modified cells or in ...</td>\n",
       "      <td>strand other diseases. The disease is caused b...</td>\n",
       "      <td>0.192308</td>\n",
       "      <td>0.476190</td>\n",
       "      <td>0.273973</td>\n",
       "      <td>0.038554</td>\n",
       "      <td>0.095808</td>\n",
       "      <td>0.054983</td>\n",
       "      <td>0.100962</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.143836</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9781908541680</th>\n",
       "      <th>ch_4</th>\n",
       "      <td>Cardiometabolic consequences\\nOverweight/obesi...</td>\n",
       "      <td>Obesity significantly affects cardiometabolic ...</td>\n",
       "      <td>InsInsulin is the most common type of diabetes...</td>\n",
       "      <td>0.135417</td>\n",
       "      <td>0.634146</td>\n",
       "      <td>0.223176</td>\n",
       "      <td>0.031332</td>\n",
       "      <td>0.148148</td>\n",
       "      <td>0.051724</td>\n",
       "      <td>0.067708</td>\n",
       "      <td>0.317073</td>\n",
       "      <td>0.111588</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                     text  \\\n",
       "book          chapter                                                       \n",
       "9783318068207 hh-7      Non-small cell lung cancer\\nLung cancer is the...   \n",
       "9781910797631 chp6      Prevention and management\\nBy far the most res...   \n",
       "9781910797426 ch03      Diseases of the gallbladder\\nEtiology and path...   \n",
       "9781908541277 ch_12     Quality of life\\nPsychiatric comorbidities\\nNe...   \n",
       "9781910797907 chp6      Supportive treatment\\nAt present, the main foc...   \n",
       "9781908541277 ch_8      Antiepileptic drugs\\nEstablished antiepileptic...   \n",
       "9781910797006 ch08      Acute exacerbations\\nAcute exacerbations of ch...   \n",
       "9781910797105 ch06      Neuroanatomy and structural imaging\\nOur knowl...   \n",
       "9783318068207 hh-5      The recent improvements in terms of available ...   \n",
       "9781910797105 ch04      The biggest single clue we have about the caus...   \n",
       "9781910797006 ch03      Clinical features\\nThe characteristic symptom ...   \n",
       "9781908541406 ch_6      Platelet disorders\\nPlatelet function defects\\...   \n",
       "9781908541277 ch_6      The diagnosis of epilepsy relies on the correc...   \n",
       "9781910797815 chp3      Diagnosis and disease burden\\nAccurate diagnos...   \n",
       "9781910797310 chp3      Staging and surgery\\nIlaria Onorati MD and Ola...   \n",
       "9781910797426 ch12      Unusual tumors of the pancreas and ampulla of ...   \n",
       "9781908541024 ch_13     Geriatric neuro-oncology\\nAlthough half of all...   \n",
       "9781910797617 chp6      Research directions\\nThe expanded genetic char...   \n",
       "9781908541994 ch02      Pathophysiology, etiology and modifying factor...   \n",
       "9781910797471 ch05      Case history\\nA 67-year-old man with diabetes ...   \n",
       "9781910797105 ch08      Neurochemical abnormalities, including changes...   \n",
       "9781912776207 ch4       Accurate diagnosis and subtyping of PTCL is ch...   \n",
       "9781910797495 chp12     Headache is a common complaint in the general ...   \n",
       "9781912776726 ch2       Clinical presentation\\nMost patients with glio...   \n",
       "9781910797815 chp2      The myeloproliferative neoplasms (MPNs) are ra...   \n",
       "9781910797433 ch05      Surgery is the cornerstone of management for b...   \n",
       "9781910797617 chp1      Epidemiology, pathophysiology and etiology\\nAc...   \n",
       "9781908541963 chapter3  Alcoholic liver disease\\nAlcoholic liver disea...   \n",
       "9781908541796 chapter1  Lymphoma is a malignancy of lymphocytes and th...   \n",
       "9781908541963 chapter5  Autoimmune liver diseases\\nThree liver disease...   \n",
       "9781910797907 chp2      Epidemiology and etiology\\nDespite being the b...   \n",
       "9781908541666 ch_13     Pregnancy and diabetes\\nDiabetic pregnancy is ...   \n",
       "9781912776153 chp3      Syncope is a significant healthcare problem, r...   \n",
       "9781908541468 ch_14     Renal replacement therapy and transplantation\\...   \n",
       "9781910797662 ch09      Future trends\\nThe mortality and morbidity of ...   \n",
       "9781910797211 ch04      Drug treatment\\nThe first drugs used to treat ...   \n",
       "9781908541727 ch03      Blurred vision\\nThe most common causes of blur...   \n",
       "9783318068207 hh-8      Preparing high-quality samples\\nIn the era of ...   \n",
       "9781908541024 ch_12     Brain tumor syndromes and tumor-like cysts\\nFa...   \n",
       "9781910797105 ch05      Developmental theories and environmental facto...   \n",
       "9781908541420 ch_6      Successful asthma management will achieve both...   \n",
       "9781908541680 ch_8      Management: behavioral therapy\\nBehavioral the...   \n",
       "9781910797457 chp8      Management of castrate-resistant prostate canc...   \n",
       "9781910797815 chp7      New treatments for myeloproliferative neoplasm...   \n",
       "9783318066685 ch4       4 Gene therapies with proven clinical efficacy...   \n",
       "9781908541680 ch_4      Cardiometabolic consequences\\nOverweight/obesi...   \n",
       "\n",
       "                                                                  bullets  \\\n",
       "book          chapter                                                       \n",
       "9783318068207 hh-7      The molecular status of, at least, EGFR, ALK, ...   \n",
       "9781910797631 chp6      The treatment rather than the prevention of de...   \n",
       "9781910797426 ch03      The prevalence of gallstones is greater in peo...   \n",
       "9781908541277 ch_12     Depression and anxiety are common in patients ...   \n",
       "9781910797907 chp6      The burden of transfusions in pyruvate kinase ...   \n",
       "9781908541277 ch_8      Sixteen new antiepileptic drugs (AEDs) have be...   \n",
       "9781910797006 ch08      Acute exacerbations of COPD are common and pla...   \n",
       "9781910797105 ch06      People with schizophrenia exhibit gray matter ...   \n",
       "9783318068207 hh-5      Comprehensive genomic profiles offer a complet...   \n",
       "9781910797105 ch04      Having a close relative with schizophrenia inc...   \n",
       "9781910797006 ch03      COPD occurs, though less commonly, in those wh...   \n",
       "9781908541406 ch_6      Thrombocytopenia may occur with some inherited...   \n",
       "9781908541277 ch_6      Epilepsy has many underlying etiologies.\\nA wi...   \n",
       "9781910797815 chp3      The World Health Organization diagnostic crite...   \n",
       "9781910797310 chp3      Better subclassification of early-stage NSCLC ...   \n",
       "9781910797426 ch12      Tumor types that occur in the ampullary and pe...   \n",
       "9781908541024 ch_13     Pathological diagnosis is critical to select a...   \n",
       "9781910797617 chp6      A wide range of targeted agencies for the trea...   \n",
       "9781908541994 ch02      Acne is a hormonally mediated disease.\\nFour m...   \n",
       "9781910797471 ch05      Assessment of functional class, based on exerc...   \n",
       "9781910797105 ch08      The dopamine hypothesis remains the major neur...   \n",
       "9781912776207 ch4       Many patients with aggressive T-cell lymphomas...   \n",
       "9781910797495 chp12     In patients without history of chronic headach...   \n",
       "9781912776726 ch2       The signs and symptoms of glioblastoma result ...   \n",
       "9781910797815 chp2      The incidence of the myeloproliferative neopla...   \n",
       "9781910797433 ch05      Surgery is one of the cornerstones of treatmen...   \n",
       "9781910797617 chp1      Acute myeloid leukemia (AML) is a relatively r...   \n",
       "9781908541963 chapter3  Alcoholic liver disease (ALD) is a common caus...   \n",
       "9781908541796 chapter1  The epidemiology of lymphoma is difficult to s...   \n",
       "9781908541963 chapter5  Autoimmune liver disease can target the hepato...   \n",
       "9781910797907 chp2      Gaps remain in our understanding of the epidem...   \n",
       "9781908541666 ch_13     Diabetic pregnancy is associated with fetal mo...   \n",
       "9781912776153 chp3      Syncope is defined as a total loss of consciou...   \n",
       "9781908541468 ch_14     Not all patients with end-stage kidney disease...   \n",
       "9781910797662 ch09      Public health preventative measures are likely...   \n",
       "9781910797211 ch04      Levodopa restores the dopamine lost due to deg...   \n",
       "9781908541727 ch03      Most patients with blurred vision have benign,...   \n",
       "9783318068207 hh-8      Different sample types (histological or cytolo...   \n",
       "9781908541024 ch_12     There are several syndromes associated with an...   \n",
       "9781910797105 ch05      Early neurodevelopmental, non-genetic risk fac...   \n",
       "9781908541420 ch_6      Drugs used in the management of asthma can be ...   \n",
       "9781908541680 ch_8      Behavioral therapy, alongside diet and lifesty...   \n",
       "9781910797457 chp8      After an initial response to androgen ablation...   \n",
       "9781910797815 chp7      A variety of new therapies directed against di...   \n",
       "9783318066685 ch4       Gene therapy, using gene-modified cells or in ...   \n",
       "9781908541680 ch_4      Obesity significantly affects cardiometabolic ...   \n",
       "\n",
       "                                          summary_allenai/led-large-16384  \\\n",
       "book          chapter                                                       \n",
       "9783318068207 hh-7      asease. A high number of mutations. A mutation...   \n",
       "9781910797631 chp6      --- I I I I I and I I, I I I I ( I,,,,s, I,,-,...   \n",
       "9781910797426 ch03      DDiagnosis and treatment. Acalculous and progn...   \n",
       "9781908541277 ch_12     QualityQuality of lifeHygiene HygieneHygieneHy...   \n",
       "9781910797907 chp6      Support. In these cases, the risk of splenecto...   \n",
       "9781908541277 ch_8      DDosage. Dosing should be increased and the am...   \n",
       "9781910797006 ch08      Ac exacerbations of COPD exacerbations in COPD...   \n",
       "9781910797105 ch06      NeNeveNeveNevevevevevegevevevevegstststststtst...   \n",
       "9783318068207 hh-5      ,, the number of nucleotide and the number and...   \n",
       "9781910797105 ch04      TheAnd so on.How to look for genes in the gene...   \n",
       "9781910797006 ch03      ,, and the presence of the presence of these s...   \n",
       "9781908541406 ch_6      DiDiagnosis. The diagnosis of the platelet cou...   \n",
       "9781908541277 ch_6      Theatheatheatheatheatheveeveveeveeveveveveevev...   \n",
       "9781910797815 chp3      DiDi.Diagnosis.Diagnosis and prognosis of MPNs...   \n",
       "9781910797310 chp3      StStaging and prognosis of lung cancer and pro...   \n",
       "9781910797426 ch12      al cystic cystic pancreatic neoplasms. The ris...   \n",
       "9781908541024 ch_13     GerGlioblastoma. Several studies have shown th...   \n",
       "9781910797617 chp6      becausebecause of a new era for clinical trial...   \n",
       "9781908541994 ch02      PathPathophysiologyFollicular hyperkeratinizat...   \n",
       "9781910797471 ch05      TableTable 5.1 provides an overview of the evi...   \n",
       "9781910797105 ch08      NeDopamine. Glutamate is the major excitatory ...   \n",
       "9781912776207 ch4       DiDiDiDiDiGiGiGiGiGiDiGiGiGiGGiGiGiGiGiGiGiGiG...   \n",
       "9781910797495 chp12     Headache and neck and neck and head and head a...   \n",
       "9781912776726 ch2       ClClinical presentation.Clinical presentation ...   \n",
       "9781910797815 chp2      TheThe myeloproliferative neoplasms (,,,, to,,...   \n",
       "9781910797433 ch05      Sur. The largest multicenter analysis of terti...   \n",
       "9781910797617 chp1      EpEp.Epidemiology and pathophysiology of AML i...   \n",
       "9781908541963 chapter3  Al. Diagnosis and treatment for patients with ...   \n",
       "9781908541796 chapter1  LLymphoma.Lymphoma is the most common form of ...   \n",
       "9781908541963 chapter5  Autoimmune. The characteristic autoantibodies ...   \n",
       "9781910797907 chp2      EpEp.Ep.Ep---h.Ep--h. Ep--h.m.Ep-h.1-h.1.1.1) ...   \n",
       "9781908541666 ch_13     P. Pregnancy may be diagnosed in the first wee...   \n",
       "9781912776153 chp3      Syncope is defined as a total loss of consciou...   \n",
       "9781908541468 ch_14     Dialysis is the most common method of peritone...   \n",
       "9781910797662 ch09      Future developments in this area will be based...   \n",
       "9781910797211 ch04      DDopopopopoponoponopoponopinoponopopinopinopin...   \n",
       "9781908541727 ch03      BlBlurred vision. Patients complain of sudden ...   \n",
       "9783318068207 hh-8      Prep. In this setting, NGS NGS analysis should...   \n",
       "9781908541024 ch_12     11.1)¯¯¯¯Neurofibromatosis is an autosomal dom...   \n",
       "9781910797105 ch05      Develop. Delta-9-9-THC, the active component o...   \n",
       "9781908541420 ch_6      oconobserve. The use of inhaled corticosteroid...   \n",
       "9781908541680 ch_8      Management of the management of the condition ...   \n",
       "9781910797457 chp8      Management of CRPC. Hormone-naïve CRPC. Treatm...   \n",
       "9781910797815 chp7      NewNew-New-New-Mammalgamalgamalgamatic-mammalg...   \n",
       "9783318066685 ch4       strand other diseases. The disease is caused b...   \n",
       "9781908541680 ch_4      InsInsulin is the most common type of diabetes...   \n",
       "\n",
       "                        rouge1_precision_allenai/led-large-16384  \\\n",
       "book          chapter                                              \n",
       "9783318068207 hh-7                                      0.397260   \n",
       "9781910797631 chp6                                      0.130531   \n",
       "9781910797426 ch03                                      0.239554   \n",
       "9781908541277 ch_12                                     0.014286   \n",
       "9781910797907 chp6                                      0.229917   \n",
       "9781908541277 ch_8                                      0.063830   \n",
       "9781910797006 ch08                                      0.134211   \n",
       "9781910797105 ch06                                      0.164706   \n",
       "9783318068207 hh-5                                      0.183463   \n",
       "9781910797105 ch04                                      0.085919   \n",
       "9781910797006 ch03                                      0.209756   \n",
       "9781908541406 ch_6                                      0.169184   \n",
       "9781908541277 ch_6                                      0.042553   \n",
       "9781910797815 chp3                                      0.311170   \n",
       "9781910797310 chp3                                      0.099715   \n",
       "9781910797426 ch12                                      0.149701   \n",
       "9781908541024 ch_13                                     0.120205   \n",
       "9781910797617 chp6                                      0.261324   \n",
       "9781908541994 ch02                                      0.000000   \n",
       "9781910797471 ch05                                      0.178571   \n",
       "9781910797105 ch08                                      0.120513   \n",
       "9781912776207 ch4                                       0.000000   \n",
       "9781910797495 chp12                                     0.107500   \n",
       "9781912776726 ch2                                       0.290323   \n",
       "9781910797815 chp2                                      0.072046   \n",
       "9781910797433 ch05                                      0.176020   \n",
       "9781910797617 chp1                                      0.247368   \n",
       "9781908541963 chapter3                                  0.092417   \n",
       "9781908541796 chapter1                                  0.102837   \n",
       "9781908541963 chapter5                                  0.141643   \n",
       "9781910797907 chp2                                      0.004854   \n",
       "9781908541666 ch_13                                     0.094527   \n",
       "9781912776153 chp3                                      0.273657   \n",
       "9781908541468 ch_14                                     0.114286   \n",
       "9781910797662 ch09                                      0.146520   \n",
       "9781910797211 ch04                                      0.326409   \n",
       "9781908541727 ch03                                      0.178571   \n",
       "9783318068207 hh-8                                      0.067751   \n",
       "9781908541024 ch_12                                     0.195402   \n",
       "9781910797105 ch05                                      0.112299   \n",
       "9781908541420 ch_6                                      0.172872   \n",
       "9781908541680 ch_8                                      0.070423   \n",
       "9781910797457 chp8                                      0.240437   \n",
       "9781910797815 chp7                                      0.109718   \n",
       "9783318066685 ch4                                       0.192308   \n",
       "9781908541680 ch_4                                      0.135417   \n",
       "\n",
       "                        rouge1_recall_allenai/led-large-16384  \\\n",
       "book          chapter                                           \n",
       "9783318068207 hh-7                                   0.094463   \n",
       "9781910797631 chp6                                   0.343023   \n",
       "9781910797426 ch03                                   0.671875   \n",
       "9781908541277 ch_12                                  0.006711   \n",
       "9781910797907 chp6                                   0.633588   \n",
       "9781908541277 ch_8                                   0.461538   \n",
       "9781910797006 ch08                                   0.573034   \n",
       "9781910797105 ch06                                   0.543689   \n",
       "9783318068207 hh-5                                   0.581967   \n",
       "9781910797105 ch04                                   0.507042   \n",
       "9781910797006 ch03                                   0.497110   \n",
       "9781908541406 ch_6                                   0.500000   \n",
       "9781908541277 ch_6                                   0.108696   \n",
       "9781910797815 chp3                                   0.676301   \n",
       "9781910797310 chp3                                   0.411765   \n",
       "9781910797426 ch12                                   0.568182   \n",
       "9781908541024 ch_13                                  0.758065   \n",
       "9781910797617 chp6                                   0.423729   \n",
       "9781908541994 ch02                                   0.000000   \n",
       "9781910797471 ch05                                   0.515873   \n",
       "9781910797105 ch08                                   0.643836   \n",
       "9781912776207 ch4                                    0.000000   \n",
       "9781910797495 chp12                                  0.477778   \n",
       "9781912776726 ch2                                    0.613636   \n",
       "9781910797815 chp2                                   0.206612   \n",
       "9781910797433 ch05                                   0.676471   \n",
       "9781910797617 chp1                                   0.576687   \n",
       "9781908541963 chapter3                               0.629032   \n",
       "9781908541796 chapter1                               0.233871   \n",
       "9781908541963 chapter5                               0.602410   \n",
       "9781910797907 chp2                                   0.013514   \n",
       "9781908541666 ch_13                                  0.463415   \n",
       "9781912776153 chp3                                   0.611429   \n",
       "9781908541468 ch_14                                  0.407407   \n",
       "9781910797662 ch09                                   0.404040   \n",
       "9781910797211 ch04                                   0.421456   \n",
       "9781908541727 ch03                                   0.507246   \n",
       "9783318068207 hh-8                                   0.446429   \n",
       "9781908541024 ch_12                                  0.500000   \n",
       "9781910797105 ch05                                   0.666667   \n",
       "9781908541420 ch_6                                   0.555556   \n",
       "9781908541680 ch_8                                   0.566038   \n",
       "9781910797457 chp8                                   0.556962   \n",
       "9781910797815 chp7                                   0.492958   \n",
       "9783318066685 ch4                                    0.476190   \n",
       "9781908541680 ch_4                                   0.634146   \n",
       "\n",
       "                        rouge1_fmeasure_allenai/led-large-16384  \\\n",
       "book          chapter                                             \n",
       "9783318068207 hh-7                                     0.152632   \n",
       "9781910797631 chp6                                     0.189103   \n",
       "9781910797426 ch03                                     0.353183   \n",
       "9781908541277 ch_12                                    0.009132   \n",
       "9781910797907 chp6                                     0.337398   \n",
       "9781908541277 ch_8                                     0.112150   \n",
       "9781910797006 ch08                                     0.217484   \n",
       "9781910797105 ch06                                     0.252822   \n",
       "9783318068207 hh-5                                     0.278978   \n",
       "9781910797105 ch04                                     0.146939   \n",
       "9781910797006 ch03                                     0.295026   \n",
       "9781908541406 ch_6                                     0.252822   \n",
       "9781908541277 ch_6                                     0.061162   \n",
       "9781910797815 chp3                                     0.426230   \n",
       "9781910797310 chp3                                     0.160550   \n",
       "9781910797426 ch12                                     0.236967   \n",
       "9781908541024 ch_13                                    0.207506   \n",
       "9781910797617 chp6                                     0.323276   \n",
       "9781908541994 ch02                                     0.000000   \n",
       "9781910797471 ch05                                     0.265306   \n",
       "9781910797105 ch08                                     0.203024   \n",
       "9781912776207 ch4                                      0.000000   \n",
       "9781910797495 chp12                                    0.175510   \n",
       "9781912776726 ch2                                      0.394161   \n",
       "9781910797815 chp2                                     0.106838   \n",
       "9781910797433 ch05                                     0.279352   \n",
       "9781910797617 chp1                                     0.346225   \n",
       "9781908541963 chapter3                                 0.161157   \n",
       "9781908541796 chapter1                                 0.142857   \n",
       "9781908541963 chapter5                                 0.229358   \n",
       "9781910797907 chp2                                     0.007143   \n",
       "9781908541666 ch_13                                    0.157025   \n",
       "9781912776153 chp3                                     0.378092   \n",
       "9781908541468 ch_14                                    0.178499   \n",
       "9781910797662 ch09                                     0.215054   \n",
       "9781910797211 ch04                                     0.367893   \n",
       "9781908541727 ch03                                     0.264151   \n",
       "9783318068207 hh-8                                     0.117647   \n",
       "9781908541024 ch_12                                    0.280992   \n",
       "9781910797105 ch05                                     0.192220   \n",
       "9781908541420 ch_6                                     0.263692   \n",
       "9781908541680 ch_8                                     0.125261   \n",
       "9781910797457 chp8                                     0.335878   \n",
       "9781910797815 chp7                                     0.179487   \n",
       "9783318066685 ch4                                      0.273973   \n",
       "9781908541680 ch_4                                     0.223176   \n",
       "\n",
       "                        rouge2_precision_allenai/led-large-16384  \\\n",
       "book          chapter                                              \n",
       "9783318068207 hh-7                                      0.041667   \n",
       "9781910797631 chp6                                      0.028825   \n",
       "9781910797426 ch03                                      0.097765   \n",
       "9781908541277 ch_12                                     0.000000   \n",
       "9781910797907 chp6                                      0.072222   \n",
       "9781908541277 ch_8                                      0.010667   \n",
       "9781910797006 ch08                                      0.052770   \n",
       "9781910797105 ch06                                      0.056047   \n",
       "9783318068207 hh-5                                      0.049223   \n",
       "9781910797105 ch04                                      0.009569   \n",
       "9781910797006 ch03                                      0.053790   \n",
       "9781908541406 ch_6                                      0.054545   \n",
       "9781908541277 ch_6                                      0.000000   \n",
       "9781910797815 chp3                                      0.168000   \n",
       "9781910797310 chp3                                      0.017143   \n",
       "9781910797426 ch12                                      0.051051   \n",
       "9781908541024 ch_13                                     0.046154   \n",
       "9781910797617 chp6                                      0.052448   \n",
       "9781908541994 ch02                                      0.000000   \n",
       "9781910797471 ch05                                      0.041322   \n",
       "9781910797105 ch08                                      0.053985   \n",
       "9781912776207 ch4                                       0.000000   \n",
       "9781910797495 chp12                                     0.025063   \n",
       "9781912776726 ch2                                       0.080863   \n",
       "9781910797815 chp2                                      0.008671   \n",
       "9781910797433 ch05                                      0.043478   \n",
       "9781910797617 chp1                                      0.089710   \n",
       "9781908541963 chapter3                                  0.021378   \n",
       "9781908541796 chapter1                                  0.021352   \n",
       "9781908541963 chapter5                                  0.039773   \n",
       "9781910797907 chp2                                      0.000000   \n",
       "9781908541666 ch_13                                     0.012469   \n",
       "9781912776153 chp3                                      0.130769   \n",
       "9781908541468 ch_14                                     0.020833   \n",
       "9781910797662 ch09                                      0.014706   \n",
       "9781910797211 ch04                                      0.080357   \n",
       "9781908541727 ch03                                      0.061381   \n",
       "9783318068207 hh-8                                      0.005435   \n",
       "9781908541024 ch_12                                     0.031700   \n",
       "9781910797105 ch05                                      0.029491   \n",
       "9781908541420 ch_6                                      0.050667   \n",
       "9781908541680 ch_8                                      0.018824   \n",
       "9781910797457 chp8                                      0.052055   \n",
       "9781910797815 chp7                                      0.031447   \n",
       "9783318066685 ch4                                       0.038554   \n",
       "9781908541680 ch_4                                      0.031332   \n",
       "\n",
       "                        rouge2_recall_allenai/led-large-16384  \\\n",
       "book          chapter                                           \n",
       "9783318068207 hh-7                                   0.009804   \n",
       "9781910797631 chp6                                   0.076023   \n",
       "9781910797426 ch03                                   0.275591   \n",
       "9781908541277 ch_12                                  0.000000   \n",
       "9781910797907 chp6                                   0.200000   \n",
       "9781908541277 ch_8                                   0.078431   \n",
       "9781910797006 ch08                                   0.227273   \n",
       "9781910797105 ch06                                   0.186275   \n",
       "9783318068207 hh-5                                   0.157025   \n",
       "9781910797105 ch04                                   0.057143   \n",
       "9781910797006 ch03                                   0.127907   \n",
       "9781908541406 ch_6                                   0.162162   \n",
       "9781908541277 ch_6                                   0.000000   \n",
       "9781910797815 chp3                                   0.366279   \n",
       "9781910797310 chp3                                   0.071429   \n",
       "9781910797426 ch12                                   0.195402   \n",
       "9781908541024 ch_13                                  0.295082   \n",
       "9781910797617 chp6                                   0.085227   \n",
       "9781908541994 ch02                                   0.000000   \n",
       "9781910797471 ch05                                   0.120000   \n",
       "9781910797105 ch08                                   0.291667   \n",
       "9781912776207 ch4                                    0.000000   \n",
       "9781910797495 chp12                                  0.112360   \n",
       "9781912776726 ch2                                    0.171429   \n",
       "9781910797815 chp2                                   0.025000   \n",
       "9781910797433 ch05                                   0.168317   \n",
       "9781910797617 chp1                                   0.209877   \n",
       "9781908541963 chapter3                               0.147541   \n",
       "9781908541796 chapter1                               0.048780   \n",
       "9781908541963 chapter5                               0.170732   \n",
       "9781910797907 chp2                                   0.000000   \n",
       "9781908541666 ch_13                                  0.061728   \n",
       "9781912776153 chp3                                   0.293103   \n",
       "9781908541468 ch_14                                  0.074766   \n",
       "9781910797662 ch09                                   0.040816   \n",
       "9781910797211 ch04                                   0.103846   \n",
       "9781908541727 ch03                                   0.175182   \n",
       "9783318068207 hh-8                                   0.036364   \n",
       "9781908541024 ch_12                                  0.081481   \n",
       "9781910797105 ch05                                   0.177419   \n",
       "9781908541420 ch_6                                   0.163793   \n",
       "9781908541680 ch_8                                   0.153846   \n",
       "9781910797457 chp8                                   0.121019   \n",
       "9781910797815 chp7                                   0.142857   \n",
       "9783318066685 ch4                                    0.095808   \n",
       "9781908541680 ch_4                                   0.148148   \n",
       "\n",
       "                        rouge2_fmeasure_allenai/led-large-16384  \\\n",
       "book          chapter                                             \n",
       "9783318068207 hh-7                                     0.015873   \n",
       "9781910797631 chp6                                     0.041801   \n",
       "9781910797426 ch03                                     0.144330   \n",
       "9781908541277 ch_12                                    0.000000   \n",
       "9781910797907 chp6                                     0.106122   \n",
       "9781908541277 ch_8                                     0.018779   \n",
       "9781910797006 ch08                                     0.085653   \n",
       "9781910797105 ch06                                     0.086168   \n",
       "9783318068207 hh-5                                     0.074951   \n",
       "9781910797105 ch04                                     0.016393   \n",
       "9781910797006 ch03                                     0.075731   \n",
       "9781908541406 ch_6                                     0.081633   \n",
       "9781908541277 ch_6                                     0.000000   \n",
       "9781910797815 chp3                                     0.230347   \n",
       "9781910797310 chp3                                     0.027650   \n",
       "9781910797426 ch12                                     0.080952   \n",
       "9781908541024 ch_13                                    0.079823   \n",
       "9781910797617 chp6                                     0.064935   \n",
       "9781908541994 ch02                                     0.000000   \n",
       "9781910797471 ch05                                     0.061475   \n",
       "9781910797105 ch08                                     0.091106   \n",
       "9781912776207 ch4                                      0.000000   \n",
       "9781910797495 chp12                                    0.040984   \n",
       "9781912776726 ch2                                      0.109890   \n",
       "9781910797815 chp2                                     0.012876   \n",
       "9781910797433 ch05                                     0.069106   \n",
       "9781910797617 chp1                                     0.125693   \n",
       "9781908541963 chapter3                                 0.037344   \n",
       "9781908541796 chapter1                                 0.029703   \n",
       "9781908541963 chapter5                                 0.064516   \n",
       "9781910797907 chp2                                     0.000000   \n",
       "9781908541666 ch_13                                    0.020747   \n",
       "9781912776153 chp3                                     0.180851   \n",
       "9781908541468 ch_14                                    0.032587   \n",
       "9781910797662 ch09                                     0.021622   \n",
       "9781910797211 ch04                                     0.090604   \n",
       "9781908541727 ch03                                     0.090909   \n",
       "9783318068207 hh-8                                     0.009456   \n",
       "9781908541024 ch_12                                    0.045643   \n",
       "9781910797105 ch05                                     0.050575   \n",
       "9781908541420 ch_6                                     0.077393   \n",
       "9781908541680 ch_8                                     0.033543   \n",
       "9781910797457 chp8                                     0.072797   \n",
       "9781910797815 chp7                                     0.051546   \n",
       "9783318066685 ch4                                      0.054983   \n",
       "9781908541680 ch_4                                     0.051724   \n",
       "\n",
       "                        rougeL_precision_allenai/led-large-16384  \\\n",
       "book          chapter                                              \n",
       "9783318068207 hh-7                                      0.232877   \n",
       "9781910797631 chp6                                      0.101770   \n",
       "9781910797426 ch03                                      0.130919   \n",
       "9781908541277 ch_12                                     0.014286   \n",
       "9781910797907 chp6                                      0.119114   \n",
       "9781908541277 ch_8                                      0.039894   \n",
       "9781910797006 ch08                                      0.071053   \n",
       "9781910797105 ch06                                      0.100000   \n",
       "9783318068207 hh-5                                      0.090439   \n",
       "9781910797105 ch04                                      0.045346   \n",
       "9781910797006 ch03                                      0.090244   \n",
       "9781908541406 ch_6                                      0.087613   \n",
       "9781908541277 ch_6                                      0.038298   \n",
       "9781910797815 chp3                                      0.167553   \n",
       "9781910797310 chp3                                      0.059829   \n",
       "9781910797426 ch12                                      0.074850   \n",
       "9781908541024 ch_13                                     0.066496   \n",
       "9781910797617 chp6                                      0.114983   \n",
       "9781908541994 ch02                                      0.000000   \n",
       "9781910797471 ch05                                      0.096154   \n",
       "9781910797105 ch08                                      0.087179   \n",
       "9781912776207 ch4                                       0.000000   \n",
       "9781910797495 chp12                                     0.072500   \n",
       "9781912776726 ch2                                       0.120968   \n",
       "9781910797815 chp2                                      0.051873   \n",
       "9781910797433 ch05                                      0.091837   \n",
       "9781910797617 chp1                                      0.113158   \n",
       "9781908541963 chapter3                                  0.056872   \n",
       "9781908541796 chapter1                                  0.088652   \n",
       "9781908541963 chapter5                                  0.076487   \n",
       "9781910797907 chp2                                      0.004854   \n",
       "9781908541666 ch_13                                     0.052239   \n",
       "9781912776153 chp3                                      0.184143   \n",
       "9781908541468 ch_14                                     0.054545   \n",
       "9781910797662 ch09                                      0.091575   \n",
       "9781910797211 ch04                                      0.139466   \n",
       "9781908541727 ch03                                      0.081633   \n",
       "9783318068207 hh-8                                      0.040650   \n",
       "9781908541024 ch_12                                     0.097701   \n",
       "9781910797105 ch05                                      0.053476   \n",
       "9781908541420 ch_6                                      0.077128   \n",
       "9781908541680 ch_8                                      0.046948   \n",
       "9781910797457 chp8                                      0.090164   \n",
       "9781910797815 chp7                                      0.062696   \n",
       "9783318066685 ch4                                       0.100962   \n",
       "9781908541680 ch_4                                      0.067708   \n",
       "\n",
       "                        rougeL_recall_allenai/led-large-16384  \\\n",
       "book          chapter                                           \n",
       "9783318068207 hh-7                                   0.055375   \n",
       "9781910797631 chp6                                   0.267442   \n",
       "9781910797426 ch03                                   0.367188   \n",
       "9781908541277 ch_12                                  0.006711   \n",
       "9781910797907 chp6                                   0.328244   \n",
       "9781908541277 ch_8                                   0.288462   \n",
       "9781910797006 ch08                                   0.303371   \n",
       "9781910797105 ch06                                   0.330097   \n",
       "9783318068207 hh-5                                   0.286885   \n",
       "9781910797105 ch04                                   0.267606   \n",
       "9781910797006 ch03                                   0.213873   \n",
       "9781908541406 ch_6                                   0.258929   \n",
       "9781908541277 ch_6                                   0.097826   \n",
       "9781910797815 chp3                                   0.364162   \n",
       "9781910797310 chp3                                   0.247059   \n",
       "9781910797426 ch12                                   0.284091   \n",
       "9781908541024 ch_13                                  0.419355   \n",
       "9781910797617 chp6                                   0.186441   \n",
       "9781908541994 ch02                                   0.000000   \n",
       "9781910797471 ch05                                   0.277778   \n",
       "9781910797105 ch08                                   0.465753   \n",
       "9781912776207 ch4                                    0.000000   \n",
       "9781910797495 chp12                                  0.322222   \n",
       "9781912776726 ch2                                    0.255682   \n",
       "9781910797815 chp2                                   0.148760   \n",
       "9781910797433 ch05                                   0.352941   \n",
       "9781910797617 chp1                                   0.263804   \n",
       "9781908541963 chapter3                               0.387097   \n",
       "9781908541796 chapter1                               0.201613   \n",
       "9781908541963 chapter5                               0.325301   \n",
       "9781910797907 chp2                                   0.013514   \n",
       "9781908541666 ch_13                                  0.256098   \n",
       "9781912776153 chp3                                   0.411429   \n",
       "9781908541468 ch_14                                  0.194444   \n",
       "9781910797662 ch09                                   0.252525   \n",
       "9781910797211 ch04                                   0.180077   \n",
       "9781908541727 ch03                                   0.231884   \n",
       "9783318068207 hh-8                                   0.267857   \n",
       "9781908541024 ch_12                                  0.250000   \n",
       "9781910797105 ch05                                   0.317460   \n",
       "9781908541420 ch_6                                   0.247863   \n",
       "9781908541680 ch_8                                   0.377358   \n",
       "9781910797457 chp8                                   0.208861   \n",
       "9781910797815 chp7                                   0.281690   \n",
       "9783318066685 ch4                                    0.250000   \n",
       "9781908541680 ch_4                                   0.317073   \n",
       "\n",
       "                        rougeL_fmeasure_allenai/led-large-16384  \n",
       "book          chapter                                            \n",
       "9783318068207 hh-7                                     0.089474  \n",
       "9781910797631 chp6                                     0.147436  \n",
       "9781910797426 ch03                                     0.193018  \n",
       "9781908541277 ch_12                                    0.009132  \n",
       "9781910797907 chp6                                     0.174797  \n",
       "9781908541277 ch_8                                     0.070093  \n",
       "9781910797006 ch08                                     0.115139  \n",
       "9781910797105 ch06                                     0.153499  \n",
       "9783318068207 hh-5                                     0.137525  \n",
       "9781910797105 ch04                                     0.077551  \n",
       "9781910797006 ch03                                     0.126930  \n",
       "9781908541406 ch_6                                     0.130926  \n",
       "9781908541277 ch_6                                     0.055046  \n",
       "9781910797815 chp3                                     0.229508  \n",
       "9781910797310 chp3                                     0.096330  \n",
       "9781910797426 ch12                                     0.118483  \n",
       "9781908541024 ch_13                                    0.114790  \n",
       "9781910797617 chp6                                     0.142241  \n",
       "9781908541994 ch02                                     0.000000  \n",
       "9781910797471 ch05                                     0.142857  \n",
       "9781910797105 ch08                                     0.146868  \n",
       "9781912776207 ch4                                      0.000000  \n",
       "9781910797495 chp12                                    0.118367  \n",
       "9781912776726 ch2                                      0.164234  \n",
       "9781910797815 chp2                                     0.076923  \n",
       "9781910797433 ch05                                     0.145749  \n",
       "9781910797617 chp1                                     0.158379  \n",
       "9781908541963 chapter3                                 0.099174  \n",
       "9781908541796 chapter1                                 0.123153  \n",
       "9781908541963 chapter5                                 0.123853  \n",
       "9781910797907 chp2                                     0.007143  \n",
       "9781908541666 ch_13                                    0.086777  \n",
       "9781912776153 chp3                                     0.254417  \n",
       "9781908541468 ch_14                                    0.085193  \n",
       "9781910797662 ch09                                     0.134409  \n",
       "9781910797211 ch04                                     0.157191  \n",
       "9781908541727 ch03                                     0.120755  \n",
       "9783318068207 hh-8                                     0.070588  \n",
       "9781908541024 ch_12                                    0.140496  \n",
       "9781910797105 ch05                                     0.091533  \n",
       "9781908541420 ch_6                                     0.117647  \n",
       "9781908541680 ch_8                                     0.083507  \n",
       "9781910797457 chp8                                     0.125954  \n",
       "9781910797815 chp7                                     0.102564  \n",
       "9783318066685 ch4                                      0.143836  \n",
       "9781908541680 ch_4                                     0.111588  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evaluate_model(df_test, 'allenai/led-large-16384')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "GlnC1NYkRrQH"
   },
   "source": [
    "#### Plot Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 398
    },
    "executionInfo": {
     "elapsed": 965,
     "status": "ok",
     "timestamp": 1610618147643,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "lQdQyFl6REbV",
    "outputId": "3fee75aa-7cf0-4994-bbd0-11f4d84eb551"
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAmUAAAF9CAYAAABF4h9MAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/Il7ecAAAACXBIWXMAAAsTAAALEwEAmpwYAAA+kUlEQVR4nO3de3zU1Z3/8deHkBgQMsUYQBIg2RASYiKoAaRoteIFV6tbFW+9aLddrBZs67aKbX8yaLteVt1epNvtqoVuvVO3xcpWVxSt1gvByyaGBBIDgSCXRshFEhOS8/vjO4QhDJDAZOab5P18POZBvud75nw/M+c74ZPzPXO+5pxDREREROJrULwDEBERERElZSIiIiK+oKRMRERExAeUlImIiIj4gJIyERERER9QUiYiIiLiA0rKRKRXmdkSM9sQ5xiCZqb1fw7DzFaZ2ap4xyEyUCkpE+nnzOwsM3OHePwu3jFGg5n9XSj5mhLvWLramxSGPfaY2RYze8zMcuId38GY2aBQ7P8Q71hEBoLB8Q5ARGLmYWBVhPIPYxxHb/k7YCGwAXivy74fA3fHOJ5IvgdsA44BTga+AZxjZgXOue1xjSyyQXjv6VLgD/ENRaT/U1ImMnC86ZzrF6NiPeWc2wPsiXccwB+dc5V7N8ysDFgMXAv8a9yiEhFf0OVLEQHAzL4durQ2NcK+z4f2zQ1tH2dm95jZu2ZWb2bNZrbGzL7czWM5MwtGKD9g/pmZXWdmz4cu97WaWY2Z/cLMUsLrAP8b2vxN2GXCYGh/xDllZnaBmb1uZp+YWUPoONO71MkMtfVjM7vCzErNrMXM1pnZFd15vYfwSujfCV2OeayZ/YuZVYVe80dm9iszO65LvSlm9qyZbQvFVGtmz5jZuLA6G8xsSYTXfsh5dmaWCbSFNq8Ne09XhfYnmNltZlZuZrvNbJeZvWdm3zqSN0JENFImMpAMM7PjI5Q3Ouc+BZ4E7geuAVZ3qXMN0Ao8Hdr+O+AqYBnwayAZuBT4LzNLcs49EsW45wHrgH8D6oFTgLnAScCZoTqv4l2eXBCK5y+h8v87WKOhhOoJoAIIAknAN4FXzGyWc+71Lk+5APga8CtgF96lx8fN7D3n3LojfG1ZoX/rwuI6BlgJnAg8BKwFJgLfAmaY2XTnXIuZpQEvhmJ5APgbMAY4DxgL1BxhTHvtwBvBW4r3fv46VL4t9O/toceS0PGTgXzgDLzRPxHpKeecHnro0Y8fwFmAO8TjurC6LwBbgEFhZUnAx8AfwsqOARK6HMfwkomKLuVLgA1dyhwQjBBrpLpDI9S7NtTGjLCyc7q+nrB9Qe/XXef24NDr3AR8Jqw8A2gEisPKMkPtNgHpYeWjgE+Be7vRB8FQG1OB44F04EKgCmgHpoTVvQUvAS7q0sZFoTa+Gdq+ZG+bhzn2BmDJ4d6TUNkqYFWX98kd5PnvAs/F+/zWQ4/+9NDlS5GB4wHg3AiP58PqPAacAHw+rGw2MAJ4dG+Bc+5T51w7gJklhS6rpeKN3EwMv7R4tJxzu0PHGWRmgdBo36uh3Qdcau2mIrzX+R/OuV1hx9qM9x6camZjujxnuXOuNqzuNqAcyO7Bcd/GG4HaDPwJL7m9wjn3Xlidq4FiYIOZHb/3AbwJfALMCtXbG/fFodG1WNsFnGhmk+JwbJF+SZcvRQaOtc65Fw9T5xng3/EuV64MlV2DN3r07N5KZmbAt/Eu903EGyUL9xmg4ehDBjObBvwEOB3vElnX4xyJzNC/ayPsKwv9m4U3mrbXxgh1dwLHRSg/mGtDbQaAL+ElvG1d6uQCQ/CSt0hGhv59Fe/y64+Am83sL8AK4DHn3N96ENOR+hHwR6DMzNbhJeTLnHMvx+DYIv2SkjIR6eScazCzPwGXmtmNeL8jvgA87ZxrCav6feAevNGzn+AlEHuAvwe+y5F/iSghfCM02fxlvEtwt4T+bQ7V+/NRHOdItB+kvGtCeih/daFvX5rZM3iv4b/MbJJzbm8CaMAbePO1ItkFoeuOcLWZ/SvepdBz8EZDbzezc8JG3w42mT/hIOXd4px73cyyw479D8CNZvaIc+7rR9O2yEClpExEunoMuBwvwRoaejzapc7VwCvOuf2+bWlms+ienXiXRLv6uy7bl4SOf6FzbkPYcXIjPLcnK/ZXh/6NdOltUpc6vcI558zse8D7eAnYN0O7KoER3RjV3NvOO8A7wJ1mdhKwBi+BvSZUpbvvdcTmD3Pserzz5TEzG4w3J/Afzewed+RffhAZsDSnTES6WoE3GnMNXvK1FXipS512uowQhb4N2N0RkvXsP2+N0FIUMyIch67HwvuWZVdNoX8jJSBdrcG7jDi3y9IaY/AuK64JG7nqNc65Ery5ZV8zs/RQ8eNAnpl9pWv90DIUx4V+HhG6jBxuLd5IYvh7sB7vW5tDwtrJxBvZOlx87UALEd5TM0vtUncPUBra7E4fiEgXGikTGThOM7OWCOU7nHOdk/2dc5+a2e/xkpMEYPHeSf1h/oA3MvMY3uXFMcD1eN9mTOtGLP+Ot57Yn/CSkkzgn4ASvPlWe/0ZLylYYWb/AXTgXU6NNI/rA2A3cIOZNeHNgyt1zpV2reic22Nm38Wbk/WmmT3CviUxEvHmy8XKXXiv6ZbQcR/AuyS41Mz+HvgrXlKaDVyGN5drCd78tPlm9t94o2uD8ZYpGY43erXXvwNXAC+a2aN4/XMjXgJ3ajfiW41314Hv4X1BYbtz7iVgrZm9Ftq/DW8u3Dy8JUbeOZI3QmTAi/fXP/XQQ4/efXD4JTHejPCcz4ftP2DJBbwEYBHeHK8WvP/g5wHXhZ6TGVZ3CQcuc2F4t+/ZEnr+26FjRqo7C3gL75uHO0J10oiwrAZe0lKKt6RE534iLP8QKv974HW8ZK4Rb0mQ07rUyQy19eMIz19F2BISh+iDYKiNCQfZvyoUw6jQdjLww9BracEbuXwfuBcYF6pzMvA7vMuszXhrnf0FuDRC+zeE6n0aanNOpPck0uvBWy/tldD77/buB27DSxj/ForxQ+AXe1+DHnro0fOHOdeTaRgiIiIi0hs0p0xERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfKDPr1N2/PHHu8zMzHiHISIiInJYa9as+ZtzLuJ6jn0+KcvMzKS4uDjeYYiIiIgclpltPNg+Xb4UERER8QElZSIiIiI+oKRMRERExAf6/JwyERERiZ62tjY2b95MS0tLvEPp05KTk8nIyCAxMbHbz1FSJiIiIp02b97M8OHDyczMxMziHU6f5Jyjrq6OzZs3k5WV1e3n6fKliIiIdGppaSE1NVUJ2VEwM1JTU3s82qikTERERPajhOzoHcl7qKRMRERE+r3i4mJuuummg+7fsmULl19+eQwjOpDmlImIiEif097eTkJCQrfrFxUVUVRUdND9Y8aMYdmyZdEI7YhppExERER8ZcOGDeTl5fGlL32JSZMmcfnll7N7924yMzO59dZbOeWUU3j66ad54YUXmDFjBqeccgpz5syhqakJgNWrV/PZz36WyZMnM23aNBobG1m1ahUXXXQRAK+88gpTpkxhypQpnHzyyTQ2NrJhwwYKCgoAb17d1772NQoLCzn55JN5+eWXAViyZAmXXnops2fPJicnh1tuuSWqr1sjZSIiIhLRomc/oGxLQ1TbzB+TwsIvnHjYehUVFTz88MPMnDmTf/zHf+SXv/wlAKmpqbzzzjv87W9/49JLL+XFF1/k2GOP5Z577uGBBx5gwYIFXHnllTz55JNMnTqVhoYGhgwZsl/b9913H4sXL2bmzJk0NTWRnJy83/7FixdjZpSUlFBeXs55553HunXrAHjvvfd49913OeaYY8jNzWX+/PmMHTs2Ku+NRspERETEd8aOHcvMmTMB+PKXv8xrr70GwJVXXgnAm2++SVlZGTNnzmTKlCksXbqUjRs3UlFRwQknnMDUqVMBSElJYfDg/cegZs6cyc0338zPf/5zdu3adcD+1157jS9/+csA5OXlMX78+M6kbNasWQQCAZKTk8nPz2fjxoPeyrLHNFI20AUDUW6vPrrtiYhI3HRnRKu3dP324t7tY489FvDWAjv33HN5/PHH96tXUlJy2LYXLFjAhRdeyIoVK5g5cybPP//8AaNlB3PMMcd0/pyQkMCePXu69bzuUFI20HU3iQoGlHCJiEjM1NTU8MYbbzBjxgwee+wxTj/9dN59993O/aeddhrf+ta3qKysZMKECXzyySfU1taSm5vLRx99xOrVq5k6dSqNjY0HXL6sqqqisLCQwsJCVq9eTXl5OVOmTOncf8YZZ/Doo49y9tlns27dOmpqasjNzeWdd97p1desy5ciIiLiO7m5uSxevJhJkyaxc+dObrjhhv32p6WlsWTJEq6++mpOOukkZsyYQXl5OUlJSTz55JPMnz+fyZMnc+655x6wiOtPf/pTCgoKOOmkk0hMTOSCCy7Yb/+NN95IR0cHhYWFXHnllSxZsmS/EbLeYs65Xj9IbyoqKnLFxcXxDqP/00iZiMiAsHbtWiZNmhTXGDZs2MBFF11EaWlpXOM4WpHeSzNb45yLuDaHRspEREREfEBJmYiIiPhKZmZmnx8lOxJKykRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERET6vSVLljBv3jwAgsEg9913X5wjOpCSMhEREfEt5xwdHR3xDiMmlJSJiIiIr2zYsIHc3Fy++tWvUlBQwJ133snUqVM56aSTWLhwYWe93/72t5x00klMnjyZr3zlKwA8++yzTJ8+nZNPPplzzjmHbdu2xetl9JjufSkiIiKR/c8C2Hr4G3z3yOhCuODuw1Zbv349S5cupaGhgWXLlvH222/jnOPiiy/m1VdfJTU1lR//+Mf89a9/5fjjj+fjjz8G4PTTT+fNN9/EzHjooYe49957uf/++6P7GnpJTJMyM5sN/AxIAB5yzt3dZf+/AZ8PbQ4FRjrnPhPLGEVERCT+xo8fz2mnncb3vvc9XnjhBU4++WQAmpqaWL9+Pe+//z5z5szh+OOPB+C4444DYPPmzVx55ZV89NFHtLa2kpWVFbfX0FMxS8rMLAFYDJwLbAZWm9ly51zZ3jrOue+G1Z8PnByr+ERERKSLboxo9ZZjjz0W8OaU3XbbbVx//fX77f/FL34R8Xnz58/n5ptv5uKLL2bVqlUEg8HeDjVqYjmnbBpQ6Zz70DnXCjwBXHKI+lcDj8ckMhEREfGl888/n0ceeYSmpiYAamtr2b59O2effTZPP/00dXV1AJ2XL+vr60lPTwdg6dKl8Qn6CMXy8mU6sClsezMwPVJFMxsPZAEvHWT/XGAuQEZGBiUl3vXu0aNHM2TIEKqrqwFISUlh3LhxnffPSkhIID8/n6qqKnbv3g3AhAkTqK+vZ8eOHQCMGTOGxMRENm7cCEAgECA9PZ2yMm9ALzExkby8PNavX09LSwsAEydOpK6urvPESE9PZ9CgQWza5L3cESNGMGrUKMrLywFISkoiNzeXiooKWltbAcjLy2Pbtm3s3LkTgLFjx9LR0UFtbS0AqamppKamsm7dOgCSk5PJycmhvLyctrY2APLz86mtraW+vh7whn7b2trYsmULAGlpaQQCASorKwEYOnQo2dnZlJWV0d7eDkBBQQE1NTU0NDQAkJWVRXNzM2lASUkJI0eOZPjw4VRVVQEwbNgwsrKyKC0txTmHmVFQUEB1dXXnByg7O5vGxka2b9+ufurlftq6dSuA+kn9pH5SPx1xPwG0tLR0fuMxOTmZPXv2sGfPnv3q7O3HwYMHM3jw4M5jDho0iOTkZJqbm3HOATBkyBBaW1s73/NjjjkG51xnG4mJiSQkJHS28emnnwLQ3NzM6aefzuWXX86MGTNwznHsscfy8MMPM2nSJG699VbOOOMMEhISOPnkk/nNb37DbbfdxuWXX86IESOYNWtW53u691iffvopbW1tnfF0dHR0nk+JiYkMGjSo8/gJCQkkJSXR3NwMgJkxZMiQA96f9vb2zjaSkpIwMz799FNaW1upqanZr58Oxfa+Yb3NzC4HZjvnvhHa/gow3Tk3L0LdW4EM59z8w7VbVFTkiouLox6vdBEMQLA+3lGIiEgvW7t2LZMmTYp3GP1CpPfSzNY454oi1Y/l5ctaYGzYdkaoLJKr0KVLERERGUBimZStBnLMLMvMkvASr+VdK5lZHjACeCOGsYmIiIjEVcySMufcHmAe8DywFnjKOfeBmd1hZheHVb0KeMLF6rqqiIiIiA/EdJ0y59wKYEWXstu7bAdjGZOIiIiIH+g2SyIiIiI+oKRMRERExAeUlImIiIiv/PznP2fSpEl86UtfincoMaUbkouIiIiv/PKXv+TFF18kIyMj3qEcoL29nYSEhF5pWyNlIiIi4hvf/OY3+fDDD7ngggsIBAJce+21nHHGGYwfP55nnnmGW265hcLCQmbPnt25iv6aNWs488wzOfXUUzn//PP56KOPAPjP//xPpk6dyuTJk7nssss675bw9NNPU1BQwOTJk/nc5z4HwJIlS5g3b9969hdddBGrVq0CvLs4/PM//zOTJ0/mjTfe4He/+x3Tpk1jypQpXH/99Z13KjhaGikTERGRiO55+x7KPy6Papt5x+Vx67RbD7r/V7/6FX/+8595+eWXefDBB3nxxRd5+eWXKSsrY8aMGfz+97/n3nvv5Ytf/CLPPfccF154IfPnz+ePf/wjaWlpPPnkk/zwhz/kkUce4dJLL+Wf/umfAPjRj37Eww8/zPz587njjjt4/vnnSU9PZ9euXYeN+ZNPPmH69Oncf//9rF27lnvuuYfXX3+dxMREbrzxRh599FG++tWvHvV7o6RMREREfOuCCy4gMTGRwsJC2tvbmT17NgCFhYVs2LCBiooKSktLOffccwHv8uIJJ5wAQGlpKT/60Y/YtWsXTU1NnH/++QDMnDmT6667jiuuuIJLL730sDEkJCRw2WWXAbBy5UrWrFnD1KlTAe/+nCNHjozKa1VSJiIiIhEdakQrVo455hjAu9F5YmIiZta5vWfPHpxznHjiibzxxoE3Arruuuv4wx/+wOTJk1myZEnn5chf/epXvPXWWzz33HOceuqprFmzhsGDB3feZBzovDk6eDcd3zuPzDnHtddey1133RX116o5ZSIiItJn5ebmsmPHjs6krK2tjQ8++ACAxsZGTjjhBNra2nj00Uc7n1NVVcX06dO54447SEtLY9OmTWRmZvLee+/R0dHBpk2bePvttyMeb9asWSxbtozt27cD8PHHH7Nx48aovBaNlImIiEiflZSUxLJly7jpppuor69nz549fOc73+HEE0/kzjvvZPr06aSlpTF9+nQaGxsB+P73v8/69etxzjFr1iwmT54MQFZWFvn5+UyaNIlTTjkl4vHy8/P58Y9/zHnnnUdHRweJiYksXryY8ePHH/Vrsb5+i8mioiJXXFwc7zD6v2AAgvXxjkJERHrZ2rVrmTRpUrzD6BcivZdmtsY5VxSpvi5fioiIiPiAkjIRERERH1BSJiIiIuIDSspERERkP319vrkfHMl7qKRMREREOiUnJ1NXV6fE7Cg456irqyM5OblHz9OSGCIiItIpIyODzZs3s2PHjniH0qclJyf3+IbqSspERESkU2JiIllZWfEOY0DS5UsRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4gJIyERERER9QUiYiIiLiA0rKRERERHxASZmIiIiID+iG5P3Z3eOhZVf02gsGotNO8mdgwcbotCUiItJPxDQpM7PZwM+ABOAh59zdEepcAQQBB7zvnLsmljH2Ky27IFgf7ygOFK3kTkREpB+JWVJmZgnAYuBcYDOw2syWO+fKwurkALcBM51zO81sZKziExEREYmnWM4pmwZUOuc+dM61Ak8Al3Sp80/AYufcTgDn3PYYxiciIiISN7FMytKBTWHbm0Nl4SYCE83sdTN7M3S5U0RERKTf89tE/8FADnAWkAG8amaFzrld4ZXMbC4wFyAjI4OSkhIARo8ezZAhQ6iurgYgJSWFcePGUVpaCkBCQgL5+flUVVWxe/duACZMmEB9fT07duwAYMyYMSQmJrJxozcRPRAIkJ6eTlmZd5U1MTGRvLw81q9fT0tLCwATJ06krq6Ouro6ANLT0xk0aBCbNnk56IgRIxg1ahTl5eUAJCUlkZubS0VFBa2trQDk5eWxbds2du7cCcDYsWPp6OigtrYWgNTUVFJTU1m3bh0AycnJ5OTkUF5eTltbGwD5+fnU1tZSX+/NIysE6urq2LJlCwBpaWkEAgEqKysBGDp0KNnZ2ZSVldHe3g5AQUEBNTU1NDQ0AJCVlUVzczNbt24FYOTIkQwfPpyqqioAhg0bRlZWFqWlpTjnMDMKCgqorq6mqakJgOzsbBobG9m+fXtnXE1NTeqnUD+NHz+etrY23/WTPk/qJ/WT+kn9FP1+OhRzzh22UjSY2Qwg6Jw7P7R9G4Bz7q6wOr8C3nLO/Sa0vRJY4JxbfbB2i4qKXHFxca/G3mcFA/6d6O/HuERERHqZma1xzhVF2hfLy5ergRwzyzKzJOAqYHmXOn/AGyXDzI7Hu5z5YQxjFBEREYmLmCVlzrk9wDzgeWAt8JRz7gMzu8PMLg5Vex6oM7My4GXg+865uljFKCIiIhIvMZ1T5pxbAazoUnZ72M8OuDn0EBERERkwdJslERERER9QUiYiIiLiA0rKRERERHxASZmIiIiIDygpExEREfEBJWUiIiIiPqCkTERERMQHlJSJiIiI+ICSMhEREREfUFImIiIi4gNKykRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPDI53ANLLgoF9P89d5f3767P2lZ25AD5/G9yXC01bvbITJsP1r8Lym+Cdpfvq3lwOH70Hj1+1r+yin0LR1/Y/zsTZcM2T8NiVsO7PYbHUQ/FvovO6RERE+hlzzsU7hqNSVFTkiouL4x2GPwUDXiLkN36NS0REpJeZ2RrnXFGkfRop6+/CR7BERETEt5SU9Xd+HJFSoigiInIATfQXERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4gJIyERERER9QUiYiIiLiA0rKRERERHxASZmIiIiID8Q0KTOz2WZWYWaVZrYgwv7rzGyHmb0XenwjlvGJiIiIxEvMVvQ3swRgMXAusBlYbWbLnXNlXao+6ZybF6u4RERERPwgliNl04BK59yHzrlW4AngkhgeX0RERMS3Ynnvy3RgU9j2ZmB6hHqXmdnngHXAd51zm7pWMLO5wFyAjIwMSkpKABg9ejRDhgyhuroagJSUFMaNG0dpaSkACQkJ5OfnU1VVxe7duwGYMGEC9fX17NixA4AxY8aQmJjIxo0bAQgEAqSnp1NW5g3oJSYmkpeXx/r162lpaQFg4sSJ1NXVUVdX573Q9HQGDRrEpk1e6CNGjGDUqFGUl5cDkJSURG5uLhUVFbS2tgKQl5fHtm3b2LlzJwBjx46lo6OD2tpaAFJTU0lNTWXdunUAJCcnk5OTQ3l5OW1tbQDk5+dTW1tLfb13v8tCoK6uji1btgCQlpZGIBCgsrISgKFDh5KdnU1ZWRnt7e0AFBQUUFNTQ0NDAwBZWVk0NzezdetWAEaOHMnw4cOpqqoCYNiwYWRlZVFaWopzDjOjoKCA6upqmpqaAMjOzqaxsZHt27d3xtXU1KR+CvXT+PHjaWtr810/6fOkflI/qZ/UT9Hvp0Mx59xhK0WDmV0OzHbOfSO0/RVgevilSjNLBZqcc5+a2fXAlc65sw/VblFRkSsuLu7N0PuuYMC/NyT3Y1wiIiK9zMzWOOeKIu2L5eXLWmBs2HZGqKyTc67OOfdpaPMh4NQYxSYiIiISV7FMylYDOWaWZWZJwFXA8vAKZnZC2ObFwNoYxiciIiISNzGbU+ac22Nm84DngQTgEefcB2Z2B1DsnFsO3GRmFwN7gI+B62IVn4iIiEg8xXKiP865FcCKLmW3h/18G3BbLGMSERER8QOt6C8iIiLiAzEdKRMREZE4CAai3J6+Qd8blJSJiIj0d91JorRcUdwpKevvov3XUTQkfybeEYiIiPiOkrL+LJp/8egvKBERkV6lif4iIiIiPqCkTERERMQHlJSJiIiI+ICSMhEREREfUFImIiIi4gNKykRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4gJIyERERER9QUiYiIiLiA0eUlJnZSWZ2mZkNDW0fY2ZK8ERERESOUI8SKTM7zsxeBt4DngJGh3YtBu6LbmgiIiIiA8fgHta/D+gAMoEPwsqXAfdHKSaRiAqXFka1vZJrS6LanoiIyNHoaVJ2HnCJc67GzMLL1wHjohaVSATdSaIKlxYq2RIRkT6pp/PAjgN2RigfjjeCJiIiIiJHoKdJ2TvA7AjlXwXeOtyTzWy2mVWYWaWZLThEvcvMzJlZUQ/jExEREemTenr5chHwBzPLABKAr5jZicAlwNmHeqKZJeB9IeBcYDOw2syWO+fKutQbDnybbiR5IiIiIv1Fj0bKnHP/C3wBmIF3ufJWvG9gnu+ce/0wT58GVDrnPnTOtQJP4CVzXd0J3AO09CQ2ERERkb6spyNlOOdeAl46gmOlA5vCtjcD08MrmNkpwFjn3HNm9v0jOIaIiIhIn9TjpKy3hBaffQC4rht15wJzATIyMigp8b5tN3r0aIYMGUJ1dTUAKSkpjBs3jtLSUgASEhLIz8+nqqqK3bt3AzBhwgTq6+vZsWMHAGPGjCExMZGNGzcCEAgESE9Pp6zMu8qamJhIXl4e69evp6XFG8ybOHEidXV11NXVAZCens6gQYPYtMnLQUeMGMGoUaMoLy8HICkpidzcXCoqKmhtbQUgLy+Pbdu2sXOn9z2KsWPH0tHRQW1tLQCpqamkpqaybt06AJKTk8nJyaG8vJy2tjYA8vPzqa2tpb6+HoDx48fT1tbGli1bAEhLSyMQCFBZWQnA0KFDyc7OpqysjPb2dgAKCgqoqamhoaEBgKysLJqbm0kDSkpKGDlyJMOHD6eqqgqAYcOGkZWVRWlpKc45zIyCggKqq6tpamoCIDs7m8bGRrZv397r/UQozoHaT1u3bgXwfT8N9M+T+kn95Md+KgQqKirUT73cT4dizrnDVuqsbNYGRHqCw7vcuA74tXPuPyM8dwYQdM6dH9q+DcA5d1doOwBUAU2hp4wGPgYuds4VHyymoqIiV1x80N0SLcEABOvjHcVhaUkMEZEj1Ed+z/d1ZrbGORfxi4w9HSn7PvD/gBeAN0JlM/Am798P5ACLzazdOfdIl+euBnLMLAuoBa4Crtm70zlXDxwfFvQq4HuHSshERERE+oueJmXTgDudcz8NK/u5mX0HmOacu8bMyoCbgP2SMufcHjObBzyP983NR5xzH5jZHUCxc275kb4IERERkb6up0nZRXgjZV39Cbgj9POzQDDSk51zK4AVXcpuP0jds3oYm4iIiEif1dPFY1vo8o3JkGnsW8JiEFrOQkRERKRHejpS9hDwKzObiLe4q8ObU/Yd4MFQnc8DmmktIiIi0gM9Tcp+CPwNuBnYe9lxC97lyp+Gtv8bWBaF2EREREQGjB4lZc5bP+MB4AEzSwmVNXSp81H0whMREREZGI548diuyZiIiIiIHLkeJWVmVk3kxWMBcM793VFHJCIiIjIAHclE/3CJwKnA6cDPohKRiIiIyADU0zllP4lUbma3AhlRiUhERERkAOrpOmUHswz4UpTaEhGJu2AwGO8QRGSAiVZSdjLQGqW2RETibtGiRfEOQUQGmJ5O9P911yJgDHAOsDhaQYmIiIgMND2d6J/TZbsD2A7cCCyNSkQiInESDAb3GyEzMwAWLlyoy5niT3ePh5Zd0WsvGIhOO8mfgQUbo9PWANLTif6f761ARETiLRgMdiZfZoa3XraIj7XsgmB9vKM4ULSSuwHmiBaPNbPBQHZos8o5tyd6IYmIiIgMPD2a6G9mCWa2CKgHyoC1wC4zC5pZtL40ICISdwsXLox3CCIywPR0pCwIfAu4DXglVHYWsBAvwbs94rNERPoYzSETkVjraVJ2HXC9c+7psLL3zewj4H6UlImIiIgckZ5echwJvBuh/F0g7ejDERERERmYejpSVglcCtzbpfxSoCoqEfUTmQuei2p7G+6+MKrtiQxo0f5mmB+//SYifU5Pk7J7gYfN7GTgL6GyzwGXA1+LZmB9XXeSqMwFzynZEomH7iRRwYCSLRGJqZ6uU7bUzP4G3ArcGSr+APgC8EmUYxMREREZMHp6m6VhwEvOuefCyk4FfgKcCyRENzwRERGRgaFbE/3NbIyZvYa3Plm9md1jZkmhe2G+AewGTu/FOEVERET6te6OlN0FpADfBuYA3wNmAhuAfOdcZa9EJyIiIjJAdDcpOxu42jn3mpk9A2wGXnTOBXstMhEREZEBpLvrlJ1AaMkL59wWoBl4qreCEhERERloupuUDQLCbzregZeYiYiIiEgU9OTbl0+bWWvo52Tgt2a2X2LmnDsvapGJiIiIDCDdTcqWdtn+XbQDERERERnIupWUOee0Wr+IiIhIL+rpDclFREREpBcoKRMRERHxgZgmZWY228wqzKzSzBZE2P9NMysxs/fM7DUzy49lfCIiIiLxErOkzMwSgMXABUA+cHWEpOsx51yhc24KcC/wQKziExEREYmnHt2Q/ChNAyqdcx8CmNkTwCVA2d4KzrmGsPrHAi6G8YmIiPQ9wcC+n+eu8v799Vn7ys5cAJ+/De7LhaatXtkJk+H6V2H5TfBO2AILN5fDR+/B41ftK7vop1D0tf2PM3E2XPMkPHYlrPtzWCz1UPyb6LyuASiWSVk6sClsezMwvWslM/sWcDOQhHd7pwOY2VxgLkBGRgYlJSUAjB49miFDhlBdXQ1ASkoK48aNo7S0FICEhATy8/Opqqpi9+7dAEyYMIH6+np27NgBwJgxY0hMTGTjxo0ABAIB0tPTKSvzcsfExETy8vJYv349LS0tAEycOJG6ujrq6uq8F5qezqBBg9i0yXu5I0aMYNSoUZSXlwOQlJREbm4uQGfseXl5bNu2jZ07dwIwduxYOjo6qK2tBSA1NZXU1FTWrVsHQHJyMjk5OZSXl9PW1gZAfn4+tbW11NfXAzB+/Hja2trYsmULAGlpaQQCASorvVuVDh06lOzsbMrKymhvbwegoKCAmpoaGhq8/DgrK4vm5mbSQrGOHDmS4cOHU1VVBcCwYcPIysqitLQU5xxmRkFBAdXV1TQ1NQGQnZ1NY2Mj27dvP2g/XfPXa2hoDc/Jj1zh0sKotDMsYRhvfPkNKioqaG31lujzez9t3er9wu2tfvLz5yna/VQI1NTUqJ983k8D/fM0Dii57LV9/TQm1E+hss5+KimB85ft308lJYw45RZGXXD/vn76qIHc3AuouPrt/ftp82Z2htrs7KeSEij8Ealn/du+fiopITlwOjmgfjrI5+lQzLnYDEaZ2eXAbOfcN0LbXwGmO+fmHaT+NcD5zrlrD9VuUVGRKy4ujnq8sZC54Dk23H1hvMPonmDA+wuolxQuLaTk2pJea/9I+DEmiaFePudFosKv56lf4/IBM1vjnCuKtC+WE/1rgbFh2xmhsoN5AviH3gxIRERExC9ieflyNZBjZll4ydhVwDXhFcwsxzm3PrR5IbAeERERObjwuV7Sp8UsKXPO7TGzecDzQALwiHPuAzO7Ayh2zi0H5pnZOUAbsBM45KVLiYKefJi7U1fD1SIiseXH37tKFI9ILEfKcM6tAFZ0Kbs97OdvxzIewZ8fZhERkQFIK/qLiIiI+ICSMhEREREfUFImIiIi4gNKykRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAcGxzsA6RuCwSDBYLBXj1G4tLBX2xcREfEzJWXSLYsWLer1pKzk2pJebb+nlCSKiEgsKSkT3whPgp646AkArvrTVZ1lN0y+gRun3MjZT53NjuYdAEw6bhJPfeEpgn8N8vv1v++su3LOSsrqypj/0vzOsttn3M6ciXP2O86ZGWfy4KwHmbdyHq9sfqWz3G8JooiI9H9KyuSggsEgixYt6tw2MwAWLlzYK6NmkRKhSGUvXfHSAWXBzwYJfnb/mEYOHdntNh+c9WAPIhUR8ZFgIN4RHCj5M/GOoE9SUiYHFT6PzMxwzsU3IBER2V+wPoptBaLbnvSYvn0pIiIi4gNKyqRbFi5cGO8QRERE+jUlZdItvf3NSxERkYFOSZmIiIiIDygpExEREfEBJWUiIiIiPqCkTERERMQHlJSJiIiI+ICSMhEREREfUFImIiIi4gMxTcrMbLaZVZhZpZktiLD/ZjMrM7P/M7OVZjY+lvGJiIiIxEvMkjIzSwAWAxcA+cDVZpbfpdq7QJFz7iRgGXBvrOITERERiadY3pB8GlDpnPsQwMyeAC4ByvZWcM69HFb/TeDLMYyvWyYveoH65raotZe54LmotBMYksj7C8+LSlsifdbd46FlV/TaCwai007yZ2DBxui0JSL9ViyTsnRgU9j2ZmD6Iep/HfifXo3oCNQ3t7Hh7gvjHcYBopXcifRpLbsgWB/vKA4UreROpJ8rXFoY1fZKri2Janu9LZZJWbeZ2ZeBIuDMg+yfC8wFyMjIoKTEe9NHjx7NkCFDqK6uBiAlJYVx48ZRWloKQEJCAvn5+VRVVbF7924AJkyYQH19PTt27ABgzJgxJCYmsnGj91dtIBAgPT2dsrKy/WJYv349LS0tAEycOJG6ujrq6uoASE9PZ9CgQWza5OWgI0aMYNSoUZSXlwOQlJREbm4uFRUVtLa2ApCXl8e2bdvYuXMnAGPHjqWjo4Pa2loAUlNTSU1NZd26dQAkJyeTk5NDeXk5bW3eyF17ezu1tbXU13v/KY0fP562tja2bNkCQFpaGoFAgMrKSgCGDh1KdnY2ZWVltLe3A1BQUEBNTQ0NDQ0AZGVl0dzczNatWwEYOXIkw4cPp6qqCoBhw4aRlZVFaWkpzjnMjIKCAqqrq2lqagIgOzubxsZGtm/fftB+Ajr7MRr9lJiYSF5e3lH1017R7qf8/Pw+20/R/jxFo5/CP0+5ofPIb/00PhSX+in6v/f0eYpePxXi/b6LZz89dspj3eqna965hjcue+Ow/QT4rp8OxZxzh60UDWY2Awg6584Pbd8G4Jy7q0u9c4BfAGc657Yfrt2ioiJXXFzcCxFHlrngOd+OlPkxru4qXFrou79o/BiTHEYw4N+RMj/GJRKuD52nffn3s5mtcc4VRdoXy29frgZyzCzLzJKAq4Dl4RXM7GTgP4CLu5OQiYiIiPQXMUvKnHN7gHnA88Ba4Cnn3AdmdoeZXRyq9q/AMOBpM3vPzJYfpDkRERGRfiWmc8qccyuAFV3Kbg/7+ZxYxiMiIiLiF1rRX0RERMQHlJSJiIiI+ICSMhGRPi4YDMY7BBGJAl+uUyYDU7QXDTxaKUkp8Q5BpFsWLVqkxEykH1BSJr4QrfVm+vLaNSIiMrDp8qWISB8UDAYxM8wMoPNnjZiJ9F0aKRMR6YOCwWBnAmZmxOruLCLSezRSJiLSB2mkTKT/0UiZiEgfpJEykf5HI2UiIiIiPqCRsiOQueC5zp+fnXc6AF948LXOsm/PyuG7505k2k9eZHvjpwAUpKfwp/lncNsz/8fjb2/qrPvWD2ZRsrmeb/y2uLPsX75YyDXTx+13nFl5I3n4uql8fclqVpbvu1f7hrsv5LG3aqL/IkX6qmBg389zV3n//vqsfWVnLoDP3wb35ULTVq/shMlw/auw/CZ4Z+m+ujeXw0fvweNX7Su76KdQ9LX9jzNxNlzzJDx2Jaz7c1gs9VD8m+i8rkNYuHBhrx9DRHqf9fUh76KiIldcXHz4ilESnij5zYa7L4x3CHGnJTEGuGDAS4T8xq9xiYTrQ+dpX/5db2ZrnHNFkfZppOwI+DH58XOyKCIicRY+shuVen0jeetrlJSJiIj0d0qi+gRN9BcRERHxAY2UiYiISK+b+fhMGlobotZetO6XnJKUwutXvx6Vto6WkjIREZEjEO25vH6crxxNDa0NvpycH63kLhqUlIlI/9Ldicp9QLT/s/Djf4h9WXeTqMwFz/X7hEuiQ0mZiPQvfpzQfISJYneTqL68PICI7KOJ/iIiIiI+oKRMRERExAd0+VJERERiwk+T6v1II2UiElPBYDDeIYiIDzxx0RM8cdET+5XdMPkGSq4tIW1IWmfZpOMmUXJtCZflXLZf3ZVzVvKLs3+xX9ntM24/YH7lmRlnUnJtCWdmnLlfecm1Jdw+4/ZovJSo0UiZiMTUokWLlJiJDFCRvpASqeylK146oCz42SDBzwb3Kxs5dGS323xw1oMHlM2ZOIc73rjjUCHHlEbKRERERHxASZmI9LpgMIiZYWYAnT9rxExEZB9dvhSRXhcMBjsTMDPDORffgEREfEgjZSIiIiI+oKRMRERExAeUlImIiIj4gOaUiUivCwaDLFq0qHN774T/hQsXRn+yvx9vSJ78mXhHICJ9gJIy6TO6uxJ0d+vpBs6xE7OJ/tG8GXkw4M+bm4tIvxXTpMzMZgM/AxKAh5xzd3fZ/zngp8BJwFXOuWWxjK+7Mhc8F+8QDhAYkhjvEHqdkigRkb7Nj7dZSklKiXcInWKWlJlZArAYOBfYDKw2s+XOubKwajXAdcD3YhVXT224+8KotZW54LmoticST939YyUw8+pu1dVnQ6R/ieYf1oVLC/vlH+qxHCmbBlQ65z4EMLMngEuAzqTMObchtK8jhnGJSBR0N4nKXKCES/xv8qIXqG9ui1p70brCEhiSyPsLz4tKW+I/sUzK0oFNYdubgelH0pCZzQXmAmRkZFBS4mXLo0ePZsiQIVRXVwOQkpLCuHHjKC0tBSAhIYH8/HyqqqrYvXs3ABMmTKC+vp4dO3YAMGbMGBITE9m4cSMAgUCA9PR0ysq83DExMZG8vDzWr19PS0sLABMnTqSuro66ujrvhaanM2jQIDZt8l7uiBEjGDVqFOXl5QAkJSWRm5sL0Bl7Xl4e27ZtY+fOnQCMHTuWjo4OamtrAUhNTSU1NZV169YBkJycTE5ODuXl5bS1eb848vPzqa2tpb7emwczfvx42tra2LJlCwBpaWkEAgEqKysBGDp0KNnZ2ZSVldHe3g5AQUEBNTU1NDQ0AJCVlUVzczNbt24FYOTIkQwfPpyqqioAhg0bRlZWFqWlpTjnMDMKCgqorq6mqakJgOzsbBobG9m+fXuf7KeKigpaW1vVT1HqJ9h33vu5nwqBmpqaPtFP4e+pPk/R6af65jae/dK4qPZTND5Pp/7rm519PdD7qampqc/83gvvp0OxWK2sbWaXA7Odc98IbX8FmO6cmxeh7hLgT92ZU1ZUVOSKi4ujHW5M6PKlDER95rzvQxP9++ulnHjy63nq17hirS+f82a2xjlXFGlfLNcpqwXGhm1nhMpEREREBrxYJmWrgRwzyzKzJOAqYHkMjy8iIiLiWzFLypxze4B5wPPAWuAp59wHZnaHmV0MYGZTzWwzMAf4DzP7IFbxiYiIiMRTTNcpc86tAFZ0Kbs97OfVeJc1RUT6tZmPz6ShtSFq7UVr/aeUpBRev/r1qLTV14V/Y/LZeacD8IUHX+ss+/asHL577kSm/eRFtjd+CkBBegp/mn8Gtz3zfzz+9r7vtr31g1mUbK7nG7/dNwf6X75YyDXTx+13nFl5I3n4uql8fclqVpZv7yzfcPeFPPZWTfRfpPiKVvQXEYmDhtYGX05U9uPinn4Qnozt9bOV6/nZyvX7lZXWNkRc/mL6v6w8oOwH/13CD/57/3NgZfn2iM/346LlEn1KykRERCLw47cclZz1b7Gc6C8iIiIiB6GkTERERMQHlJSJiIiI+ICSMhEREREf0ER/EZE4Cf+m4xMXPQHAVX+6qrPshsk3cOOUGzn7qbPZ0ezdV2/ScZN46gtPEfxrkN+v/31n3ZVzVlJWV8b8l+Z3lt0+43bmTJyz33HOzDiTB2c9yLyV83hl8yud5SXXlvD0uqej/yJFpNuUlImIxEmkJTEilb10xUsHlAU/GyT42eB+ZSOHjux2mw/OevCAsjkT53DHG3ccKmQR6UVKykRE4kRrgvmbH5efCAxJjHcIvaonn4nu1PXjWoCHoqSsl3T3w9zden5cL0dEjo4f/8NQouiJ5u/czAXP6Xd4N/nxMxFLSsp6iT6A0p9MXvQC9c1tUWsvGiMQgSGJvL/wvChEIyLiD0rKROSw6pvbfPeHhh8vLYmIHA0tiSEiIiLiA0rKRERERHxASZmIiIiID2hOmYh0S/gcrmfnnQ7AFx58rbPs27Ny+O65E5n2kxfZ3vgpAAXpKfxp/hnc9sz/8fjbmzrrvvWDWZRsrucbvy3uLPuXLxZyzfRx+x1nVt5IHr5uKl9fspqV5ds7y/02v01EJBqUlIlIt0RKhCKVvf3Dcw4ou+vSk7jr0pP2KxuVn9ztNh++bmpPQu0z/Lj8REpSSrxDEBmwlJSJSLfo247RFc31mAqXFg749Z1E+gMlZSLSLX67ZKgkUUT6GyVlIiIiR6Anfxh0p67f/vCR2FNSJiIicgSUREm0aUkMERERER9QUiYiIiLiA7p8KSLd4reJ9YEhifEOQUQkqpSUichhRXPuTOaC5zQXR0QkAiVlIjLwBANRrld/5LGIiIQoKRORgUdJlIj4kCb6i4iIiPiAkjIRERERH9DlSxERn+rJDcu7U1f3xxTxNyVlIiI+pSRKZGCJaVJmZrOBnwEJwEPOubu77D8G+C1wKlAHXOmc2xDLGEXkyOg+gCIiRydmSZmZJQCLgXOBzcBqM1vunCsLq/Z1YKdzboKZXQXcA1wZqxhF5MgpiRIROTqxnOg/Dah0zn3onGsFngAu6VLnEmBp6OdlwCwzsxjGKCIiIhIXsUzK0oFNYdubQ2UR6zjn9gD1QGpMohMRERGJoz450d/M5gJzATIyMigp8SbDjh49miFDhlBdXQ1ASkoK48aNo7S0FICEhATy8/Opqqpi9+7dAEyYMIH6+np27NgBwJgxY0hMTGTjxo0ABAIB0tPTKSvzrrImJiaSl5fH+vXraWlpAWDixInU1dVRV1cHQHp6OoMGDWLTJi8HHTFiBKNGjaK8vByApKQkcnNzqaiooLW1FYC8vDy2bdvGzp07ARg7diwdHR3U1tYCkJqaSmpqKuvWrQMgOTmZnJwcysvLaWtrAyA/P5/a2lrq672FMcePH09bWxtbtmwBIC0tjUAgQGVlJQBDhw4lOzubsrIy2tvbASgoKKCmpoaGhgYAsrKyaG5uZuvWrQCMHDmS4cOHU1VVBcCwYcPIysqitLQU5xxmRkFBAdXV1TQ1NQGQnZ1NY2Mj27dvVz+pn9RP6if1k/ppQPfToZhz7rCVosHMZgBB59z5oe3bAJxzd4XVeT5U5w0zGwxsBdLcIYIsKipyxcXFvRu8iIiISBSY2RrnXFGkfbG8fLkayDGzLDNLAq4Clnepsxy4NvTz5cBLh0rIRERERPqLmF2+dM7tMbN5wPN4S2I84pz7wMzuAIqdc8uBh4H/MrNK4GO8xE1ERESk34vpnDLn3ApgRZey28N+bgHmxDImERERET/QvS9FREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4QMxW9O8tZrYD2BjvOAaA44G/xTsIkRjSOS8Djc752BjvnEuLtKPPJ2USG2ZWfLDbQoj0RzrnZaDROR9/unwpIiIi4gNKykRERER8QEmZdNev4x2ASIzpnJeBRud8nGlOmYiIiIgPaKRMRERExAeUlImIiIj4gJIyiQkzSzaz35jZu2bWamaV8Y5JpDeZ2Rlm9nsz22xmzWa23syCZnZMvGMT6S1mdpaZOTPLiHcsfZGSsn7KzJLiHUMXCUAr3kTSJ+Ici/RDPjznZwJVwDVAPnArcCPw0zjGJP2MD897OQpKyvoJM1tlZg+b2Z1m9hFQY2anmdmrob/Sd5rZY2Y2Muw5wa4jVmZ2euivnMywsqvNrMrMWszsr2Z2UajO6WF1JoRGBXaFjvWCmRXu3e+c+8Q5d71z7t+BD3v1zZABoQ+c83c7525xzr3qnKt2zj0D3A1c0Zvvi/Rvfj/v5egoKetfrgDSgFnAHOAFYDMwDfgCUAAs60mDZnYq8CjwODAZuJcuf+mb2SjgNWA7cAZwGlABrDKziLeSEImSvnbOfwb4pCfxiETQ18576abB8Q5Aouoj4EbnXIeZ3Qk0ANc551oBzOwrwHtm9jnn3KvdbPNm4HXn3I9C2xVmNhr497A6NwAbnHM37C0ws5uAvwe+hC7XSO/pM+e8mU0CvgP8oAevTySSPnPeS89opKx/WeOc6wj9fCLw5t4PKYBz7n2gPrSvu/KBN7uUvdFleypwqpk17X0AjUAmkNODY4n0VJ84580sB2804wnn3IM9iEUkkj5x3kvPaaSsf+npZZEOwLqUJUaod7gVhgcBK4F5EfbV9zAmkZ7w/TlvZgXA/wJ/xBtpEDlavj/v5cgoKeu/PgC+ZmZJYUPak4EAUBqqsx0YaWYJzrn2UNkpXdopA2Z0KTuty3YxcB2w2TnXEqX4RXrKd+e8mU0F/gz8DviO0y1UJPp8d97LkdPly/7rQSAFWGJmBaFvz/wX8Bfn3F9CdV4GhgJ3mFm2mc0BvtWlnQeAmWZ2h5lNNLOLgX8O7dv7H8yDeEte/NG8tZkyQ9/s+YmZfXZvQ2aWb2ZTgNFAkplNCT30lW6JBl+d82b2ObxRhT8CdwGjzGx0aJ6OSLT46rwPkx/2O37vY2h0X3o/5JzTox88gFXAQ13KTgNeBZqBXcBjwMgudf4Rb4mKZuB/gKvwPoCZYXWuxltv6VO8OQZXhOqcGlZnPN43d3aE6m3EGx3ICquzIfS8ro/MaL8fevT/h9/PeWDJQc53F+/3To++++gD5/1ZBzvvgdPi/f75/aEbkkuPmdlXgd8Aqc65XXEOR6TX6ZyXgUjnfexpTpkclpl9D2/4+2O8b9/cAzytD6n0VzrnZSDSeR9/SsqkO07Cm1twHLAJb6h6YVwjEuldOudlINJ5H2e6fCkiIiLiA/r2pYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4gJIyERERER/4/7HM4ZKH3it/AAAAAElFTkSuQmCC\n",
      "text/plain": [
       "<Figure size 720x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_evaluation('allenai/led-base-16384')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAmUAAAF9CAYAAABF4h9MAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/Il7ecAAAACXBIWXMAAAsTAAALEwEAmpwYAAA/8klEQVR4nO3deXyU5b3//9eHmBgQkmIMIAlLTggJMRHQACJaWnHB4/atilsXtQtWC7b1dMG2Pxm0rcuxfrtIT09PtdBTcbetC0f9iqLVuhBcTmJIIDEQCLIYIUtJTEiu3x/3JA7DAAlMZu4k7+fjMY/Mfd3XXPdn5r4n+eS6r/u6zTmHiIiIiMTXoHgHICIiIiJKykRERER8QUmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiUivMrNlZrYxzjEEzEzz/xyCma02s9XxjkNkoFJSJtLPmdnnzMwd5PHneMcYDWb2L8Hka0q8YwnXmRSGPPaa2VYzW2FmOfGO70DMbFAw9v8T71hEBoKj4h2AiMTMfcDqCOUfxDiO3vIvwGJgI/Bu2LqfAnfEOJ5IvgdsB44GpgJfB840swLn3I64RhbZILzPdDnw1/iGItL/KSkTGTjecM71i16xnnLO7QX2xjsO4G/OucrOBTMrA5YCVwP/HreoRMQXdPpSRAAws28HT61Ni7Du88F184PLx5rZnWb2jpnVm1mzma01sy91c1vOzAIRyvcbf2Zm15jZc8HTfa1mVmNmvzGzlNA6wP8LLv4x5DRhILg+4pgyMzvXzF4zs3+aWUNwOzPC6owPtvVTM7vMzErNrMXM1pvZZd15vwfxcvDnhLBtHmNmPzezquB7/tDMfmdmx4bVm2JmT5nZ9mBMtWb2hJmNDamz0cyWRXjvBx1nZ2bjgbbg4tUhn+nq4PoEM7vZzMrNbI+Z7Tazd83sW4fzQYiIespEBpKhZnZchPJG59wnwMPAL4CrgDVhda4CWoFHg8v/AlwBPAb8HkgGLgb+28ySnHP3RzHuBcB64P8C9cBJwHzgRGB2sM4reKcnFwXj+Xuw/H8P1GgwoXoIqAACQBLwTeBlM5vjnHst7CXnAtcCvwN24516fNDM3nXOrT/M95YV/FkXEtfRwCrgBOAPwDpgIvAtYKaZzXDOtZhZOvBCMJZ7gI+A0cDZwBig5jBj6rQTrwdvOd7n+ftg+fbgz1uCj2XB7ScD+cDpeL1/ItJTzjk99NCjHz+AzwHuII9rQuo+D2wFBoWUJQEfA38NKTsaSAjbjuElExVh5cuAjWFlDghEiDVS3SER6l0dbGNmSNmZ4e8nZF3A+3XXtXxU8H1uBj4TUp4JNALFIWXjg+02ARkh5SOBT4C7urEPAsE2pgHHARnAeUAV0A5MCan7A7wEuCisjfODbXwzuHxRZ5uH2PZGYNmhPpNg2Wpgddjn5A7w+neAZ+J9fOuhR3966PSlyMBxD3BWhMdzIXVWAMcDnw8pmwsMBx7oLHDOfeKcawcws6TgabU0vJ6biaGnFo+Uc25PcDuDzCw12Nv3SnD1fqdau6kI733+p3Nud8i2tuB9Bieb2eiw1zzpnKsNqbsdKAeye7Ddt/B6oLYAT+Mlt5c5594NqXMlUAxsNLPjOh/AG8A/gTnBep1xXxjsXYu13cAJZjYpDtsW6Zd0+lJk4FjnnHvhEHWeAP4D73TlqmDZVXi9R091VjIzA76Nd7pvIl4vWajPAA1HHjKY2XTgZ8BpeKfIwrdzOMYHf66LsK4s+DMLrzet06YIdXcBx0YoP5Crg22mAl/ES3jbwurkAoPxkrdIRgR/voJ3+vUnwE1m9ndgJbDCOfdRD2I6XD8B/gaUmdl6vIT8MefcSzHYtki/pKRMRLo45xrM7GngYjO7Ae93xAXAo865lpCq3wfuxOs9+xleArEX+Ffguxz+RUQJoQvBweYv4Z2C+0HwZ3Ow3rNHsJ3D0X6A8vCE9GD+4YJXX5rZE3jv4b/NbJJzrjMBNOB1vPFakeyG4HlHuNLM/h3vVOiZeL2ht5jZmSG9bwcazJ9wgPJucc69ZmbZIdv+P8ANZna/c+5rR9K2yEClpExEwq0ALsVLsIYEHw+E1bkSeNk5t8/VlmY2h+7ZhXdKNNy/hC1fFNz+ec65jSHbyY3w2p7M2F8d/Bnp1NuksDq9wjnnzOx7wHt4Cdg3g6sqgeHd6NXsbOdt4G3gNjM7EViLl8BeFazS3c86YvOH2HY93vGywsyOwhsT+FUzu9Md/sUPIgOWxpSJSLiVeL0xV+ElX9uAF8PqtBPWQxS8GrC7PSQb2HfcGsGpKGZG2A7h28K7yjJcU/BnpAQk3Fq804jzw6bWGI13WnFtSM9Vr3HOleCNLbvWzDKCxQ8CeWb25fD6wWkojg0+Hx48jRxqHV5PYuhnsAHvqs3BIe2Mx+vZOlR87UALET5TM0sLq7sXKA0udmcfiEgY9ZSJDBynmFlLhPKdzrmuwf7OuU/M7HG85CQBWNo5qD/EX/F6ZlbgnV4cDVyHdzVjejdi+Q+8+cSexktKxgPfAErwxlt1ehYvKVhpZv8JdOCdTo00jut9YA9wvZk14Y2DK3XOlYZXdM7tNbPv4o3JesPM7ufTKTES8cbLxcrteO/pB8Ht3oN3SnC5mf0r8A+8pDQbuARvLNcyvPFpC83sL3i9a0fhTVMyDK/3qtN/AJcBL5jZA3j75wa8BO7kbsS3Bu+uA9/Du0Bhh3PuRWCdmb0aXL8dbyzcArwpRt4+nA9CZMCL9+WfeuihR+8+OPSUGG9EeM3nQ9bvN+UCXgKwBG+MVwveH/gFwDXB14wPqbuM/ae5MLzb92wNvv6t4DYj1Z0DvIl35eHOYJ10IkyrgZe0lOJNKdG1ngjTPwTL/xV4DS+Za8SbEuSUsDrjg239NMLrVxMyhcRB9kEg2MaEA6xfHYxhZHA5Gfhx8L204PVcvgfcBYwN1pkK/BnvNGsz3lxnfwcujtD+9cF6nwTbnBfpM4n0fvDmS3s5+Pm7zvXAzXgJ40fBGD8AftP5HvTQQ4+eP8y5ngzDEBEREZHeoDFlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDfX6esuOOO86NHz8+3mGIiIiIHNLatWs/cs5FnM+xzydl48ePp7i4ON5hiIiIiBySmW060DqdvhQRERHxASVlIiIiIj6gpExERETEB/r8mDIRERGJnra2NrZs2UJLS0u8Q+nTkpOTyczMJDExsduvUVImIiIiXbZs2cKwYcMYP348ZhbvcPok5xx1dXVs2bKFrKysbr9Opy9FRESkS0tLC2lpaUrIjoCZkZaW1uPeRiVlIiIisg8lZEfucD5DJWUiIiLS7xUXF3PjjTcecP3WrVu59NJLYxjR/jSmTERERPqc9vZ2EhISul2/qKiIoqKiA64fPXo0jz32WDRCO2zqKRMRERFf2bhxI3l5eXzxi19k0qRJXHrppezZs4fx48fzwx/+kJNOOolHH32U559/npkzZ3LSSScxb948mpqaAFizZg2nnnoqkydPZvr06TQ2NrJ69WrOP/98AF5++WWmTJnClClTmDp1Ko2NjWzcuJGCggLAG1d37bXXUlhYyNSpU3nppZcAWLZsGRdffDFz584lJyeHH/zgB1F93+opExERkYiWPPU+ZVsbotpm/ugUFl9wwiHrVVRUcN999zFr1iy++tWv8tvf/haAtLQ03n77bT766CMuvvhiXnjhBY455hjuvPNO7rnnHhYtWsTll1/Oww8/zLRp02hoaGDw4MH7tH333XezdOlSZs2aRVNTE8nJyfusX7p0KWZGSUkJ5eXlnH322axfvx6Ad999l3feeYejjz6a3NxcFi5cyJgxY6Ly2ainTERERHxnzJgxzJo1C4AvfelLvPrqqwBcfvnlALzxxhuUlZUxa9YspkyZwvLly9m0aRMVFRUcf/zxTJs2DYCUlBSOOmrfPqhZs2Zx00038etf/5rdu3fvt/7VV1/lS1/6EgB5eXmMGzeuKymbM2cOqampJCcnk5+fz6ZNB7yVZY+pp2ygC6RGub366LYnIiJx050erd4SfvVi5/IxxxwDeHOBnXXWWTz44IP71CspKTlk24sWLeK8885j5cqVzJo1i+eee26/3rIDOfroo7ueJyQksHfv3m69rjuUlA103U2iAqlKuEREJGZqamp4/fXXmTlzJitWrOC0007jnXfe6Vp/yimn8K1vfYvKykomTJjAP//5T2pra8nNzeXDDz9kzZo1TJs2jcbGxv1OX1ZVVVFYWEhhYSFr1qyhvLycKVOmdK0//fTTeeCBBzjjjDNYv349NTU15Obm8vbbb/fqe9bpSxEREfGd3Nxcli5dyqRJk9i1axfXX3/9PuvT09NZtmwZV155JSeeeCIzZ86kvLycpKQkHn74YRYuXMjkyZM566yz9pvE9Ze//CUFBQWceOKJJCYmcu655+6z/oYbbqCjo4PCwkIuv/xyli1btk8PWW8x51yvb6Q3FRUVueLi4niH0f+pp0xEZEBYt24dkyZNimsMGzdu5Pzzz6e0tDSucRypSJ+lma11zkWcm0M9ZSIiIiI+oKRMREREfGX8+PF9vpfscCgpExEREfEBJWUiIiIiPqCkTERERMQHlJSJiIiI+ICSMhEREen3li1bxoIFCwAIBALcfffdcY5of0rKRERExLecc3R0dMQ7jJhQUiYiIiK+snHjRnJzc/nKV75CQUEBt912G9OmTePEE09k8eLFXfX+9Kc/ceKJJzJ58mS+/OUvA/DUU08xY8YMpk6dyplnnsn27dvj9TZ6TPe+FBERkcj+ZxFsO/QNvntkVCGce8chq23YsIHly5fT0NDAY489xltvvYVzjgsvvJBXXnmFtLQ0fvrTn/KPf/yD4447jo8//hiA0047jTfeeAMz4w9/+AN33XUXv/jFL6L7HnqJkjIRERHxnXHjxnHKKafwve99j+eff56pU6cC0NTUxIYNG3jvvfeYN28exx13HADHHnssAFu2bOHyyy/nww8/pLW1laysrLi9h55SUiYiIiKRdaNHq7ccc8wxgDem7Oabb+a6667bZ/1vfvObiK9buHAhN910ExdeeCGrV68mEAj0dqhRozFlIiIi4lvnnHMO999/P01NTQDU1tayY8cOzjjjDB599FHq6uoAuk5f1tfXk5GRAcDy5cvjE/RhUk+ZiIiI+NbZZ5/NunXrmDlzJgBDhw7lz3/+MyeccAI//vGPmT17NgkJCUydOpVly5YRCASYN28ew4cP54wzzqC6ujrO76D7zDkX7xiOSFFRkSsuLo53GP1fIBUC9fGOQkREetm6deuYNGlSvMPoFyJ9lma21jlXFKm+Tl+KiIiI+EBMkzIzm2tmFWZWaWaLIqz/v2b2bvCx3sx2xzI+ERERkXiJ2ZgyM0sAlgJnAVuANWb2pHOurLOOc+67IfUXAlNjFZ+IiIhIPMWyp2w6UOmc+8A51wo8BFx0kPpXAg/GJDIRERGROIvl1ZcZwOaQ5S3AjEgVzWwckAW8eID184H5AJmZmZSUeLMNjxo1isGDB3ddaZGSksLYsWMpLS0FICEhgfz8fKqqqtizZw8AEyZMoL6+np07dwIwevRoEhMT2bRpEwCpqalkZGRQVuZ16CUmJpKXl8eGDRtoaWkBYOLEidTV1XVdlpuRkcGgQYPYvNl7u8OHD2fkyJGUl5cDkJSURG5uLhUVFbS2tgKQl5fH9u3b2bVrFwBjxoyho6OD2tpaANLS0khLS2P9+vUAJCcnk5OTQ3l5OW1tbQDk5+dTW1tLfb03IH/cuHG0tbWxdetWANLT00lNTaWyshKAIUOGkJ2dTVlZGe3t7QAUFBRQU1NDQ0MDAFlZWTQ3N5MOlJSUMGLECIYNG0ZVVRXgXQWTlZVFaWkpzjnMjIKCAqqrq7suX87OzqaxsZEdO3ZoP/Xyftq2bRuA9pP2k/aT9tNh7yeAlpaWrvtNJicns3fvXvbu3btPnc79eNRRR3HUUUd1bXPQoEEkJyfT3NxM58WEgwcPprW1teszP/roo3HOdbWRmJhIQkJCj9vo6OjoOhYSExMZNGgQn3zySddnevTRR3e1YWYMHjyYTz75pEdtJCUl0dzcDNDVRvjn097e3tVGUlISZsYnn3xCa2srNTU1++yng4nZ1Zdmdikw1zn39eDyl4EZzrkFEer+EMh0zi08VLu6+jJGdPWliMiAoKsvo8fPV1/WAmNCljODZZFcgU5dioiIDEi//vWvmTRpEl/84hfjHUpMxfL05Rogx8yy8JKxK4CrwiuZWR4wHHg9hrGJiIiIT/z2t7/lhRdeIDMzM96h7Ke9vZ2EhIReaTtmPWXOub3AAuA5YB3wiHPufTO71cwuDKl6BfCQ6+uz2oqIiEiPffOb3+SDDz7g3HPPJTU1lauvvprTTz+dcePG8cQTT/CDH/yAwsJC5s6d2zWOa+3atcyePZuTTz6Zc845hw8//BCA//qv/2LatGlMnjyZSy65pGu83qOPPkpBQQGTJ0/ms5/9LADLli1jwYJPR1Sdf/75rF69GvDGEf7bv/0bkydP5vXXX+fPf/4z06dPZ8qUKVx33XVdY9SOVExvs+ScWwmsDCu7JWw5EMuYREREJLI737qT8o/Lo9pm3rF5/HD6Dw+4/ne/+x3PPvssL730Evfeey8vvPACL730EmVlZcycOZPHH3+cu+66iy984Qs888wznHfeeSxcuJC//e1vpKen8/DDD/PjH/+Y+++/n4svvphvfOMbAPzkJz/hvvvuY+HChdx6660899xzZGRksHv37kPG/M9//pMZM2bwi1/8gnXr1nHnnXfy2muvkZiYyA033MADDzzAV77ylSP+bHTvSxEREfGtc889l8TERAoLC2lvb2fu3LkAFBYWsnHjRioqKigtLeWss84CvNOLxx9/PAClpaX85Cc/Yffu3TQ1NXHOOecAMGvWLK655houu+wyLr744kPGkJCQwCWXXALAqlWrWLt2LdOmTQOgubmZESNGROW9KikTERGRiA7WoxUrRx99NOBNk5GYmIiZdS3v3bsX5xwnnHACr7++/1D0a665hr/+9a9MnjyZZcuWdZ2O/N3vfsebb77JM888w8knn8zatWs56qijuqa5ALqm5wBv2ovOcWTOOa6++mpuv/32qL9X3ftSRERE+qzc3Fx27tzZlZS1tbXx/vvvA9DY2Mjxxx9PW1sbDzzwQNdrqqqqmDFjBrfeeivp6els3ryZ8ePH8+6779LR0cHmzZt56623Im5vzpw5PPbYY11z0H388cddc8cdKfWUiYiISJ+VlJTEY489xo033kh9fT179+7lO9/5DieccAK33XYbM2bMID09nRkzZtDY2AjA97//fTZs2IBzjjlz5jB58mTAmzg4Pz+fSZMmcdJJJ0XcXn5+Pj/96U85++yz6ejoIDExkaVLlzJu3Lgjfi8xmzy2t2jy2BjR5LEiIgOCJo+NHj9PHisiIiIiB6CkTERERMQHlJSJiIiI+ICSMhEREdlHXx9v7geH8xkqKRMREZEuycnJ1NXVKTE7As456urqSE5O7tHrNCWGiIiIdMnMzGTLli3s3Lkz3qH0acnJyT2+obqSMhEREemSmJhIVlZWvMMYkHT6UkRERMQHlJSJiIiI+ICSMhEREREfUFImIiIi4gNKykRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4QEyTMjOba2YVZlZpZosOUOcyMyszs/fNbEUs4xMRERGJl6NitSEzSwCWAmcBW4A1Zvakc64spE4OcDMwyzm3y8xGxCo+ERERkXiKZU/ZdKDSOfeBc64VeAi4KKzON4ClzrldAM65HTGMT0RERCRuYtZTBmQAm0OWtwAzwupMBDCz14AEIOCceza8ITObD8wHyMzMpKSkBIBRo0YxePBgqqurAUhJSWHs2LGUlpYCkJCQQH5+PlVVVezZsweACRMmUF9fz86dOwEYPXo0iYmJbNq0CYDU1FQyMjIoK/M69BITE8nLy2PDhg20tLR4QU+cSF1dHXV1dd4bzchg0KBBbN7svd3hw4czcuRIysvLAUhKSiI3N5eKigpaW1sByMvLY/v27ezatQuAMWPG0NHRQW1tLQBpaWmkpaWxfv16AJKTk8nJyaG8vJy2tjYA8vPzqa2tpb6+HoBx48bR1tbG1q1bAUhPTyc1NZXKykoAhgwZQnZ2NmVlZbS3twNQUFBATU0NDQ0NAGRlZdHc3Ew6UFJSwogRIxg2bBhVVVUADB06lKysLEpLS3HOYWYUFBRQXV1NU1MTANnZ2TQ2NrJjxw7tp17eT9u2bQPQftJ+0n7SftJ+8ul+Ohhzzh2yUjSY2aXAXOfc14PLXwZmOOcWhNR5GmgDLgMygVeAQufc7gO1W1RU5IqLi3sz9L7rjnHQsjveUewv+TOwaFO8oxAREYk5M1vrnCuKtC6WPWW1wJiQ5cxgWagtwJvOuTag2szWAznAmtiE2M+07IZAfbyj2F8gNd4RiIiI+E4sx5StAXLMLMvMkoArgCfD6vwV+ByAmR2HdzrzgxjGKCIiIhIXMUvKnHN7gQXAc8A64BHn3PtmdquZXRis9hxQZ2ZlwEvA951zdbGKUURERCReYnn6EufcSmBlWNktIc8dcFPwISIiIjJgaEZ/ERERER9QUiYiIiLiA0rKRERERHxASZmIiIiIDygpExEREfEBJWUiIiIiPqCkTERERMQHlJSJiIiI+ICSMhEREREfUFImIiIi4gNKykRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4gJIyERERER9QUiYiIiLiA0rKRERERHxASZmIiIiIDygpExEREfEBJWUiIiIiPhDTpMzM5ppZhZlVmtmiCOuvMbOdZvZu8PH1WMYnIiIiEi9HxWpDZpYALAXOArYAa8zsSedcWVjVh51zC2IVl4iIiIgfxCwpA6YDlc65DwDM7CHgIiA8KZNoCqTGOwIRERHphlgmZRnA5pDlLcCMCPUuMbPPAuuB7zrnNodXMLP5wHyAzMxMSkpKABg1ahSDBw+muroagJSUFMaOHUtpaSkACQkJ5OfnU1VVxZ49ewCYMGEC9fX17Ny5E4DRo0eTmJjIpk2bAEhNTSUjI4OyMi93TExMJC8vjw0bNtDS0gLAxIkTqauro66uznujGRkMGjSIzZu90IcPH87IkSMpLy8HICkpidzcXCoqKmhtbQUgLy+P7du3s2vXLgDGjBlDR0cHtbW1AKSlpZGWlsb69esBSE5OJicnh/Lyctra2gDIz8+ntraW+vp6AAqBuoUfsHXrVgDS09NJTU2lsrISgCFDhpCdnU1ZWRnt7e0AFBQUUFNTQ0NDAwBZWVk0Nzezbds2AEaMGMGwYcOoqqoCYOjQoWRlZVFaWopzDjOjoKCA6upqmpqaAMjOzqaxsZEdO3Z4cT1+Gk1NTdpPwf00btw42trafLef9H3SftJ+0n7Sfor+fjoYc84dslI0mNmlwFzn3NeDy18GZoSeqjSzNKDJOfeJmV0HXO6cO+Ng7RYVFbni4uLeDL3vCqRCoD7eUezPr3GJiIj0MjNb65wrirQulgP9a4ExIcuZwbIuzrk659wnwcU/ACfHKDYRERGRuIplUrYGyDGzLDNLAq4AngytYGbHhyxeCKyLYXwiIiIicROzMWXOub1mtgB4DkgA7nfOvW9mtwLFzrkngRvN7EJgL/AxcE2s4hMRERGJp1gO9Mc5txJYGVZ2S8jzm4GbYxmTiIiIiB9oRn8RERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4QEwnjxUREZE4CKRGub366LYngJKy/i/0izh/tffz95/7tGz2Ivj8zXB3LjRt88qOnwzXvQJP3ghvL/+07k3l8OG78OAVn5ad/0sounbf7UycC1c9DCsuh/XPhsRSD8V/jM77EhGR7utOEhVIVbIVZ+aci3cMR6SoqMgVFxfHOwx/8usXzK9xiYgMZPrdHBNmttY5VxRpncaUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4gJIyERERER9QUiYiIiLiA0rKRERERHzgqMN5kZmdCOQA/+Oc22NmRwNtzrmOqEYnEqJweWFU2yu5uiSq7YmIiByJHiVlZnYs8DgwG3B4idkHwFKgAbgp2gGKdOpOElW4vFDJloiI9Ek9PX15N9ABjAf2hJQ/BpwTpZhEREREBpyenr48G7jIOVdjZqHl64GxUYtKREREZIDpaU/ZscCuCOXD8HrQREREROQw9LSn7G1gLvDbsPKvAG9GJSKJrkBqvCPYX/Jn4h2BiIiI7/Q0KVsC/NXMMoEE4MtmdgJwEXBGtIOTIxSoj2JbqdFtT0RERPbRo9OXzrn/B1wAzMQ7XflDYBRwjnPutUO93szmmlmFmVWa2aKD1LvEzJyZFfUkPhEREZG+qsfzlDnnXgRe7OnrzCwBb+qMs4AtwBoze9I5VxZWbxjwbXQ6VERERAaQWM7oPx2odM594JxrBR7CO+0Z7jbgTqAlhrHFRSAQiHcIIiIi4hM9SsrMrM3MWiM8PjGzejNbY2bfOMDLM4DNIctbgmWh7Z8EjHHOPdOjd9FHLVmyJN4hiIiIiE/09PTl94H/D3geeD1YNhPvlOQv8Gb4X2pm7c65+3vSsJkNAu4BrulG3fnAfIDMzExKSrwZ3EeNGsXgwYOprq4GICUlhbFjx1JaWgpAQkIC+fn5VFVVsWePN/fthAkTqK+vZ+fOnQCMHj2axMRENm3aBEBqaioZGRmUlXlnWRMTE8nLy2PDhg20tHideRMnTqSuro66ujoAMjIyGDRoEJs3ezno8OHDGTlyJOXl5QAkJSWRm5sL0BV7Xl4e27dvZ9cub8aRMWPG0NHRQW1tLQBpaWmkpaWxfv16AJKTk8nJyaG8vJy2tjYA8vPzqa2tpb7eG5A/btw42tra2Lp1KwDp6emkpqZSWVkJwJAhQ8jOzqasrIz29nYACgoKqKmpoaGhAYCsrCyam5tJD8Y6YsQIhg0bRlVVFQBDhw4lKyuL0tJSnHOYGQUFBVRXV9PU1ARAdnY2jY2N7Nixo9f3U+dnGs39VFFRQWtra5/YT9u2bQPw/X7qje+T9pP2k/bTke2nQqCiokL7qZf308GYc+6Qlboqm60A3nLO/TKs/DvAdOfcVWb2PeBLzrkpYXVmAgHn3DnB5ZsBnHO3B5dTgSqgKfiSUcDHwIXOueIDxVRUVOSKiw+42ncCgUDEHrLFixf7+3RmH7n6UrdZEhE5TH3k93xfZ2ZrnXMRL2Ts6Ziy84GnIpQ/HVxHcP2ECHXWADlmlmVmScAVwJOdK51z9c6545xz451z44E3OERC1hcFAgGcc3Qmw53PfZ2QiYiISK/raVLWAsyIUD6dTwfmDyLCIH3n3F5gAfAcsA54xDn3vpndamYX9jAOERERkX6lp2PK/gD8zswm4k1Z4fDGlH0HuDdY5/NAxPNHzrmVwMqwslsOUPdzPYytz1m8eHG8QxARERGf6GlS9mPgI+AmoDOZ2goEgF8Gl/8CPBaF2Po9nbIUERGRTj1Kypw3EOoe4B4zSwmWNYTV+TB64YmIiIgMDD2e0b9TeDImIiIiIoevR0mZmVXjjSOLyDn3L0cckYiIiMgAdDgD/UMlAicDpwG/ikpEIiIiIgNQT8eU/SxSuZn9EMiMSkQiIj4QCAR0MY6IxFS0bkj+GPDFKLUlIhJ3ujetiMRatJKyqUBrlNoSERERGXB6lJSZ2e/DHv9lZs8ADwAreidEEZHYCAQCmBlmBtD1XKcxRSQWejrQPydsuQPYAdwALI9KRCIicRI6jszMuu5RKyISCz0d6P/53gpEREREZCA7rMljzewoIDu4WBW82biISL+he9OKSKz1dExZgpktAeqBMmAdsNvMAmYWrYsGRETiTuPIRCTWetpTFgC+BdwMvBws+xywGC/BuyXiq0RERETkoHqalF0DXOecezSk7D0z+xD4BUrKRERERA5LT085jgDeiVD+DpB+5OGIiIiIDEw9TcoqgYsjlF8MVB15OCIiIiIDU09PX94F3GdmU4G/B8s+C1wKXBvNwEREREQGkp7OU7bczD4CfgjcFix+H7gA+GeUYxMREREZMHqUlJnZUOBF59wzIWUnAz8DzgISohueiIiIyMDQrTFlZjbazF7Fm5+s3szuNLMkM/s98DqwBzitF+MUERER6de621N2O5ACfBuYB3wPmAVsBPKdc5W9Ep2IiIjIANHdpOwM4Ern3Ktm9gSwBXjBORfotchEREREBpDuJmXHE5zywjm31cyagUd6Lap+YPyiZw5dqQc23nFeVNsTERERf+luUjYICL3peAfQHP1w+o/uJFHjFz2jZEtERESAnl19+aiZtQafJwN/CvaYdXHOnR21yEREROTg7hgHLbuj114gNTrtJH8GFm2KTlsDSHeTsuVhy3+OdiAiIiLSQy27IVAf7yj2F63kboDpVlLmnNNs/SIiIiK9qKf3vhQRERGRXqCkTERERMQHYpqUmdlcM6sws0ozWxRh/TfNrMTM3jWzV80sP5bxiYiIiMRLzJIyM0sAlgLnAvnAlRGSrhXOuULn3BTgLuCeWMUnIiIiEk+x7CmbDlQ65z5wzrUCDwEXhVZwzjWELB4DuBjGJyIiIhI3PZmn7EhlAJtDlrcAM8Irmdm3gJuAJLzbO4mIiIj0e7FMyrrFObcUWGpmVwE/Aa4Or2Nm84H5AJmZmZSUlAAwatQoBg8eTHV1NQApKSmMHTuW0tJSABISEsjPz6eqqoo9e/YAMGHCBOrr69m5cycAo0ePJjExkU2bvEnvUlNTycjIoKysDIDExETy8vLYsGEDLS0tAEycOJG6ujrq6uoAyMjIYNCgQWze7OWgw4cPZ+TIkZSXlwOQlJREbm4uQFfseXl5bN++nV27dgEwZswYOjo6qK2tBSAtLY20tDTWr18PQHJyMjk5OZSXl9PW1gZAfn4+tbW11Nd7c9aMGzeOtrY2tm7dCkB6ejqpqalUVnr3jx8yZAjZ2dmUlZXR3t4OQEFBATU1NTQ0eJ2WWVlZNDc3kx6MdcSIEQwbNoyqqioAhg4dSlZWFqWlpTjnMDMKCgqorq6mqakJgOzsbBobG9mxY0ev76fOzzSa+6miooLW1tY+sZ+2bdsG4Pv91BvfJ+0n7aeBuJ/G8unfEV/tJ9B+OsD36WDMudicITSzmUDAOXdOcPlmAOfc7QeoPwjY5Zw76Ax0RUVFrri4ONrhxkSfus1SINWfExSGKVxeSMnVJfEOQ0QkNvz6u9mvcfmAma11zhVFWhfLnrI1QI6ZZQG1wBXAVaEVzCzHObchuHgesAERkWiL9mzj+uMjIlEQs6TMObfXzBYAzwEJwP3OuffN7Fag2Dn3JLDAzM4E2oBdRDh1KSJyxLqTROk/fRGJsZiOKXPOrQRWhpXdEvL827GMR0RERMQvNKO/iIiIiA8oKRMRERHxASVlIiIiIj7gu3nKZGCa9eAsGlobDl2xGwqXF0alnZSkFF678rWotCUiInIoSsrEFxpaG3w3v1i0kjsREZHu0OlLERERER9QUiYiIiLiA0rKRERERHxAY8pERET6smjfNkziRkmZiIhIX+bH24H1cqIYCAQIBAK9uo140OlLERER6VOWLFkS7xB6hZIyERERER9QUiYiIiK+FwgEMDPMDKDreX86jakxZSIiIn1Z6Pit+au9n7//3KdlsxfB52+Gu3OhaZtXdvxkuO4VePJGeHv5p3VvKocP34UHr/i07PxfQtG1+25n4ly46mFYcTmsfzYklnoo/mN03leY0HFkZoZzrle2E09KykRERPqySAP9I5V9r2L/sgt/7T1CpRzf/Tavenj/sqJr4envRAxVDk6nL0VERKRPWbx4cbxD6BVKykRERKRP6U/jyEIpKRMRERHxASVlIiIivai/9upI9CkpExHp4/RH39/660Sn8dRfj3klZSIifZz+6MtA01+PeSVlIiIiUTYQJjqV6FNSJiLSB+mPvr8FAgGcc10TnHY+1/45fAPhmNfksSIifdBAmN1cJNRAOObVUyYiItKL+utEpxJ9SspERPo4/dH3t/50es0v+usxr6RMRKSP0x99GWj66zGvMWXiG4XLC+MdgoiISNyop0x86aHzH+Kh8x/ap+z6yddTcnUJ6YPTu8omHTuJkqtLuCTnkn3qrpq3it+c8Zt9ym6ZeQslV5fsUzY7czYlV5cwO3P2PuXh9URERHqbesrENyIlQpHKXrzsxf3KAqcGCJwa2KdsxJAR3W7z3jn39iBSERGR6ItpUmZmc4FfAQnAH5xzd4Stvwn4OrAX2Al81Tm3KZYxioiI9CmB1HhHsL/kz8Q7gj4pZkmZmSUAS4GzgC3AGjN70jlXFlLtHaDIObfHzK4H7gIuj1WMA1JPvszdqRuoP/xYRESkZ6L5OzeQqt/hcRbLnrLpQKVz7gMAM3sIuAjoSsqccy+F1H8D+FIM4xuY9AUUERHxhVgO9M8ANocsbwmWHcjXgP/p1YhEREREfMKXA/3N7EtAETD7AOvnA/MBMjMzKSnxBm6PGjWKwYMHU11dDUBKSgpjx46ltLQUgISEBPLz86mqqmLPnj0ATJgwgfr6enbu3AnA6NGjSUxMZNMmbyhbamoqGRkZlJV5HXqJiYnk5eWxYcMGWlpaAJg4cSJ1dXXU1dUBkJGRwaBBg9i82ctBhw8fzsiRIykvLwcgKSmJ3NxcgK7Y8/Ly2L59O7t27QJgzJgxdHR0UFtbC0BaWhppaWmsX78egOTkZHJycigvL6etrQ2A/Px8amtrqa/3er/GjRtHW1sbW7duBSA9PZ3U1FQqKysBGDJkCNnZ2ZSVldHe3g5AQUEBNTU1NDQ0AJCVlUVzczPbtm0DYMSIEQwbNoyqqioAhg4dSlZWFqWlpTjnMDMKCgqorq6mqakJgOzsbBobG9mxY8cB91PoZ+GX/dSpoqKC1tZW7Seff5+ivZ8KgZqaGu0nn+8nfZ+it58K8X7faT/17n46GIvVvaPMbCYQcM6dE1y+GcA5d3tYvTOB3wCznXM7DtVuUVGRKy4u7oWIe9/4Rc+w8Y7z4h2GLxQuL/TdNBR+jEliSONrZKDRMR8TZrbWOVcUaV0se8rWADlmlgXUAlcAV4VWMLOpwH8Cc7uTkMXD5CXPU9/cFrX2xi96JirtpA5O5L3FZ0elLRERkXiI9iTife0f65glZc65vWa2AHgOb0qM+51z75vZrUCxc+5J4N+BocCjZgZQ45y7MFYxdkd9c5sve7eildyJiEh0BQKBfntboGjrbhLVX89kxHRGf+fcSufcROdctnPuZ8GyW4IJGc65M51zI51zU4IPXyVkIiJ+pD/4/rZkyZJ4hyB9hG6zJCLSx+mPvkj/oKRMREQkygKBAGZGcChO13P1asrBKCkTEemD9Eff3wKBAM45Omc46Hyu/SMH48t5ykRE5OBCB4+bGbGa3khEeo96ykQkptRTIAPN4sWL4x2C9BHqKRORmFqyZEnvJWZ3jIOW3dFrL5AanXaSPwOLNkWnrQj0R9/f9I+IdJeSMhHpP1p2+3NG8mgldwdqXn/0RfoFJWUi0usCgcA+0zZ0Dk5fvHixEgrps6I9abcfJyaX2FJSJiK9ToPSpT/qbhKl+xxLd2mgv4iIiIgPKCkTkZjSoHQRkciUlIlITGkMmYhIZErKRERERHxAA/3FNwqXF8Y7hH2kJKXEOwQRERlAlJQdhtDLoJ9acBoAF9z7alfZt+fk8N2zJjL9Zy+wo/ETAAoyUnh64enc/MT/8uBbm7vqvvmjOZRsqefrfyruKvv5Fwq5asbYfbYzJ28E910zja8tW8Oq8h1d5RvvOI8Vb9ZE/03GWMnVJVFpp3B5YdTaEhERiSUlZYch0qXNkcre+vGZ+5XdfvGJ3H7xifuUjcxP7nab910zbb+yq2aM5Ud/USIiIiLSl2lMmYiIiIgPqKdMRMSnoj3OUqf2JZ5mPTiLhtaGqLUXre9HSlIKr135WlTaOlJKykREfKq7SZTGUkpf0NDa4Mvj1E8XmSkpOwzRvt+ZyEASesslERH5lJKyw+DHe5gpUZS+YsmSJUrKREQi0EB/ERERER9QUiYivS4QCGBmmBlA13P1mImIfEqnL0Wk14WOIzMznHO9uLHUT5/PX+39/P3nPi2bvQg+fzPcnQtN27yy4yfDda/AkzfC28s/rXtTOXz4Ljx4xadl5/8Siq7ddzsT58JVD8OKy2H9syGx1EPxH6PzvkSk31NSJiL9V2gy1unlO7xHqA/f2zfJ6nRP3v5lT3/He4Ra/2zk10cqExE5ACVlIhJTixcv7t0NBOp7t/3DoeRMRLpBSZmIxJTGkYkMXH6aE8yPlJRJt2huKREROVKaPPbglJRJt2huKREROVKhCdBD5z8EwBVPf3ohzfWTr+eGKTdwxiNnsLN5JwCTjp3EIxc8QuAfAR7f8HhX3VXzVlFWV8bCFxd2ld0y8xbmTZy3z3ZmZ87m3jn3smDVAl7e8nJXecnVJTy6/tHov8kjoKRMREREYiJST1mkshcve3G/ssCpAQKnBvYpGzFkRLfbvHfOvfuVzZs4j1tfv/VgIcdUTOcpM7O5ZlZhZpVmtijC+s+a2dtmttfMLo1lbLI/zS0lIiISOzFLyswsAVgKnAvkA1eaWX5YtRrgGmBFrOKSAwsEAjjnuuaU6nyupExERCT6Ynn6cjpQ6Zz7AMDMHgIuAso6KzjnNgbXdcQwLhEREZG4i+Xpywxgc8jylmCZ9AGzZ8+OdwgiIiL9Wp8c6G9m84H5AJmZmZSUeAP6Ro0axeDBg6murgYgJSWFsWPHUlpaCkBCQgL5+flUVVWxZ88eACZMmEB9fT07d3pXeYwePZrExEQ2bdoEQGpqKhkZGZSVle0Tw4YNG2hpaQFg4sSJ1NXVUVdXB0BGRgaDBg1i82YvBx0+fDgjR46kvLwcgKSkJHJzc6moqKC1tRWAvLw8tm/fzq5duwAYM2YMHR0d1NbWApCWlkZaWhrr168HIDk5mZycHMrLy2lrawOgvb2d2tpa6uu9yTPHjRtHW1sbW7duBSA9PZ3U1FQqKysBGDJkCNnZ2ZSVldHe3g5AQUEBNTU1NDQ0AJCVlUVzczMvv/wyJSUljBgxgmHDhlFVVQXA0KFDycrKorS0FOccZkZBQQHV1dU0NTUBkJ2dTWNjIzt27Oj1/QRQUlJCYmIieXl5vtxP+fn5vbaftm3zbhvk9/3U+X2K9n7KDe5/v+2nccG4ems/dR73fWU/9YXv06l3v0pDi7c+GsYveiYq7aQkH8UDl4wGor+fCsH7HvXSfoJPj1M//d4LjSuWeUQk1qv3oAvdkNlMIOCcOye4fDOAc+72CHWXAU875x47VLtFRUWuuLg4ytEeWLS+WNGWOjiR9xaf3Wvt9/r9CqOkcHmhL+fBGQii/d3YeMd5PX9RINW/M/r3Ylw67qNv/KJnDu8Y7GW9GtcAPU5jHZeZrXXOFUVaF8uesjVAjpllAbXAFcBVMdx+VETzy+DXL32nQCDAkiVLupY7r8JcvHixBvvLfrp7LPv9uBcRiZeYjSlzzu0FFgDPAeuAR5xz75vZrWZ2IYCZTTOzLcA84D/N7P1YxSf709WXIiIisRPTMWXOuZXAyrCyW0KerwEyYxmTiIiIiB/0yYH+EnuLFy+OdwgiItLH+ek+k51SklLiHUIXJWXSLTplKSIiRyKag+n9etHAkVJSJiISB7MenEVDa0PU2otWD0RKUgqvXflaVNrq60KvKH5qwWkAXHDvq11l356Tw3fPmsj0n73AjsZPACjISOHphadz8xP/y4NvfTo155s/mkPJlnq+/qdPZwv4+RcKuWrG2H22MydvBPddM42vLVvDqvIdXeUb7ziPFW/WRP9Niq8oKRMRiYOG1gZf/qfvx9NLfhCajHX61aoN/GrVhn3KSmsbIk4PM+Pnq/Yr+9FfSvjRX/Y9BlaV74j4er9OxyTRpaRMREQkAj9O3aLkrH+L5W2WREREROQAlJSJiIiI+ICSMhEREREfUFImIiIi4gMa6C8i/UsgNd4R7C/5M/GOQET6ACVlItJ/BOqj2FZqdNsTETkEJWUiInESOifYQ+c/BMAVT1/RVXb95Ou5YcoNnPHIGexs3gnApGMn8cgFjxD4R4DHNzzeVXfVvFWU1ZWx8MWFXWW3zLyFeRPn7bOd2ZmzuXfOvSxYtYCXt7zcVV5ydQmPrn80+m9SRLpNSZmISJxEmjw2UtmLl724X1ng1ACBUwP7lI0YMqLbbd475979yuZNnMetr996sJClr+ruaf1u11Mvcm9QUiYihzR5yfPUN7dFrb1oTICZOjiR9xafHYVo4kez5/ubHydqTR2ceHgvVBLVJygpE5FDqm9u893s5n78g9lTus2Sf0XzeB+/6BnffX/EnzQlhoiIiIgPKCkTERER8QElZSIiIiI+oDFlItItoWO4nlpwGgAX3PtqV9m35+Tw3bMmMv1nL7Cj8RMACjJSeHrh6dz8xP/y4Fubu+q++aM5lGyp5+t/Ku4q+/kXCrlqxth9tjMnbwT3XTONry1bw6ryHV3lGp8jIv2RkjIR6bHQZKzTr1Zt4FerNuxTVlrbEHFA/oyfr9qv7Ed/KeFHf9l34Puq8h0RX98fBvmLiIRTUiYi3eK33iklZiLS32hMmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAc00F9EJE78eEujlKSUeIcgMmApKZNuCQQCBAKBeIch0m9E876XhcsLfXkfTelb9Hs+/pSUSbcsWbJEX9YBzm9TUKQOTox3CCL9in7Px5+SMhE5pGjOUTZ+0TO+m/NMRMQPNNBfDigQCGBmmBlA13P9JyUi0j/o97y/qKdMDih0fIGZ4ZyLb0AiIhJV+j3vLzFNysxsLvArIAH4g3PujrD1RwN/Ak4G6oDLnXMbYxmjfCoQCLBkyZKu5c7/pBYvXqz/okRE+gG//Z7v7hXJH9z+AYUcum5fuwAmZkmZmSUAS4GzgC3AGjN70jlXFlLta8Au59wEM7sCuBO4PFYxyr70H5SISP/mt9/z3U2i7BrrcwlXd8RyTNl0oNI594FzrhV4CLgorM5FwPLg88eAOdaZtouIiIj0YxarrNjMLgXmOue+Hlz+MjDDObcgpE5psM6W4HJVsM5HYW3NB+YDZGZmnrxy5UoARo0axeDBg6murgYgJSWFsWPHUlpaCkBCQgL5+flUVVWxZ88eACZMmEB9fT07d+4EYPTo0SQmJrJp0yYAUlNTycjIoKzM69BLTEwkLy+PDRs20NLSAsDEiROpq6ujrq4OgIyMDE666/Vofnz848appKWlsX79egCSk5PJycmhvLyctrY2APLz86mtraW+vh6AcePG0dbWxtatWwFIT08nNTWVyspKAIYMGUJ2djZlZWW0t7cDUFBQQE1NDQ0NDVx77bWsXbt2v1hOO+00fvvb3wIwdOhQsrKyKC0txTmHmVFQUEB1dTVNTU0AZGdn09jYyI4dO4DD30/TH5ke1c/05QteZtCgQWzevBmA4cOHM3LkSMrLywFISkoiNzeXiooKWltbAcjLy2P79u3s2rULgDFjxtDR0UFtbS0AaWlpMd9PAFlZWTQ3N7Nt2zYARowYwbBhw6iqqgJis58ueKAmmruHp744FvC+T9HeT4WPnxbVWEsuebVX9tNVb18V1ThXnLQC6L3fewPt+xTtaWI23nFeTP4+he6n+fPn88Ybb+wXy7Rp07jvvvsA/+ynBQsW8Morr+wX68knn8wf//jHuPzeO5z9dOKJJ651zhVFOgb6ZFIWqqioyBUXF/du8OKLbm0REek9fen3fF+KNZyZHTApi+Xpy1pgTMhyZrAsYh0zOwpIxRvwLyIiItKvxTIpWwPkmFmWmSUBVwBPhtV5Erg6+PxS4EXXV1Phfmb27NnxDkFERHpRX/o935di7YmYnb4EMLN/BX6JNyXG/c65n5nZrUCxc+5JM0sG/huYCnwMXOGc++Bgber0pYiIiPQVBzt9GdN5ypxzK4GVYWW3hDxvAebFMiYRERERP9BtlkRERER8QEmZiIiIiA8oKRMRERHxASVlIiIiIj6gpExERETEB5SUiYiIiPiAkjIRERERH1BSJiIiIuIDSspEREREfCCmt1nqDWa2E9gU7zgGgOOAj+IdhEgM6ZiXgUbHfGyMc86lR1rR55MyiQ0zKz7QvbpE+iMd8zLQ6JiPP52+FBEREfEBJWUiIiIiPqCkTLrr9/EOQCTGdMzLQKNjPs40pkxERETEB9RTJiIiIuIDSspEREREfEBJmcSEmSWb2R/N7B0zazWzynjHJNKbzOx0M3vczLaYWbOZbTCzgJkdHe/YRHqLmX3OzJyZZcY7lr5ISVk/ZWZJ8Y4hTALQijeQ9KE4xyL9kA+P+VlAFXAVkA/8ELgB+GUcY5J+xofHvRwBJWX9hJmtNrP7zOw2M/sQqDGzU8zsleB/6bvMbIWZjQh5TSC8x8rMTgv+lzM+pOxKM6sysxYz+4eZnR+sc1pInQnBXoHdwW09b2aFneudc/90zl3nnPsP4INe/TBkQOgDx/wdzrkfOOdecc5VO+eeAO4ALuvNz0X6N78f93JklJT1L5cB6cAcYB7wPLAFmA5cABQAj/WkQTM7GXgAeBCYDNxF2H/6ZjYSeBXYAZwOnAJUAKvNLOKtJESipK8d858B/tmTeEQi6GvHvXTTUfEOQKLqQ+AG51yHmd0GNADXOOdaAczsy8C7ZvZZ59wr3WzzJuA159xPgssVZjYK+I+QOtcDG51z13cWmNmNwL8CX0Sna6T39Jlj3swmAd8BftSD9ycSSZ857qVn1FPWv6x1znUEn58AvNH5JQVwzr0H1AfXdVc+8EZY2ethy9OAk82sqfMBNALjgZwebEukp/rEMW9mOXi9GQ855+7tQSwikfSJ4156Tj1l/UtPT4t0ABZWlhih3qFmGB4ErAIWRFhX38OYRHrC98e8mRUA/w/4G15Pg8iR8v1xL4dHSVn/9T5wrZklhXRpTwZSgdJgnR3ACDNLcM61B8tOCmunDJgZVnZK2HIxcA2wxTnXEqX4RXrKd8e8mU0DngX+DHzH6RYqEn2+O+7l8On0Zf91L5ACLDOzguDVM/8N/N059/dgnZeAIcCtZpZtZvOAb4W1cw8wy8xuNbOJZnYh8G/BdZ1/YO7Fm/Lib+bNzTQ+eGXPz8zs1M6GzCzfzKYAo4AkM5sSfOiSbokGXx3zZvZZvF6FvwG3AyPNbFRwnI5ItPjquA+RH/I7vvMxJLpvvR9yzunRDx7AauAPYWWnAK8AzcBuYAUwIqzOV/GmqGgG/ge4Au8LOD6kzpV48y19gjfG4LJgnZND6ozDu3JnZ7DeJrzegayQOhuDrwt/jI/256FH/3/4/ZgHlh3geHfx/uz06LuPPnDcf+5Axz1wSrw/P78/dENy6TEz+wrwRyDNObc7zuGI9Dod8zIQ6biPPY0pk0Mys+/hdX9/jHf1zZ3Ao/qSSn+lY14GIh338aekTLrjRLyxBccCm/G6qhfHNSKR3qVjXgYiHfdxptOXIiIiIj6gqy9FREREfEBJmYiIiIgPKCkTERER8QElZSIiIiI+oKRMRERExAeUlImIiIj4wP8P/2B/iUnSsiwAAAAASUVORK5CYII=\n",
      "text/plain": [
       "<Figure size 720x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_evaluation('allenai/led-large-16384')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "accelerator": "GPU",
  "colab": {
   "collapsed_sections": [
    "P95DxvqWi_2Y",
    "tvSGvNzvKbvP",
    "S0FByNNOIRvG",
    "JFd0ppeJyX1o",
    "dllOnKR9Os5i",
    "U2mpXoSaQiQE",
    "k0qONrX4Qkkm",
    "JiYIkI5xN2VA",
    "KV669nVZQnzT",
    "WIiEnpvbMkJa",
    "fSqOx7kdMoNJ",
    "UTUY8QgQa2WM",
    "bKYnUXhvMszX",
    "mIcAg1ss4qIR",
    "GlnC1NYkRrQH"
   ],
   "name": "assign_bullets_para.ipynb",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.9"
  },
  "widgets": {
   "application/vnd.jupyter.widget-state+json": {
    "01e3a51fe914437187fb471f042cbc4e": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_a503362a1d6c49958365ce7e93f4d67d",
       "IPY_MODEL_1249b68a0e2c459eae68dfede2dc5b34"
      ],
      "layout": "IPY_MODEL_9b00208076e345faaa7c1d3b38df79c4"
     }
    },
    "0795dec75e4f4a9cad293877eddef047": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_cdd09db5faa14b609970f2a3d37dc430",
       "IPY_MODEL_efc306b702aa4dc0a5e6257cc71ac3aa"
      ],
      "layout": "IPY_MODEL_ec56f7bbfb29414f89c168dfdddd3465"
     }
    },
    "37bb8348b38e45b981c8e2c580de608b": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_4c2fd32ed07b47a89011f42fe95af039",
       "IPY_MODEL_5d0caa7b27f044cb851b38b299d0de86"
      ],
      "layout": "IPY_MODEL_88830eabf77a4c4aa1130c37dc2ffa5d"
     }
    },
    "8ef14e9327d84807a95686427993ebcd": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_3c8709747e444e2e99d5f5d4bd0c4513",
       "IPY_MODEL_8a9da00575624af09987d6936e79f41b"
      ],
      "layout": "IPY_MODEL_e0202968e0864b7ea3ce26fabdde768d"
     }
    },
    "a77961a700f2489f8af86af7aecb7a36": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_23e74f006e7d44e7aee69e3a3394a37d",
       "IPY_MODEL_aa51b0fd1e9648719c0c2b39f252a199"
      ],
      "layout": "IPY_MODEL_66be567c4a0a41e086ac00af108ec408"
     }
    },
    "addb9bfe4b084b61a77f19962f2919d1": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_e6baed9b364643e2a628ec2fa20eda17",
       "IPY_MODEL_1af98602915a4304a38cb231c85076b4"
      ],
      "layout": "IPY_MODEL_0fee59c682d04276b99c86a112570588"
     }
    }
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
